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1CHAPTER-1
 Synthesis and Characterization of Some Novel
 1-(Un)substituted phenyl-10H-[1,2,4]-triazolo
 [3’,4’:3,4][1,2,4]triazino[5,6-b]indoles
2Introduction
Azoles and azines are well known for their diversed biological activities. It
is also known that fusion of the heterocyclic nuclei enhances the pharma-
cological activities more than its parent nucleus. The importance of the in-
dole nucleus is well established in pharmaceutical chemistry as it’s corre-
sponding derivatives are used as antipyretic, anticonvulsant, antianalgesic
and antidepresant agents1.
A few naturally occurring members of this class of compounds, pyridindolol
2,3 and the two antibiotics CV-14  and gualamycin5-7, have been isolated
from different species of Streptomyces. Valuable biological activities are
known to be associated with the 1,2,4-triazolo[4’,3’:2,3]-1,2,4-triazino[5,6-
b]indole skeleton. 3-hydrazino-1,2,4-triazino[5,6-b]indoles show antihyper-
tensive8,9, antiviral8, blood-platelet aggregation inhibitory9,10, analgesic11,
and antibacterial activities12. Hydrazone derivatives of 3-hydrazino-1,2,4-
triazino[5,6-b]indoles have been found to possess antiumor activity against
P388 lymphocytic leukemia in mice13 and antibacterial activity14,15. In addi-
tion, 1,2,4-triazolo[3’,4’:3,4]- and -[4’,3’:2,3]-1,2,4-triazino[5,6-b]indoles
exhibit antiviral16-19 and antibacterial properties20.
1(a).M.Bell, A.Zalay, R.Oesterlin, S.Clemans, D.Dum, J.Bradford, J.Rozitis, J.Med.Chem., 22, 537(1977)
(b).F.Popp, J.Heterocycl.Chem., 21, 1641(1984)
(c).K.Joshi, V.Pathak, S. Jain, Pharmazie, 35, 677(1980)
2.T.Aoyagi, M.Kumagai, T.Hazato, M.Hamada, T.Takeuchi, H.Umezawa, J. Antibiot., 28,555(1975)
3.M.Kumagai, H. Naganawa, T. Aoyagi, H.Umezawa, H.Nakamura, Y.Iitaka, J. Antibiot.,28,876(1975)
4.T.Yasuzawa, M. Yoshida, M. Ichimura, K. Shirahata, H. Sano, J. Antibiot.,40, 727(1987)
5.K.Tsuchiya, S. Kobayashi, T.Harada, T.Kurokawa, T.Nakagawa, N. Shimada, K.
Kobayashi, J. Antibiot.,48, 626(1995)
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36.K.Tsuchiya, S. Kobayashi,T. Kurokawa, T. Nakagawa, N.Shimada, H. Nakamura, Y.
Iitaka, M. Kitagawa, K.Tatsuta, J. Antibiot., 48, 630(1995)
7.K.Tatsuta, M.Kitagawa, T. Horiuchi, K.Tsuchiya, N.Shimada, J.Antibiot., 48, 741(1995)
8.D.Kaminsky, US Patent 3: 752 891, Chem Abstr. 79, 149328 (1973)
9.  A.Monge, J.Palop, C.Ramirez, E.Fernandez-Alvarez,  Acta Farm Bonaerense, 6,
157(1987), Chem Abstr .,109, 121991(1988)
10.A.Monge, J.Palop , C. Ramirez, M. Font , E.Fernandez-Alvarez , Eur J Med Chem 26, 179(1991)
11. A.Tomchin, M. Ignat’eva, G. Masyuta, Khim-Farm Zh, 6, 23(1972), Chem Abstr
77,43170(1972)
12.A.Dave, K.Bhatt, N.Undavia, P.Trivedi, J Indian Chem Soc 66, 246(1989)
13.N.Eshba, H. Salama, I.Labouta, A. Omar, Pharmazie, 42, 664(1987)
14. K.Joshi, S. Jain, A. Jain, Curr Sci, 51, 346(1982), Chem Abstr., 97, 55784 (1982)
15.B.Holla, K. Udupa, J Indian Chem Soc., 65, 524(1988)
16.J.Gladych, J.Hunt, D.Jack,R. Haff, J.Boyle, C.Stewart, R.Ferlauto, Nature, 221,286(1969)
17. J.Gwaltney, J Proc Soc Exp Biol Med, 133, 1148(1970)
18.J.Boyle, W. Raupp, F.Stanfield, R.Haff, E.Dick, D. D’Alessio, C. Dick, Ann N Y Acad
Sci, 173, 477(1970)
19. E.Katz, E.Margalith, Antimicrob Agents Chemother .,25, 195(1984) , Chem Abstr
100,132158(1984)
20. F.Abdel-Latif, R.Shaker , S. Mahgoub, M. Badr, J Heterocycl Chem, 26, 769(1989)
21.S.Baginski, D.Pevear, M.Seipel, S. Sun, C. Benetatos, S. Chunduru, C.Rice, M.
Collett, Proc. Natl. Acad. Sci. U.S.A.,97, 7981(2000)
22.K.Hirata, J. Araya, S.Nakaike, K. Kitamura, T. Ishida,,Chem. Pharm. Bull.,49, 44(2001)
23.V.Ram, Arch.Pharm.,313,108(1980)
24.J.Gladych, R.Hornby, J.Hunt, D. Jack, J. Boyle, R.Ferlauto, C.Kormendy, F.Stanfield,
R.Stewart, J.Med.Chem., 15(3), 277(1972)
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Polycyclic fused heteroaromatics of  functionalized isatin derivatives are
of interest because of their potential biological activity in analogy to the
ant iv i ra l  drug VP32947 21 and the DNA- in terca la t ing drug/DNA
topoisomerase II inhibitor NCA042422.
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Polycyclic fused heteroaromatics with established biological activies
4The triazino[5,6-b]indole derivatives have aroused considerable interest
as a result of their broad spectrum of antibacterial, antifungal and anti-
parasitic activities23. The majority of the 5H-as-triazino[5,6-b]indoles are
active in vitro against a variety of viruses including several strains of rhi-
novirus24. Since they are purine analogues, it is expected that they should
exert their pharmacological effects by interfering with DNA metabolism.
Pharmacology
Triazino[5,6-b]indole derivatives are Purine analogues and exhibit diversed
pharmacological activities. They have been described to have activity
against  A.niger and when provided as seed dressing, they protected sor-
ghum seeds from infection with this organism25. The modes of action of
these drugs are not known. Some triazinoindoles have antiviral properties.
SK&F 30097 was active against picornavirus in vitro and RNA synthesis
was inhibited26, while SK&F 21681 had activity against herpes simplex vi-
rus, in which DNA synthesis was suppressed 27. Triazinoindoles were also
shown to have antihypertensive properties 28 and inhibit thromboxane syn-
thetase in rats. Some triazinoindoles are also mutagenic29. The literature
survey reviewed on pharmacological profile of Triazino[5,6-b]indole- and-
Triazolotriazino[5,6-b] derivatives highlighed the following classification of
the major therapeutic activity as per mention below.
? Antiviral activity ? Antifungal Activity ? Anticancer Activity
? Antimalarial activity
? Antihypertensive and Platelet aggregation Inhibitors / Thromboxine syn-
thetase Inhibitors
? Antibacterial activity
25. R. Abdel Rahman, Z. El Gendy, M.Mahmoud. Ind. J. Chem., 29B,352-358(1990)
26.R.Haff, W.Flagg, J.Gallo, J.Hoover, J.Miller, C.Pinto, J.Pagano., Proc. Soc. Exp.
Biol.Med., 141, 475(1972)
27.E.Katz, E. Margalith, Antimicrob. Agents Chemother., 25,195(1984)
28.A.Monge, J. Palop, C. Ramirez, M. Font, E. Fernandez-Alvarez.,Eur. J. Med. Chem.,
26,179(1991)
29.A.Lopez-de-Cerain, E. Garcia,  A. Gullon.Mutagenesis, 7,37(1992)
30.T.Ueda, I.Nakata, Yakugaku Zasshi, 80, 1068(1960), Chem.Abst.,55,562(1961)
31.D.Bauer, F.Sheffield, Nature, 184,1496(1959)
32.R.Thompson, A. Minton,  S.Jun, J.Officer,  G. Hitchings,, J. Immunol., 70, 229 (1953).
5? Antiviral activity
The antiviral activity of as-triazines30 and clinical efficacy of methisazone31
were well documented. The action of isatin-3-thiosemicarbazone  is known
to have antiviral activity against certain poxviruses32,33. The antiviral spec-
trum of 1-methylisatin 3-thiosemicarbazone, which reportedly extends to
adenoviruses, may be rather broader but is still limited to several groups of
DNA viruses33,34. It was therefore an unexpected finding that these compounds
are also active against certain rhinoviruses. J.M.Z.Gladych35 and co-work-
ers have studied Isatin thiosemicarbazone analogues among which two com-
pounds were found to have activity against all rhinovirus strains used so far.
Human rhinovirus (HRV) is a primary cause of mild upper respiratory
infection in humans36. Although rhinovirus infection, as the “common cold”
is known to spread easily throughout human populations, only higher
primates are susceptible 37,38; thus, the virus possesses a narrow host
range. This narrow host range is reflected in tissue culture in that the HRV
replicates only in cells of primate origin.
In vitro testing of the 5H-triazino[5,6-b]indoles shown a broad spectrum
antiviral activity against both DNA and RNA viruses. A notable feature of
the series is the wide spread action against several strains of rhinovirus
which is  most  cons is tent ly  shown by compounds conta in ing
hydroxyalkylamino substituents at C-3.
33.D.Bauer, P. Sadler, Brit. J. Pharmacol. Chemother., 15, 101 (1960).
34.D.Bauer, K. Apostolov, Science, 154, 796 (1966).
35.J.Gladych, J.Hunt, D. Jack, R.Haff, J.Boyle, R.Stewart, R.Ferlauto, Nature, 221, 286(1969)
36.D.Tyrrell, M.Bynoe,Lancet i,76(1966)
37.E.Dick, Proc. Soc. Exp.Biol. Med.,127,1079(1968)
38.C.Pinto, R.Huff,Nature (London), 224,1310(1969)
N
O
NNHCSNH2
R
Isatin-3-thiosemicarbozones
R = CH3  Methisazone or 
(1-methylisatin-3-thiosemicarbazone) 
N
N
N
N
R2
R3
R1
    5H-as-triazino[5,6-b]indoles                                
R1 = H,Cl, NO2, Me, Pr, NO, OMe    R2 = H, Me, C6H5(CH2)2, C6H5CH2  
R3 =  OH(CH2)2NH, OH(CH2)3NH, NH2, Me2N, Morphonyl, Me2CH(CH2)2NH, 
Me(CH2)11NH, CH3(CH2)17NH, OHCH2CH(OH)CH2NH, OH(CH2)4NH, 
MeO(CH2)3NH, OH(CH2)2NH(CH2)2NH, Me2N(CH2)3NH, OH(CH2)6NH etc.
6The search for effective antirhinovirus agents has yielded a wealth of
compounds be long ing to  wide ly  vary ing chemica l  c lasses:
thiosemicarbazones35, isoquinolines 39,40, triazinoindoles41, guanidines42,
benzoates43, furanyls44, benzimidazoles45, thiourea46, diketones47,48,49,
flavans50,51, flavones52, chalcones53, nitrobenzenes54,55, and isoxazoles56,57.
The most recently developed antirhinovirus compounds50, 56, 53, 57 reach their
MICs within the range of 0.001 to 0.01 µg/ml.
A wide variety of purine nucleoside (mainly tubercidin and adenosine)
analogs, which had previously been shown to inhibit the replication of a
broad spectrum of RNA viruses, were evaluated for their antirhinovirus
activity in human diploid (WI-38) fibroblasts58. Among the 5- or 6-substituted
tubercidin analogs, several derivatives, i.e., tubercidin, sangivamycin,
toyocamycin, 5-(1-hydroxyethyl)tubercidin, and 5-(2-buten-1-yl)tubercidin
(the later being a mixture of E and Z isomers at a 2:1 ratio)(Figure-1),
inhibited the cytopathogenicity of rhinovirus types 1A, 1B and 9 at
concentrations well below 1µg/ml, the most potent being tubercidin itself
with an MIC50 of 0.03 µg/mI. Of the sugar-modified tubercidin analogs, only
2'-deoxytoyocamycin exhibited an MIC50 of <1 µg/ml (against rhinovirus
types 1B and 9). Of the carbocyclic adenosine analogs, carbocyclic 7-
deazaadenosine proved the most potent, with an MIC50 of 2 µg/ml (against
rhinovirus types 1B and 9). Acyclic adenosine analogs were totally ineffective
as antirhinovirus agents, and from the miscellaneous reference compounds
formycin A, pyrazofurin, and 3-deazaguanine showed the lowest MIC50s
(within the range of 5 to 25 µg/ml).
39.S.Reed, M.Bynoe. J. Med.Microbiol.,3,346(1970).
40.A.Zerial, G.Werner, R.Philipotts, J.Wilmann, P.Higgins, D.Tyrrell, Antimicrob. Agents
Chemother.,27,846(1985)
41.S.Matsumoto, F.Stanfield, M.Goore, R.Haff, Proc. Soc. Exp. Biol.Med.,139,455(1972).
42.R.Bucknall, D.Swallow, H. Moores, J. Harrad,Nature (London), 246,144(1973)
43.H.Ohnishi, K. Yamaguchi, S. Shimada, S. Himuro, Y. Suzuki. Antimicrob. Agents
Chernother.,22,250(1982)
44.R.Ash,R.Parker, A.Hagan, G.Mayer, Antimicrob. Agents Chemother.,16,301(1979).
45.D.DeLong, S.Reed, J.Infect. Dis., 141,87(1980).
46.A.Galabov, E.Velichkova, G.Vassilev, Chemotherapy,23,81(1977).
47.G.Diana, P.Carabateas, R. Johnson, G.Williams, F. Pancic, J.Collins,J. Med. Chem.,
21,889(1978).
48.G.Diana, U.Salvador, E.Zalay, P.Carabateas, G.Williams, J.Collins, F. Pancic, J.
Med.Chem., 20,757(1977).
749.G.Diana, U.Salvador, E.Zalay, R.Johnson, J.Collins, W.Johnson, W. Hinshaw, R.
Lorenz, W.Thielking, F. Pancic, J. Med. Chem., 20,750(1977).
50.D.Bauer, J.Selway, J.Batchelor, M. Tisdale, I.Caldwell, D.Young, Nature (Lon-
don),292,369(1981).
51.R.Phillpotts, J. Wallace, D.Tyrrell, D.Freestone, W.Shepherd, Arch. Virol.,75,115(1983).
52.H.Ishitsuka, C. Ohsawa, T. Ohiwa, I. Umeda, Y. Suhara,Antimicrob. Agents Chemother.,
22,611(1982).
53.H.Ishitsuka,Y. Ninomiya, C. Ohsawa, M. Fujiu, Y. Suhara.Antimicrob. Agents
Chemother., 22,617(1982).
54.R.Powers, J.Gwaltney,F.Hayden, Antimicrob. Agents Chemother.,22,639(1982).
55.H.Torney,  J. Dulworth, D.Steward, Antimicrob. Agents Chemother., 22,635(1982).
56.G.Diana, M.McKinlay, C.Brisson, E.Zalay, J.Miralles, U.Salvador., J. Med. Chem., 28,748(1985)
57.M.Otto, M.Fox, M.Fancher, M.Kuhrt, G.Diana, M.McKinlay, Antimicrob.Agents
Chemother., 27,883(1985).
58.E.Clercq, R.Bernaerts, D.Bergstrom, M.Robins, J. Montgomery, A.Holy, Antimicrob.
Agent.Chemother.,29(3),482(1986)
59.D.Bauer, Chemotherapy of virus diseases,1,35(1972)
60.C. Pfau, Handbook of experim.pharmcol.,61,147(1982)
Despite their higher potency as antirhinovirus compounds, tubercidin, 5-(1-
hydroxyethyl)tubercidin, 5-(2-buten-1-yl)tubercidin, sangivamycin, and
toyocamycin did not display much selectivity in their antirhinovirus action.
Their selectivity indexes fell in the range of 3 to 30 (index A) and 1.3 to 4
(index B). Of the sugar-modified tubercidin analogs, only the ara analog of
sangivamycin showed some selectivity (index A = 8.6; index B = 3.1). Of the
carbocyclic and acyclic adenosine analogs, none proved to be a selective
inhibitor of rhinovirus; and of the miscellaneous group of compounds, 3-
deazaguanine showed the highest selectivity (index A = 50; index B = 33).
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Fig-1. Structural formulas of selected purine nucleoside analogues.
5-or 6-substituted 
tubercidin analogues)
Sugar modified tubercidin analogues R1 = H, 
CN,CONH2 and R2=H (2'deoxy) or OH(ara)
Neplanocin(carbocyclic 
adenisine analogues)
3-deazaguanine
(miscellaneous)
R1   R2 Compound Name                                                              
H   H Tubercidin (7-deazaadenosine)                      
CH(OH)CH3          H 5-(1-hydroxyethyl)tubercidin                         
CHOCH2CH3 H 5-(1-methoxyethyl)tubercidin                    
CH2CH=CHCH3 H 5-(2-buten-1-yl)tubercidin                                       
CONH2  H Sangivamycin                                                                
CN   H Toyocamycin                                                                   
H   Br 6-Bromotubercidin
(RS)-9-(2,3-dihydroxypropyl)adeni
ne (acyclic adenosine analogues
8With the compounds that proved most potent or selective or both in inhibiting
rhinovirus-induced cytopathogenicity, i.e., 5-(2-buten-1-yl)tubercidin, 5-(1-
hydroxyethyl)tubercidin, sangivamycin, and 3-deazaguanine, further
experiments were undertaken to determine their inhibitory effects on the
production of rhinovirus type 1A progeny (yield). 5-(2-Buten-1-yl)tubercidin
effected a 3 to 4 log10 reduction in virus yield at a concentration as low as 1ì g/
ml (Fig. 2). 3-Deazaguanine achieved a 1.5 to 2 log10 reduction in virus yield,
but only if added at a concentration of 100 ì g/ml and in contrast with the virus
yield reductions obtained with 5-(2-buten-1-yl)tubercidin (Fig. 2A) and the two
other compounds [5-(1-hydroxyethyl)tubercidin and sangivamycin]  the virus
yield reduction achieved by 3-deazaguanine (Fig. 2B) was only transient. The
reduction of rhinovirus type 1A yield by 5-(1-hydroxyethyl)tubercidin, 5-(2-buten-
1-yl)tubercidin, sangivamycin, and 3-deazaguanine may be interpreted to mean
that their inhibitory effects on rhinovirus cytopathogenicity probably result from
an inhibition of virus replication.
FIG. 2. Effects of 5-(2-buten-1-yl)tubercidin (A) and 3-deazaguanine (B) on
the replication of rhinovirus type 1A in WI-38 cells.Concentration of the com-
pounds: 100 ì g/ml , 10ì g/ml  or control 
9Isatin-3-thiosemicarbazone exhibits antiviral activity, mainly against
poxviruse59,60. A group of 3-substituted triazinoindoles, which are structurally
related to isatin thiosemicarbazone, inhibit the growth of several
rhinoviruses 35,17. Ehud Katz et al27suggested SK&F 21681 (3,10-dimethyl-
10-H-s-triazolo[4',3':2,3]-astriazino-[5,6-b]indole) is an inhibitor of the
growth of herpes simplex viruses types 1 and 2 at a concentration of 60ì g/
ml without causing any morphological alterations in BSC1 cells. The DNA
synthesis rate of BSC1 affected by 16% between 0.5 to 7 hrs and this
inhibition increased upto 33% between 2 to 22 h.p.i.
.
N
N
N
N
N
N
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CH3 SK&F 21681 
FIG. 3. Growth of HSV-1 and HSV-2 in the
presence of different concentrations of SK&F
21681. BSC1 cells were infected with the viruses
at a multiplicity of infection of 1 PFU per cell. After
adsorption, maintenance medium containing
different concentrations of SK&F 21681 was
added. The cultures were harvested at 22 h p.i.,
and virus titers were determined.
a To BSC1 cells infected with HSV-1 and HSV-2 at a multiplicity
of infection of 1 PFU per cell, medium containing SK&F 21681
(60ug/ml) was added or removed at different time intervals p.i.
The cultures were harvested at 22 h p.i., and virus titers were
determined.
The growth of HSV-1 and HSV-2 in BSC1 cells was followed in the presence
of different concentrations of SK&F 21681. It was shown that the highest
rate of inhibition occurred at the concentration of 60ì g/ml (the upper limit
of solubility of this compound in aqueous solution); decreasing the
concentration resulted in a parallel loss in the efficiency of the inhibition
(Fig. 3). Concentrations of SK&F 21681 lower than 10 ì g/ml were not active.
The results also suggest that the susceptibility of the growth of HSV-2 to
this compound is higher than that of HSV-1 (Fig. 3). When formation of
plaques of HSV in the presence of SK&F 21681 (60 p.g/ml) was studied, a
remarkable inhibition was observed.
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The examination with respect  of  inhibition caused by SK&F 21618 was
reversible upon removal of the compound suggested(Table-1) that  when
the compound was removed at 2 or 4 h p.i., it was still possible to recover
most of the virus infectivity, but when the removal of the compound was
delayed to 7.5 h p.i., the rate of rescue of viral infectivity was much lower.
The study of effect  on formation of  viral particles indicated that in un-
treated cultures infected with HSV-1 or HSV-2, a clear peak which was
resistant to DNase was observed. The position of this peak was similar to
that of purified HSV particles. In SK&F 21681-treated cultures, virus par-
ticles were almost entirely missing (Fig. 4).
FIG. 4. Sedimentation of HSV particles in sucrose gradients.[3H]thymidine-labeled infected cells were
analyzed for virus particles as described in the text. Symbols:  ,control ; ,SK&F21681(60ìg/ml)
Since HSV virus particles are not formed in the presence of SK&F 21681
(Fig. 4), it is possible that an inhibition in viral DNA synthesis does occur
under these conditions. The experimental results indicated (Fig.5) that
although the inhibitory effect of SK&F 21681 on the synthesis of cellular
DNA is very minor, the synthesis of viral DNA of both HSV-1 and HSV-2 is
highly suppressed by this compound.
The polypeptide profile of HSV-1was significantly different from that of HSV-
2, but the profiles of both viruses were very similar in the absence and
presence of SK&F 21681 (60ì g/ml). Mutants of herpes simplex viruses
types 1 and 2 which are able to grow in the presence of SK&F 21681 were
isolated.
1 1
Fig-5.Cellular (C) and viral (V) DNA in CsCl gradients. Analysis of the DNA made in HSV-
1- and HSV-2-infected BSC1 cells in the absence and presence of SK&F 21681 (60 ì g/ml)
Scott Baginski and co-researchers61 have reported the discovery of a small
molecule inhibitor of pestivirus replication. The compound, designated VP32947,
inhibits the replication of bovine viral diarrhea virus (BVDV) in cell culture at a
50% inhibitory concentration of approximately 20 nM. VP32947 inhibits both
cytopathic and noncytopathic pestiviruses, including isolates of BVDV-1, BVDV-
2, border disease virus and classical swine fever virus. However, the compound
shows no activity against viruses from unrelated virus groups.
Bovine viral diarrhea virus (BVDV), the prototypic representative of the
pestivirus genus, family Flaviviridae, is ubiquitous and causes a range of
clinical manifestations, including abortion, teratogenesis, respiratory
problems, chronic wasting disease, immune system dysfunction, and
predisposition to secondary viral and bacterial infections62. Certain BVDV
strains can cause acute fatal disease with mortality rates of 17–32%63,64,65.
BVDV is also able to establish persistent infections in fetuses66,67. When
born, these persistently infected animals remain viremic throughout life and
serve as continuous sources for virus spread in herds. Persistently infected
animals may also succumb to fatal mucosal disease on superinfectionwith
closely related BVDV strains. Vaccines are used in some countries in an
attempt to control pestivirus disease with varying degrees of success62,68.
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Time of drug addition studies indicated that VP32947 acts after virus
adsorption and penetration and before virus assembly and release. Analysis
of viral macromolecular synthesis showed VP32947 had no effect on viral
protein synthesis or polyprotein processing. The investigation of the effect
of VP32947 on viral RNA synthesis indicated when virus-infected cells,
treated with actinomycin D(to inhibit cellular RNA synthesis) with or without
VP32947 in the cell culture medium. There was a clear inhibition of
incorporation of 3H-uridine into viral RNA found in the drug treated
culture(Fig. 6). Although the drug-free culture showed the time-dependent
incorporation of 3H-uridine into viral RNA. When this experiment was
performed in the absence of actidomycin D, no change of 3H-uridine uptake
in the presence of drug was observed for cellular RNA synthesis, indicating
that VP32947 had no obvious effect on uridine uptake by the cells or on
cellular RNA synthesis. These results suggest that VP32947 exerted its
antiviral effect at the level of viral RNA synthesis.
Fig. 6. Effect of VP32947 on viral RNA synthesis in WT virus-
infected cells.Incorporation of 3H-uridine into viral RNA in the
absence   or presence   of 167 nM VP32947 was determined
as described in Materials and Methods.
VP32947
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Hepatitis C virus (HCV) and bovine viral diarrhea virus (BVDV) are both
members of the Flaviviridae family and share many molecular and virological
similarities 69,70. They both have single-strand RNA genomes that replicate via
negative strand intermediates and produce a single polyprotein that is cleaved
into individual proteins by a combination of host and viral proteases. Although
HCV is a hepacivirus and BVDV is a pestivirus, there is a low degree of
sequence homology between their respective nonstructural proteins and both
RNAdependent RNA polymerases are structurally very similar 71.
Current therapies are limited to interferon treatment, either alone or in combination
with ribavirin72,73, but patient response for certain genotypes is still unsatisfactory.
This unmet medical need has created an urgent demand for the development of
new drugs to treat chronic hepatitis C. However, the lack of an in vitro infection
system has hampered HCV drug development. For this reason, BVDV has
sometimes been used as a surrogate infectivity model in vitro.
In search of HCV-specific, non nucleoside-based antivirals Nigel Horscroft
et al74 have developed a bi-cistronic, subgenomic replicon for BVDV that
replicates efficiently in Huh-7 cells. This have made enable to compare RNA
replication of HCV and BVDV in similar cellular backgrounds and to identify
antiviral compounds specific for HCV in the absence of significant
cytotoxicity. Although BVDV and HCV are closely related, there was low
sequence similarity or identity between the corresponding proteins. The high
degree of structural similarity between the polymerase motifs of BVDV and
HCV NS5B 71,75 suggests that compounds that inhibit viral replication by
targeting the catalytic site of the polymerase (e.g., nucleosideor nucleotide-
based inhibitors) will likely be inhibitory in both systems. However,
compounds that are inhibitory but target less-conserved regions of the
polymerase enzyme may not be cross-active against both viruses.
To validate such an approach, the Huh-7–HCV and Huh-7–BVDV replicons
were tested  in parallel against a number of inhibitor compounds with known
specificities (Fig. 7). 2’-â-C-methyl ribonucleosides are known to inhibit HCV
polymerase by incorporation into viral RNA and causing chain termination76
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As substrate-based inhibitors targeting the catalytic center of the polymerase
enzyme, this class of compounds would be predicted to be active against BVDV
as well. As expected, 2’-â-C-methyl adenosine (Fig. 7A) and 2’-â-C-methyl
cytosine (Fig. 7B) showed comparable EC50 values in the parallel replicon
assays. For 2’-â-C-methyl adenosine, the EC50 values against Huh-7–BVDV
and Huh-7–HCV were 0.4 & 1.2ì M, respectively, while for 2’-â-C-methyl
cytosine those values were 0.3 & 3.0 ì M, respectively. In contrast, when two
nonnucleoside polymerase inhibitors were tested, a greater difference in virus
specificity was observed. VP32947 is a triazinoindole derivative that is a potent
inhibitor of BVDV polymerase which acts by targeting a region near the amino
terminus and away from the active site77; GSK compound 4 (GSK-4) is a
benzothiadiazine derivative that shows specific activity against the HCV
polymerase78. As shown in Fig. 7C, VP32947 showed potent activity against Huh-
7–BVDV, with an EC50 of < 0.14 ì M, but was not active against Huh-7–HCV.
The EC50 of VP32947 against BVDV–Huh-7 was subsequently determined
to be 25 nM, giving a selectivity index (SI) of 12,000. Conversely, for GSK-4
FIG-7. Demonstration of viral specificity with known inhibitor compounds. BVDV/Huh7 or
HCV/Huh7 cells expressing luciferase were plated in white 96-well plates and allowed to
attach overnight (~18 h) before treatment with known small-molecule inhibitors for a fur-
ther 48 h. (A and B) 2-â-C-methyl adenosine (A) and 2’-â-C-methyl cytosine (B) showed
comparable EC50 values in the parallel replicon assays. (C) VP32947, a triazinoindole
derivative, showed potent activity against BVDV/Huh-7, with an EC50 of < 0.14 M, but
was not active against HCV/Huh-7.(D) GSK-4, a benzothiadiazine derivative, showed
specific activity against HCV/Huh7 but much lower activity against BVDV/Huh7.
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the EC50 values against Huh-7–BVDV and Huh-7–HCV were 25 & 0.4 ì M,
respectively, which resulted in an SI of  63 (Fig. 7D). The relatively low SI for GSK-
4 may be due to the intrinsic cytotoxicity associated with the compound, which
affected both replicons. Taken together, these results illustrated the utility of the
parallel replicon assays in quickly separating antiviral activity from cytotoxicity
and the identification of compounds with high specificity towards HCV.
? Antifungal activity
Triazinoindoles have been described to have activity against A.niger. and when
provided as seed dressing, they protected sorghum seeds from infection with
this organism25. The description of the antifungal activities of triazinoindole
compounds was new and no mode of action is suggested from the literature.
Oonagh Kinsman and co-workers77 have described GR99060 and GR99062
as representatives of a series of 1,2,4-triazino[5,6-b]indole compounds. This
series possessed broad-spectrum antifungal activity in vitro. The MIC ranges of
the two compounds were as follows: 0.25 to 4 ì g/ml for Candida albicans,
0.25 to 16 ì g/ml for Candida sp., 1 to 8 ì g/ml for Asperigllus spp., and 0.25
to 16 ì g/ml for Cryptococcus neoformans. GR99062 was metabolized to
corresponding N-oxide analogue GR107867 in vitro by a mouse liver mi-
crosomal preparation, while GR99060 was stable. GR99060 was efficacious
in a murine model of systemic candidiasis by oral or parenteral administra-
tion, although no clear dose-response was achieved, suggesting that other
factors adversely affected the compound’s in vivo activity.
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GR99060 showed a therapeutic effect in mice with systemic C. albicans
infections when it was administered by both the oral and subcutaneous
routes. Since the levels of the drug in blood after subcutaneous dosing were
low, the compound may be released slowly over a longer period of time. In
the efficacy test, the dose-response was variable by both routes. Toxicity
in infected animals may account for the reduced activity at high doses, since
a lower survival rate was noted in mice that received 100 mg/kg than in
those that received lower doses. Variations in bioavailability and possible
further metabolism may also account for the lack of good dose-responses.
Similarly, in the subacute infection model, the oral route of administration
was more effective than the subcutaneous route in reducing kidney counts
when a dose of 100 mg/kg was used.
3. Anticancer activity(c-MET Inhibitors)
Protein kinases(PKs) are the enzyme that catalyses the phosphorylation of
hydroxy group on tyrosine, serine and threonine residues of protein. The
consequences of this seemingly simple activity are staggering cell growth,
differentiation and proliferation i.e. virtually all aspects of cell life in one
way or another depend on PK activity. The PKs can be conviniently broken
into two classes, the protein tyrosine kinase(PTKs) and the serine threo-
nine kinase(STKs).
One of the prime aspect of PTK activity is their involvement in growth fac-
tor receptors. Growth factor receptors are cell-surface proteins, when bound
by a growth factor ligand, converted into an active form which interacts with
proteins on the inner surface of a cell membrane, leads to phosphorylation
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on tyrosine residue of the receptor and other proteins and to the formation
inside the cell of complexes with a variety of cytoplasmic signaling mol-
ecules that in turn effect numerous cellular responses such as cell
division(proliferation), cell differentiation, cell growth, expression of meta-
bolic effects to the extracellular microenvironment etc78.
Growth factor receptors with PTK activity are known as receptor tyrosine
kinase(RTKs). They comprise a large family of transmembrane receptors
with diversed biological activity. There were 19 distinct families of RTKs
have been identified79 including EGFR(epithelial growth factor receptor),
Insulin receptor(IR), PDGFR(platelet derived growth factor receptor,
FGR(fibroblast growth factor etc.
Still another member of the tyrosine kinase growth factor receptor family is
MET often referred as c-MET or hepatocyte growth factor receptor or scat-
ter factor receptor. c-MET is thought to play a role in primary  tumor growth
and metastasis. c-MET is a receptor tyrosine kinase that is encoded by
the Met protooncogene80, tranduces the biological effect of hepatocyte
growth factor(HGF) and their expression confined predominantly to cell of
epithelial and mesenchymal origin. c-MET and HGF are required for nor-
mal mammalian development and have been shown to be important in cell
migration, cell proliferation, survival, morphogenic differentiation and or-
ganization of 3-dimentional tubular structures(eg. renal tubular cells, gland
formation etc.). c-MET is an attractive target from a clinical perspective
because (1) c-MET has been implicated to in the growth and metastases
of most types of cancer, (2) growth at the secondary site appears to be the
rate limiting step in metastases and (3) by the time of diagnosis, it likely
that the disease has already spead.
Tomas Vijkovsky et al81 have patented compounds of formula I and II for
treating c-MET related disorders or in another preferred embodiment, the
cancer selected from the group consisting breast cancer, lung cancer, pros-
tate cancer, pancreatic cancer, glioma, liver cancer, gastric cancer, throat
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cancer, melanoma, renal cancer, leucamia, myeloma and sarcoma. The
investion deals with a family of novel tetracyclic compounds which exhibits
c-MET modulationg activity and have ameliorating effect against disorders
related to abnormal c-MET activity.
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Formula -1 Formula -2
R1=substituted aryl or heteroaryl 
group
R2 & R3=H, halogen, OH, OR, N(R)2, 
-CN, -COR, COOR, CON(R)2, CF3, lower 
alkyl, cycloalkyl, heterocycle, alkenyl 
and alkynyl or R2 & R3 togather form 
cycloalkyl or heterocyle
R4, R5, R6 and R7= H, halogen, OR, 
N(R)2, -CN, -COR, COOR, CON(R)2, 
NO2, S(O)nR (where n=0,1,2), CF3,lower 
alkyl, cycloalkyl, heterocycle, alkenyl, 
alkynyl or  aryl
p=0,1,2,3,4 or 5
R10=OH,OR, COR, COOR, CON(R)2, N(R)2, CN, 
NO2, SO2R, SO2N(R)2, CF3, lower alkyl, 
cycloalkyl, heterocycle, alkenyl or aryl
q=1,2,3,4 or 5 G = C or N 
R2 & R3=H, halogen, OH, OR, N(R)2, -CN, -COR, 
COOR, CON(R)2, CF3, lower alkyl, cycloalkyl, 
heterocycle, alkenyl and alkynyl or R2 & R3 
togather form cycloalkyl or heterocyle
R4, R5, R6 and R7= H, halogen, OR, N(R)2, -CN, 
-COR, COOR, CON(R)2, NO2, S(O)nR (where 
n=0,1,2), CF3,lower alkyl, cycloalkyl, 
heterocycle, alkenyl, alkynyl or  aryl
p=0,1,2,3,4 or 5
? Antimalarial activity
Recent hypothesis seem to suggest that quinoline-type antimalarial drugs
coordinate to the malarial parasite’s endogenous antimalarial agent, Fer-
riprotoporphyrin IX(FP), thus disrupting the conversion of haematin to
haemazoin(malaria pigment)82. A free FP as a toxic substance to the ma-
laria parasites, serves as a receptor for the accumulation of antimalarial
drugs in the food vacuoles83. The parasites which are lacking in heam oxy-
genase are unable to detoxify the free FP by metabolism, but the malaria
parasites have evolved an autocatalytic detoxification process in which FP
is oxidised to heamatin84. In this process the malarial parasites convert the
haematin to a haemazoin, a repeating array of coordinated dimers held
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together in a crystalline matrix by hydrogen bonding interactions85,86. The
accumulation of FP allows for a significant concentration of the free haematin
and haematin-antiviral drug complex to remain in the food vacuole and in
this way, the ability of the parasite and host red blood cells to maintain cat-
ionic gradients is impaired, leading to the death of parasites87-90.
The activities of these antimalarial drugs are a function of both the ability of the
drug to accumulate to pharmacologically relevant concentrations at the site of
drug action, and the ability of the drugs to the to interfere with the haemozoin
formation91. It is also possible that haematin-antimalarial drug complex cause
paracytic death by multiple mechanism92, with evidence suggesting that haem,
rather than the haem drug complex, is responsible for actual lysis of the vacu-
olar membrane88. The free FP and its complex with chloroquine-type drugs in-
hibits protease, which are essential for the degradation of haemoglobin, and
thus affect the growth of the parasite93. The binding of the quinoline-type antima-
larial drugs may stabilize the ì -oxo dimer to the monomers, shifting the dimer-
ization equilibrium to the right and reducing the amount of haematin monomers
available for incorporation into the growing haemazoin94.
Since the discovery of the non-phototoxic, but highly effect ive
quinolinemethanol antimalarial agent, mafloquine95 and halofantrine, the
trifluoromethyl group has aroused considerable interest as a pharmacophore.
Both compounds being effective against multidrug resistant Plasmodium
falciparum, including strains, which are highly resistant to chloroquine96,97 and
associated with reduced concentration of the drug from the acid food vacu-
oles of the parasite due to increased efflux of the drug from cell99. The emer-
gence of multidrug-resistant strain of Plasmodia, has created a near desper-
ate situation, where the need for new antimalarials to circumvent the parasite’s
resistance mechanism has become vital98.
Mefloquine Halofantrine
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Joseph Kgokong et al100  have synthesized the unsubstituted and the 6-
trifluoromethyl-1,2,4-triazino[5,6b]indole analogues and evaluated for antimalarial
activity in vitro against the chloroquine sensitive and chloroquine-resistant strains
of P. falciparum. The results have revealed that the CF3 group tends to lead
to an increased in vitro antimalarial activity of the 1,2,4-triazino[ 5,6b]indole
albeit to a smaller degree in some compounds. Analogues without the
trifluoromethyl group, which were evaluated simultaneously, were all devoid
of activity even at concentrations as high as 400 ì M. The increased activity
resulting from the presence of this group could be ascribed to the increased
lipophilicity of the compound, as this group is known to be more hydrophobic
than even the fluorine atom.101 In this series, the size of the substituent on
the thiol group have no significant effect on in vitro antimalarial activity.
Replacement of a thiol group by a hydrazino group in the trifluoromethyl
substituted derivatives leads to compounds with half  the potency of those
with alkyl groups on the thiol group. On the other hand, the activity of the 6-
trifluoromethyl-5H-1,2,4-triazolo[1’,5’,2,3]-1,2,4-triazino[5,6b]indole series
was a lmost  ident ica l  to  those o f  the 6- t r i f luoromethy l -1 ,2 ,4-
triazino[5,6b]indole-3-alkylthiols, with the exception of compound
containing the 6-CF3  and the 3-CH3 groups. The later exhibited a four fold
improvement in activity against the chloroquine-sensitive strains. However,
introduction of a second CF3 particularly at position 3 tends to lead to
compounds with diminished antimalarial activity. Further consideration of
the structure–activity relationship of compounds in the series without the
6-CF3  indicates that  compound with 3 –CH3 substitution was the most
active against the chloroquine-sensitive strains followed by unsubstituted
skeleton. The former exhibited  activity against the chloroquine-sensitive
strains in the same molar range as chloroquine and mefloquine under
identical experimental conditions, while later was the most active against
the chloroquine-resistant strains of P. falciparum. Both –CF3 and –C6H4Cl
groups at position 3 without CF3 at position 6 lead to relatively inactive
compounds. The fact that the P. falciparum lactate dehydrogenase
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(PfLDH)activity can be distinguishable from the host LDH102 by using the 3-
acetyl pyridine adenine dinucleotide analogue of nicotinamide adenine
dinucleotide (APAD) has afforded an opportunity for the development of an
enzymatic method for the evaluation of antimalarial compounds.103 The
compounds selected for screening against the chloroquine-resistant strain
of P. falciparum have shown identical but much higher in vitro activity than
against the chloroquine-sensitive strain, with the exception of compound
having no substitution, which has a IC50 value of 48.0 ì M, which was very
close to that of chloroquine (IC50 of 277.5 ì M) against this strain. The 3-CF3
substitution did not lead to any improvement on the in vitro antimalarial activity
than it did when attached at position 6. The 3,6-bis(trifluoromethyl)-5H- 1,2,4-
triazolo-[10,50,2,3]-1,2,4-triazino-[5,6b]indole has a much lower activity
against both the chloroquine- sensitive and chloroquine-resistant strains of
P.falciparum than the other 6-CF3 substituted derivatives. As a result of a
direct relationship between the level of drug accumulation in the parasite
food vacuole and antimalarial drug potency, but no simple relationship
between accumulation and either pKa or lipophilicity,84,104,105,106 it could be
inferred that the bulkiness of the molecule conferred by the second CF3 group
will affect the relative membrane permeability of the molecule, leading to
reduced drug accumulation within the parasite food vacuole.
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? Antihypertensive and Platelet aggregation Inhibitors/Thromboxine
synthetase Inhibitors
The action of antithrombotic drugs that act on platelet aggregation has been
largely due to inhibition of platelet cyclooxygenase, the foremost example
being acetylsalicylic acid (ASA)107.  A more effective approach may be the
selective inhibition of thromboxane (TXA2) synthetase
108.  TXA2, which rapidly
hydrolyzes under physiological conditions to TXB2 is a potent vasoconstrictor
and platelet aggregating agent109.  An additional advantage would be that
some precursor of TXA2, like prostaglandin H2(PGH2), may increase the
production of the vasodilator prostacyclin (PGI2) in the vessel wall
110. The
control of the PGI2/TXA2 system may have a great biological significance in
the treatment or prophylaxis of several cardiovascular diseases111.
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The antiaggregation properties of several indolic derivatives were well
documented112 and there are also many examples of selective TXA2
synthetase inhibitors113.
Based on the these consideration Monge A. et al114 have studied the regulation
of the PGI2/TXA2 system with antihypertensive effects by synthesizing a series
of 4-hydrazino-5H-pyridazino[4,5-b]indole and 4-hydrazinopyridazino[4,5-
a]indole derivatives (Scheme-1), structurally related to hydralazine115 (1-
hydrazinophthalazine) and dihydralazine(1,4-dihydrazinophthalazine),
peripheral vasodilators used in the treatment of  hypertension. The
demonstration of selective inhibitory actions of the compounds was
determined in concordance with the Gorman mode116, namely, the inhibition
of the second wave of platelet aggregation induced by adenosine 5'-
diphosphate (ADP), inhibition of aggregation induced by arachidonic acid
(AA), and prostaglandin H, (PGH2) and prostaglandin H2(PGH2) production
with AA as aggregating agent with concomitant inhibition of TXA2 production.
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Marcinkiewicz, Thromb. Diath. Hemorrh.,40, 66(1978).
(b) K.Nicolau,  Ann. Rep. Med. Chem.,14, 178(1979).
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Compounds 3,5, and 10-12 were studied as potential inhibitors of the blood
platelet aggregation induced by ADP and/or AA, PGH2, and adrenaline.
Compounds 3c and 5a.HCl were found to be the most potent inhibitors in
all of these experiments. These compounds were inhibitors of the in vitro
platelet aggregation induced by ADP, AA, and PGH,, and compound 5a.HCl
also inhibited the aggregation induced by adrenaline.
Compounds 3c and 5a-HCl were subsequently studied with ASA as reference
as potential inhibitors of thromboxane synthetase in the in vitro blood platelet
aggregation induced by AA and in the ex vivo blood platelet aggregation
induced by ADP and AA. In both types of experiments, 3c and 5a.HCl showed
an inhibitory effect on the synthesis of TXB2 and a stimulation of the synthesis
of prostaglandin E2 (PGE2). Both effects are more significant with 5a-HCl.
To a 100 ì M concentration, this compound as compared with ASA showed  no
significant inhibitory effect on the PGI2 release from rat aortic tissue.
The antihypertensive effect of the compounds was measured in spontaneously
hypertensive rats (SHR), after intraperitoneal, oral, and intravenous administration
to SHR for compounds 3-8, 12  and hydralazine.  The introduction of the hydrazino
group in the position 4 of the 5H-pyridazino[4,5-b]indole system considerably
increased the antihypertensive activity and toxicity. However,  compounds 6a and
6b  were less active as compared with  compounds 5. Considering the results
together following decreasing order of activity may be stated for compounds 5:
hydralazine >/=  5a = 5d >/= 5 (R’ = H)>/=5b >> 5c.
The results for 5a, 5b, 5d, and hydralazine for a short time after iv
administration revealed that decreasing order of activity seems to be
5d > hydralazine = 5a > 5b.
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The effects on cardiac rhythm (CR) caused by the titled compounds
suggested  the following increasing order of stimulation.
 hydralazine = 5a = 5b << 5d and at a higher dose 5b = 5a << 5d.
After this, the same group have extended their study with a series of 5H-triazino[5,6-
b]indole. Only one compound 3-hydrazino-5H-[1,2,4]triazino [5,6-b] indole
hydrochloride was found to be most potent as antihypertensive agent with slighly
affecting the cardiac rhythm but did not present any antiaggregative effect.
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3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole
? Antibacterial activity
Morsy J.M. and Abd el-Monem W.R.118 have synthesized 3-(5,6-Diphenyl-
1,2,4-triazin-3-yl)-5-substituted-1,2,4-triazino[5,6-b]indole derivatives
showed pronounced effect on the Cellobiase produced by Thermomyces
lanuginosus and Chaetomium thermophilum.
N
N N
N
N
N
N
R
3-(5,6-diphenyl-1,2,4-triazine-3-yl)-5-s
ubstituted-1,2,4-triazino[5,6-b]indoles
117a. A.Monge, J.Palop, C.Ramirez, M.Font, E.Fernandez-Alvarez, Eur.J.Med.Chem.,26, 179(1991)
118.J.Morsy, W. Abd el-Monem, Boll.Chim.Farm.,140(2), 83(2001)
119. A.Lopez-de-Cerain, E. Garcia , A.Gullon, J.Recalde, A.Monge, Mutagenesis, 5(4), 307(1990)
Ethyl 1,2,3-triazino[5,4-b]indole-4-carboxylate N(3)-oxide (13) and 2-chloroethyl
1,2,3-triazino-[5,4-b]indole-4-carboxylate N(3)-oxide (14) have shown potent plate-
let antiaggregating and hypotensive activity, and their precursors 2-ethoxy-
carbonylmethyl-1-methylindole-3-carboxylic acid (15) and 2-(2-chloroethoxy
carbonylmethyl)-1-methylindole-3-carboxylic acid (16) were tested in four strains
of Salmonella typhimurium (TA98, TA100, TA97 and TA102) using the standard
plate incorporation technique. 15 &  16 were not mutagenic whereas 13 was
mutagenic to all the strains and 14 was mutagenic to TA97, TA98 and TA100119.
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In  continuation with this, Garcia  et al120 have  studied quantitative struc-
ture-mutagenic activity relationship  of 3-(4’-benzylidenamino)-5H-
1,2,30triazin[5,4-b]indole-4-one derivatives. The titled compounds was
assayed with the Ames test using the Salmonella typhimurium strains
TA97, TA98, TA100 and TA102. The adaptive least-squares method (ALS
method) was used to carry out a quantitative structure-activity relationship
(QSAR) analysis. Three equations, based on 10 congeners, were found for
strains TA97, TA98 and TA100. The results suggest that lipophilicity of the
substituent decreases the mutagenicity of the series.
Holla B.S. et al121 synthesized a series of 6H-5-aryl-9-halo-1,2,4-triazolo
[3’ , 4’ :3,4]-1,2,4-triazino[5,6-b]-indoles  and 5H-1-aryl-5-halo-1,2,4- triazolo
[4’ ,3’ :2,3]-1,2,4-triazino [5,6-b]-indoles. The titled compounds assayed
against B. subtilis, E.coli, P. aeruginosa and S.aureus.
120.E.Garcia, A.Lopez-de-Cerain , Martinez-Merino, A.Monge, Mutat. Res, 268(1),1(1992)
121. B.Holla, N.Shashidhara, K.Udupa, B.Poojary, Ind.J.Heterocycl.Chem., 14(4), 347(2005)
N
H
N N
N
O
NH2
3-(4'-benzylidenamino)-5H-[1,2,3]
triazino[5,4-b]indol-4-one
N
H
N N
N N
NX
R
6H-5-aryl-9-halo-1,2,4-triazolo             
[3’ , 4’ :3,4]-1,2,4-triazino[5,6-b]-indoles
N
H
N N
N
N
N
X
R
5H-1-aryl-5-halo-1,2,4- triazolo              
[4’ ,3’ :2,3]-1,2,4-triazino [5,6-b]-indoles
2 7
Synthetic approaches and Chemistry
Joshi et al122 reported that the reaction of 3-hydrazino[1,2,4]triazino[5,6-
b] indole (17)  wi th n i t rous ac id (sodium ni t r i te /PPA) gave 10H-
tetrazolo[5’,1’:3,4][1,2,4]triazino[5,6-b]indole(18), where as reaction of (17)
with nitrous acid gave azide(19)123-124, the structure of the azide was con-
firmed by its analytical and spectral data. The azide (19) was cyclized to
tetrazolo compound (18b) on treatment with acetic anhydride, while cycliza-
tion with ethyl cyanoacetate in presence of sodium ethoxide afforded 5-
amino-4-carboxy[1,2,3]-triazolyl-[1,2,4]-triazino-[5,6-b]indole (20)127. On the
other hand  treatment of (17) with sodium nitrite/concentrated hydrochloric
acid gave the corresponding tetrazolo compound 18a (Scheme-2).
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F.F.Abdel-Latif et al128 have studied reactivity of hydrazino compound (21)
toward different condensing cyclization reagents129(Scheme-3) , found that
when (21) treated with acetic anhydride affords the fused triazolo compound
(22) namely 10-acety l -1-methyl -10H-[1,2,4] t r iazolo[3 ’ ,4 ’ :3,4[-
1,2,4]triazino[5,6-b]indole. Refluxing (21) with carbon disulphide produced
1,2-dihydro-10H-[1,2,4]triazolo[3’,4’:3,4][1,2,4]triazino[5,6-b]indol-1-thione
(23a). In the same manner, refluxing (21) with ethyl chloro formate produced
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1,2-dihydro-10H-[1,2,4] triazolo[3’,4’:3,4][1,2,4]triazino[5,6-b]indol-1-one (23b).
On the other hand refluxing (21) with 1-napthaldehyde in absolute ethanol pro-
duced 1-naphthylidine-(5H-[1,2,4]-triazino[5,6-b]indol-3-yl)hydrazone (24a),
where as  upon heating in glacial acetic acid gave corresponding triazolo com-
pound, namely 10-acetyl-1-(1-naphthyl)-10H-[1,2,4]triazolo[3’,4’:3,4]
triazino[1,2,4] [5,6-b]indole (25a). Treatment of (21) with benzaldehyde or p-
nitrobenzaldehyde in ethanol and/or in glacial acetic acid similarly afforded
both benzylidene((5H-[1,2,4]-triazino[5,6-b]indol-3-yl)hydrazone(24b) and 10-
acetyl-1-(p-nitrophenyl)-10H-[1,2,4]triazolo[3’,4’:3,4 ]triazino[1,2,4] [5,6-
b]indole (25b) respectively. Cyclization of (21) with ethyl acetoacetate yielded
the pyrazolino compound-3-(5’-hydroxy-3’-methyl-1H-pyrazol-1-yl)-5H-
[1,2,4]triazino[5,6-b]indole (26a). Similarly, refluxing (21) with acetyl acetone
produced 3(3’,5’-dimethyl-1H-pyrazolo-1-yl)-5H-[1,2,4]triazino[5,6-b]indole
(26b). Condensation of (21) with malanonitrile resulted 3-(3’,5’-diamino-1H-
pyrazol-1-yl)-5H-[1,2,4]triazino[5,6-b]indole (27a), while treatment of (21) with
ethyl cyanoacetate gave 3-(3’-amino-5’-hydroxy-1H-pyrazol-1-yl)-5H-
[1,2,4]triazino[5,6-b]indole (27b).
The reaction of (21) with á-dicarbonyl compounds was assumed to involve
one or both carbonyl groups in the condensation. Thus, heating of (21) and
diacetyl in ethanol gave only the corresponding mono hydrazone namely 2-
(5H-[1,2,4]triazino[5,6-b]indol-3-yl)-hydrazono-3-oxobutane (28). However
in the presence of excess of (21) the corresponding 2,3-bis(5H-
[1,2,4]triazino[5,6-b]indol-3-yl)hydrazonobutane (29) was formed.. The same
result was also obtained if the monohydrazone (28) was heated with ex-
cess of hydrazine(21). All the resulting compounds were well character-
ized by IR and NMR spectral data and elemental analysis.
122. K.Joshi, P.Chand, J.Heterocycl. Chem., 17, 1783(1980)
123.E.Alcalde, J.Mendoza,  J.Elguero, J.Heterocycl.Chem., 11,921(1974)
124.A.Monga Vega, I.Aldana, M.Rabbani,  E.Fernandez-Alvarez, J.Heterocycl.Chem.,
17,77(1980)
125.J.Vilarrasa,  R.Granados, J.Heterocycl.Chem., 11, (1974)
126.R.Granados, M.Rull, J.Vilarrasa, J.Heterocycl.Chem., 13,281(1976)
127.J.Hoover,  A.Day, J.Am.Chem.Soc., 78, 5832
128.F.Abdel-Latif, R.Shaker, S.Mahgoub, M.Badr, J.Heterocycl.Chem.,26,769(1980)
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Joseph Kgokong et al100 have synthesized a series of  unsubstituted and 6-
trifluoromethyl-1,2,4- triazino[5,6b]indole and 5H-1,2,4-triazolo[1’,5’,2,3]-
1,2,4-triazino[5,6b]indole derivatives and their chemical structures con-
firmed by 1H NMR and 13C NMR, elemental, IR and mass spectrophotomet-
ric analyses. The synthetic stretegy discribed as Isatin or the 6-
trifluoromethyl isatin was condensed with thiocarbazide in K2CO3 solution
to form 1,2,4-triazino-[5,6b]indole-3-thione (30) or 6-trifluoromethyl-
1,2,4-triazino-[5,6b]indole-3-thione (31) as show in scheme below. Each
of one of these products was alkylated with each of methyl chloride,
ethylchloride and chlorocyclopropylmethane to form 3-methylthio- (32),
3-methylthio-6-trifluoromethyl- (33), 3-ethylthio- (34), 3-ethylthio-6-
t r i f luoromethy l - (35)  and 3-cyc lopropy lmethy l th io- (36)  and 3-
cyclopropylmethylthio-6-trifluoromethyl-(37) 1,2,4-triazino-[5,6b]indole
derivatives following a known procedure23 Refluxing a mixture of 30 or 31
with hydrazine hydrate in HCl resulted in the formation of 3-hydrazo-1,2,4-
triazino-[5,6-b]indole (38) or 3-hydrazo-6-trifluoromethyl-1,2,4-triazino-
[5,6b]indole (39), which on reaction with sodium nitrite resulted in the
formation of 3-azido derivatives. In the presence of HCl, formic, acetic,
3 0
trifluoroacetic or chlorobenzoic acid, the hydrazo and azido derivatives cyclize
to form fused tetrazole compounds, 5H-1,2,4-triazolo-[1’,5’,2,3]-1,2,4-triazino-
[5,6-b]indole derivatives (40 and 41), 3-methyl- (42 and 43), 3-trifluoromethyl-
(44) and 3,6-bis(trifluoromethyl)-(45) and 3-(2-chlorophenyl)- (46 and 47) 5H-
1,2,4-triazolo-[1’,5’,,2,3]-1,2,4-triazino-[5,6-b]indole derivatives (Scheme-4).
     Scheme 4. Reagents: (a) NH2CSNHNH2, K2CO3; (b) NaNO2/HCl; (c) HCOOH;
         CF3COOH; ClC6H4COOH in 4% NaOH.
Tomas Vijkovsky et al81 have described general procedure for synthesis of
3-(4-hydroxybenzyl-10H-[1,2,4]triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indole
derivatives(Scheme-5) .
129.M.Badr, S.Mahgoub, A.Fahmey, F.Abdel-Latif,Acta.Chim.Hung.,124,413(1987)
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The synthetic approach suggested that p-hydroxyphenyl acetic acid methyl ester
was condensed with neat hydrazine-hydrate to afford corresponding hydrazide.
The hydrazide was treated with cyanogen bromide in the presence of potassium
hydrogen carbonate to yield appropriate 1,3,4-oxadiazole, which on treatment
with hydrazine hydrate would converted into 1,2-diamino-1,3,4-triazole derrivative.
Condensation of later with substituted isatins afforded the 3-(4-hydroxybenzyl-10H-
[1,2,4]triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indole derivatives.
Monge et al117a have reported a series of 5H-1,2,4-triazino[5,6-b]indole de-
rivatives of type 50 and 51 as per shown in scheme below. The 1,2,4-
triazino[5,6-b]indoles (49 & 50) were obtained by cyclization of isatin(48)
with semicarbazide or thiosemicarbazide in the presence of potassium car-
bonate. When a mixture of 50 and hydrazine hydrate was boiled, 90% of 51a
was obtained. The compound was characterized as the free base and its
monohydrochloride by elemental analysis and spectroscopic data (IR &1H-
NMR). Several other hydrazones, not reported earlier (51d, 51e, and 51f),
were prepared by standard methods and also characterized. Upon boiling,
solutions of 50 with piperidine and morpholine, compound 51b and 51c were
obtained in good yields 80 and 83% respectively(Scheme-6).
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Sterically Controlled Regiospecific Cyclization
Synthesis of 1,2,4-triazolo-1,2,4-trizino[5,6-b]indoles by cyclocondensation
of various 3-hydrazono and 3-thiosemicarbazido derivatives of 1,2,4-
triazino[5,6-b]indoles generated contradictions130,131 regarding assignment
of their correct structures. Products of heterocyclization of 5-substituted-3-
hydrazino-1,2,4-triazino[5,6-b]indoles such as 52(R  H) with one carbon
cyclizing agents were assigned to either angularly annulated 1,2,4-
triazolo[3’,4’:3,4]-1,2,4-triazino[5,6-b]indole 53 structure16,17,132 or it’s linearly
annulated regioisomeric 1,2,4-triazolo[4’,3’:2,3]-1,2,4-triazino[5,6-b]indole
54133-137(Scheme-7); in no case has the formation of a mixture of both
regioisomers(53 and 54) been reported. Assignment of either of these two
structures was based on only on electronic factors that enhance the nu-
cleophilicities of N2 and N4 in the 1,2,4-triazine ring. Unexpectedly, steric
factors that might dominate electronic influences in determinating the
regiospecific(or regioselective) outcome of the reaction havebeen over-
looked. Inspection of molecular models indicated that cyclization of
the N5 unsubstituted hydrazine 52(R=H) with one carbon cyclizing
reagents would only be electronically controlled and might, accord-
ingly, lead to 53(R=H) or 54(R=H) depending on factors affecting the
comparative nucleophilicities of N2 or N4 of the 1,2,4-triazine ring.
Molecular models and computer optimized geometries (Figs.8-11)predicted that
introduction of even the least bulky methyl group at N5 (52,R = CH3)would im-
pose a steric control upon regiochemical outcome of cyclization. Proximity of
C1 and N10 substituents in the angular regioisomers (53, R=CH3, R1=CH3,
Ph)(Figs.8 & 9) would generate enough steric interaction to force the direction
N
N N
N
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N
N N
N
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N
R
N
N
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of cyclization towards the formation of linear regioisomers(54, R = CH3, R1
= CH3, Ph)(Figs. 10 & 11)which are free of unfavorable steric interactions.
Computer optimized Geometry
Fig.9 (R = CH3,  R1 = Ph)
Fig.10(R=R1=CH3)
In order to validate or refute the aforementioned observations, Mohammed135
some relevant heterocyclization reactions of 3-hydrazino-5-methyl-1,2,4-
triazino[5,6-b]indole(55) have been studied138. In description, heating the
later hydrazine with acetic acid(i) gave the single product which showed IR
and 1H NMR spectral data consistent with either of the angular or the linear
tetracyclic structures 57a or 61a(Scheme-8), which must have been formed
through the dehydrative cyclization of the unisolable hydrazide 56a. The
UV spectrum of the product  was identical with the spectrum of authentic
samle 61a unequivocally prepared by cyclocondansation of 1-methylisatin
(59) with 3,4-diamino-5-methyl-1,2,4-triazole(60a)135. Corraboration of the
assigned linear structure 61a has been pinpointed by its failure to undergo
Dimroth-like rearrangement  upon heating with acetic acid or piperidine.
This result agreed with a 1,2,4-triazolo[4,3-b]-1,2,4-triazine type of fusion
(eg.61a), which was known to be unable to undergo Dimroth rearrange-
ment  and not with the 1,2,4-[3,4-c]-1,2,4-triazine type fusion (eg.57a)which
undergoes facile rearrangement to yield thermodynamically
Fig.8 (R = R1 = CH3)
Fig.11(R=CH3,  R1=Ph)
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more stable 1,2,4-triazino[5,1-c]-1,2,4-triazine type compound 58a139,140. It
was evident that  the enhanced nucleophilicity of N2 of triazine ring together
with steric interruption by N5 substituted methyl group in 55 operated syn-
ergistically toward the regiospecific formation of sterically prefered linearly
annulated regioisomer 61a(Fig.3).
Cyclization of 55 with a methine moiety has been made under neutral condi-
tions by heating with ethyl formate(ii) or triethylorthoformate(iii) as well as under
acidic conditions by the heating with formic acid(iv) or oxalic acid(v).  The inter-
mediate obtained with ethyl formate showed NH and CONH IR absorption and
a formyl hydrazino and a hydrazido 1H NMR proton signals . This data along with
elemental analysis indicated that the intermediate is the formayl hydrazino de-
rivative 56b(scheme 8). Fusion of 56b (vi) caused its dehydrocyclization to a
single product which was assigned the linearly annulated tetracyclic structure
61b rather than angularly annulated 57b on the following bases: (a) direct UV
spectral comparison with an unequivocally prepared sample obtained by
cyclocondansation between 1-methylisatin(59) and 3,4-diamino-5-methyl-1,2,4-
triazole(60b)135. (b)resistance of the obtained product to undergo acid, base or
thermaly induced Dimroth rearrangement to 58b. (c) proton of triazole ring
showed 1H NMR absorption in down field region at chemical shift value of 9.53
äppm which is closer to those ( ä  = 9.15-9.30) for the more deshielded proton of
linearly annulated 1,2,4-triazolo[4,3-b]-1,2,4-triazines(61b) than proton of angu-
larly cyclized 1,2,4-triazolo-[3,4-c]-1,2,4-triazines(57b)139,141(Scheme-8).
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Condensation of 55 with aromatic aldehydes(62c-h) gave the correspond-
ing 3-arylidenehydrazino-1,2-4-triazinoindoles(63c-h)(scheme-9). Oxidative
cyclization of 63c-h was accomplished by heating with 10% ethanolic
iron(III)chloride, thionyl chloride or 30% aqueous sodium hypochloride so-
lution in dioxane. All the three reagents produced same cyclic product from
a perticular hydrazone, which was again assigned to be linear structure(61)
and not  the angular regioisomeric structure (57) on the basis of the
afforementioned steric and electronic parameters and corroborated by their
failure to undergo acid,base or thermally induced Dimroth rearrangement.
Compound 61c was also prepared through the benzoylation of 55 with ben-
zoyl chloride followed by the acid catalysed dehydrocyclization of the
benzoylhydrazide intermediate (56c)(scheme 9).
React ion o f  55 wi th  pheny l  isocyanate a t  100 oC af forded the
phenylsemicarbazide 64a(Scheme 10). Heating 64a above its melting point
gave only one product to which the 10-methyl-3-oxo-1,2,4-triazolo[4’,3’:2,3]-
1,2,4-triazino[5,6-b]indole(66a)structure was assigned. Formation of 66a
from 64a took place throughout  the elimination of an aniline molecule. Un-
der this thermal cyclization condition, aniline appears to be a better leav-
ing entity than water since the 3-phenylamino derivative 61k has not been
formed. Molecular models showed that, whereas the C3 carbonyl and N10
methyl groups in the linear structure 66a were far apart, the C1 carbonyl
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and N10 methyl groups in the corresponding angular structure were in close
proximity to each other and should suffer mild steric crowding. 1H NMR
spectra of 66a showed an exchangeable one-proton broad signal at ä  =
5.30 ppm indicating that, amide-imidic acid equilibrium142 exist in this com-
pound. Compound 66a was also obtained directly by heating 4 with phenyl
isocyanate, urea or ethyl chloroformate(Scheme 10)
Reaction of 55 with phenyl isothiocyanate gave the phenylthiosemicarbazide 64b
which was thermally cyclized to the 10-methyl-3-thioxo-1,2,4-triazolo [4’,3’:2,3]-
1,2,4-triazino[5,6-b]indole(66b). Compound 66b was also obtained by reacting
55 with phenyl isocyanate, thiourea, phenylthiourea or caron disulfide.
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In continuation with this study, Shaban and Morgaan143 have described that
condensation of aldoses with 5-ethyl-3-hydrazino-1,2,4-triazino[5,6-b]indole
gave the corresponding aldose-5-ethyl-1,2,4-triazino[5,6-b]indol-3-
ylhydrazones which were acetylated to their poly-O-acetyl derivatives. The
later underwent sterically controlled regiospecific oxidative cyclization with
bromine in acetic acid and sodium acetate to sterically favourable linearly
annelated 3-polyacetoxyalkyl-10-ethyl-1,2,4-triazole[40,30:2,3]-1,2,4-
triazino[5,6-b]indoles rather than to their sterically unfavourable angularly
annelated  regioisomers.(Scheme-11)
.
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Oxidative cyclization of the hydrazone acetates 69a-g with bromine in acetic
acid in the presence of anhydrous sodium acetate or one-pot oxidative cyclization
afforded a single crystalline product. These spectroscopic data together with
the elemental analyses of the cyclization products were in agreement both with
the angularly annelated 1-polyacetoxyalkyl-10-ethyl-1,2,4-triazolo[3’,4’:3,4]-1,2,4-
triazino[5,6-b]indole (73) and the linearly annelated 3-polyacetoxyalkyl-10-ethyl-
1,2,4-triazole[4’,3’:2,3]-1,2,4-triazino[5,6-b]indole (74a-g) structure types
(Scheme 11). Formation of 73 or 74 presumably took place via hydrazonoyl
bromide (71) and nitrilimine (72) intermediates144 as a result of nucleophilic
attack of the triazine ring N4 (route a) or N2 (route b) on the nitrilimine carbon.
Previous results on heterocyclization of 5-hydrazino-1,2,4-triazino[5,6-b]indoles
with one-carbon cyclizing reagents indicated that the choice of routes (a5-7,17-19
or b17,131,135-137,23,147-149) depends on electronic factors that enhance the
nucleophilicity of N4 or N2 of the triazine ring 130,16,138-140,150-155. Surprisingly, steric
factors that may dominate electronic factors in determining the regiospecificity
(or regioselectivity) of this cyclization have been disregarded. In contrast,
molecular models and computer optimized geometries predicted that cyclization
of N5-substituted 3-hydrazino-1,2,4-triazino[5,6-b]indoles (e.g. 68) with one-
carbon cyclizing reagents would be sterically controlled to preferably produce
the linearly annelated 3,10-disubstituted regioisomer (e.g. 74) rather than the
angularly annelated 1,10-disubstitutesd regioisomer (e.g. 73). The angular
structure (e.g. 73a) suffers crowding of the C1 and N10 substituents (Fig. 12).
Entry 3 shows the adverse steric interaction between the ethyl group and
the alditolyl chain even when the methyl portion of the ethyl group is directed
away from the alditolyl chain. Entry 4 shows, on the other hand, that the
linear structure (e.g. 74a) is free of such adverse steric interactions. This
argument is taken to favor the assignment of the linearly annelated structure
(74) to the cyclization products which also concords with electronic factors
favoring cyclization at the more nucleophilic N2 of the 1,2,4-triazine ring
rather than at the less nucleophilic N4 
138-140,149-154. Evidently, both electronic
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steric factors operated synergistically towards the regiospecific production
of the linear isomer (74). Experimental evidences in favour of the linear
structure 74 were discussed as per described in previous part of this study.
Fortunately however, crystals of 10-ethyl-3-(4-methoxyphenyl)-1,2-4-
triazolo[40,30:2,3]-1,2,4-triazino[5,6-b]indole (77), prepared by a similar
oxidative cyclization of the corresponding hydrazone156 were found
amenable for X-ray analysis and shown to possess the linear and not  the
angular skeleton157. This X-ray analysis result may reasonably be extended
to confirm the assigned linear structure 74.
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  Fig-12. Computer optimized geometries of angularly annelated 73a (1-3) and its
linearly annelated regioisomer 74a (4)
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Rajur S.B. et al158 have synthesized ten new 4,8-disubstituted 10-methyl-
1,2-dihydro-1-oxo-1,2,4-triazino(4,5-a)indoles by refluxing various 5-sub-
s t i tu ted indo le-2-carbohydraz ides wi th  t r ie thy lor thoformate or
triethylorthoacetate in dimethylformamide. These derivatives were evalu-
ated for their antimicrobial activity. Some of the title compounds possess
fairly potent antimicrobial activity (Scheme-12).
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A.Dandia et al159  have synthesized tetracyclic ring systems viz. 2-methyl-1-
oxo-11H-1,2,4-triazino [32 ,42 :3,4] [1,2,4] triazino [5,6-b] indole  and 3-me-
thyl-4-oxo11H-1,2,4-triazino [42 ,32 :2,3] [1,2,4] triazino [5,6-b] indole  by the
cyclization of 2-oxo-propionic acid [5H-1,2,4-triazino] [5,6-b] indole-3-yl
hydroazone. Cyclization of  7-fluoro- as well as 8-fluoro -2-oxo-propionic acid
[5H-1,2,4-triazino] [5,6-b] indole-3-yl hydroazone  afforded the angular prod-
uct exclusively, while cyclization of defloro and 9-CF3 substitution gave a mix-
ture of angular  and linear products  in the ratio 3 : 1 (Scheme-13).
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N.Rashed et al149 have suggested that reaction of 3-phenyl-10H-1,2,4-
triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indole  with ethyl chloroacetate gave
10-carbethoxymethyl-3-phenyl-1,2,4-triazolo[4',3':2,3][1,2,4]triazino[ 5,6-
b]indole. Condensation of the later  with hydrazine hydrate gave (3-phenyl-
1,2,4-triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indol-10-yl)a cetylhydrazine.
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Reactions  with a number of aromatic aldehydes, acetophenone & D-galactose
gave the corresponding hydrazones, while condensation with acetylacetone
gave the pyrazole .  Cycl izat ion with CS2 gave (3-phenyl-1,2,4-
triazolo[4',3':2,3][1,2,4] triazino[5,6-b]indol- 10-yl)(2-thiol-1,3,4-oxadiazol-5-
yl)methane, while reaction with ethyl chloroacetate gave the carbethoxy
alkylated derivative (3-phenyl-1,2,4-triazolo[4',3':2,3][1,2,4]triazino[5,6-b]indol-
10-yl)[2-(thiocarbethoxymethyl)1,3,4-oxadiazol-5-yl]methane (Scheme-14).
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Current Work
The importance of the indole nucleus is well established in pharmaceutical
chemistry.  Azoles and azines are well known for their diversed biological
activities. It is also known that fusion of the heterocyclic nuclei enhances
the pharmacological activities more than its parent nucleus.
On the other hand, as described in the chemistry part, cyclization of the N5
unsubstituted 1,2,4triazino[5,6-b]indol-3-hydrazine derivatives  with one car-
bon cyclizing reagents would only be electronically controlled and might, ac-
cordingly, lead to angularly annulated 1,2,4-triazolo[3’,4’:3,4]-1,2,4-
triazino[5,6-b]indoles or it’s linearly cyclized 1,2,4-triazolo[4’,3’:2,3]-1,2,4-
triazino[5,6-b]indole derivatives  depending on factors affecting the compara-
tive nucleophilicities of N2 or N4 of the 1,2,4-triazine ring. In order to study the
mode of cyclization of 1,2,4triazino[5,6-b]indol-3-hydrazine derivatives based
on only on electronic factors, by affecting the comparative nucleophilicities
of N2 or N4 of the 1,2,4-triazine ring, we have synthesized a series of angu-
larly annulated 1,2,4-triazolo[3’,4’:3,4]-1,2,4-triazino[5,6-b]indole derivatives
afforded by electronically controlled cyclization of N5 unsubstituted
1,2,4triazino[5,6-b]indol-3-hydrazine derivatives by using thionyl chloride as
cyclizing agent. All the synthesized compounds were well characterized by
spectroscopic data and elemental analysis revealed to agree with the cy-
clization of the N5 unsubstituted 1,2,4triazino[5,6-b]indol-3-hydrazine deriva-
tives  with one carbon cyclizing reagents would only be electronically con-
trolled and because of annulation with thionyl chloride forced toN5 compara-
tively become more nucleophilic, resulting into angularly cyclized 1,2,4-
triazolo[3’,4’:3,4]-1,2,4-triazino[5,6-b]indoles.In addition to this the angular
cyclization of the synthesized compounds were also confirmed by it’s char-
acteristic  to undergo facile acid or base catalysed or thermally induced
Dimroth rearrangement to convert into thermally stable rearranged  1,2,4-
triazino[5,1-c]-1,2,4-triazine type product.
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The reaction scheme involves four steps for the synthesis of 1-substituted
phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole in which first
step deals with the condensation between isatin and thiosemicarbazide in
the presence of potassium carbonate & water as solvent to yield 2,5-
dihydro-3H-[1,2,4]tr iazino[5,6-b ] indole-3-thione, which underwent
hydrazinolysis  in second step, to afford as-triazino[5,6-b]indol-3-yl-hydra-
zine. In the third step different substituted aromatic aldehydes were con-
densed with 3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole to give corresponding
hydrazones.
Cyclization of the above hydrazones using thionyl chloride affored angular
cyclization to give 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]
triazino[5,6-b]indole, which were finally characterized by FT-IR, NMR and
Mass spectral data.
The appearance of a base peak at m/z 346 in the mass spectrum of com-
pound is consistant with its molecular formula C18 H14 N6 O2. The appear-
ance of an intense molecular ion peak also indicates the aromatic nature
of this angularly fused Triazolotriazinoindole.
The molecular ion, in this case, underwent fragmentation with lose of  C7 H3
N  (m/z 102) which could be attributed to the benzonitrile diradical obtained
by the initial fragmentation of the triazole ring and nitrogen molecule to
give an ion at m/z 173. An ion at m/z 128 is obtained by the loss of  nitro-
gen molecule and HCN. However, products obtained by cycliztion using
bromine in acetic acid are found different and characterized as linearly
cyclized compounds.
The newly synthesized compounds were screened for antitubercular, antimi-
crobial, anti HIV, antiinflammatory, anticancer and antihypertensive activi-
ties
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REACTION SCHEME
  Ä
N
H
O
O +
NH2 NH
NH2
S
 (i) K2CO3 , H2O
Reflux with Stirring, 24 Hrs
N
H
N NH
N
S
NH2 NH2
   . OH2 , - H2S
N
H
N N
N
NH NH2
N
H
N N
N
NH N
OHC
R
R
(ii) H+ / Glacial CH3COOH 
+
Glacial CH3COOH  
(catalytic amount)
S O
Cl
Cl
N
H
N N
N N
N
R
1H-indole-2,3-dione Hydrazine carbothioamide
2,5-dihydro-3H-[1,2,4]
triazino [5,6-b]indole-3-thione
3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole(Un)substitutedbenzaldehyde
 5H-[1,2,4]triazino[5,6-b]indol-3- arylhydrazones
1-(un)sub.phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indoles
R = Different electron donating or 
 electron withdrawing groups
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Experimental Protocols
All the starting materials, Isatin, thiosemicarbazide, hydrazine and sub-
st i tuted aromatic aldehydes were obtained from the commercial
sources. Melting points of the synthesized compounds were recorded
by open capillary method  on controlled temperature using standard
Zeal’s thermometer and are uncorrected.  The commencement of the
reaction and purity of the synthesized compounds  were ensured using
thin layer chromatography (TLC) silica gel-G, used as stationary phase,
the TLC plates were purchased from Merck India Ltd. Ethyl acetate:
Hexane  was used as the mobile phase. However, other solvent systems
like acetone :benzene and chloroform:methanol were also employed but
the best results observed with ethyl acetate:hexane system.
3-Hydrazino-as-triazino[5,6-b]indoles were used for the synthesis of
linearly fused triazinoindoles, however treatment with nitrous acid was
reported to yield angularly fused triazolotriazinoindoles. The present
invest igat ion deals  wi th  cyc l isat ion of  as- t r iaz ino[5,6-b] indoly l
hydrazones in the presence of thionyl chloride  to  afford angularly fused
triazolotriazinoindoles.
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Experimental
Synthesis of 2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione:
The appropriate isatin (0.1mole), thiosemicarbazidde (0.11mole), potassium
carbonate(0.15mole) and distilled water (500ml) were stirred and refluxed
for 7-10hrs. On cooling, the mixture was filtered and acidified with acetic
acid. The solid was filtered off, washed with water and dried. Recrystallized
from dimethylformamide. Yield 78%, m.p. >300oC(Reported m.p. >300oC24).
Purity was checked  by TLC using ethylacetate:hexane(4:6) as mobile phase.
Synthesis of 3-hydrazino-5H-[1,2,4]triazino[5,6-b]indole :
2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione (0.01mole) was re-
fluxed with 99% Hydrazine hydrate (15ml) for 4 hrs. On cooling, crystals
seperated which were filtered washed with ethanol to afford 1.4gms (71%)
Yield. Recrystallized from dimethylformamide. Yield 60% m.p. 275-
278oC(Reported m.p. >276-277oC122). Purity was checked  by TLC using
ethyl acetate:hexane (4:6) as mobile phase.
Synthesis of 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4] triazino
[5,6-b]indole(General Method):
A mixture of substituted benzaldehyde (0.01mole) and  3-hydrazino-5H-
[1,2,4]triazino[5,6-b]indole (0.01mole) with catalytic amount of glacial acetic acid
were refluxed  in ethanol, on cooling it gives crystals of corresponding aryl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl-hydrazone in good yield(70-80%), which were
purified by recrystallization from dimethylsulfoxide. Purity of each compound was
checked by TLC using ethylacetate:hexane (5:5)as mobile phase. A mixture of
appropriate hydrazone (0.3gms) and thionyl chloride (10ml) was refluxed on water
bath for four hrs. The excess of thionyl chloride was removed by distillation un-
der reduced pressure. The residue was washed with hot petroleum ether and
cooled. The product so obtained was recrystallized from DMSO to yield pow-
dery crystals of title compounds. The purity of each compound was checked by
TLC using Ethyl acetate:Hexane (5:5) as mobile phase.
The elemental analysis of all the compounds performed by PERKIN ELMER
470R are in total agreement with the theoritical values.The physical con-
stants and elemental analysis of all compounds were shown in Table-1.1
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SPECTRAL CHARACTERIZATION
The constitution of newly synthesized compounds were supported by FT -
IR, 1H NMR and  EI-Mass spectral study.
IR Spectral Study
Instrument: SHIMADZU FT-IR 8400 Spectrophotometer
Sample technique: KBr pellet
Frequency range: 400-4000 cm-1
 The 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-
b]indoles (KUITT Series) indicates the presence of very specific func-
tional groups like 2oamino group of indole skeleton, azo group of triazine
residue, C=N vibration of triazole ring, aromatic ring skeleton etc.,  which
absorb IR radiations of specific frequency and show sharp, medium or
weak intense signals and hence supports in identif iction and confir-
mation of the molecule.
The IR spectrums of 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4]
[1,2,4]triazino[5,6-b]indoles shows common  frequences as 3430-3350cm-
1 for 2oamino group, 3150-3100cm-1 for aromatic C-H str.,1620-1605cm-1
for C=Nstr., N=N(azo)str. merges with aromatic ring skeleton observed be-
tween 1590-1510cm-1 where as aromatic region was observed  extended
upto 1450cm-1. Tertiary N-Cstr. was observed range between 1400-1300cm-
1,while medium intense bands between 1370-1220cm-1 for secondary N-C
str.  mono,di & tri Phenyl substitutions  observed between 970-730cm-1.
While characteristic vibration corresponds to substitution at phenyl resi-
due was clearly observed in each case. The IR spectral data of all com-
pounds of KUITT series were shown in Table-1.2
5 4
 IR Spectrum of 1-(2-chloro)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole (KUITT-6)
   IR Spectrum of 1-(4-fluoro)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole (KUITT-5)
  KUITT-6 KUITT-5
N
H
N N
N N
N
Cl
N
H
N N
N N
N
F
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HN- .rtsH-N 0143
HC-
citamorA .rtsH-C- 2313
N=C- .rtsN=C 2161
/ozA
citamorA
notelekS
.rts-C=C-/.rts-N=N- 1641,2151,8851
noitutitsbusid2:1 537
3o C-N .rtsC-N- 3031
2o C-N .rtsC-N- 8321
negolaH .rtslC-C- 657
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HN- .rtsH-N 0143
HC-
citamorA .rtsH-C- 2313
N=C- .rtsN=C 2161
/ozA
citamorA
notelekS
.rts-C=C-/.rts-N=N- 1641,2151,8851
noitutitsbusid2:1 537
3o C-N .rtsC-N- 3031
2o C-N .rtsC-N- 8321
negolaH .rtslC-C- 657
5 5
IR Spectrum of 1-(2,5-dimethoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole
   (KUITT-13)
 IR Spectrum of 1-(2-methoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indoleKUITT-15)
  KUITT-13 KUITT-15
N
H
N N
N N
N
OCH3
H3CO
N
H
N N
N N
N
OCH3
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HN- .rtsH-N 4343
HC-
citamorA .rtsH-C- 8213
N=C- .rtsN=C 0261
/ozA
citamorA
notelekS
.rts-C=C-/.rts-N=N- 0541,0941,2551
noitutitsbusirt5:2:1 498
3o C-N .rtsC-N- 0041
2o C-N .rtsC-N- 1721
HCO- 3 .rtsC-O-C-,rtsH-C- 8121,9382
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HN- .rtsH-N 3243
HC-
citamorA .rtsH-C- 4213
N=C- .rtsN=C 6161
/ozA
citamorA
notelekS
.rts-C=C-/.rts-N=N- 3841,0551,7851
noitutitsbusid2:1 537
3o C-N .rtsC-N- 0041
2o C-N .rtsC-N- 3521
HCO- 3 .rts-C-O-C-,.rtsH-C- 7121,4792
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1H NMR Spectral Study
1H NMR Spectrums of the 1-substituted phenyl-10H-[1,2,4]triazolo
[3',4':3,4][1,2,4]triazino[5,6-b]indoles show  signals relevant to the number
of protons and their  electronic environment known as chemical shift.
Chemical  shi f t  may move to e i ther upf ie ld (Shield ing) or  down
field(deshielding), according to the  electronic environment of the corre-
sponding proton.  In addition  to  this, each 1H NMR signal  further splitted  into
number of subpeaks  according  to  the  number of neighbouring  protons present
in the skeleton of molecule. The splitting of the NMR signal further provides sig-
nification about the degree of  interaction  between  neighbouring  protons by means
of spin-spin coupling constant  J.
Instrument : BRUKER AC 300MHz FT-NMR
Internal Reference : TMS Solvent : CDCl3  or DMSO d6
1-(3,4-Dimethoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino
[5,6-b]indole(KUITT-1)
1H NMR Spectrum of KUITT-1 shows two singlets, each relevant to three
protons of two methoxy substituents occupied at 3,4-position of phenyl resi-
due  at chemical shift  δ 3.88  and δ 3.92 respectively. While a singlet for
the proton of an amine group appears at δ  12.28. Protons H(c), H(b) & H(a) of
the phenyl residue shows a singlet at δ 7.995 , a doublet  at δ 7.219 with J
value of 8.4Hz and a doublet at δ 8.084 with J value of 6Hz respectively,
which reveals that H(b) & H(a) are in ortho position to each other where as
H(a) & H(c) are relatively in meta position.. Protons H(5) , H(6), H(7) & H(8) of the
benzenoid part shows a doublet at δ 8.229 with J value 7.5Hz, a triplet at δ
7.37 with J value of 7.8 & 7.2Hz, a triplet at δ 7.74 with J value of 7.2 &
7.2Hz and a doublet at δ 7.461 with J value 8.1Hz respectively, which re-
veals that H(5) & H(6) , H(6) & H(7) and H(7) & H(8)  are in ortho position to each
other, while H(5) & H(7) and H(6) & H(8) are relatively in meta position.
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1-(4-Methoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-
b]indole(KUITT-2)
1H NMR Spectrum of KUITT-2 shows a singlet relevant to  three protons of
a methoxy substituent at chemical shift value δ 3.9 ppm. A singlet due to
secondary amine proton appears at δ13.04. Phenyl residue substituted at
triazole ring possess two pair of chemically equivalent but magnetically non-
euivalent protons viz. H(d) & H(e) appear as two doublet at δ 8.389 with J
value of 9Hz and 7.248δ ppm with J value of 8.7Hz respectively. Protons
H(5) , H(6), H(7) & H(8) of the benzenoid part shows a doublet at δ 8.337 with J
value 7.8Hz, a triplet at δ 7.464 with J value of 7.5 & 7.5Hz, a triplet at δ
7.827with J value of 7.5 & 8.1Hz and a doublet at δ 7.584δ with J value
8.1Hz respectively, which reveals that H(5) & H(6) , H(6) & H(7) and H(7) & H(8)
are in ortho position to each other, while H(5) & H(7) and H(6) & H(8) are rela-
tively in meta position.
1-phenyl-10H-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-b]indole
(KUITT-10)
1H NMR Spectrum of KUITT-10 shows a singlet the proton of an amine group
appears at δ13.03. Phenyl residue substituted at triazole ring possess five
protons among which proton H(b) & H(c) signals with integration value of three
protons, were merge due to close electronic environment, hence appears
as multiplet at δ 7.677, while H(a) shows a doublet at δ 8.436 with J value of
6.6Hz. Protons H(5), H(6),H(7) & H(8) of the benzenoid part shows a doublet at
δ 8.348 with J value 7.8Hz, a triplet at δ 7.454 ppm with J value of 7.5 &
7.5Hz, a triplet at δ7.823 with J value of 7.5 & 7.8Hz and a doublet at δ
7.583  with J value 7.8Hz respectively, which reveals that H(5) & H(6) , H(6) &
H(7) and H(7) & H(8)  are in ortho position to each other, while H(5) & H(7) and
H(6) & H(8) are relatively in meta position.
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1H NMR Spectrum of 1-(3,4-dimethoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4]
[1,2,4]triazino[5,6-b]indole (KUITT-1)
H(5)
H(8)
(7)H
N
H
N N
N N
N
OCH3(2)
(1)H3CO
H(6)
H(c)H(a)
H(b)
                      KUITT-1
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HCO- )1(3 23.3 3 s -
HCO- )2(3 9.3 3 s -
HN- 82.21 1 s -
H-rA )c( 599.7 1 s -
H-rA )a( 480.8 1 d 6
H-rA )b( 912.7 1 d 4.8
H-rA )6( 73.7 1 t 2.7&8.7
H-rA )8( 164.7 1 d 1.8
H-rA )7( 47.7 1 t 2.7&2.7
H-rA )5( 922.8 1 d 5.7
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1H NMR Spectrum of 1-(4-Methoxy)phenyl-10H-[1,2,4]triazolo[3',4':3,4]
[1,2,4]triazino[5,6-b]indole (KUITT-2)
H(5)
H(8)
(7)H
N
H
N N
N N
N
H(e)
H3CO
H(6)
H(d)H(d)
H(e)
                      KUITT-2
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HCO- 3 9.3 3 - -
HN- 40.31 1 s -
H-rA )d( 983.8 2 d 9
H-rA )e( 842.7 2 d 7.8
H-rA )6( 464.7 1 t 5.7&5.7
H-rA )8( 485.7 1 d 1.8
H-rA )7( 728.7 1 t 1.8&5.7
H-rA )5( 733.8 1 d 8.7
6 2
1H NMR Spectrum of 1-Phenyl-10H-[1,2,4]triazolo[3',4':3,4] [1,2,4]triazino[5,6-
b]indole (KUITT-10)
H(5)
H(8)
(7)H
N
H
N N
N N
N
H(b)
H(c)
H(6)
H(a)H(a)
H(b)
                      KUITT-10
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HN- 30.31 1 s -
H-rA )a( 634.8 2 d 6.6
H-rA )c,b( 776.7 3 m -
H-rA )6( 454.7 1 t 5.7&5.7
H-rA )8( 385.7 1 d 8.7
H-rA )7( 328.7 1 t 8.7&5.7
H-rA )5( 843.8 1 d 8.7
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El Mass Spectral Study.
Instrument: SHIMADZU GCMS-QP-2010
Sample technique: Direct injection probe
m/z range: 40-400
EI Mass spetrums of 1-substituted phenyl-10H-[1,2,4]triazolo[3',4':3,4]
[1,2,4]triazino[5,6-b]indoles become the most important  tool to character-
ize the structure of the molecule as the signals correspond to m/z value of
the relevant fragments suggest very important structural feature like mode
of cyclization and aromatic nature of the molecule. which lead this analyti-
cal technique advantageous over NMR, IR and UV spectroscopy in this
perticular case.
1-(3 ,4-dimethoxy)phenyl -10H-[1 ,2 ,4] t r iazolo[3 ’ ,4 ’ :3 ,4] [1 ,2 ,4]
triazino[5,6-b]indole(KUITT-1)
In the EI Mass spectrum of 1-(3,4-dimethoxy)phenyl-10H-[1,2,4]triazolo
[3’,4’:3,4][1,2,4] triazino[5,6-b]indole, the appearance of an intense Mo-
lecular Ion Peak  at m/z 346, aromatic nature of the triazolotriazinoindole
fused system, a signal at m/z value 101relevent to benzonitrile suggest the
loss of benzonitrile fragment exhibits foolproof evidence of angular cycliza-
tion. More over, an ion corresponds to m/z 331 suggest loss of methyl group
from the molecular ion, subsequently ions relevant to m/z 304, m/z 174, m/
z 126 were also detected.
1-(4-methoxy)phenyl-10H-[1,2,4]triazolo[3’,4’:3,4][1,2,4] triazino[5,6-
b]indole(KUITT-2)
In the EI Mass spectrum of 1-(4-methoxy)phenyl-10H-[1,2,4]triazolo
[3’,4’:3,4][1,2,4] triazino[5,6-b]indole, the appearance of an intense Mo-
lecular Ion Peak  at m/z 316, aromatic nature of the triazolotriazinoindole
fused system, a signal at m/z value 101 relevent to benzonitrile suggest the
loss of benzonitrile fragment exhibits foolproof evidence of angular cycliza-
tion. More over, an ion corresponds to m/z 301 suggest loss of methyl group
from the molecular ion, subsequently ions relevant to m/z 273, m/z 158, m/
z 128 were also detected.
6 4
1-(4-methyl)phenyl-10H-[1,2,4]triazolo[3’,4’:3,4][1,2,4] triazino[5,6-
b]indole(KUITT-21)
In the EI Mass spectrum of 1-(3,4-dimethoxy)phenyl-10H-[1,2,4]triazolo
[3’,4’:3,4][1,2,4] triazino[5,6-b]indole, the appearance of an intense Mo-
lecular Ion Peak  at m/z 300, aromatic nature of the triazolotriazinoindole
fused system, a signal at m/z value 101relevent to benzonitrile suggest the
loss of benzonitrile fragment exhibits foolproof evidence of angular cycliza-
tion. More over, ions relevant to m/z 271, m/z 155, m/z 128, m/z 118 were
also detected.
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     Synthesis and Characterization of Some
  4-Hydroxy-3-(2(un)substituted phenyl-2,3-dihydro
-1,4-benzothiazepine-4-yl)-2H-chromen-2-ones
CHAPTER-2
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Introduction
1,5-Benzothiazepine refered as benzo  fused seven membered heterocylic
ring with two hetero atoms viz. sulphur and nitrogen occupied by 1and 5
position of  the seven membered cyclic system. 1,5-benzothiazepine is one
of three possible benzo condensed derivatives, viz. 1,4-, 4,1- and 1,5-benzo
thiazepines of the 1,4-thiazepine1. The parent  1,5-benzothiazepine itself
has not hitherto been described in the literature. However, its derivatives
are the most  frequently studied-benzothiazepines. This may be due to their
easy accesibility and wide range of  therapeutic activities like cardiovas-
cular2, vasodilator3,4 and antiarrythmic5. Actions of some 2,3-dihydro-1,5-
benzothiazepin-4(5H)-ones have already been published in the early sev-
enties. Later on haemodynamic effects6, antiulcer activity7,8, calcium an-
tagonistic and spasmolytic activities9-13, angiotensine converting enzyme
inhibition14,15 etc have been described as their major activities. More over
antihypertensive drugs with 1,5-benzothiazepine active ingredients have
already been marketed. Thus, the 1,5-benzothiazepines are useful com-
pounds in the drug research which stimulated the invention of various syn-
thetic procedures for their preparation and chemical transformations16.
1. A. Levai. Trends Heterocyclic Chem., 4, 51(1995)
2. M.Sato, T.Nagao, I. Yamaguchi, H. Nakajima,  A. Kiyomoto, Arzneim-Forsch (Drug
Res.), 21, 1338(1971)
3. T.Nagao, H. Nakajima,  A. Kiyomoto, Japan J. Pharmacol., 22, 1(1972)
4. T.Nagao, M.Sato, H. Nakajima,  A. Kiyomoto, Chem. Pharm. Bull., 21, 92(1973)
5. K.Yamada, T. Shimamura, H.Nakajima, Japan J. Pharmacol., 23, 321(1973)
6. R.Kusukawa, M.Kinoshita, Y.Shimono, G.Tomonaga, T.Hoshino, Arzneim-Forsch (Drug
Res.), 27, 878(1977)
7. H.Yamamoto, H.Asai, Chem. Pharm. Bull., 34, 3844(1986)
8. T.Asano, T.Okumura, K.Hirano, T.Adachi, M.Sugiura, Chem. Pharm. Bull., 34,
4238(1986)
9. M.J.Kendall, J.V.Okopski, J. Clin. Hospital Pharm., 11, 159(1986)
10. H.Narita, S.Murata, H.Yabana, K.Kikkawa, Y.Sugawara, Y.Akimoto, T.Nagao, Arzneim-
Forsch (Drug Res.), 38, 515(1988)
11. S.Murata, H.Yabana, K.Kikkawa, Y.Sugawara, Y.Akimoto, T.Nagao, Arzneim-Forsch
(Drug Res.), 38, 521(1988)
12. S.Murata, K.Kikkawa, T.Nagao, Arzneim-Forsch (Drug Res.), 38, 526(1988)
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The importance of the 1,5-benzothiazepine nucleus has been well proved
and illustrated by large number of patents filed, as chemotherapeutic
agents. A  number of  therapeutic activities have been associated with it,
such as antihypertensive17,18, antiasthmatic18,19, analgesic20, cardio vascu-
lar21, platelet aggregation inhibitor and calcium channel antagonists18
Ahmed et al22,23 patented 1,5-benzothiazepine derivatives as potential an-
ticancer drugs.
13. H.Narita, M.Gaino, T.Suzuki, H.Kurosawa, H.inoue, T.Nagao, Chem. Pharm. Bull.,
38, 407(1990)
14. Y.Inada, K.Itoh, K.Kamiya, H. Sugihara,  K. Nishikawa, Japan J. Pharmacol., 47,
135(1988)
15. K.Itoh, M.Kori, Y.Inada, K. Nishikawa, Y.Kawamatsu, H.Sugihara, Chem. Pharm.
Bull., 34, 1128, 2078, 3747(1986)
16. A. Levai. J. Heterocyclic Chem., 37, 199(1999)
17.H.Salim,R. Abdul, S. Mohamed, G. Dahab,  J. Appl. Toxicol.,13(2), 85(1993); Chem.
abstr.,118, 204993(1993).
18. A.Lochead, J. Muller, C.Hoornaert, C.Denys, Eur. Pat. Appl. EP320,362 (ClA61 K31/
55)(1989), FR Appl 87/17044,13(1987); Chem Abstr.,112, 172330(1990).
19.H.Ben, S.Ruben, S. Melissa, M. Kenneth, Life Sci.,51(26)  2049 (1992); Chem. Abstr.
,118, 52185(1993).
20.H.Miranda, T. Pelissier, F. Sierralta, Gen.Pharmacol.,24(1), 201 (1993); Chem. Abstr.
,118, 22558(1993).
21. Y.Hiroki, F. Koichi, S. Yasuo, K. Takuro, K.Hiroyuki, N. Hiroshi, Eur. Pat. Appl. EP
353,032 (ClCO7D281/10)(1990), JP Appl.88/185097,67((1988)); Chem. Abstr.,114,
122434(1991).
22.N. Ahmed, Can. Pat. Appl. CA 2030159 (Cl.A61k31/55) (1991); US Appl. 441 083,
43((1989)).
23. N.Ahmed,  Eur. Pat. Appl. EP430, 036(ClA61k31/55) (1991); US Appl. 440121, 7(1989);
Chem. Abstr., 116, 717(1992).
1,5-Benzothiazepine derivatives are of particular interest for lead discov-
ery because they have been shown to have activity against different fami-
lies of targets24. The 1,5-Benzothiazepine scaffold has been used as a
dipeptide mimic not only in protease inhibitors, but also interleukin-1â con-
verting enzyme inhibitors25, elastase26 or angiotensin-converting enzyme
inhibitors27, and as in antagonists of several G-protein coupled receptors
such as cholecystokinin29 receptor or the angiotensin II receptor30, too.
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24.M.George, J.Salvino, R.Labaudinière and T.Herpin,Tetrahedron Letters, 41, 3029 (2000)
25.J.Golec, D.Lauffer, D.Livingston, M.Mullican, P.Nyce, A.Robidoux, M.Wannamaker,
PCT intl Appl. WO 9824804(1998).
26.J.Skiles, R.Sorcek, S.Jacober, C.Miao, P. Mui, D. McNeil, A. Rosenthal, Bioorg. Med.
Chem. Lett. , 3, 773(1993)
27. J.Slade, J.Stanton, D.Ben-David, G.Mazzenga,  J. Med. Chem., 28, 1517(1985)
28. A.Nagel, WO 9401421-A1 (1994).
29.P.Buhlmayer, P.Furet, P. WO 9413651-A1, 23 (1994).
30.F.Michwli, F.Degiorgis, A.Feriani, A.Paio, A.Pozzan, P. Zarantonello, P. Seneci, J.
Comb. Chem., 3, 224(2001)
Pharmacology
1,5-Benzothiazepines are widely used in different therapeutic areas and
therefore an interesting scaffold for De Novo exploration. The 1,5-
Benzothiazepine scaffold is extremely versatile and widely used in a num-
ber of famous drugs. Currently 1,5-Benzothiazepin-2-ones are being clini-
cally used as coronary vasodilators (e.g. Diltiazem), as calcium antago-
nists (e.g.Clentiazem) and as antidepressant (e.g. Thiazesim)30
S
N
OCH3
O
CH2 CH2 N
CH3
CH3
OCOCH3
Diltiazem
S
N
OCH3
O
CH2 CH2 N
CH3
CH3
OCOCH3
Cl
Cletiazem
S
N O
CH2 CH2 N
CH3
CH3
Thiazesim
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Atta-ur-Rahman et al31 have reported that Benzothiazepine derivatives may
act as calcium antagonists32, angiotensin converting enzyme inhibitors33,
anticonvulsant and tranquilizers34, anticancer drugs35,36 and endogenous
natriuretic activities37. The coveted drug diltiazem, for example is being
used as calcium channel blocker38, calcium channel modulator39-43, blood
platelet aggregation inhibitors44, antiarrhythmic45, antithrombotic46,
antianginal47, and antiischemic48 and also for other cardiovascular activities.
The literature survey reviewed that the pharmacological profile of 1,5-
benzothiazepine can classified into following categories.
?Calcium channel antagonist and Vasodilator
? Peripheral and Mitochondrial Benzodiazepine receptor antagonist /
Anti convulsant / CNS depressant
? Antiplatelet aggregation ? Anticancer
 ? Anti-HIV ? Antimicrobial ? Miscellaneous
31.F.Ansari, S. Umbreen, L. Hussain, T. Makhmoor, S.Nawas, M. Lodhi, S.Khan, F.
Shaheen, M.Choudhry, A.Rahman, Chemistry and Biodiversity, 2, 487(2005)
32. M.Chaffman, R.Brogden, Drug , 29, 387(1985)
33. J.Slade, J.Stanton, D.David, G.Mazzenga, J.Med.Chem , 28, 1517(1985)
34. M.Bock, R.Dipardo, B.Evans, K.Rittle, W.Whittner, D.Veber, P.Anderson, R.Freidinger,
J.Med.Chem , 32, 13(1989)
35. K.Nahed, Can. Pat. Appl. CA 2,030,159(1991),Chem. Abstr.,115, 198515f(1991)
36. K.Nahed, Eur. Pat. Appl. EP 430,036(1991), Chem. Abstr.,116, 717c(1992)
37. D.Kantoci, E.Murray, D.Quiggle, W.Wechter, J.Med.Chem , 39, 1196(1996)
38. J.Belusa, V.Hruskova, Z.Haas, Z.Kaminska, F.Picha, J.Dusek, M.Trefulka, V.Kyasilka,
V.Wojnar, Czech. Pat. Appl. CS 274,231(1992),Chem. Abstr.,117, 117,245906w(1992)
39. L.Vaghy, S.Williams, A.Schwartz, Am. J. Cardiol., 9A, 59(1987)
40. K.Bacon, J.Westwick, R.Camp,Biochem. Biophys. Res. Commun.,165, 349(1989)
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? Calcium channel antagonist
Ca+2 channel antagonists are classified into three major chemical classes,
the 1,4-dihydropyridines (Nifedipine), phenylalkylamines(Varapamil) and
1,5-benzothiazepines (Diltiazem). In addition, several unrelated new
chemicals have been identified as Ca+2 channel antagonists. It is widely
accepted that these chemical classes of Ca+2 channel antagonists have
distinct but allosterically interacting binding sites within the á1 subunit of
the L-type Ca+2 channel49. Each class of Ca+2 channel antagonists
suppresses the L-type Ca+2 channel current (ICa(L)) in a distinctive manner,
and has unique tissue selectivity 50-52
49.T.McDonald, S.Pelzer, W.Trautwein, D.Pelzer, Physiol. Rev.,74,365(1994)
50.N.Taira, Am. J. Cardiol.,24B, 59(1987)
51.D.Triggle, J. Cardiovasc.Pharmacol. 18 (Suppl.10) , S1 (1991)
52.M.Spedding, R. Paoletti, Pharmacol. Rev., 44, 363(1992)
53.M.Hagiwara, S. Adachi-Akahane, T. Nagao,J. Pharmacol. Exp. Ther.(1997)
54.J.Kurokawa, S.Adachi-Akahane, T.Nagao, European Journal of Pharmacology, 325,
229(1997)
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Hagiwara et al53 have introduced a novel 1,5-benzothiazepine derivative,
(+)-cis-3- acetyloxy -5- 2- 2- 3,4-dimethoxyphenyl ethyl -methylaminoethyl -
2,3-dihydro-2- 4-methyoxyphenyl -1,5-benzothiazepine-4 5H -one (DTZ323),
In rabbit crude T-tubule membranes, DTZ323 has been shown to produce
complete inhibition of [3H] diltiazembinding with a Hill coefficient close to
unity, indicating competitive inhibition. DTZ323 (Ki= 6.6×10-9 M) was 48
times more potent than diltiazem (Ki= 3.1×10-7 M) and nine times more
potent than clentiazem (Ki= 6.1×10-8 M). Thus, DTZ323 has the highest
affinity for 1,4-dihydropyridine receptors of skeletal muscle membrane of
all the 1,5-benzothiazepine derivatives studied to date.
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Junko Kurokawa et al54 have characterized pharmacological effects of
DTZ323 on membrane currents54  in guinea-pig ventricular  myocytes using
the whole-cell patch-clamp technique. DTZ323 suppressed the L-type Ca+2
channel currents(ICa(L)) more selectively than the T-type Ca
+2 channel and
the Na+ channel currents. DTZ323 inhibited (ICa(L)) in a use- and a voltage-
dependent manner with 24 times higher potency than that of diltiazem. Rate
of recovery of (ICa(L)) from the conditioned block by DTZ323 was faster
compared with diltiazem and verapamil, and was steeply dependent on the
holding potential at resting membrane potential range in ventricular
myocytes (-90mV to -60 mV ). The result suggested that DTZ323 is a
selective Ca+2 channel antagonist, the most potent among the 1,5-
benzothiazepine Ca+2 channel antagonists and that the voltage- and use-
dependent effect of DTZ323 on (ICa(L)) is due to the steep voltage
dependence of the rate of dissociation from the cardiac L-type Ca+2
channels.
55.J. Kurokawa, S.  Adachi-Akahane, T. Nagao, Mol. Pharmacology, 51, 262(1997)
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In addition to this, by using same technique Taku Nagao et al55 have tested
this novel potent 1,5-benzothiazepine derivative (DTZ323) and its
quaternary ammonium derivative (DTZ417) on guinea pig ventricular
myocytes to determine whether 1,5-benzothiazepine Ca+2 channel blocker
approaches its binding domain within the cardiac L-type Ca+2 channel from
inside or outside of the membrane. The extracellular application of DTZ417
suppressed the L-type Ca+2 channel currents(ICa(L)) with an IC50 value of
1.2 ± 0.02 ì M, which was close to the IC50 value of diltiazem (0.63 ± 6
0.01 ì M). The suppression of (ICa(L)) by DTZ417 was voltage and use
dependent but lacked tonic which has allowed to investigate the onset of
the effect on (ICa(L))  by changing the holding potential (HP) from 290 to 250
mV in the presence of DTZ417. DTZ417 did not have significant effects on
(ICa(L)) at an HP of 290 mV. At 250 mV, DTZ417 (50 ì M) applied from the
extracellular side completely suppressed (ICa(L)), whereas it had no effect
from the intracellular side.DTZ323 (1 ì M) also inhibited (ICa(L)) only  from
the extracellular side, without any effects by the intracellular application of
less than or equal to 10ì M. However, a quarternary phenylalkylamine
derivative, D890(0.1 ì M), acted only from the intracellular side. These
results suggest that in contrast to the phenylalkylamine binding site, in
cardiac myocytes, the 1,5-benzothiazepine binding site is accessible from
the extracellular side of the L-type Ca+2 channel.
56.J. Das, D. Floyd, D. Kimball, K. Duff, T. Vu, M. Lago, R.Moquin, V. Lee, J. Gougoutas,
M. Malley, S. Moreland, R. Brittain, A. Hedberg, G. Cucinotta, J. Med. Chem.35,773-
780(1992)
57.K.Schleifer, E.Tot, Pharmaceutical Research, 16(10), 1506(1999)
58.N.Ueyama, S.Wakabayashi, T.Tomiyama,Yakugaku Zasshi,116(2),106(1996)
59.H.Shiga, S.Miyake, M.Ideka, Y.Ito, H.Yanagisawa, H.Koike, Arzneimittel-Forschung/
Drug Research,42(5),617(1992)
60.(a)T.Nagao, M.Sato, H.Nakajima, A.Kiyomoto, Chem.Pharm.Bull., 21, 92(1973)
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M.Takeda, S.Murata, H.Narita, T.Nagao, J.Med.Chem.,34,675(1991)
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Jagbandhu Das et al56 have indentified 3-alkylbenzazepinones as novel
analogues of diltiazem. Structure-activity relationship studies in this series
have led to identification of several analogues as potent calcium channel
blocking agents, both in vitro and in vivo. Analogues containing a 6-
trifluoromethyl substituent (1a and 1b) are the most potent vasorelaxants
in vitro. The oral antihypertensive activity of these compounds is compa-
rable to its 3-acetoxy derivative 1 (X = 6-CF3)  and 8-chlorodiltiazem. The
3-allyl analogue 1c is a more potent antihypertensive agent than 1a, 1b or
8-chlorodiltiazem and has a longer duration of action in vivo. The present
study demonstrated that like the benzothiazepinone (diltiazem) series, both
the absolute and relative stereochemistry of the C3  and C4
(benzazepinone numbering)substituents are important to calcium channel
blocking activity in the benzazepinone series. The general structure activity
re la t ionsh ip  e l ic i ted that   in  the ana logous ser ies  o f  3-
acetoxybenzazepinones, the 6-trifluoromethyl substituent appears to be
important to maximal potency in vitro and antihypertensive activity.These
studies have resulted in the identification of some of the most potent
benzazepinone/benzothiazepinone calcium channel blocking agents
reported to date.
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Schleifer and Tot57 have attempted molecular modeling study of diltiazem
mimics at L-type calcium channels, to generate a pharmacophore model
for chemically diverse structures that specifically interact with the diltiazem
binding site of L-type calcium channels by using molecular mechanics and
quantum chemical methods solvation energies, logP values, conformational
and electronic features of classical 1,5-benzothiazepine-4(5H)one (BTZ,
e.g.,dilt iazem),1-benzazepin-2-one(BZ),pyrrolo[2,1- d][1,5] benzo-
thiazepine, pyrrolo[2,1-c][1,4]benzothiazine & benzobicyclo[2.2.2]octyl
amines derivatives were determined. Furthermore, the molecular electro-
static potentials (MEPs) and common interaction fields derived from use
of the GRID programme were compared. A  pharmacophore model with
three crucial pharmacophoric characteristics, identified with (1) two aro-
matic ring systems in a distance of about 6.7 A, (2) a basic side chain with
pK(a) in the physiological range, and (3) a 4'-methoxy moiety. In addition,
a strong negative MEP in 4-position (carbonyl oxygen) and hydrophobic
electron-rich features in the position equivalent to the sulphur atom of BTZ
derivatives were explored to be favourable for receptor binding and cal-
cium antagonistic effect. Moreover, the stabilizing effect of substituents in
3-position of BZs on the bioactive ‘M’ twist-boat conformation of the hep-
tagonal ring could be demonstrated by molecular dynamics simulations.
Based on these molecular descriptors, the quinazolinone derivative MCI-
176 is predicted to be a potential ligand of the diltiazem binding site.
Ueyama, N. et al58 have studied a series of 2,3,4,5-tetrahydro-1,5-
benzothiazepine for the intracellular Ca2+ inhibitory effects using methox-
amine- or caffeine-induced contraction of isolated rabbit arteries. Struc-
ture-activity relationship studies of these compounds are discussed and
the resu l ts  suggest  that  nove l  5- [3- [2- (3 ,4-  d imethoxypheny l )
ethyl]aminopropionyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine fumarate
showed the most potent inhibitory action on the intracellular Ca2+ release.
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Shiga, H and coworkers59  have examined in vitro cardiovascular effects
of a new 1,5-benzothiazepine derivative, RS-5773 ((2S,3S)-3-acetoxy-8-
benzyl-2,3-dihydro-5-[2- (dimethylamino) ethyl]-2-(4-methoxyphenyl)-1,5-
benzothiazepine-4-(5H)-one hydrochloride, CAS 129173-57-5), in isolated
rat aorta and isolated guinea pig heart preparations. Like diltiazem or
nifedipine, RS-5773 preferentially relaxed K+-contracted aorta rather than
phenylephrine-contracted aorta, suggesting that the agent interfered with
calcium channels. Vasorelaxant effects of RS-5773 on K+-contracted aorta
was about 5 times more potent than those of diltiazem. The vasorelaxation
with RS-5773 developed very slowly and was resistant to washout. The
negative effects of the agent on contractile force of guinea pig papillary
muscles and beating rate of guinea pig atria were not much different from
those of diltiazem, although the actions of RS-5773 developed more slowly
than those of diltiazem. These results indicated that RS-5773 is a diltiazem
congener with vascular preference and long-lasting actions. In this respect,
RS-5773 resembled clentiazem. But vascular and cardiac effects of RS-
5773 developed more slowly than those of clentiazem and they were more
resistant to washout.
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Nagao T. et al60 described that the structure activity relationships(SAR) of some
40 derivatives of diltiazem made clear the effect of substituents at the position
2,3 and 5 and their stereochemical requirements for the activity60. Prior to this
study, the effect of substitution on the fused benzene ring of diltiazem remain
uncertain since only 7-chloro derivative (2, X=7-Cl, R1=OCH3,  R2=Ac, R3,
R4=Me) has been synthesized
61. In an attempt to improve the effectiveness
and duration of action of diltiazem and to gain further insight into the SAR,
Hirozumi Inoue et al62 have introduced halogen substituents at the position 6-
9(i.e.halogen substituents on the fused benzene ring) of diltiazem. These com-
pounds were evaluated for their effects on vertebral and coronary blood flows
and antihypertensive  activity. The 8-chloro derivative ((+)-2b), the ,most po-
tent compound in this series was selected for clinical evaluation as a cerebral
vasodilating and antihypertensive agent(Table 1).
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Arround 75compoundsof the titled series were tested for their effects on
vertebral blood flow(VBF) in anesthetized dogs and coronary blood
flow(CBF) in isolated guinea pig hearts and their antihypertensive activity
in SHR. The core structure activity relationship of the present study  was
summerized below in correlation with the compounds listed in the table.
Effect on Vertebral Blood flow(VBF).
Introduction of a chloro substituent at the 8-position of diltiazem confers
increased activity with longer duration of action ((+)-2b). The activity of the
7-Cl ((+)-2cc) and 9-Cl((+)-2x) derivatives is comparable to that of diltiazem.
In spite of being racemic modifications, the 6-Cl (2a) and 7,8-Cl2(2aa)
derivatives exhibit moderate activity. The fluoro (2y and 2z) and 8,9-Cl2
(2bb) substitution result in a decrease in activity. Generally, the 3-OH
derivatives are less potent than the corresponding acetoxy derivatives,
except for the 9-Cl and 8,9-Cl2 derivatives (2x vs 3c and 2bb vs 3d).
Duration of the action of the 3-OAc derivatives, however,is usually longer
than that of the 3-OH derivatives.Therefore, when compared, the total
increase in blood flow,which is calculated by multiplying the potency
ratio(maximum increase) by half duration, the 3-OAc derivatives (2x and 2bb)
are more potent than the 3-OH congeners 3c and 3d. The 2,3-trans isomer
of the 8-Cl derivative (2u) and the levorotatory isomers of 2b, 2x and 2cc are
only marginally active. The importance of 2S,3S stereochemistry in this series
of derivatives has already been reported62.
In view of the good activity of the 8-Cl derivative (2b), the effect of modifying
the substituents at the 2, 3, and 5 position was further examined. With regard
to the effect of the length of the 3-acyloxy group on activity, maximum activity
was seen in the acetoxy (2b) and propionyloxy (2d) derivatives. Gradual
decrease in activity was observed with the lower (2c) or higher (2e and
2f)analogues. The methoxy (2l), carbamate, carbonate(2g) and various
benzoyl (2h-k) derivatives exhibit decreased activity. When the dimethylamino
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group in the side chain of 2b is replaced by larger amino groups (2m-t), a
significant decrease in potency is observed. Only the methylallylamino
derivative (2q) exhibits good potency with short duration of action.
Replacement of the 4-Me0 group in the 2-phenyl moiety of 2b with MeS
(2w) and Me (2v) groups results in a considerable decrease in activity.
Effect on Coronary Blood flow(CBF).
The most effective compounds in this test are (+)-2e,(+)-2f, (+)-2x  and (+)-2o.
No clear relationships are observed between the effects on CBF and VBF
Hypotensive Effect in SHR
Some of the compounds showed interesting effects on VBF and CBF were
tested for their hypotensive activity in SHR.The hypotensive activity of the
compounds is roughly parallel with their effect on VBF. Thus, the 3-acyloxy
derivatives ((+)-2b, (+)-2x, (+)-2o), (+)-2c, and (+)-2d with strong increasing
effect on VBFexhibit long-lasting and potent hypotensive action. The most
active compound in this series,(+)-2b, was found to be 3 or 4 times as
potent as diltiazem.The corresponding carbinols ((+)-3a, & (-)-3b  and(+)-
3c) of these o-acyl derivatives exhibit much-reduced activity. Compounds
(+)-2l, 2y, and 2z show good activity in spite of their moderate effect on
VBF. As a consequence of the above SAR, (+)-(2S,3S)-3-acetoxy-8-chloro-
5- [ 2-(dimethylamino)ethyl]-2,3-dihydro-2- (4-methoxyphenyl)-l,5-
benzothiazepin-4(5H)-one((+)-2b) was selected for further study. The
maleate of(+)-2b is currently under clinical trial as a cerebral vasodilating
and antihypertensive agent under the code name of  TA-3090.
63(a). T.Nagao,M. Sato, H.Nakajima, A.Kiyomoto,Chem.Pharm. Bull.,21, 92(1973).
  (b) T.Nagao, M.Sato, H.Nakajima, A.Kiyomoto, Jpn. J. Pharmacol.,22,1(1972)
64.S.Kimoto, M.Haruna, E.Matsuura, O.Uno, M.Ishii, S.Hirono, K.Yoshimura, M.Ueda,
K.Iwaki,J Cardiovasc Pharmacol.,29(2):180(1997)
64a.M.Masui, S.Funakawa, O.Uno, S.Mihara, Y.Takahara, K.Matsunaga, K.Iwaki,J
Cardiovasc Pharmacol.,28(4):526(1996)
65. A.Chimirri, R.Gitto, S.Grasso, A.Monforte & M.Zappalà, Adv. Heterocycl. Chem.  63,61(1995).
66. W.Haefely, A.Kulcsar, H.Mohler, L.Pieri, P.Polc, R.Schaffiner, In Advance in
Biochemical Psychopharmacology, 14, 131(1975)
67. E.Costa, A.Guidotti, Annu. Rev. Pharmacol. Toxicol., 19, 531(1979)
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Iwaki K et al64,64a have studied on a new antihypertensive agent, S-2150, a
benzothiazepine derivative for its hypotensive, antimyocardial-stunning effects
in dogs as well as  antinecrotic and antiarrythmic effects in reperfused rat hearts.
S-2150 (30 mg/kg, p.o.) decreased the blood pressure in conscious renal
hypertensive dogs. Although the maximal hypotensive effect of S-2150 was
observed at 5-9 h after administration, the effect of diltiazem was seen at
2.0 h. Arrhythmia was not observed as a hypotensive effects of S-2150 but
was markedly induced by diltiazem. In anesthetized open-chest dogs, S-
2150 (20 micrograms/kg/min, i.v.) caused by hypotensive effect similar to
that of diltiazem but decreased myocardial work (double product) by much
less than did diltiazem. S-2150 more promptly improved the local myocar-
dial stunning caused by occlusion of the left anterior descending coronary
artery and its reperfusion. This effect did not accompany the energy-spar-
ing action in ischemic/reperfused myocardium, which was different from
the case of diltiazem. Blockage of both Ca2+ channels and alpha 1-
adrenoceptors by S-2150 seems to lead to cardiovascular effects differ-
ent from those of diltiazem.
The effects of S-2150 on ischemia/reperfusion injury revealed that S-2150
reduced the myocardial infarct size (IS) induced by 20-min coronary artery
occlusion followed by reperfusion. The incidence of arrhythmia was blocked
by S-2150, and this effect offered protection against cardiac death.
Prazosin did not modify the IS or incidence of reperfusion arrhythmias, but
combined treatment with a noneffective dose of diltiazem showed signifi-
cant cardioprotective effects.Both drugs decreased mechanical function
and increased coronary flow, with S-2150 being less cardiodepressive and
more vasodilatory. S-2150 is cardioprotective at doses comparable to hy-
potensive doses even though its cardiodepressant effect is much weaker
than that of diltiazem. This effectiveness may be partly explained by its
dual characteristics: blocking the Ca channel and the alpha 1-adrenoceptor.
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? Peripheral / Mitochondrial Benzodiazepine receptor antagonist /
 Anti convulsant / CNS depressant
There were numerous studies directed towards the development of  new
annelated 1,5-benzothiazepine derivatives owing to their remarkable phar-
macological properties on CNS65.
Benzodiazepine interacts with two major classes of recognitions sites, the
“central” and “peripheral” types.
The central benzodiazepine receptors(CBR), located in the neuronal
tissues65a,65b, more specifically on the synaptic membranes65c.
The principal site action of benzodiazepines in the central nervous system
is believed to be a domain that regulates chloride channel gating activated
by ã-aminobutyric acid(GABA) on GABAA receptors
66-68. CBR mediate clas-
sical pharmacological properties like anxiolytic, anticonvulsant, sedative
and muscle relaxant of the clinically widely used benzodiazepine65a.
By contrast, the GABA-independent69,71 peripheral or “mitochondrial” ben-
zodiazepine receptors(MBR) have been identified in a wide range of pe-
ripheral tissues as well as in central nervous system88,89 and their subcellu-
lar location has been reported to be mainly on mitochondrial68a,68b,82,84,
nuclear69,71 and in the plasma membrane87.
Benzodiazepine peripheral type receptors have been identified in nearly
all the mamalian tissues, including heart73-76, endocrine glands73,74,77, kid-
ney71,76 and erythrocytes78,79. In the CNS they are essentially located on glial
cells, mainly astrocytes80,81.
Subcellular  fractionation studies demonstrated that they are principally as-
sociated with the outer mitochondrial membranes 82-84. Hence termed as mi-
tochondrial benzodiazepine receptors or MBR.  Thus the ‘peripheral-type’
benzodiazepine receptor (PBR) is pharmacologically distinct from the cen-
tral-typebenzodiazepine receptor (CBR), and in the last decade has been
the object of extensive studies in order to elucidate its biological and phar-
macological role. This receptor protein, expressed in central and peripheral
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tissues, is located in the outer mitochondrial membrane 83-90. The physiologi-
cal role of MBR is still not clear; they are involved in various cellular
funct ions 68c-68h,  inc lud ing regulat ion of  mytochondr ia l  ox idat ive
phosphorylation68i,68j, inhibition of cell proliferation70, immune response
modulation and most importantly steroidogenesis68k,68l.
They might be useful in the diagnosis of central nervous system tumors
and infact, glial tumors selectively concentrate MBR72.
In rodents, diazepam is rather nonselective, while its 4-chloro derrivative
designated as Ro - 5-4864, shows high affinity for peripheral and very low
affinity for GABAA receptors91,92.
Subsequently other classes of organic compounds were found to have high
affinity and specificity for peripheral benzo diazepine receptors. Some
isoquinolinecarboxamides (e.g.PK 11195) have shown high affinity and
great  selectivity for peripheral receptors73,74,93.
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Among these derivatives, PK11195 was the most widely used specific
probe for peripheral benzodiazepine receptors.
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Fiorini and Greco et al94-95  have proposed Pyrrolobenzothiazepine deriva-
tives  as a new class of ligand specific for mitochondrial  benzodiazepine
receptor. The majority of newly synthesized compounds showed micro or
nanomolar affinity for PK11195 binding inhibition. A structure activity rela-
tionships study on 42 compounds and a molecular modeling approach led
to a preliminary structural selectivity profile: 6,7-double bond, the
carbamoyloxy, alkanoyloxy and mesyloxy side chains at the 7-position and
prospective chloro substitution at the 4-position seemed to be the most
impor tant  s t ruc tura l  features improv ing a f f in i ty.  Therefore ,  7-
[(dimethylcarbamoyl)oxy]- and 7-acetoxy-4-chloro-6-phenylpyrrolo[2,1-
d][1,5]benzothiazepine (4 and 5) were synthesized along with 7-
[(dimethylcarbamoyl)oxy]-6-(p-methoxyphenyl)pyrrolo [2,1-d][1,5]
benzothiazepine(6). These were the most promising compounds with IC50
values of  9,8 and 9 nM respectively, under conditions where PK11195 had
an IC50 of 2 nM.
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In continuation with the previous work,  Alessandro Dalpiaz et al96 reported
the X-ray crystallographic structure of potent (7-13) and two inactive(10
and 11) 7-(acyloxy)-6-arrylpyrrolo[2,1-d][1,5]benzothiazepine derivatives,
as well as binding affinity constants for two newly assayed analogs in which
the acyloxy side chain was replaced by a methoxy group(12) or removed
(13). Structure-affinity relationships and molecular mechanics calculations
performed using crystal structures as references led to a revised 3D
pharmacophore model accounting for all the data available. Interestingly
the hypothetical receptor-bound conformations of 7-9 displayed a consid-
erable degree of similarity with their crystal geometries. Additional calcu-
lations have confirmed that the poor affinities of benzothiazepines bearing
an aroyloxy group (10 and 11) should be ascribed to the steric and/or elec-
tronic features of the side chain aryl moieties rather than unfavorable con-
formational properties.
100. A.Cappelli, M. Anzini, S. Vomero, P.Benedetti, M. Menziani, G. Giorgi, C. Manzoni,
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101.I. Fiorini, V. Nacci, S. Ciani, A. Garofalo, G.Campiani, L. Savini, E. Novellino, G.
Greco, P.Bernasconi, T. Mennini,  J. Med. Chem., 37, 1427(1994).
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Nunzia Cinone and coworkers97 afforded to develop a unique 3D interac-
tion model of endogenous and synthetic peripheral benzodiazepine recep-
tor ligands. Different classes of Peripheral-type Benzodiazepine Receptor
(PBR) ligands were examined and common structural elements were de-
tected and used to develop a rational binding model based on energeti-
cally allowed ligand conformations. Two lipophilic regions and one electro-
static interaction site were suggested as essential features for high affinity
ligand binding, while a further lipophilic region expressed as important for
modulator role. A comparative molecular field analysis, performed over 130
PBR ligands by means of the GRID/GOLPE methodology. The outcome
from the 3D QSAR model and the GRID interaction fields computed on the
putative endogenous PBR ligands DBI (Diazepam Binding Inhibitor) and
TTN (Tetracontatetraneuropeptide) was used to identify the amino acids
most probably involved in PBR binding. Three amino acids, bearing lipo-
philic side chains, were detected in DBI (Phe49, Leu47 and Met46) and in
TTN (Phe33, Leu31 and Met30) as likely residues underlying receptor bind-
ing. Moreover, a qualitative comparison of the molecular electrostatic po-
tentials of DBI, TTN and selected synthetic ligands indicated also similar
electronic properties. Convergent results from the modeling studies of syn-
thetic and endogenous ligands suggest a common binding mode to PBRs.
This may help the rational design of new high affinity PBR ligands.
The compounds studied so far belong to approximately three different
classes of PBR ligands, which are structurally unrelated:
(1) pyrrolobenzothiazepine99, 101,102,104 & pyrrolobenzoxazepine derivatives103,
(2) quinoline and isoquinoline derivatives 100,
(3) pyrrolopyridin-5-one and pyrroloquinolin-1-one derivatives 98.
105.V.Ambrog i ,  G.Grando l in i ,  L .Per io l i ,  L .Gius t i ,  A .Lucacch in i ,  C.Mar t in i  ,
Eur.J.Med.Chem.,30429(1995)
106.V.Ambrogi, A.Giampietri, G.Grandolini, L.Perioli, M.Ricci, L.Tuttobello, Archiv der
Pharmazie.,325(9),569(1992)
107.V. Ambrogi, G.Grandolini, L.Perioli, A.Lucacchini, Ars Pharmaceutica, 33(1-4Part 2),1091(1992)
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Figure-1. Non cross-validated GRID/GOLPE contour plots (lipophilic DRY
probe).  Red contours represent regions of interaction decreasing binding
affinity. Molecules shown to help interpretation are: 15 (pIC50= 5.30); 14
(pIC50=4.00) (contour level –0.13). Green contours represent regions of
interaction enhancing binding affinity. Molecules shown to help interpretation:
18 (pIC50=8.70); 16 (pIC50=8.89); 17 (pIC50=8.77) (contour level 0.12).
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Figure-1 reveals that close to position 1 of the arylpyrrolobenzothiazepine
15, there is no space for substituents, thus the occupation of this space by
even a methyl substituent produces  unfavourable effects on binding. The
amide nitrogen of compound 14 bears a bulky substituent, whose interaction
with the probe is also unfavourable for binding. The green areas in Figure
indicate the regions where lipophilic interactions enhance binding affinity.
In fact, on the amide nitrogen atom of compounds 16, 17 and 18 lipophilic
substituents favour the receptor binding. It is worthy to note that green and
red polyhedra occupy regions where additional lipophilic interactions may
take place. This could be due to the presence of a region of limited
accessibility, where substituents of small size can be accommodated, but
where repulsive interactions can occur as the substituent size increases.
In addit ion, halogen atoms, especial ly the chloro subst i tuent of
arylpyrrolobenzoxazepine (16) and isoquinoline derivatives (18), enhance
the receptor affinity, as demonstrated by the presence of an additional green
region close to it.
In contrast to these, Ambrogi V. et al105, have evaluated imidazo[2,1-
d][1,5]benzothiazepine derivatives for their affinity for the benzodiazepine
receptor and tested their ability to displace [3H]Flunitrazepam from bovine
brain membrane protein. A few of the tested compounds showed good affinity
among which (19) found to be most potential with the dissociation constant
Ki = 0.043ì M with refernce to that of Chlordiazepoxide(Ki = 0.72) as a
standard. The GABA(γ -amino butyric acid) ratio of the active compound
suggested that it could act as an antagonist or an inverse agonist. The binding
results showed the importance of presence of the lipophilic phenyl substituent
at the 2-position on imidazole nucleus and a proton acceptor (nitrogen at 3-
position) in the 5-membered ring and was devoid of proton donor group. As
the similar structural features found with benzodiazepine ligands, these
structural requirment considered to be essential for the Benzodiazepine
receptor antagonist or inverse agonist activities.
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Prior to this the same author have studied annelated[1,5]benzothiazepines viz.
N-2 alkyl amino derivatives of 4,5-dihydro-s-triazolo[3,4-d][1,5] benzothiazepines
and screened for their CNS activity in mice and several of them showed inter-
esting activity106. In addition to this, the tricyclic 1,5-benzothiazepine derivatives
containing tetrazole and triazine nucleus were described107, among which a com-
pound of triazinothiazepine series expressed significant antimicrobial activity
while another compound of tetrazolothiazepine series showed moderate affin-
ity for the benzodiazepine receptor.
De Sarro and coworkers108 have studied  a series of 5H-[1,2,4]oxadiazolo
[5,4-d][1,5]benzothiazepine and screened as anticonvulsant agents in DBA/
2 mice. The 5-(4-bromophenyl)-1,3-diphenyl derivative, the most active com-
pound of  the ser ies was 20 t imes more potent  that  the parent
benzothiazepine and shown an activity comparative to clobazam and bet-
ter than desmethylclobazam.
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108.G.Sarro, A.Chimirri, A.Sarro, R.Gitto, S.Grasso, M.Zappala, M.,Eur. J. Med.Chem.,30
(12),925(1995)
109.V.Nacci, I.Fiorini, S.Vomero, I.Taddei, E. Taddei,Farmaco [Sci].39(4),289(1984)
110.M.Genton, H.Barnett, W. Field, M.Gent, J.Hoak, Stroke.,8,150(1977)
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In 1984, Nacci and Fironi109 have studied 9-chloro-, 9-trifluoromethyl- and
9-methoxy-5- phenylpyrrolo [2,1-d] [1,5] benzothiazepine (20 a-c) and cis-
9-chloro- and cis-9-trifluoromethyl-4,5-dihydro-4-hydroxy-5- phenylpyrrolo
[2,1-d] [1,5] benzothiazepine with the respective acetyl derivatives (21a-d)
as sedative agents and were tested against the anti-amphetamine activity
in the rat. The  pyrrolo [2,1-d] [1,5] benzothiazepine -5-carboxamide showed
sedative activity similar to that of diazepam.
In cont inuat ion wi th  th is ,  6-p-methoxyphenylpyrro lo[2,1-d] [1 ,5]
benzothiazepine derivatives were evaluated for their affinit ies for
Benzodiazepines and GABA receptor subtypes. Under present study 6-
p-Methoxyphenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one (22), cis-7-
a c e t o x y - 6 , 7 - d i h y d r o - 6 - p - m e t h o x y p h e n y l p y r r o l o [ 2 , 1 - d ]
[1 ,5 ]benzoth iazepine (23)  and some s ign i f icant  7-acy loxy-6-p-
methoxyphenylpyrrolo[2,1-d][1,5]benzothiazepines (24 a-g) were
synthesized and tested in vitro  for inhibition of the specific binding of
3H-Flunitrazepam, 3H-PK 11195, 3H-Muscimol and 3H-(-)Baclofen to
central and peripheral benzodiazepine, GABA-A & GABA-B receptors,
respectively. The compounds (22), (24 a) and (24 c) were active on the
peripheral benzodiazepine receptor; in particular (24 a) and (24 c) were
very active. The compound (24 g) showed an affinity, even though scanty,
for the central benzodiazepine receptor109a.
109(a).V. Nacci, I.Fiorini, A.Garofalo, A.Cagnotto, Farmaco., 45(5), 545(1990)
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? 1,5-Benzothiazepine derivatives as Platelet aggregation inhibitors.
 It is generally accepted that platelets play a pivotal role in the progress
and development of thrombotic disorders110-114 especially cerebral vascular
diseases such as transient ischemic attack,115 ischemic heart diseases such
as myocardial infarction,116-118 and peripheral vascular diseases.119 Recently,
the inhibition of platelet functions by drugs is thought to be a useful
therapeutic means for the prophylaxis and treatment of these diseases. For
this purpose, many inhibitors of platelet aggregation such as Acetyl Salicylic
Acid, Sulfinpyrazone, Dipyridamole, and Ticlopidine have been used
clinically.120-129
As discussed earlier, diltiazem, a Ca2+ antagonist of the 1,5-benzothiazepine
structure, has been developed, and its efficacy on angina pectoris,
hypertension, and myocardial infarction has been well established.130 It has
already been reported that diltiazem shows antiplatelet action,131-135 and it
has also been reported that diltiazem,136-137 its derivative clentiazem, and
their basic metabolites138 have inhibitory effects on platelet aggregation.
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Similarly, Akio Odawara et al139 have suggested, TA-993, an l-cis 4',8-
dimethyl derivative of the Ca2+ antagonist diltiazem, and some of its
metabolites inhibited platelet aggregation induced by collagen, ADP,
epinephrine, platelet activating factor, arachidonic acid, and U-46619 in
human platelets in vitro. Among the metabolites, MB3 was the most potent
(IC50 <1 µmol/L; several hundred times more potent than the parent
compound). The d isomer of MB3 was >100 times less potent than the l
isomer. Unlike acetylsalicylic acid (ASA), TA-993 inhibited both primary
and secondary phases of ADP-induced platelet aggregation and also
exhibited a disaggregating effect on human platelet aggregates. The
inhibitory effect of TA-993 was enhanced when used in combination with
ASA. In ex vivo studies involving rats, TA-993 (0.3 to 100 mg/kg PO) dose-
dependently inhibited collagen-induced platelet aggregation (ED50 3 mg/
kg po). In the whole-blood platelet aggregation system in rats, orally
administered TA-993 was also inhibitory in single (3 to 30 mg/kg) or
repeated daily (10 mg/kg per day for 10 days) dosage. Orally administered
TA-993 dose-dependently inhibited ADP-induced platelet aggregation ex
vivo in dogs (0.3 to 10 mg/kg), significantly protected mice against
collagen+epinephrine–induced thromboembolic death (10 mg/kg), and
inhibited thrombus formation in an arteriovenous shunt in rats (30 mg/kg).
The Ca2+-antagonistic action of TA-993 was very weak in depolarized canine
basilar arteries: the potency was 1/10 that of diltiazem (d-cis) and d-TA-
993. These results suggest that antiplatelet action is more characteristic of
the l-cis than the d-cis 1,5-benzothiazepine structure and that TA-993 may
become a clinically useful antiplatelet agent of this structure series.
114.D.Sherman, H.Hart, J Am Coll Cardiol.,8:88B(1986)
115.C.Hjemdah-Monsen, H.Lewis, J.Cairns, J.Chesebro, V.Fuster, J Am Coll Cardiol.,8,67B(1986)
116.P.Grande, A.Grauholt, J.Madsen, Circulation.,81(suppl I):I-16(1990)
117.M.Trip, V.Cats, F.Capelle, J.Vreeken, N Engl J Med.,322,1549(1990)
118.E.Genton, G.Clagett, E.Salzman, Chest,89:75S(1986)
119.P.Steele, J.Rainwater, Circulation,62:462(1980)
120.M.Busser, E.Escwege, M.Haguenau, J.Lefaucconnier, N.Thibult, D.Touboul, P. Touboul,
Stroke,14,5(1982)
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In continuation with this, Doi H. and co-researchers140 have suggested that
TA-993 (c is - ( - ) -2- (4-methy lpheny l ) -3-acetoxy-2,3-d ihydro-5- (2-
dimethylamino ethyl)-8-met hyl-1,5-benzothiazepine-4(5H)-one maleate),
has a selective increasing action on limb blood flow in addition to an
antiplatelet action. In this report  the effect of TA-993 on a time dependent
decrease in developed tension of electrically-induced contraction of tibi-
alis anterior muscle in a rat model of peripheral circulatory insufficiency
induced by occlusion of abdominal aorta was studied. The developed ten-
sion decreased by 20-30% in a sham-operated group and 30-40% in an
abdominal aorta-occluded group at the end of the experimental period of
60 min. Intraduodenal administration (i.d.) of TA-993 (10 mg/kg) to the ab-
dominal aorta-occluded rats ameliorated the decrease in developed ten-
sion to the level of the sham-operated group. Moreover, TA-993 at 10 mg/
kg, i.d. significantly increased femoral arterial blood flow supplied through
collateral circulation and decreased the whole blood viscosity in this model.
These results suggest that TA-993 improves dysfunction of skeletal muscle
contraction due to peripheral circulating insufficiency through an increase
in collateral blood flow and an improvement of red blood cell deformability.
In addition to this, Minako Kaburaki et al141 have stated that TA-993
has unique and selective increase action on limb blood flow with little arte-
rial pressure besides antiplatelet action, and described the mechanism of
the increase action on limb blood flow caused by TA-993 in anasthetized
dogs. In a canine blood-perfused hindlimb preparation with a donor dog,
TA-993(100 mg/kg i.v.) did not increase femoral blood flow when adminis-
tered to the donor dog, but did when administered to a recipient dog. TA-
993 did not show the increasing action on femoral blood flow in the pres-
ence of hexamethonium or phentolamine, where as it did in the presence
of propranolol or atropine. TA-993 also showed a weak increasing effect
on heart rate, which was inhibited by any one of these blockers. TA-993
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(300 mg/kg i.v.) did not alter the phenylephrine (1–100 mg/kg i.a.)- or the
talipexole (3–100 mg/kg i.a.)-induced increase in perfusion pressure in an
autoperfused hindlimb. These results suggest that the increasing action of
TA-993 on limb blood flow is mediated by the sympathetic nervous system
but that the adrenergic receptors are not likely to be the central point of
action of this new agent. There is a possibility that the mechanism of the
increasing action on heart rate is different from that of its increasing action
on limb blood flow.
Inoue, H et al142 have studied 2,3-Dihydro-1,5-benzothiazepin-4(5H)-ones
substituted with an alkyl, alkoxy, alkylthio, hydroxy, or amino group on the
fused benzene ring of the 1,5-benzothiazepine skeleton and evaluated for
vasodilating, antihypertensive, and platelet aggregation-inhibitory activi-
ties. (-)-cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8- methyl-2-
(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one (25) was selected for fur-
ther studies as a potent inhibitor of platelet aggregation.
N
S
OCOCH3
O
CH2 CH2 N
CH3
CH3
CH3
CH3
25: (-)-cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8- methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one 
? Anticancer agents/Apoptotic agents.
The regulation of apoptosis or programmed cell death is critical to the
normal development and maintenance of tissue homeostasis. The molecular
machinery of  apoptosis has been studied extensively, and many
components have been identified. Two main pathways of cell death have
been elucidated (1)a death-receptor mediated pathway and (2)a
mitochondrial pathway. During receptor mediated apoptosis, ligand
interaction at the cell surface initiates signal transduction cascades by
adaptor complexes that lead to activation of downstream substrates such
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as caspases.143,144  Activation of the mitochondrial apoptotic pathway occurs
in response to various stimuli including cellular stress, DNA damaging
agents, and UV irradiation results in the release of apoptogenic proteins,
which activate downstream substrates143,145,146. Signaling cascades that
regulate mitochondrial apoptotic pathways are incompletely defined, but
some have been shown to involve mitogen activated protein (MAP) kinases
and members of the Bcl-2 protein family.145,147
MAP kinases are a group of serine/threonine protein kinases that control a
wide variety of cellular processes including cell growth and differentiation.
In mammalian cells, three MAP kinases have been characterized in detail,
the c-Jun N-terminal kinase (JNK), the p38 MAP kinase, and the extracellular
signal regulated kinase (ERK). The JNK and p38 kinases are activated
primarily by cellular stress such as heat shock, osmotic shock, and DNA
damaging drugs, whereas the ERK subgroup is primarily activated by
mitogens such as growth factors.
 The consequence of JNK activation in cells is dependent on a number of
factors including the death-inducing stimulus and the cell type, and these
have been shown to mediate both pro- and antiapoptotic responses.148
Proapoptotic JNK signaling cascades are mediated in response to a variety
of stimuli such as the TNFR death receptor and the DNA damaging agent
etoposide149 and in some cases have been shown to regulate apoptosis by
a direct interaction with a number of regulators such as members of the
Bcl-2 family.147,150
Margaret Mc Gee et al151 have developed five novel pyrrolo-1,5-benzoxazipines
as proapoptotic agents. Their JNK-dependent induction of apoptosis in tumor
cells suggested their potential as novel anticancer agents. The core structure
of the apoptotic agent 6 was investigated, and the SARs were expanded
with the design and synthesis of several analogues including  pyrrolo-1,5-
benzoxazipines and  pyrrolo-1,5-benzothiazipines. The apoptotic activity of
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the compounds reported demonstrated that the presence of an oxygen or a
sulfur atom does not significantly influence potency and efficacy.Therefore,
SAR analysis was performed by considering the effects of the fused A-ring
and R’ and R” substituents placed on both pyrrolobenz(pyrido)oxazepine
and pyrrolobenzothiazepine skeletons.
To rationalize the structural parameters responsible for apoptotic activity,
a systematic conformational search  on compounds 26, 28, 29, 32, 33, and
34 was performed. Each generated conformation was subjected to a
geometry optimization. Conformers were energetically selected and then
grouped into families by fitting the atoms of the tricyclic ring system.
Structural and conformational features of the active compounds were
compared to the ones of the inactive pyrrolobenzoxa(thia)zepines, allowed
to identify three main areas of interaction with the molecular target,
schematically represented in Figure-2.
The R’ group could be accommodated into the L1 region of the putative
binding site. The potent apoptic agents 27 and 28 demonstrated that an
extension of the aromatic ring system is responsible for the activity. It was
clearly indicated that a shape dependant effect of the substituent placed at
C-6 on the pyrrolooxa(thia)zepines-induced apoptotic event (Figure 3). In
particular, the additional aromatic ring is able to favorably interact with L1
N
X
R'
O
R"
O
R 3 6
7
X = O or S
A = Benzo, Naptho[2,3], Pyrido[3,2-b]
R = H, COOEt, COOH
R' = Ph, 4-MePh, 4-MeOPh, 1-naphthyl, 2-napthyl
R" = Me, N(Me)2, n-butyl, n-pentyl, n-(Et)2, 4-pyridyl
L1
L2
L3
Figure - 2
A
Comp.  X    A    R    R'    R"
 26    O   Naptho[2,3]  H          Ph        N(Me)2
 27     O    Benzo   H   1-naphthyl Me
 28    O    Benzo  H        1-naphthyl     N(Me)2
 29    O    Benzo  H   2-naphthyl    N(Me)2
 30    S    Benzo  H   1-naphthyl Me
 31    S    Benzo  H   1-naphthyl     N(Me)2
 32    S       Benzo  H   1-naphthyl     N(Et)2 
 33    S    Benzo  H  4-MeOphthyl   4-pyridyl
 34    S    Benzo  H   1-naphthyl     4-pyridyl
 35    O    Benzo          COOEt   1-naphthyl     N(Me)2
 36     O    Benzo      COOH   1-naphthyl     N(Me)2
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if it protrudes along the X direction of the Cartesian axes displayed in Figure
3 (1-naphthyl derivatives 28, 34; Figure 3A) while it is not tolerated along
the Y direction (29, Figure 3B).
Figure 3. (A) Superimposition of the conformers of active pyrrolobenzooxa(thia)zepines
(26, orange; 28, green; 33, violet; 34, cyan).
(B) Superimposition of the conformers of inactive compounds (29, white; 32, green-blue).
Heteroatoms are colored by atom type:O, red; N, blue. Hydrogens are omitted for clarity.
The R” substituents interact with a second region in the putative binding
site (L2, Figure 2).Accordingly the combination of a 1-naphthyl group at C-
6 with a 4-pyridyl at C-7 led to one of the most potent apoptotic agent of
the series (34). The apoptotic activity shown by 34 on HL-60 cells indicated
that a planar aromatic substituent (i.e., 4-pyridyl group) could be well-
accommodated in the L2 pocket of the putative receptor binding site.
In the pharmacophore hypothesis, the aromatic ring A may establish
interactions in the putative binding site pocket L3 (Figure 2). In this region,
polycyclic aromatic systems such as a naphtho-fused group strengthen
apoptotic activity, and the introduction of a polar ethoxycarbonyl function in
the benzo-fused system of 6 led to a potent, cell-penetrating apoptotic agent
(35), probing tolerance at the L3 site. The cell-penetrating compound 35
induced apoptosis in tumor cells, while its nonpenetrating analogue 36,
was incapable of inducing apoptosis or activating JNK. Plasma membrane
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permeabilization of tumor cells resulted in 36-induced JNK activation,
suggesting that the pyrrolo-1,5-benzoxazepine molecular target is
intracellular. Interestingly, compound 26 displayed cytotoxic activity against
a panel of human tumor cell lines but demonstrated negligible toxicity in
vivo with no effect on the animal’s haematology parameters.
? Non nucleoside Reverse Transcriptase Inhibitors/Anti-HIV agents.
Roberto De Santo and Roberta Costi152  have designed , synthesized and
tested 2H-Pyrrolo[3,4-b][1,5]benzothiazepine derivatives(PBTAs) and the
related intermediates 3-pyrrolyl aryl sulphones(PASs) as potential anti HIV-
1 agents targeted at the reverse transcriptase(RT). The PBTAs were con-
ceived as tricyclic analogs of nevirapine, pyrrolo[1,2-b] [1,2,5]benzo
thiadiazepine 37(PBTD) and pyrrolo[2,1-d] [1,2,5]benzothiadiazepine38,
NNRTIs endowed with potent anti-HIV-1 activities. The majority of tested
PBTAs were active against HIV-1-induced cytopathicity in MT-4 cells at
concentrations ranging from 0.3 to 40 µM. In particular, compound 39 was
the most potent derivative with EC50 = 0.3 µM, comparable to that of
nevirapine used as reference drug. In the 3-pyrrolyl aryl sulfones  series
only three sulfones were found active against HIV-1 replication cycle. The
following preliminary SAR could be depicted for the title derivatives:
 i) the conformationally restrained PBTAs are more potent than the
146. N.Waterhouse, J.Ricci, D. Green,  Biochimie, 84, 113(2002)
147.K.Lei, R.Davis,  Proc. Natl. Acad. Sci. U.S.A., 100, 2432(2003)
148. R.Schwabe,H.Uchinami,T.Qian, B.Bennett, J. Lemasters, D. Brenner, FASEB J.,18,
720(2004)
149.K.Saeki,N. Kobayashi,Y. Inazawa,H. Zhang, H. Nishitoh, H.Ichijo, K. Saeki,M.Isemura,
A. Yuo,  Biochem. J.,368, 705(2002)
150. R.Srivastava, Q. Mi, J.Hardwick, D. Longo,  Proc. Natl. Acad. Sci. U.S.A., 96, 3775(1999)
151. M.Mc Gee, S. Gemma, S. Butini,  A. Ramunno, D. Zisterer, C. Fattorusso,
B.Catalanotti, G. Kukreja, I.Fiorini, C.Pisano,C.Cucco, E. Novellino, V. Nacci, C.
Williams, G. Campiani, J. Med. Chem., 48, 4367(2005)
152.R.Santo , R. Costi, Il Farmaco, 60(5),385(2005)
153.(a) K.Jadhav, D. Ingle,  Indian J. Chem., 22B, 180(1983)
         (b)S.Dike, D.Ner, A.Kumar, A. Bioorg. Med. Chem. Lett.,1, 383(1991).
        (c) V.Naik, H. Naik, Asian J. Chem., 11, 661(1999)
        (d) V.Naik, H.Naik, Asian J. Chem.,12, 305( 2000).
        (e) R.Mane, D. Ingle,  Indian J. Chem., Sect. B , 21B, 973(1982)
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corresponding open counterparts (PASs);
ii) the DMA group give the highest anti-HIV-1 potency in the PBTAs series;
iii) PBTAs and the corresponding thiones are equipotent;
iv) an unsubstituted amino group, as part of p-chloroanilino moiety, is a
strong determinant for the antiviral activity in the PASs series.
The most potent derivatives in cell-based assays were proven to target the
RT in enzyme assays. Unfortunately, none of the test compounds inhibited
the multiplication of clinically relevant drug-resistant viruses (mutants of HIV-
1 carrying K103N and Y181C mutations) at concentrations lower than 30
µM. However, the good results obtained against replication of wt HIV-1,
lead us to consider compound 39 as a lead compound for further investi-
gation in this field. In particular, efforts were directed to modifications of
compound 39 devoted to obtain new derivatives active against HIV-1 mu-
tant strains.
? Antimicrobial agents.
The [1,5]benzothiazepine scaffold is extremly  versatile, features in a great num-
ber of  famous drugs and are widely used in a number of different therapeutic
areas and therefore represent an interesting scaffold for De Novo exploration.
Recent  literature report suggested their value as antimicrobial agents. In addi-
tion to this, some authors shed light on the possibility to elicit antibacterial
properties within this class153
N
N
H
N
N
O
CH3
Nevirapine
S
N
NH
39. 2H-Pyrrolo[3,4-b][1,5]benzo 
thiazepine derivatives (PBTAs)
S N
N
37. Pyrrolo[1,2-b][1,2,5]benzo 
thiadiazepine 5 (PBTD) S N
N
38. Pyrrolo[2,1-d][1,2,5]benzo 
thiadiazepine  6(PBTD)
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Combinatorial chemistry  has recently been highlighted as an important
tool for drug discovery activities.154 As a part of this, Fabrizio et al155 af-
forded to exploit a novel combinatorial approach to the[1,5]benzothiazepine
scaffold in order to investigate its antibacterial properties.
154.J.Ellman, Acc. Chem. Res., 29, 132(1996)
155. F.Micheli, F.Degiorgis,  A.Feriani,  A.Paio,  A.Pozzan,P.Zarantonello, P. Seneci, J.
Comb. Chem., 3, 224(2001)
156.V.Ambrogi, A.Furlani, G.Grandolini, A.Papaioannou, L.Perioli, V.Scarcia, L. Tuttobello,
European Journal of Medicinal Chemistry,  28( 9), 659(1993)
157.L.Bonsignore, G.Loy, D.Secci, A.Logu, G.Palmieri, Farmaco,45(5):545(1990)
158.J.Hess,  J.Borkowski ,  G.Young, C. t rader,  R.Ransom, Biochem. Biophys.
Res.Commun, 184, 260(1992)
159.J.Menke, J.Borkowski, K.Bierilo, T.MacNeil,  A. Derrick, K. Schneck, R.Ransom, C.
Strader, D.Linemeyer, J. Hess, J. Biol. Chem., 269, 21583(1994)
Diversity is obviously the driver to explore compounds potentially endowed
with pharmacological activity and the [1,5]benzothiazepine scaffold affords
the possibility to introduce three points of diversity quite readily as depicted
in Figure-4.
O
R1 R2
NH2 SH
R3
N S
R1 R2
R3
Figure - 4
V. Ambrogi and co-workers156 have studied antimicrobacterial and cyto-
static activities of  Indolo[2,3-b][1,5]benzothiazepines and its 5,6-dihydro
derivatives and several of them showed good activity against Gram possitive
bacteria and Cryptococci.
N
H
N
S
Indolo[2,3-b][1,5]benzothiazepine
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Bonsignore L. et al157  have studied in vitro antimicrobial activity of benzo
fused seven membered heterocycles viz. 2,4-dione derivatives of 1,5-
benzodithiepine, 1,5-benzodiazepine and 1,5-benzothiazepine along with
analogous of 1,5-benzodioxepine, 1,5-benzoxathiepine and 1,5-
benzoxazepine. Some of these compounds showed a good activity against
some Gram positive micro organisms and blastomycetes.
? Miscellaneous activities.
Bradykinin (B2) receptor agonist activity.
Bradykinin (BK), a linear nonapeptide hormone (HArg-Pro-Pro-Gly-Phe-
Ser-Pro-Phe-Arg-OH), and related kinins are thought to be involved in a
wide variety of physiological and pathophysiological responses through
activation of two types of receptors named B1 and B2 that have been
cloned.158,159 Bradykinin induces vascular and bronchial smooth muscle
contraction and causes vasodilation and microvascular leakage.160,161 After
local injection into the skin, bradykinin produces all of the classical signs
of inflammation: pain, swelling, redness, and heat.159,162,163 Due to the
pathophysiological role of bradykinin, considerable effort toward the
development of bradykinin receptor antagonists as potential therapeutic
agents has been carried out for several years. Since the initial discovery
of bradykinin, a large number of peptidic and pseudopeptidic antagonists
of bradykinin receptors have been described.164,165 One of the most potent
and selective bradykinin B2 receptor antagonists described so far is HOE
140, a decapeptide (H-D-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-D-Tic7-Oic8-
Arg9-OH)166 containing several unusual amino acids. This antagonist has
sufficient high receptor affinity and in vivo life time to be investigated as a
potential drug. On the other hand, it has been suggested that the
cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors
are due, at least in part, to a metabolic protection of bradykinin167-169 and
are therefore resulting from bradykinin B2 receptor activation. These findings
along with the studies indicating that potent bradykinin pseudopeptide
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agonists were useful in the delivery of anticancer drugs into brain tumors
by increasing the permeability of the blood-brain barrier170 suggest that the
development of agonists having improved metabolic stability and oral
bioavailability might be of great interest. Among them, one of the most
studied bradykinin agonist, RMP-7170 (H-Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-Pro7-
4-Me-Tyr8Ø(CH2NH)-Arg
9-OH), was shown to enhance penetration of various
anticancer drugs into human brain tumors171,172 and of antiviral drugs through
the blood-ocular barrier in the guinea pig.173,174
Extensive spectroscopic studies have shown that bradykinin possesses a
high degree of conformational flexibility in solution, although evidence of a
â-turn-like structure spanning the residues Ser6-Pro7-Phe8-Arg9 has been
reported in DMSO and SDS micelles.175,176 Based on 1H NMR and
computational studies performed on several bradykinin analogues, it has
been suggested that the high affinity of bradykinin antagonists, including
HOE 140, for the B2 receptor was related to their propensity to adopt C-
terminal â-turn conformations.177-179 However, ACE, a major bradykinin-
degrading enzyme,180 cleaves its substrate at Pro7-Phe8 and Phe5-Ser6
amide bonds suggesting that ACE inhibitors may display features
complementary to the bradykinin receptor.
In an attemp to design bradykinin and HOE 140 analogues peptidic moieties
at positions 7 and 8 since these positions are thought to be important for the
agonist/antagonist activity and represent the cleavage site for ACE, because
of design of peptidomimetics, incorporation of nonpeptide scaffolds into
bioactive molecules has been the focus of extensive research over the last
10 years181. Muriel  Amblard and coworkers182 have synthesized bradykinin
analogue (H-Arg-Pro-Pro-Gly-Phe-Ser-D-BT-Arg-OH, 40) in which the Pro-
Phe dipeptide was replaced by the (3S)[amino]-5-(carbonylmethyl)-2,3-
dihydro-1,5-benzothiazepin-4(5H)-one (D-BT) moiety. The same modification
was performed on the potent bradykinin B2 receptor antagonist HOE 140
(H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH),
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in which the -D-Tic-Oic- moiety was replaced by D-BT to yield H-D-Arg-
Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-Arg-OH, 41(JMV1116). These compounds
were examined in vitro for their binding affinity toward bradykinin B1 and
B2 receptors as well as for their ability to interfere with bradykinin-induced
contraction of both human umbilical vein and rat uterus. The two compounds
40 and 41 competed with [3H]bradykinin binding to the human cloned B2
receptor giving K i values of 13± 2 and 0.7± 0.1 nM, respectively.
Unexpectedly, both compounds were full bradykinin B2 receptor agonists
on the human umbilical vein (pD2 = 6.60± 0.07 for 40 and 6.80± 0.08 for
41) and rat uterus (pD2=7.20± 0.09 for 40 and 7.50± 0.09 for 41)
preparations with the same efficacy as bradykinin. In addition 41 induced
a concentration dependent phosphoinositide production in CHO cells
expressing the human cloned B2 receptor. These data provide evidence
for a bioactive conformation of bradykinin constrained at the dipeptide Pro-
Phe.
N
S
NH-Ser-Thi-Gly-Hyp-Pro-Arg-D-Arg-H
O
CH2
C
Arg-OH
CH3
CH3
O
41 (JMV 1116)N
S
NH-Ser-Phe-Gly-Pro-Pro-Arg-H
O
CH2
C
Arg-OH
CH3
CH3
O
40 
160.D.Regoli, J.Barabe, Pharmacol. Rev.32, 1(1980)
161.K.Bhoola, C.Figueroa, K.Worthy, K. Pharmacol.Rev.,44, 1(1992)
162.A.Dray, M.Perkins, Trends Neurosci.,16, 99(1993)
163(a)L.Steranka, D.Manning, C.Haas, J.Ferkany, S.Borosky, J.Connor, R. Vavrek,
J.Stewart, S. Snyder, Proc. Natl. Acad. Sci. U.S.A.,85, 3245(1988)
(b) J.Stewart, Agents Actions, 42S, 145(1993).
164.J.Stewart, L.Gera, D.Chan, E.Whalley, W.Hanson, J. Zuzack,Immunopharmacology,
36, 167(1997)
165.D.Regoli, S. Allogho, A.Rizzi, F.Gobeil, Eur. J. Pharmacol,348,1(1998)
166.F.Lembeck, T.Griesbacher, M.Eckhardt, S.Henke, G.Breipohl, J.Knolle, Br. J. Pharmacol.,
102, 297(1991)
167.G.Bao, P.Gohlke, T.Unger, J. Cardiovasc. Pharmacol.,20, S96(1992)
168.P.Martorana, B.Kettenbach, G.,Breipol, W.Linz, B.Scholkens, Eur.J.Pharmacol.,182, 395(1990)
169.K.McDonald, J.Mock, M.D’Ajoia, T.Parrish, K.Hauer, G.Francis, A.Stillman, J.Cohn,
Circulation, 91, 2043(1995)
107
170.T.Inamura, R.Nomura, K.Black, J.Neurosurg.,81, 752(1994)
171. J.Ford, C.Osborn, T.Barton, N.Bleehen, Eur. J. Cancer, 34, 1807(1998)
172.D.LeMay, M.Kittaka, E.Gordon, B.Gray, M.Stins, J.McComb, S.Jovanovic, P.Tabrizi,
M.Weiss, R.Bartus, W. Anderson, B. Zlokovic, Hum. Gene Ther.,9, 989(1998)
173.P.Elliot, J.Mackic, W. Graney, R. Bartus, B. Zlokovic, Invest. Ophthalmol. Vis.Sci.,36,
2542(1995)
174.P.Elliot, R.Bartus, J.Mackic, B.Zlokovic, Pharm.Res,14,80(1997)
175.J.Cann, R.London, N.Matwiyoff, J.Stewart, Adv. Exp. Med. Biol. , 156A, 495(1983)
176. S.Lee, A.Russel, W.Laidig, Int. J. Pept. Protein Res.,35,367(1990)
177.D.Kyle, J.Martin, S.Farmer, R.Burch, J. Med. Chem.,34,1230(1991)
178.D.Kyle, J.Martin, R.Burch, J.Carter, S.Lu, S.Meeker, J.Prosser, J.Sullivan, J.Togo,
L.Noronha-Blob, J.Sinsko, R.Walters, L. Whaley, R.Hiner, J.Med. Chem.,34, 2649(1991)
179.D.Kyle, P.Blake, D.Smithwick, L.Green, J.Martin, J.Sinsko, M.Summers, J. Med.
Chem.,36, 1450(1993)
180.F.Dorer, J.Ryan, J.Steward,  Biochem. J.,14, 915(1974)
181.(a) G.Olson, D.Bolin, M.Bonner, M. Bo¨s, C. Cook, D. Fry, B.Graves, M.Hatada, D.
Hill, M.Kahn, V.Madison, V. Rusiecki, R.Sarabu, J.Sepinwall, G.Vincent, M. Voss,
J.Med.Chem.,36, 3039(1993)
(b) D.Fairlie, G.Abbenante, D.March, Curr. Med. Chem.,2, 654(1995)
182.M.Amblard, I.Daffix,  P.Bedos,  G.Berge´,  D.Pruneau,  J.Paquet, J. Luccarini,
P.Be´lichard, P.Dodey, J.Martinez, J. Med. Chem., 42, 4185(1999)
183.Y.Inada, K.Itoh, K.Kamiya, H.Sugihara, K.Nishikawa, Jpn.J.Pharmacol.,47(2),135(1988)
S
N
O
OH O
NH
O
O
NHCV - 5975
Angiotensin converting enzyme inhibitors
Inada Y et al183 have described (R)-3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-
benzothiazepine-5-acetic acid derivatives as structurally new angiotensin
converting enzyme(ACE)inhibitors. A number of compounds has shown po-
tent ACE inhibion in vivo and in vitro. Structure activity studies indicated
that a piperidinyl moiety on the amino group at 3-position conferred long
lasting ACE inhibitory activity and that the duration of activity on the length
of the carbon chain in the 1-carboxy-ù -(4-piperidyl) alkyl group. (R)-3-[(S)-
1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-
benzothiazepine-5-acetic acid(CV-5975) was selected as most promising
ACE inhibitor for further studies because of its marked inhibitory activity.
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Synthetic Approaches
1,5-benzothiazepine are useful compounds in the drug research which
stimulated the invention of various synthetic procedures for their prepara-
tion and chemical transformations1.
There were number of synthetic approaches proposed in literature for the
development of different 1,5-benzothiazepine derivatives among which
important  aspects discussed are as per following.
? Isolated approaches
?[4+3] Cycloaddition reaction.
?Glycidic ester condensation with 2-amino thiophenol.
?Solid phase reactions, microwave assisted &/or one pot synthesis and
Green chemistry approach &/or solvent free synthesis.
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? Isolated approaches.
Fiorini et al94 have synthesized 6-arylpyrrolo[2,1-d][1,5]benzothiazepine
derivatives as shown in scheme-1. Esters(48-53) were obtained in good
yield starting from bis(2-N-pyrrolylphenyl)disulphides(42-47) by reduc-
tion with sodium borohydride184 followed by treatment with ethyl-á-bromo-
p-methoxyphenylacetate109a. Hydrolysis of esters 48-53 with sodium hydrox-
ide afforded acids 55109a,56,58,60,62 and 63. Acids 54186,57185,59 and 61 were
one step prepared starting from the appropriate disulphide, sodium hydrox-
ide and commercially available á-bromo acetic acid. Intramolecular cycliza-
tion of acids 54-63 using phosphorus pentachloride gave ketones 64-73. Oxi-
dation of 64 and 65 with m-chloroperbenzoic acid (MCPBA) afforded sulfox-
ides and sulphones. Finally sulfoxides and sulphones were converted to the
desired esters using potassium hydride and the selected acid chlorides.
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Ester derivatives
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K.Petrova et al187 have described method of synthesis of novel tricy-
clic ring system Benzo[b]imidazo[1,5-d][1,5]thiazepine. A method for
synthesis of the title compounds 78, consisted of an intramolecular cycliza-
tion of 1-(2-carboxymethylthiophenyl)-2H-imidazol-2-ones 77 in poly phos-
phoric acid.  Compound 77 was prepared by a react ion of 1-(2-
mercaptophenyl)-2H-imidazol-2-one 76 with chloroacetic acid. 2H-
Imidazolones 76 were obtained by a ring transformation of substituted 2(3H)-
benzothiazolones 75 in reactions with primary amines. The method is
convenient because of its simplicity and good yields(Scheme-2).
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R1= H,Br, R2=CH3, C2H5, n-C3H7, i-C4H9, C6H5, CH2C6H5 
Benzo[b]imidazo[1,5-d][1,5]thiazepines 
7778
Scheme-2
An isomerization ring closing metathesis(RCM) strategy afforded 2,5-
dihydro-1,5-benzothiazepine-1,1-dioxide, from the protected N-allyl-2-
(allylsulfonyl)aniline188. (Scheme-3)
NH
S
O O
N-allyl-2(allylsulphonyl)aniline
Isomerization
Ring closing metathesis
N
H
S
O O
2,5-dihydro-1,5-benzothiazepine-1,1-dioxide
Scheme-3
Blitzke T. et  al189 have synthesized 2,5-dihydro-1,5-benzothiazipine(79) by in-
corporating heterocycles segments originating from the precursor dimethyl(E)-
2-oxoglutaconate by cyclocondensation  with 2-aminobenzenethiol(Scheme-4).
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Ogawa M. and coworkers190 have demonstrated facile synthesis of
furobenzoth iazep ines.  Thus,  The react ion o f  methy l  5- (2-
isocyanatophenylthio)-2-furancarboxylate  with N-methylpiperazine gave
5(2-N-piperazinocarbamoylphenylthio)-2- furancarboxylate. Furthermore, 4-
N-methylpiperazinyl-2- methoxycarbonylfuro[2,3-b][1,5]benzothiazepine
was obtained by the Bischler-Napieralski reaction of   with phosphorus oxy-
chloride in the present of phosphorus pentoxide. Three furobenzothiazepines
could be obtained using the same method. Based on the pharmacological
studies of these compounds, i t  was found that 4-morphol inyl-2-
methoxycarbonylfuro[2,3- b][1,5]benzothiazepine 4b had anti-inflammatory
activity similar to flufenamic acid (Scheme-5).
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O CH3
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CH3
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phenylthio)-2-furancarboxylate
methyl-5-(2-N-piperazinocarbamoylphenylthio)-
2-furancarboxylate
4-N-methylpiperazinyl- 
2-methoxycarbonylfuro 
[2,3-b][1,5]benzothiazepine
POCl3, P2O5
Bischler Napieralski Reaction
Scheme-5
Ganesh T & Krupadanam G.191 have synthesized 1,5-benzothiazepine deriva-
tives by the reaction between 2-aminobenzene thiol and 2-bromomethyl-3-
aryloxirane in acetone or acetonitrile and potassium carbonate.(Scheme-6)
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Santo et al192 have synthesized pyrrole annulated 1,5-benzothiazepines. The
synthetic stretegy involved condensation of 2-nitrothiophenol with ethyl
propiolate afforded 3-(2- nitrophenylthio)propenoate. Oxidation of sulfur atom to
sulfone group gave ethyl 3-(2-nitrophenylsulfonyl)propenoate, which underwent
condensation with tosyl methylisocyanide (TosMIC) to yield ethyl 4-(2-
nitrophenylsulfonyl)pyrrole-3-carboxylate. Reduction of nitro group afforded ethyl
4-(2-aminophenylsulfonyl)-1H-pyrrole-3-carboxylate, which was cyclized to 2H-
pyrrolo[3,4-b][1,5] benzothiazepin-10(9H)-one 4,4-dioxide. Similar procedure was
used for the synthesis of 9,10-dihydro-10-methyl-2H- pyrrolo[3,4-
b][1,5]benzothiazepine 4,4-dioxide (Scheme-7).
2-methyl-1,5-benzothiazepine-4(5H)-one has been prepared by the re-
action of 2-aminothiophenol with ethylacetoacetate in xylene at reflux
temperature193,194. While 2,3-disubstituted 1,5-benzothiazepine-4(5H)-ones
were synthesized by the reaction of 2-aminothiophenol with á-chloro-â-
chlorocarbonyl enamines in the presence of pyridine195(Scheme-8).
SH
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CH3
CH3 O
O
ethyl 
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H O
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R1
R2
S
N
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NR2R3
R1
2-N,N-disubstituted amino-3-alkyl 
-1,5-benzothiazepin-4(5H)-one
Scheme-8
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A series of 4-aryl-2,3-dihydro-1,5-benzothiazepine was synthesized by the
reaction of 2-aminothiophenol with N,N-disubstituted(2-aminoethyl)aryl
ketones by Hideg and Hankovszky196-198. Similarly 4-substituted-2,3-dihydro-
1,5-benzothiazepines have been synthesized by the reaction of 2-
aminothiophenol with â-haloketones199,200(Scheme-9).
SH
NH2
X
R
O
2-aminobenzenethiol
S
N
R
4-substituted-2,3-dihydro-1,5-benzothiazepine
R1
N
Ar
O
R2
S
N
Ar
4-aryl-2,3-dihydro-1,5-benzothiazepine
Scheme-9
A chemoenzymatic enatioselective synthesis of the (R)-2,3-dihydro-2-me-
thyl-1,5-benzothiazepine-4(5H)-one has been propossed by Dike et al201.
The procedure starts with Baker’s yeast reduction of ethylacetoacetate.
The optically active ester obtained in this was used for the preparation of
the (R)-3-(phenylmercapto)butyric acid as key intermediate of this synthe-
sis. The later was then cyclized into (R)-2-methyl-1-thiochromone, oxime of
which yielded the (R)-2,3-dihydro-2-methyl-1,5-benzothiazepine-4(5H)-one
by Beckmann rearrangement (Scheme-10).
S
COOH
CH3
S
N
H O
CH3
(3S)-3-(phenylsulfanyl)butanoic acid
S
O
CH3 S
NOH
CH3
(2R)-2-methyl-2,3-dihydro
-4H-thiochromen-4-one
(2R)-2-methyl-2,3-dihydro-4H-
thiochromen-4-one oxime
(2R)-2-methyl-2,3-dihydro-
1,5-benzothiazepin-4(5H)-oneScheme-10
An efficient one pot synthesis of the (R)-2,3-dihydro2,5-dimethyl-1,5-
benzothiazepin-4(5H)-one, has been described by Breitschuh and
Seebach202.  (S)-â-Butyrolactone was al lowed to react with 2-(N-
methylamino)thiophenol to yield the taget compound without isolation of
the appropriate carboxyllic acid intermediate (Scheme-11).
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2-(methylamino)benzenethiol (4R)-4-methyl-2-oxetanone (2R)-2,5-dimethyl-2,3-dihydro-
1,5-benzothiazepin-4(5H)-one
Scheme-11
Optically active 3-amino-2,3-dihydro-1,5-benzothiazepine-4(5H)-ones are
very interesting and useful benzothiazepine owing to their angiotensin con-
verting enzyme(ACE)inhibition activity. It was first synthesized by Slade et
al203. 2-Fluoronitrobenzene was allowed to react with N-acetylcysteine to
afford corresponding nitrocarboxylic acid derivative which afforded the tar-
get compound on several steps (Scheme-12).
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H O
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+
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SH
COOH
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COCH3
N-acetylcysteine
(3R)-3-amino-2,3-dihydro-1,5-
benzothiazepin-4(5H)-one
S
N
+
O
-
O
COOH
NH
COCH3
N-acetyl(2-nitrophenyl)cysteine
Scheme-12
? 4+3 cycloaddition reaction
2,4-disubstituted-1,5-benzothiazepine derivatives were synthesized from
2-aminobenzenethiol, allowed to react with alkynones in a mixture of hot
methanol and acetic acid204,205. General procedure for 1,5-benzothiazepin-
4(5H)-ones followed 2-aminothiophenol heated either with propiolic acid
(R=H) or its â-substituted derivatives206-208 (Scheme-13).
SH
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2-aminobenzenethiol
R
Ph
O
alkyn
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N
R
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2,4-disubstituted-1,5-benzothiazepine
S
N
H
R
O
2-substituted-1,5-benzothiazepin-4(5H)one
R
OH
O
Scheme-13
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The 2,4-disubstituted 2,3-dihydro-1,5-benzothiazepines can easily be syn-
thesized by the reaction of 2-aminothiophenol with á,â-unsaturated
ketones.These synthetic procedures have been thoroughly investigated in
numerous laboratories. The intense studies resulted in the better under-
standing of various steric and electronic factors influencing the formation
of such 1,5-benzothiazepines209. More over 4-aryl-2,3-dihydro-1,5-
benzothiazepin-2-carboxylic acids have been synthesized in the late eight-
ies by the reaction of 2-aminothiophenols with â-aroyl acrylic acids210,211.
á,â
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2-aminobenzenethiol
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R2
O
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S
N
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2,4-disubstituted-2,3-dihydro-1,5-benzothiazepine
S H
N H 2
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COOH
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O
-a ro yla c rylic  a c id
S
N
COOH
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4 -a ry l-2 ,3 -d ih yd ro -1 ,5 -b e n zo th iaze p in -2 -ca rb o xylic
S chem e-14
â-
Similar reaction of exocyclic á,â-unsaturated ketones with 2-aminothio
phenol afforded tetracyclic benzothiazepines212-215. Stereochemistry of the
targeted compounds has been elucidated by a combined utilization of vari-
ous  techniques. The spectroscopic measurments unequivocally proved that
only one diastereomer was obtained in each case which revealed a com-
pletely diastereoselective formation of such benzothiazepines under the
reaction conditions used for their synthesis (Scheme-15).
SH
NH2
X
O
CH3
Ar S
N
X
2-aminobenzenethiol X = CH2, (CH2)2, (CH2)3, OCH2, SCH2, OCHPh
Tetracyclic-1,5-benzothiazepine
+
Scheme-15
117
2,2-disubstituted-2,3-dihydro-1,5-benzothiazepin-4(5H)ones were synthe-
sized by reaction between 2-aminothiophenol and 3,3-disubstituted-á,â-un-
saturated carboxylic acids216. While, the simplest method for synthesis of
2,3-disubstituted-2,3-dihydro-1,5-benzothiazepin-4(5H)ones based on reac-
tion between 2,3-disubstituted-á,â-unsaturated carboxylic acids208,217,218
(Scheme-16).
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Scheme-16
2,3-disubstituted-2,3-dihydro-1,5-benzothiazepin-4(5H)ones comprises the
ethyl-2-aryl-2,3-dihydro-1,5-benzothiazepine-4(5H)-one-3-carboxylates7,8,219-221.
Both their cis-  and trans- isomers have been synthesized by the reaction of
arylidene malonates and 2-aminothiophenol. The resulting ethyl-2-aryl-2,3-
dihydro-1,5-benzothiazepine-4(5H)-one-3-carboxylates cam be reduced to
corresponding alcohol by lithium aluminum hydride in tetrahydrofuran. The
alcohols afforded the appropriate chlorides on treatment with thionyl chloride,
methanesulfonylchloride or p-toluenesulfonylchloride, which on heating with N-
methylpiperazine yielded2-aryl-2,3-dihydro-3-(4-methylpiperazinylmethyl)-1,5-
benzothiazepin-4(5H)-ones. Some of these benzothiazepines were found to
possess considerable antiulcer and gastric disorder inhibitors (Scheme-17).
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2,4-diaryl-2,3-dihydro-1,5-benzothiazepine were usually prepared by
[4+3]cyclocondensation between 2-aminothiophenol with á,â-unsaturated
ketones in the presence of catalytic amount of acid222 or under neutral con-
ditions223,224. A.R.Katritzky et al225 have described that reductive cleavage
of benzothiazoles provides good yield of functionalized 2-aminothiophenols
or the stable funct ional ized di(2-aminophenyl)disulphides as 2-
aminobenzenethiols precursors. In an attempt  to reduce disulfides in pres-
ence of chalcone with hydrazine hydrate gave 3,5-diarylpyrazoline, while
reduction of disulfides by using triphenylphospine in 20% of water/acetone
mixture with Chalcones (2 equivalent ) in the presence of a slight excess of
triphenylphosphine (1.1 equivalents) gave 46% ring opened product (80).
During this reaction, the fast and complete cleavage of disulphide was pro-
gressively followed by reverse oxidation of the yielded o-aminothiophenol.
By repeating the condensation under argon or nitrogen the air oxidation of
the intermediate 2-aminothiophenol was avoided and compound 80 was
obtained in 89% yield. Compound 80a (X = H) was cyclized to correspond-
ing benzothiazepine by refluxing in toluene in catalytic amount of p-
toluenesulphonic acid, while intermediates 80b(X = 6-OCH3 ) and 80g((X =
6-CH3 ) occured in situ to obtain appropriate benzothiazepine. Surprisingly
analogous self cyclization was observed with compound 80f (X = 6-Cl)upon
conservation at room temperature for 15 days (Scheme-18).
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Atta-ur-Rahman et al31 have synthesized 2,4-diaryl-2,3-dihydro-1,5-
benzothiazepines(81) by cycloaddition reaction between substituted
chalcones and o-aminothiophenol in acidic methanol, among which com-
pounds having substitutions(R1=2-OH, R2=H), (R1=2-OH, R2=4-F), (R1=2-OH,
R2=4-Cl), (R1=2-OH, R2=4-OMe) and (R1=2-OH, R2=4-Me) were reduced
with lithiumaluminumhydride in anhydrous tetrahydrofuran afforded
diastereomeric mixture of corresponding tetrahydro analogues(82). All the
synthesized compounds viz.chalcones, 2,4-aryl-2,3-dihydro-1,5-benzo
thiazepines(81) and 2,4-diaryl-2,3,4,5-tetrahydro-1,5-benzothiazepines(82)
were screened as DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavengers
and esterase,Urease and á-Glucosidase Inhibitors(Scheme-19).
O CH3
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O H
4 M NaOH, C2H5OH, 3h
O
R2 R1
R2 R1
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R2 R1
N S
R2 R1
NH S
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LiAlH4
Anh. THF
2,4-diaryl-2,3-dihydro-1,5-benzothiazepines2,4-diaryl-2,3,4,5-dihydro-1,5-benzothiazepines
R1 = H, OH, 4-NH2                                                                     
R2 = H, 2-OH, 2-Cl, 4-Cl, 2-OMe, 3-OMe, 4-OMe, 
4-Me, 4-N(Me)2, 4-F, 3,4-(OMe)2, 3,4-[OCH2O], 
3-OH-4-OMe, 4-NO2, 2-Br        
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U.C.Pant and coworkers239 have studied the reactions between á,â-unsat-
urated carbonyl compounds and 2-amino benzenethiols under various re-
action conditions by using i) acidic medium-methanol/ethanol containing
glacial acetic acid 226,227, ethanol saturated with hydrogen chloride gas 228,
toluene containing traces of trifluoroacetic acid 229 ii) basic medium-pyri-
dine 230 or toluene containing piperidine 231 and iii) neutral medium-anhy-
drous toluene 232,233 or  o-xylene 234,235. Since the yields of the products were
found satisfactory in acidic medium containing hydrogen chloride gas 236,237,
this method was used for the syntheses of 2-(p-dimethylaminophenyl)-4-
methoxyphenyl-8-substituted-1,5-benzothiazepines(83).(Sceme-20)
In the literature, 2-amino benzenthiol has been reported to react with á,â-
unsaturated ketones or chalcones to give a Michael addition type adduct
238, formed by the nucleophilic attack of the electron rich S of the thiol on
the â-carbon atom of the chalcone, rendered electrophilic by a carbonyl
group, when the reaction is carried out under milder conditions by using a
neutral medium such as toluene 232,233. It has also been reported that a
mixutre of intermediate and final products or only final products are obtained
under acidic or basic reaction conditions. The Michael addition products,
when isolated, were cyclized to obtain the final product thereby establishing
the reaction product as formed in two steps, the Michael addition product
is an intermediate which is subsequently cyclized to give the final product.
121
236.M.Khanna, D. Kumar, C.Garg, R.Kapoor, Indian J. Chem., 34B, 333(1995)
237.M.Mushfiq, G.Mudgal, J. Chem. Res. Synop.,5, 168(1992)
238.J.Lancelot, B.Letois, C.Saturnino, P.Caprariis, M.Robba, Org. Prep. Proceed. Int.,
24, 204(1992)
239.S.Pant, B.Singhal, M.Upreti,  U.C.Pant, Molecules, 3,159(1998)
240.V.Rao, A.Gupta, C.Gupta, Syn.Commun.,30(15), 2763( 2000).
241.L.Nagarapu, R.Narendar, K.Sucheta, Heterocyc.Commun., 9(1), 35( 2003)
X SH
NH2
+
X N(CH3)2
O
OCH3
C2H5OH+ HCl gas
X S
NH2 O
H
OCH3
N(CH3)2
H
H
X S
N
H
OCH3
N(CH3)2
H
HX S
N
H
H
OCH3
N(CH3)2
H
X= Cl, Br, CH3, OCH3 Scheme-20
83 83
V.S.Rao et al have utilized á-(4-Nitrophenoxy)chalcones as intermediate
for the synthesis of some new cis- (±)-2-aryl-3-(4-nitro phenoxy)-4-phenyl-
1,5- benzothiazepine by cyclocondensation of 2-amino thiophenol in the
presence of mild base240 (Scheme-21).
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2-aminobenzenethiol
(2S,3S)-2-aryl-3-(4-nitrophenoxy)-
4-phenyl-2,3-dihydro-1,5-benzothiazepine
+
Scheme-21
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Nagarapu et al241 have developed convenient procedures for the synthesis of 2-
aryl-4-(4-hydroxy-6-methyl-2-pyrone-3-yl)-2,3-dihydro-1,5-benzothiazepines by
the condensation reaction between 2-aminothiophenol  and 3-cinnamoyl-4-hy-
droxy-6-methyl-2-pyrones  with MCM-41(H) Zeolite in ethanol (Scheme-22).
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Nikalje M.A.G. and co-workers243 have described that 3-Formyl chromones
1 were synthesized by using Vilsmeier-Haack reaction and  were converted
to respect ive 2-propane-1-ones  by Claisen condensat ion.  The
cyclocondensation of the2-propane-1-ones and 2-aminobenzenethiol gave
2-chromonyl-4-substituted phenyl-2,3-dihydro-1,5-benzothiazepines. The
1,5-benzothiazepines  and P2S5 when refluxed in pyridine were found to
yield thiochromonyl-1,5-benzothiazepines. These compounds were also ob-
tained from 3-formyl chromones by their conversion to 3-formyl
thiochromones  with P2S5 in pyridine. The 3-formyl thiochromones when con-
densed with aromatic aldehydes in presence of piperidine yielded á,â-un-
saturated ketones. The cyclocondensation of this á,â-unsaturated ketones
and 2-aminobenzenethiol gave identical products, 2-thiochromonyl-1,5-
benzothiazepines (Scheme-23).
242.X.Chen, W.Zhong, Y. Zhang, J.Chem.Res. - Part S, 8,  386(2000)
243.M.Nikalje, R.Ingle, V.Bhingolikar, R.Mane, Indian J. Heterocycl Chem.,13(1), 37( 2003)
Chen X. et al242 have suggested that Nitrodisulfides on treatment with Sml2
in anhydrous THF at room temperature lead to reactive intermediates, which
are ‘living’ double-anions and react smoothly with á,â-unsaturated ketones
to afford 2,3-dihydro-1,5-benzothiazepines in good yields under mild and
neutral conditions.
123
S
N
Ar
SO
NH2
SH
2-aminobenzenethiol
+
Ar
S
OO
P2S5 in Pyridine
Ar
O
OO
OHC
O
O
ArCH3
O
+
S
N
CH3
OO P2S5 in Pyridine
Ar
O
OO
NH2
SH
2-aminobenzenethiol
+
3-(4-aryl-2,3-dihydro-1,5-benzothiazepin-2-yl)
-4a,8a-dihydro-4H-chromen-4-one
3-(4-aryl-2,3-dihydro-1,5-benzothiazepin-2-yl)
-4a,8a-dihydro-4H-thiochromen-4-one
4-oxo-4a,8a-dihydro-4H-
chromene-3-carbaldehyde
Substituted Acetophenones
3-[(1E)-3-oxo-3-aryl-1-propenyl]
-4a,8a-dihydro-4H-chromen-4-one
3-[(1E)-3-oxo-3-aryl-1-propenyl]
-4a,8a-dihydro-4H-chromen-4-one
3-[(1E)-3-oxo-3-aryl-1-propenyl]
-4a,8a-dihydro-4H-thiochromen-4-one
Scheme-23
Liu F.M. and coworkers244 have illustrated that 1,5-Benzothiazepines contain-
ing 2-phenyl-1,2,3-triazole which have potentially useful pharmacological prop-
erties were synthesized from á,â- unsaturated ketones and 2-aminothiophenol,
and then underwent 1,3-dipolar cycloaddition reaction with aryl nitrile oxides
“in situ” and a series of 1,2,4-oxadiazolo[4,5-d][1,5] benzothiazepine deriva-
tives containing 2-phenyl-1,2,3-triazole were obtained. The experimental re-
sults show that if  the substituent R1 or R2 at phenyl of 1,5-benzothiazepine is
electron-donated, it will facilitate the 1,3-dipolar cycloaddition reaction. The
structures of the products were confirmed by IR, 1H NMR, MS and elementary
analyses  and their spectrum characters were also discussed.
244.F.Liu, B.Wang, Y. Li, Chemical Journal of Chinese Universities, 23(11), 2101( 2002)
245.V.Krishnan, P.Dubey, S.Srinivas Rao, P.Prasada Reddy, Indian Journal of
Heterocyclic Chemistry,13(1), 5( 2003)
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Krishnan et al245 used substituted acetanilides  for treatment with DMF-
POCI3 complex (Vilsmeier reagent) to obtain 2-chloro-quinoline-3-
carboxaldehydes  which on treatment with chromanones  in ethanol in the
presence of sodium methoxide gave chalcones. The later on treatment with
o-aminothiophenol in the presence of catalytic quantity of acetic acid gave
benzothiazepine system flanked by quinoline and chromanone moieties
(Scheme-24).
Abd El Latif F.M.246 have synthesized 4-aryl-3-methyl-1-phenylpyrazolo[3,4-
b][1,5]benzothiazepine derivatives via regioselective nucleophilic addition.
4-Arylidene-3-methyl-1-phenylpyrazole-5-one reacted with 2-aminobenzene
thiol in ethanol-acetic acid solution to produce a mixture of 4-aryl-3-methyl-
1-phenylpyrazolo[3,4-b][1,5]benzothiazepines, 2-arylbenzothiazoles and 3-
methyl-1-phenylpyrazole-5-one (Scheme-25).
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Ding Z.  et  a l 247 have narrated an expedient  synthesis of  novel
[1,2,4]triazolo[3,2- d][1,5]benzothiazepine derivatives via cycloaddition of the
allene-like cations derived from thiochroman-4- one arylhydrazones, to the
triple bond of nitriles and ensuing ring expansion annulation. The structure of
one product has been unambiguously determined by X-ray diffraction.
?Glycidic ester condensation with 2-amino thiophenol.
This perticular route of synthesis implimented selectively for the prepara-
tion of 2-substituted-2,3-dihydro-3-hydroxy-1,5-benzothiazepine-4(5H)ones.
Some of their optically active derivatives are important antihypertensive
agents. Depending on the reaction conditions, both 2,3-cis and 2,3-trans
diastereomers can be prepared selectively.
The general route of synthesis included condensation of 2-nitrophenol with
phenylglycidic esters afforded nitrocarboxylic acid esters which were re-
duced to their corresponding amino carboxylic acid esters. Ring closure of
the later gave 2-aryl-2,3-dihydro-3hydroxy-1,5-benzothiazepine-4(5H)ones1
(Scheme-26).
H.Inoue et al61 have synthesized cis-2-aryl-2,3-dihydro-3-hydroxy-1,5-
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benzothiazepine-4(5H)-one(86) as shown in scheme -27. Fusion of the halo-
gen substituted 2-aminothiophenol (84) with the trans -3-arylglycidic es-
ter(85) at about 160oC gave the cis lactam(86). This reaction involved cis
opening of the oxirane ring of (85) by the thiol group(84) followed by in-
tramolecular cyclization to give the cis lactam (86) predominantly along with
minor quantity of trnas isomer (87). Although the yield was rather poor, this
simplest method was mainly employed for the preliminary synthesis of (86).
The stereochemistry of cis and trans lactams(86 & 87) was deduced from
the vicinal coupling constant between the methine protons at C2 and C3
(about 6Hz and 11Hz for cis and trans isomers respectively)
The reaction of 2-aminothio-3-chlorothiophenol(84a) with glycidic ester (85a)
gave intermediate aminoester (88e) predominantly together with the
lactams(86a & 87a). More practically the cis lactam 86 was prepared via the
amino ester(88). Heating of 2-amino-5-chlorothiophenol(84c) wth glycidic es-
ters 85a and 85b in a nonpolar solvents at lower temperature(65-130oC) gave
the threo aminoester 88a and 88b in moderate yield. Alkaline hydrolysis of 88
gave the amino acid 91.
Lewis acids such as halides or carboxylates of tin or zinc, catalytically ef-
fect ready and highly stereoselective cis opening of 3-arylglycidic esters
with thiophenols248-250. In the presence of catalytic amount of zinc acetate,
5-or 6-chloro-2-nitrophenols(95a or 95b) smoothly reacted with 3-(4-
methoxyphenyl)glycidic ester 85a at room temperature, giving the threo ni-
tro esters 89a and 89b in good yield. In the presence of sodium bi carbon-
ate , the erythro nitro ester 90a was obtained as a sole product by trans
opening of 85a251. The nitro esters 89 & 90 were converted to the amino
acids 91 & 92 through the nitro acids 93 & 94 or the amino ester 88.
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Cyclodehydration of the amino acids 91 & 92 in boiling xylene gave the
lactams 86 & 87 in good yield, respectively. Treatment of the amino acid
91 with dicyclohexylcarbodiimide(DCC) and 1-hydroxybenzotriazole (HOBt)
also effected cyclization to give the lactam (86). Treatment of the amino
ester (88) with methylsulfinyl carbanion in dimethyl sulfoxide (DMSO) eas-
ily gave the lactam 86 at room temperature.
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For the synthesis of optically active isomers of (86b) optical resolution of
the intermediate amino acid (91a) was effected with methyl L- or D-(4-
hydroxyphenyl)glycinate. More practically the nitro acid 93a could be re-
solved into its enantiomers via diastereoisomeric salts of L-lysine.
Yamada S.-I. et al252  suggested that among the various esters of 3-(4-
methoxyphenyl)glycidic acid, 4-chloro- 3-methylphenyl ester (±)-96 was
found to exist as a conglomerate, and could be alternately resolved into
(+)- and (-)-96 of >98% ee by a preferential crystallization procedure. Fur-
thermore, a 1,5-benzothiazepine derivative, (+)-97, a significant interme-
diate of diltiazem, was prepared in one pot in 76% overall yield through the
treatment of enantiomerically pure (-)-96 with 2-aminothiophenol followed
by a ring closing reaction (Scheme-28).
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G.Singh et al253 have synthesized (±)-cis-2-(4-Methoxyphenyl)-3-hydroxy/
methoxy-6-ethoxy/phenoxy-2,3-dihydro-1,5-benzothiazepin-4-[5H/5-
chloroacetyl/5-(4’ -methylpiperazino-1’ )acetyl]-ones by the condensation
of 2-amino-3-ethoxy/phenoxybenzenethiol with methyl-(±)-trans-3-(4-
methoxyphenyl)glycidate in xylene. Ribofuranosides, viz. (±)-cis-2-(4-
methoxyphenyl)-3-methoxy-6-ethoxy/phenoxy-2,3-dihydro-1,5-be
nzothiazepin-4-[5-(2’ ,3’ ,5’ -tri-O-benzoyl-â-D-ribofuranos yl)]-ones, have
been synthesized by the treatment of 3-methoxy derivatives of 1,5-
benzothiazepines with a derivative, sugar viz. â-D-ribofuranose-1-acetate-
2,3,5-tribenzoate, in toluene in vacuo. The structures of all the synthesized
ribofuranosides and their precursors have been characterized on the ba-
sis of elemental analyses and IR, 1H NMR, and 13C NMR spectral data. These
compounds were screened for their antimicrobial activity (Scheme-29).
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(±)-cis-2-(4-Methoxyphenyl)-3-hydroxy/methoxy-6-
ethoxy/phenoxy-2,3-dihydro-1,5-benzothiazepin-4-
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Scheme-29
?Solid phase reactions, microwave assisted &/or one pot synthesis
and   Green chemistry approach &/or solvent free synthesis.
Developing solution or solid-phase synthetic routes which can provide a
large range of medicinally relevant compounds in high purity has remained
a challenge which has been successfully met in several instances254-255.
George C. Morton et al256 have synthesized 3-amino-1,5-benzothiazepine-
4-one derivatives using 3-amino group as a point of attachement to the
Wang resin and exploited wide variety of commercially available o-halo
nitro benzene derivatives and facile substitution of the benzothiazepine
amide nitrogen. As per shown in scheme 30, cysteine (99) was reacted
with the nitrophenyl carbonate derivative of Wang resin 100 by first using
bis-(trimethylsilyl)-acetamide(BSA) to dissolve the amino acid (Scheme 30).
The thiol 100 was then reacted with a variety of halo-nitrobenzene deriva-
tives 101. Formation of up to 25% of cystine by dimerization of
the resin-bound cysteine was observed during this step. This could be
suppressed by us ing a  s t r ic t ly  iner t  a tmosphere and 1 ,8-
diazabicyclo[5.4.0]undec-7-ene(DBU) as base. Alternatively, cysteine could
be cleanly reduced with tributyl phosphine and further reacted with the
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Scheme-30: (a) (1) BSA, DMF, argon, rt; (2) 10% AcOH in DMF;
(b) X=Cl, Br or F, DBU, DMF, argon, rt; (c) SnCl22H2O, DMF, rt;
(d) EDC, NMP, rt; (e) m-CPBA, DCM, rt
halo-nitrobenzene derivative. Reduction of the nitro group with tin-dichloride
dihydrate and cyclization with ethylene dischloride afforded the benzothiazepine
derivative 104. Further diversity could be obtained by oxidation of the sulfide
104 to the sulfone 105 with m-chloro per benzoic acid.
Schwarz M.K. et al257 suggested a solid-phase route affording novel 3,5-dis-
ubstituted 1,5- benzothiazepin-4(5H)-ones in optically pure form. S(N)Ar re-
action of polymer-bound 4-fluoro-3-nitrobenzoic acid, 108, with L-Fmoc- cys-
teine, L-13, under basic conditions, followed by tin(II) chloride mediated nitro
group reduction, furnished the primary aniline 110. Reductive alkylation of 110
to the corresponding secondary anilines 112 was shown to be feasible for a
wide range of aldehydes, using an optimized solvent system composed of
trimethylorthoformate, dimethylformamide, methanol, and acetic acid, with
sodiumcyanoborohydride as the reducing agent. Subsequent cyclization of the
secondary anilines 112 using DIC in apolar solvents furnished the correspond-
ing N(5)-alkylated 1,5-benzothiazepin-4- ones 114. Following Fmoc removal
from 114, the primary amino group was finally reacted with carboxylic acids,
isocyanates, sulfonyl chlorides, or aldehydes to afford the respective amides,
ureas, sulfonamides, or secondary amines. Performing the synthesis with the
D-form of  Fmoc-cysteine, D-13, resulted in the corresponding antipodal prod-
ucts, with no detectable scrambling at C-3.(Scheme-31)
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Roland Braun et al258 have synthesized 2,4-Di(hetero)aryl substituted 2,3-
dihydro 1,5-benzoheteroazepines (hetero ) NH, O, S) in a one-pot process
initiated by a coupling-isomerization sequence of an electron poor
(hetero)aryl halide and a terminal propargyl alcohol subsequently followed
by a cyclocondensation with 2-amino, 2-hydroxy, or 2-mercapto anilines.
The investigation based on the principle that  palladium/copper catalyzed
crosscoupling reactions of electron poor halogen substituted ð-systems and
1-aryl prop-2-yn-1-ols do not furnish the expected propargyl alcohols but
rather the isomeric enone components259. Mechanistically, this isomeriza-
tion, occurring after the cross-coupling reaction, is purely base catalyzed
and opens a new access to electron deficient propenones (Scheme-32).
EWG-   -Hal + CH
Ar
OH 2% (Ph3P)2PdCl2, 1%CuI
NEt3, THF, reflux
EWG-   Ar
O
NH2
SH
S
N
Ar
-EWG
X = NH,S,O
2,4-Di(hetero)aryl substituted 
2,3-dihydro-1,5-benzoheteroazepines
1-aryl prop-2-yn-1-ols Scheme-32
Mitsuo Kodomari et al260 have described solvent free synthesis of 1,5-
benzothiazepines on inorganic supports, from chalcones and o-
aminophenol. The results of the reaction of o-aminothiophenol with chal-
cone in the presence of various solid supports were shown in Table 1.1.
From these results, Silica was found to be an effective support for the syn-
thesis of 1,5-benzothiazepines, under identical experimental conditions.
NH2
F
NO2
COOH
HATU, DiEA 
DMF
NH
O
F
NO2
1. L-Fmoc-Cys (L)-13, 
DiEA DMF       
2. SnCl2.2H2O, DMF NH
O
NRR'
S
NHFmoc
COOH
109, 109aa (R, R' = O)      
110, 110ab (R, R' = H)  
111 (R=H, R' = Me)  
1. R1-CHO, CH(OMe)3, DMF, AcOH, MeOH 
2. NaCNBH3, THF, 3. 2% AcOH/H2O
NH
O
NH
S
NHFmoc
COR R1
1. DIC, Benzene, CH2Cl2        
2. Piperidine, DMF
NH
O
N
S
O
R1RHN
114. R = Fmoc 
115. R = H
112. R = OH                                       
113. R = N(i-Pr)CO-NH(i-Pr)
108
107
106
a Product derived from TFA cleavage of 109    bProduct derived from TFA cleavage of 110
Scheme-31
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+
S
N
Ar1
Ar2
NH2
SH
2-aminobenzenethiol
Ar1 Ar2
O
SiO2, 80
oC, 3h
Chalcones
1,5-benzothiazepinesTable 1.1 : Reaction of o-aminothiophenol 
with chalcones in the presence of various 
supports
Support       %Yield of benzothiazepine
Silica Jel                87
Acidic alumina      28
Basic alumina       2
Neutral alumina      21
Molecular sieves(5 oA)     30
Keiselguhr       5
None        22
Scheme-33
Cheng Leng Lee et al261 demonstrated solid phase combinatorial synthe-
sis of 2,3-dihydro-1,5-benzothiazepines from bis-2(2-nitro-4-carboxy
phenyl)disulphide loaded on Wang resin. The nitro group was reduced to
its amine with concomitant cleavage of the disulphide bond using
tin(II)chloride, which followed by nucleophillic attack on α,â-unsaturated ke-
tone and tri fluoro acetic acid cleavage from  resin (Scheme-34).
254.M.Bilodeau, A.Cunningham, J. Org. Chem.,63, 2800(1998)
255.B.Dressma, L.Spangle, S.Kaldor, Tetrahedron Lett.,37, 937(1996)
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F. Herpin, Tetrahedron Lett., 41, 3029(2000)
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Scheme-34
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WORK DONE AT OUR LABORATORY
The literature survey of the work done on benzofused seven membered
heterocycles suggest  that 1,5-benzothiazepine derivatives have shown
diversed pharmacolocal profile including  antihypertensive/Ca+2 channel
antagonist, coronary vasodilators, peripheral or mitochondrial benzodiaz-
epine receptor antagonist, anticonvulsants, antiischemics, antiarrhythmics,
anticancer agents, anti HIV agents(non nucleotide reverse transcriptase
inhibitors), platelet aggregation inhibitors, antimicrobial agents and
angiotensine converting enzyme inhibitors etc.
In addition to this, 4-hydroxy coumarin and its derivatives are well known
for their anticoagulant and antimicrobial activities.3-substituted-4-hydroxy
coumarins generated considerable interest in designing HIV protease in-
hibitors with high therapeutic index. Among these, most  interestingly find-
ing suggested that 4-hydroxy coumarin derivatives substituted with bulky
group occupied at 3-position exhibited a wide range of diversed biologi-
cal activity profile.
 With this innovative idea, in the current chapter  we decided to synthesize
2-arylsubstituted-2,3-dihydro-1,5-benzothiazepine derivatives possesing 4-
hydroxy coumarin substitution at  4-position of 1,5-benzothiazepine sys-
tem, which were not studied so far in the literature. The chemistry devel-
oped to synthesize such derivatives included Pechmann condensation to
afford (un)substituted-4-hydroxy coumarin system followed by acetylation
with selective Lewis acids and chalcone formation by Knoevenagel reac-
tion with different substituted aromatic aldehydes. Finally regioselective
nucleophilic attack followed by Micheal additionby reaction of á,â- unsatur-
ated ketones with o-aminothiophenol yielded target compounds.
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The reaction scheme designed to synthesize target compound  consist of
four steps. The first step deals with the synthesis of (un)substituted 4-hy-
droxy coumarins by Pechmann condensation between (un)substituted
phenols  and malonic acid using anhydrous zinc chloride and phosphorous
oxy chloride as condensing agents, which are further acetylated in second
step with glacial acetic acid and POCl3 to yield 3-acetyl-4-hydroxy
coumarins, due to comparative acidic nature of methyl group of 3-acetyl
substitution, on treatment with different aromatic aldehydes it undergoes
Knoevenagel condansation in basic condition to give corresponding
chalcones. There were 21 chalcones synthesized using corresponding aro-
matic aldehydes in third step. Finally these chalcones on treatment with 2-
aminothiophenol under basic condition afforded 4-hydroxy-3-(2-substituted
phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H-chromen-2-ones.
All the synthesized compounds were characterized by IR,H1NMR and Mass
spectral data and C,H,N elemental analysis.
Finally the synthesized compounds were screened for different biological
activities.
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 Experimental Protocols
All the starting materials, Phenol, Malonic acid, Zinc chloride, POCl3,
Gla. AcOH, substituted aro matic aldehydes and o-Aminothiphenol were
obtained from Spectrochem Ltd., Sisco Research Lab., s.d.fine chem. Ltd.,
Ranbaxy Lab., and other commercial sources. Melting points of the synthe-
sized compounds were recorded by open capillary method  on controlled
temperature using standard Zeal’s thermometer and are uncorrected.
The commencement of the reaction and purity of the synthesized compounds
were ensured using thin layer chromatography (TLC) silica gel-G, used as
stationary phase, the TLC plates were purchased from Merck India Ltd.
ethyl acetate: hexane  was used as the mobile phase. However other sol-
vent systems like acetone :benzene and CHCl3:CH3OH were also employed
but the best results observed with Ethyl acetate:Hexane system.
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Experimental
Synthesis of 4-Hydroxy-2H-chromen-2-one:
In  a  250ml  Round Bot tomed Flask,  phenol (0.1mole)  ,  malon ic
acid(0.11mole),  anhyd .  z inc chlor ide(36gms) and  phosphorous
oxychloride(40ml) were mixed together  and heated on a waterbath at
65-70oC till the reaction mass become viscous. The reaction mass
poured into crushed  ice. The crude product was filtered and  thoroughly
washed  with water till became acid free. The crude product was treated
with saturated solution of sodium carbonate and  filtered. The filterate
was acidified with 30%HCl solution to give 4-hydroxy-2H-chromen-2-one,
which was filtered and dried and recrystallized from methanol. Yield 73%,
m.p. 212-213oC(Reported m.p. 210oC262). Purity was check by TLC using
ethyl acetate:hexane(4:6) as mobile phase.
Synthesis of 3-Acetyl-4-hydroxy-2H-chromen-2-one :
4-hydroxy-2H-chromen-2-one (0.06mole, ) was dissolved in glacial ace-
tic acid(50ml) then POCl3(40ml) was added and the reaction mixture
was refluxed in a waterbath  for 2 hrs. Pour the reaction mass into crushed
ice. Filter the solid and wash thoroghly with water till become acid free.
Recrystallized from methanol, Yield was 87%, m.p. 122oC(Reported m.p.
121oC262). Purity was checked  by TLC using ethyl acetate: hexane(3:7) as
mobile phase.
Synthesis of  4-Hydroxy-3-[(2E)-3-substituted phenyl-2-propenoyl]-2H-
chromen-2-ones (General Method):
A mixture of (un)substituted benzaldehyde (0.01mole) and 3-acetyl-4-hy-
droxy-2H-chromen-2-one (0.01mole) with catalytic amount of caustic lye
were refluxed  in ethanol, which on cooling give corresponding  chalcone
in  good yields which were purified by recrystallization from methanol. Pu-
rity of each compound was checked  by TLC using ethyl acetate:hexane(5:5)
as mobile phase.
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Synthesis of 4-Hydroxy-3-(2-substituted phenyl-2,3-dihydro-1,5-
benzothiazepin-4-yl)-2H-chromen-2-ones (General method):
A  mixture of appropriate 4-hydroxy-3-[(2E)-3-substituted  phenyl-2-
propenoyl]-2H-chromen-2-one (0.01mole) and o-Aminothiophenol
(0.01mole)  were refluxed in chloroform using piperidine as catalyst. The
commencement and completion of  the reaction was governed by TLC.
At the end of reaction solid product obtained was filtered, washed with
little amount of solvent. The crude product was recrystallized from chlo-
roform. Purity was checked by TLC using ethyl acetate:hexane (5:5) as
mobile phase.
The elemental analysis of all the compounds performed by PERKIN ELMER
470R are in total agreement with the theoritical values.
The physical constants and elemental analysis of all compounds were
shown in Table. 2.1.
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SPECTRAL CHARACTERIZATION
The constitution of newly synthesized compounds were supported by FT -
IR, 1H NMR and  EI-Mass spectral study.
 IR Spectral Study
Instrument: SHIMADZU FT-IR 8400 Spectrophotometer
Sample technique: KBr pellet
Frequency range: 400-4000 cm-1
The 4-hydroxy-3-(2-substituted phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H-
chromen-2-ones (KUT Series), indicates the presence of very specific
functional groups like hydroxy group of coumarin skeleton, carbonyl group
of  the lactone system, C=Nstr, C-H str.( methylene and methyne group)
and C-S str. vibration of thiazepine ring, aromatic ring skeleton etc.,  which
absorb IR radiations of specific frequency and show sharp, medium or
weak intense signals and hence supports in identif ict ion and confir-
mation of the molecule.
The IR spectrums of 4-hydroxy-3-(2-substituted phenyl-2,3-dihydro-1,5-
benzothiazepin-4-yl)-2H-chromen-2-one  shows common  frequences as 3460-
3300cm-1 for hydroxy group, 3150-3110cm-1 for aromatic C-H str.,1690-
1760cm-1 for  C=O str. of lactone group, 1630-1605cm-1 for C=Nstr. merge
with aromatic ring  where as aromatic region was observed  extended upto
1480cm-1. C-H inplane deformation of methylene group was observed in
range between 1470-1450cm-1,while that of methyne group was observed
bet ween 1400-1320cm-1. Thioether linkage of thiazepine ring shows C-S
str. range between 700-555 cm-1. Mono,di & tri phenyl substitutions ob-
served between 875-740cm-1.  While characteristic vibration corresponds
to substitution at phenyl residue was clearly observed in each case.
A comparative chart of IR spectral data of all compounds is shown in Table-2.2.
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  IR Spectrum of 4-Hydroxy-3-(2-(3,4,5-trimethoxy)phenyl-2,3-dihydro-1,5-benzothiazepin-4-
   yl)-2H-chromen-2-one (KUT-18)
      KUT-6 KUT-5
S
N
O
OH
O
OCH3
H3CO OCH3
SN
O
O
H
O
O
C
H
3
   IR Spectrum of 4-Hydroxy-3-(2-(3-methoxy)phenyl-2,3-dihydro-1,5-benzothiazepin-4-
   yl)-2H-chromen-2-one (KUT-5)
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HO- .rtsH-O 3243
HC-
citamorA .rtsH-C- 5313
O=C- .rtsO=C 3171
N=C- N=C- 8061
citamorA
notelekS
.rts-C=C- 1641,2151,8851
noitutitsbusartet5:4:3:1 578
enelyhteM .rtsH-C- 2541
enyhteM .rtsH-C- 6231
rehteoihT .rtsC-S-C 666
HCO- 3
.rtsH-C-
.rts-C-O-C-
0382,2392
5911,7221
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HO- .rtsH-O 6043
HC-
citamorA .rtsH-C- 5313
O=C- .rtsO=C 2171
N=C- N=C- 0161
citamorA
notelekS
.rts-C=C- 2841,3551,1851
noitutitsbusid3:1 577
enelyhteM .rtsH-C- 7641
enyhteM .rtsH-C- 8931
rehteoihT .rtsC-S-C 007
HCO- 3 .rts-C-O-C-,.rtsH-C- 8911,5192
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  IR Spectrum of 4-Hydroxy-3-(2-(3,nitro)phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H -
   chromen-2-one (KUT-3)
   IR Spectrum of 4-Hydroxy-3-(2phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H-chromen-2-
   one (KUT-1)
      KUT-3 KUT-1
S
N
O
OH
O
N+
O-
O
S
N
O
OH
O
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HO- .rtsH-O 9833
HC-
citamorA .rtsH-C- 2513
O=C- .rtsO=C 9961
N=C- N=C- 8061
citamorA
notelekS
.rts-C=C- 7251,7551,4851
noitutitsbusid4:1 128
enelyhteM .rtsH-C- 3841
enyhteM .rtsH-C- 6931
rehteoihT .rtsC-S-C 086
ON- 2 .rtsO-N 5531
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HO- .rtsH-O 9833
HC-
citamorA .rtsH-C- 5313
O=C- .rtsO=C 1171
N=C- N=C- 9061
citamorA
notelekS
.rts-C=C- 1841,3551,1851
noitutitsbusonom 557
enelyhteM .rtsH-C- 7641
enyhteM .rtsH-C- 6231
rehteoihT .rtsC-S-C 356
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1H NMR Spectral Study
1H NMR Spectrum of the 4-hydroxy-3-(2-substituted phenyl-2,3-
dihydro-1,5-benzothiazepin-4-yl)-2H-chromen-2-ones show  signals relevant
to the number of protons and their  electronic environment known as chemi-
cal shift.  Chemical shift may move to either upfield (Shielding) or down
field(deshielding), according to the  electronic environment of the corre-
sponding proton.  In addition  to  this each 1H NMR signal  further splitted
into  number of subpeaks  according  to  the  number of neighbouring  pro-
tons present in the skeleton of molecule. The splitting of the NMR signal
further provides signification about the degree of  interaction  between
neighbouring  protons by means of spin-spin coupling constant  J.
4-Hydroxy-3-(2-(4-thiomethyl)phenyl-2,3-dihydro-1,5-benzothiazepin-4-
yl)-2H-chromen-2-one (KUT-16)
1H NMR Spectrum of KUT-16 shows a singlet for  thiomethyl protons , at
chemical shift value δ 2.469 ppm.  A  triplet relevant  to methyne proton
of the thiazepine ring, appears at  δ 2.741 with J value of 12 & 12Hz,
which reveals the presence of one methylene neighbouring group. A
dounlet due to two protons of methylene group,  appears at  δ  4.320  with
J value of 10Hz,  which reveals the presence of one adjacent methyne  group
in the same thiazepine ring. Proton H(5)& H(D) of benzenoid part of coumarin
residue and 1,5-benzothiazepine system become most deshielded, hence
each appears as doublet at chemical shift value of δ 8.118  & 7.771 with J
value of 6.6Hz  and 6.6Hz respectively, which reveals that because of only
one proton involve in the splitting of their signals, H(5) &  H(d)  become near-
est protons from junction of  fusion,  Protons H(8) & H(A) are also protons of
another ends of  the benzenoid part of the coumarin ring and 1,5-
benzothiazepine, evidence by  their appear ance as two doublets at merge
chemical shift value 7.558δ ppm with J value of 8.7 & 7.2Hz respectively.
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Protons H(B), H(C), H(6), H(7), H(d) and H(e) experience almost same elec-
tronic environmnet resulting to give merge signal as multiplet at chemi-
cal shift range between δ 7.397-7.198. The hydroxy proton resonates at δ
13.623.
4-Hydroxy-3-(2-(4-nitro)phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H-
chromen-2-one (KUT-15)
In 1H NMR Spectrum of KUT-15  a triplet due to methyne proton, appears at
δ 2.801 with J value of 11.4 & 12.6Hz, where asa doublet relevant  to two
methylene protons appears at δ 3.339 with J value of 13.2Hz,  which re-
veals that methyne &  methylene are neighbouring protons in a same
thiazepine ring. Proton H(5), H(A) & H(D) of benzenoid part of coumarin resi-
due and 1,5-benzothiazepine system become most deshielded,  experi-
ence almost same electronic environmnet resulting to give multiplet at
chemical shift  range between δ 8.212-8.099. Protons H(e)  of phenyl resi-
due appears as doublet at δ 7.453 with J value of  8.4Hz. Proton H(7) of
benzenoid part of coumarin ring resonate at 7.632δ ppm as triplet with
Jvalue of 7.8 & 7.5Hz.  Protons H(B), H(C), H(A), H(d) & H(6)  experience almost
same electronic environment and their resonance resulting as multiplet at
chemical shift range between δ 7.402-7.261 ppm.  A signal for the hydroxy
proton appears at  δ 13.628.
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4-Hydroxy-3-(2-(4-chloro)phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-2H-
chromen-2-one (KUT-10)
1H NMR Spectrum of KUT-10 shows a triplet  for methyneproton at  δ2.725
ppm with  J value of 12.3 & 12.3Hz,  where as a doublet  due  to two pro-
tons of methylene group  appears at  δ 4.330  with J value of 11.1Hz,  which
reveals the presence of a methyne &  a methylene group as neighbour  to
each other . Proton H(5) &  H(D) of benzenoid part of coumarin residue and
1,5-benzothiazepine system become most deshielded, hence each appears
as doublet at chemical shift value of 8.125  & 7.776δ ppm with J value of
7.8Hz  and 7.5Hz respectively.  Protons H(8) & H(7)  as well as  protons H(d) &
H(e)  felt almost same electronic environment  and resonated  to give mul-
tiplets at range between δ 7.638-7.532 and δ 7.412-7.357 respectively. Pro-
tons H(A), H(B), H(C) and H(6) experience almost same electronic environment
resulting to give merge signal as multiplet at chemical shift value range
between δ 7.309-7.260 ppm. Where as a the hydroxy proton resonates at
12.625δ ppm
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1H NMR Spectrum of 4-Hydroxy-3-(2-(4-thiomethyl)phenyl-2,3-dihydro-1,5-
benzothiazepin-4-yl)-2H-chromen-2-one (KUT-16)
                           KUT-16
S
N
O
OH
O
H(e)
H(e)
SCH3
H(A)
(B)H
(C)H
H(D)
H(b)
H(b)
H(d)
H(d)
H(8)
H(7)(6)H
(5)H
H(a)
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM
eulaVJ
)zH(
HC- )a( 147.2 1 t 0.21&0.21
HC- )b(2 023.4 2 s 01
HCS- 3 964.2 3 s -
H-rA )D( 177.7 1 d 6.6
H-rA )8,A( 855.7 2 d2 2.7&7.8
H-rA )7,6,e,d,c,b( 891.7-793.7 8 m -
H-rA )5( 811.8 1 d 6.6
H-O 326.31 1 s -
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1H NMR Spectrum of 4-Hydroxy-3-(2-(4-nitro)phenyl-2,3-dihydro-1,5-
benzothiazepin-4-yl)-2H-chromen-2-one (KUT-15)
                           KUT-15
S
N
O
OH
O
H(e)
H(e)
H(A)
(B)H
(C)H
H(D)
H(b)
H(b)
H(d)
H(d)
H(8)
H(7)(6)H
(5)H
H(a)
N+ O-
O
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HC- )a( 108.2 1 t 6.21&4.11
HC- )b(2 933.3 2 d 2.11
H-rA )D,8,5( 990.8-212.8 3 m -
H-rA )e( 454.7 2 d 4.8
H-rA )7( 236.7 1 t 5.7&8.7
H-rA )6,d,A,C,B( 162.7-204.7 6 m -
H-O 826.31 1 s -
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1H NMR Spectrum of 4-Hydroxy-3-(2-(4-chloro)phenyl-2,3-dihydro-1,5-
benzothiazepin-4-yl)-2H-chromen-2-one (KUT-10)
                           KUT-10
S
N
O
OH
O
H(e)
H(e)
H(A)
(B)H
(C)H
H(D)
H(b)
H(b)
H(d)
H(d)
H(8)
H(7)(6)H
(5)H
H(a)
Cl
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HC- )a( 527.2 1 t 3.21&3.21
HC- )b(2 033.4 2 d 1.11
H-rA )D( 677.7 1 d 5.7
H-rA )8,7( 235.7-836.7 2 m -
H-rA )e,d( 753.7-214.7 4 m -
H-rA )8,C,B,A( 062.7-903.7 4 m -
H-rA )5( 521.8 1 d 8.7
H-O 526.21 1 s -
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EI MASS Spectral Study
As EI-Mass spectrum of the  4-Hydroxy-3-(2-substituted phenyl-2,3-
dihydro-1,5-benzothiazepin-4-yl)-2H-chromen-2-ones exhibited special fea-
tures like molecular ion peak and fragmentation pattern relavent  to the
nature of the molecule, it become one of the most important tool for char-
acterization of the the structure of molecule.
4 - H y d r o x y - 3 - ( 2 - ( 4 - t h i o m e t h y l ) p h e n y l - 2 , 3 - d i h y d r o - 1 , 5 -
benzothiazepin-4-yl)-2H-chromen-2-one (KUT-16)
Molecular Ion peak  at m/z 445, a peak due to loss of methyl and hydroxy
group from molecular ion was observed at m/z 412, the peak at m/z 308
reveals loss of hydroxy and thiomethyl phenyl group from the molecular ion,
where as base peaks observed at m/z 137 and 150, other ions observed
are m/z 295, m/z 175, m/z 122 etc.
 4-Hydroxy-3-(2-(4-nitro)phenyl-2,3-dihydro-1,5-benzothiazepin-4-yl)-
2H-chromen-2-one (KUT-15)
Molecular Ion peak  at m/z 444, a peak due to loss of 4- hydroxycoumarin group
from molecular ion was observed at m/z 280, where as base peak observed at
m/z 308, other ions observed are m/z 252, m/z 188, m/z 160, m/z 121 etc.
4-Hydroxy-3-(2-(4-Fluoro)phenyl-2,3-dihydro-1,5-benzothiazepin-4-
yl)-2H-chromen-2-one (KUT-12)
Molecular Ion peak along with typical characterestic ionization patern of
(m+1), (m+2), (m-1) peaks of fluoro substitution observed  at m/z 417, a
peak due to loss of 4- hydroxycoumarin group from molecular ion was ob-
served at m/z 280,  where as base peak observed at m/z 308, other ions
observed are m/z 295, m/z 256, m/z 160, m/z 175 etc.
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CHAPTER-3
 Synthesis and Characterization of Some 2-
     Amino -6-alkyl/alkylaryl-5-oxo-4-substi
tuted phenyl-5,6-dihydro-4H-pyrano[3,2-c]
  quinoline -3-carbonitriles
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Introduction
4-hydroxy-2-quinolones are important compounds, not only because this moiety
is present in a number of natural products but quite a few derivatives exhibit
variety of interesting pharmacological properties1. While pyranofused hetero-
cycles are biologically important as antibacterial2, antihistamines3, antimicrobi-
als4, enzyme substrates5 and alkaloids6. Pyranoquinolinones shows good phar-
macological activities1,7 such as, antibacterial, antimicrobial, anti-HIV and anti-
viral and antitumor. The derivatives of fused 2-quinolones are useful as cardio-
vascular agents7. Quinolone alkaloids are known to possess antimicrobial ac-
tivity and marked cytotoxicity against animal and plant tumors7.1. A novel class of
4-hydroxyquinolin-2(1H)-ones has recently been described7.2 as selective
glycinesite NMDA antagonists with potent in vivo activity after oral administra-
tion. However, depending on their structural types, quinolone derivatives exhibit
different activities 7.3. Furo[2,3-c]quinolin-4(5H)-one and 2H-pyrano[3,2-
c]quinolin-5(6H)-one derivatives are abundantly distributed in nature 7.4.
?Quinolone alkaloids
1-methyl tetradecylquinolin-4(1H)-one (1), was isolated from the fruits of
Evodia rutaecarpa together with evocarpine (2) and related alkadienes (3)
and (4) after act ivi ty-guided fract ionation based on inhibit ion of
diacylglycerol acyltransferase (DGAT)8.
These are the first quinolone alkaloids to have been tested as DGAT inhibitors;
the moderate activity of the purified compounds (IC50 69.5, 23.8, 20.1 and
13.5 ì M, respectively) indicates possible ut i l i ty in the design of
hypolipidaemic and antiobesity agents. Evocarpine and the positional isomer
(5) showed strong antibacterial activity against Helicobacter pylori both in
vitro and in vivo by inhibiting respiration, the results reinforcing previous
indications of this class of alkaloids as novel therapeutical agents for the
treatment of ulcers9. Another Evodia alkaloid, 1-methyl-2-undecylquinolin-
4(1H)-one (6), has proved to be an irreversible and selective inhibitor of
type B monoamine oxidase (Ki 0.01 ì M), suggesting potential value in the
treatment of neurological disorders such as Parkinson’s andAlzheimer’s
diseases and Huntington’s chorea10. The related alkaloids (7–9) from the
genus Boronia, all with saturated side chains, showed moderate to significant
ability to inhibit the growth of several pathogenic bacteria11.
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8 R1 = H, R2 = n-C9H19  
9 R1 = R2 = CH3  
The herb rue (Ruta graveolens), known since antiquity for its medicinal
properties, continues to yield new alkaloids. Bioassaydirected isolation of
antifungal compounds from a leaf extract produced the previously unknown
alkaloid (10), and the related compounds graveoline (11) and rutavarin (12)
in which methylene “spacers” of different lengths separate the quinolone
and aromatic moieties, as well as 1-methyl-2-nonylquinolin-4(1H)-one12. All
of the purified alkaloids inhibited the growth of seven different fungi to a
greater or lesser extent; Phomopsis species were especially sensitive,
while the new alkaloid (10) was highly active against Botrytis cinerea even
at a low concentration (30 ì M). In a separate investigation of the biological
activity of R. graveolens metabolites, graveoline (11) was found to be
cytotoxic towards the HeLa cancer cell line (ED50 3.35 ì g ml-1), and its
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isomer graveolinine (13) was an effective inhibitor of platelet aggregation
induced by arachidonic acid and collagen at low concentration (5 ì g  ml-1)13.
A related alkaloid from Galipea longi.ora, compound (14), inhibited the
growth of cells infected with human T-lymphotropic virus type 1 (HLTV-1) at
a concentration of 10 ì M, but less effectively than a number of synthetic
quinolines, among them the simple compound 2-vinylquinoline14.
N
O
R
(CH2)n O
O
10 R = CH3  n = 6                   
11 Graveoline R = CH3 n = 0 
12 Rutavarine R = H, n = 4  
13 Graveoliline R = OCH3 n = 0  
14 R = H; n = 2  
N
R
(CH2)n O
O
It has been known for some time that simple quinoline alkaloids from Galipea
and related rutaceous genera show substantial trypanocidal, antileishmanial
and antimalarial activity. Some of these findings have now been reviewed
by Fournet and Munoz15. One of the simplest Galipea alkaloids,2-
propylquinoline, has been proposed as a new oral treatment for visceral
leishmaniasis after it was found to have decreased intestinal P-glycoprotein
activity in mice infected with Leishmania donovani16.
The unique structural feature in helietidine (15), a new alkaloid isolated
from the Brazilian medicinal plant Helietta longifoliata17, is the pyrano[3,2-
g]quinoline ring system, hitherto unprecedented among the hemiterpenoid
quinoline alkaloids; indeed, even 6-prenylquinolines, likely precursors for
this tricyclic ring system, are unknown as natural products. The structure
was presented as a quinolin-2-ol, but the quinolin-2-one tautomer is
undoubtedly more plausible.
8.J.Ko, M.Rho, M.Chung, H.Song, J.Kang, K.Kim, H.Lee,Y.Kim, Planta Med.,68,1131(2002)
9.K.Tominaga, K.Higuchi, N. Hamasaki, M.Hamaguchi, T.Takashima, T.Tanigawa,
T.watanabe, Y.Fujiwara, Y.Tezuka, T.Nagaoka, S.Kadota, E.Ishii, K.Kobayashi, T.Arakawa,
J.Antimicrob.Chemother., 50, 547(2002)
10.M.Lee, B.Hwang, S.Lee,G.Oh,W.Choi, S.Hong, K.Lee, J.Ro, Chem. Pharm. Bull.,
51, 409( 2003).
11.S.Islam, A. Gray, P. Waterman, M. Ahasan,Phytother. Res.,16, 672( 2002).
12.A. Oliva, K.Meepagala, D.Wedge, D. Harries, A.Hale, G. Aliotta, S.Duke, J. Agric.
Food Chem., 51, 890(2003).
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CH3
CH3
OH
CH2
CH3 CH3
15 Helietidine  
Among the Melicope metabolites, confusadine (16)  was found to be a
noteworthy inhibitor of platelet aggregation triggered by various inducers18.
The new alkaloids were generally poorly cytotoxic towards a range of human
cancer cell lines, and substantially worse than the previously isolated Melicope
alkaloids confusameline (18) and dutadrupine (20) (ED50 0.03–2.3 ì g ml-1)19.
New furo[2,3-b]quinoline alkaloids with more conventional structures isolated
from the wood of the Madagascan plant Vepris punctata include 5-
methoxymaculine (21), 5,8-dimethoxymaculine (22)  and 4,5,6,7,8-
pentamethoxyfuroquinoline (23)20. The somewhat rare 6,7-methylenedioxy
substituent seen in the first two compounds is also present in flindersiamine
(24) and maculine, alkaloids previously isolated from this plant species and
confirmed in the present study. All the isolated compounds were weakly
cytotoxic towards the A2780 human ovarian cancer cell line. Among a range
of furoquinoline alkaloids isolated from Ruta graveolens, skimmianine (17)
and dictamnine (25) were significant inhibitors of platelet aggregation, while
dictamnine(25) and kokusaginine (19) were cytotoxic towards HeLa cancer
cell lines21. Dictamnine has itself been used as a starting material for the
synthesis of 4-anilinofuro[2,3-b]quinolines (26) (ArNH in place of OMe), several
of which were highly potent inhibitors of a number of human cancer cell lines.22,23.
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O
H3CO
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 = R3 = OCH3, R1 = H 
18 Confusameline R1
 = R3 = H, R2 = OH 
19 Kokusaginine R1
 = R2 = OCH3, R3 = H   
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23 R1
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26 R1 = H, R2 = NHAr   
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A cytotoxic fraction fromthe stem bark extract of Stauranthus perforatus,
was analysed by the comparatively rare technique of HPLC–NMR, HPLC–
MS measurements, showed the new compounds to be analogues of
veprisine (27) (7,8-dimethoxy-N-methyl.indersine), which had previously
been found in this species and which was again detected in this study. One
of the new alkaloids was (28), the 7,8-methylenedioxy equivalent of
veprisine, to which the name stauranthine was given. The remaining
alkaloids were oxidised analogues of both veprisine and stauranthine, and
included the trans-3,4-dihydroxy-3,4-dihydro derivatives (29) and (30), the
3,6-dihydroxy-3,6-dihydro derivatives(31) and (32), and the 6-hydroxy-3-
keto analogues (33) and (34). The 3,4-dihydroxypyran component in (29)
and (30) has previously been found in other rutaceous quinoline and acridone
alkaloids, but the involvement of the hemiterpenoid moiety in the remaining
alkaloids in hemiketal formation with a quinolin-4-one is unprecedented. It
is likely that trans-3,4- dihydroxy-3,4-dihydroveprisine (30) is identical to
the alkaloid araliopsinine, reported from Araliopsis tabouensis by Ngadjui
et al. in 198824.  Interestingly, the alkaloids of the stauranthine series were
all more stable than those of the veprisine series, perhaps reflecting the
greater tendency towards oxidation of the vicinal dimethoxy grouping as
compared with the methylenedioxy substituent. A pyrano[3,2-c]quinolone
alkaloid ravesoline was isolated from the leaves of Ravenia spectabilis24a.
20. V.Chaturvedula, J.Schilling, J.Miller, R.Andriantsiferana, V.Rasamison, D.Kingston,
J. Nat. Prod.,66, 532(2003).
21.T.Wu, L.Shi, J.Wang, S.Iou, H.Chang, Y.Chen, Y.Kuo, Y.Chang, C.Teng, J. Chin.
Chem. Soc.,50, 171(2003).
22.I.Chen, Y.Chen, C.Tzeng, I.Chen, Helv. Chim.Acta,85, 2214(2002).
23.I.Chen,Y.Chen, C.Tzeng, Chin. Pharm. J.,55,49(2003),Chem.Abstr., ,140,16835(2004).
24.B.Ngadjui, J.Ayafor, B.Sondengam, M.Koch, F.Tillequin, J.Connolly, Phytochemistry,
1988, 27, 2979.
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Pyranoquinoline alkaloids simulenoline (35, R=OH)25,26 and huajiaosimuline
(36)27 were isolated from root barks of Zanthoxylum simulans, a shrub found
in Taiwan and mainland China. While simulenoline (35, R=OH) was the most
recently isolated of the two alkaloids, a third pyranoquinoline alkaloid
zanthodioline (37) from the same species was just recently disclosed in the
literature25. These novel monoterpenoid pyranoquinolines are potent
inhibitors of platelet aggregation. For example, at a concentration of 100
ì g/mL, simulenoline (35, R=OH) demonstrates a nearly complete suppression
of platelet aggregation induced in vitro by collagen, arachidonic acid, and
PAF in general25.  While simulenoline (35, R=OH) and zanthodioline (37)
are not cytotoxic, huajiaosimuline(36) is toxic toward several human cultured
cell lines, especially the estrogen receptor-positive breast cancer cells, ZR-
75-127. Structurally, these alkaloids contain three fused six-membered rings
with a unique terpenoid side chain at C-2. The BC-ring is essentially the
quinolone nucleus, and the A-ring is a 2H-pyran. Where as three
pyranoquinoline alkaloids isolated were from stem bark of Formasan
Zanthoxylum simulans Hance(Rutaceae), namely simulenoline(35, R=OH),
peroxysimulenoline(35, R=OOH) and benzosimuline25
O
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O
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Pyrano[3,2-c]quinolin-5-one derivatives constitute a large group of naturally
occurring alkaloids represented by, e.g., flindersine 3826. These pyrano[3,2-
c]quinolin-5-one derivatives and their synthetic analogues are of current
research interest not only because they have a wide range of biological
activities and therefore have potential medical and other applications27b,28, but
also because they are often used as synthetic precursors for the preparation
of other natural products such as dimeric quinoline alkaloids29 and other
polycyclic heterocycles31. Several syntheses of  flindersine and benzene-ring-
substituted flindersine derivatives have been reported32. A suite of pyrano[3,2-
c]quinolinones isolated from the leaf extract of Vepris bilocularis, a forest tree
of south India,includes the known compound haplamine(6-methoxy flindersine)
and three new flindersine derivatives , namely 7-methoxyflindersine, 7-
prenyloxyflindersine  and Nmethyl-7-prenyloxyflindersine32a.
38: Flindersine O
N
H
O
CH3 CH3
O
N
H
O
CH3 CH3
H3CO
7-methoxy
flindersine
O
N O
CH3 CH3
OCH3
CH3
R
R=H Prenyloxyflindersine             
R=Me N-methyl prenyloxyflindersine 
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83B, 103(1983)
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?Antibiotic activity profile of Quinolone derivatives
The quinolone anti-infective agents are of wholly synthetic origin and are
not modeled knowingly after any natural antibiotic. Several ring systems
are or have been involved. Those of greatest prominence and their
numbering systems are illustrated in figure below33.
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The first antimicrobial quinolone discovered called nalidixic acid  demon-
strated Gram negative antibacterial activity , remains in the market today,
so-called first generation quinolones. Despite its convenient oral activity,
bactericidal action, and ease of synthesis, its limited antimicrobial spec-
trum (primarily activity against Escherichia coli) and poor pharmacokinetic
characteristics limit its use primarily to treatment of sensitive community
acquired urinary tract infections.
Norfloxacin, the first of the second-generation family of quinolones34. This
agent had dramatically enhanced and broader spectrum anti Gram-negative
activity and possessed significant anti Gram-positive activity as well. The
potency of norfloxacin was in the same range as that of many fermentation-
derived antibiotics, and its comparative structural simplicity and synthetic
accessibility lead to a very significant effort to find even more improved
analogues. Norfloxacin and its N-methyl analogue pefloxacin ultimately
failed to find major use outside of the genitourinary tract because of poor
active blood levels and limited potency against Gram-positives.
Shortly thereafter, ciprofloxacin35-37 and ofloxacin, 37,38 as well as its optically
active form levofloxacin39,  were introduced. The second-generation agents
have significant broad-spectrum antimicrobial activity including important
Gram-positive pathogens. This is coupled with gratifying safety and
pharmacokinetic characteristics.
A wide variety of clinical indications have been approved for quinolones
including many infections commonly encountered in community practice
including upper and lower respiratory, gastrointestinal and gynecologic
infections, sexually transmitted diseases, prostatitis, and some skin,bone,
and soft tissue infections40.
34.H.Koga, A.Ito, S.Murayama,  S.Suzue, T.Irikura,  J. Med.Chem.,23,1358(1980).
35. L.Jaber, E.Bailey, M.Rybak, Clin. Pharm., 8,97(1989).
36.R.Wise,  J.Andrews, L.Edwards, Antimicrob. Agents Chemother., 23, 559(1983).
37.K.Sato, Y.Matsuura, M.Inoue, T.Une, Y.Osada, H.Ogawa, S.Mitsuhashi, Antimicrob.
Agents Chemother.,22, 548(1982).
38.I.Hayakawa, T.Hiramitsu, Y.Tanaka, Chem. Pharm. Bull., 32, 4907(1984).
39. S.Atarashi, S.Yokahama, K.Yamazaki, K.Sakano, M.Imamura, I.Hayakawa, Chem.
Pharm. Bull.35, 1896(1987).
40.Physicians’ Desk Reference; Thompson PDR: Montvale, NJ, 2004.
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Recently introduced members of the fluoroquinolone family belong to the
third generation. These include gatifloxacin41 and moxifloxacin42 which
possess further enhanced activity against Gram-positive infections, and
anti-anaerobic coverage is now present although at present only
trovafloxacin43 is approved for this indication. Among the agents still in
preclinical study, clinifloxacin44 is the most promising anti-anaerobic agent.
When first introduced, there was no idea of the molecular mode of action
of these agents. Indeed, the availability of nalidixic acid was instrumental
in assisting the discovery of the targeted bacterial type II topoisomerases45.
Those of importance to the quinolones are bacterial topoisomerase II,46
also known as DNA gyrase, and bacterial topoisomerase IV47,48. These
enzymes are vital for dictating the proper topology of DNA important for
protein biosynthesis, DNA replication and repair, and DNA decatenation.
Fluoroquinolones form a ternary complex consisting of drug, DNA, and
enzyme that interferes with DNA transcription, replication, and repair and
promotes its cleavage, leading to rapid bacterial cell death. They are without
apparent  s ign i f icant  act ion on ind iv idual  molecules of  DNA or
topoisomerases alone, but the interaction of DNA with enzyme creates a
binding pocket for the quinolones.
Generally anti Gram-negative activity is more closely associated with DNA
gyrase inhibition and anti Gram-positive activity is more closely associated
with bacterial topoisomerase IV inhibition49. With a number of quinolones
activity is attributed to interference with the function of both of these
enzymes. For example, a survey of the ability of a collection of quinolones
to inhibit the catalytic action of topoisomerases showed that the ratio of
DNA gyrase to topoisomerase IV action for E. coli was between about 15
and 27, whereas for Staphylococcus aureus the ratio was reversed, with
topoisomerase IV inhibition over DNA gyrase inhibition being from about
1.7 to 2150. In a later study of 15 quinolones, they were divided into three
groups on the basis of their relative ability to inhibit S. aureus strains with
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a resistance mutant toward one or the other enzyme. With group I
(norfloxacin, enoxacin, fleroxacin, ciprofloxacin, lomefloxacin, trovafloxacin,
grepafloxacin, ofloxacin, and levofloxacin) topoisomerase IV was the more
sensitive target. With group 2 (sparfloxacin and nadifloxacin) DNA gyrase
was the more sensitive target. With group 3 (gatifloxacin, pazufloxacin,
moxifloxacin, and clinafloxcin) both were equivalently sensitive. The later
were termed the dual targeting quinolones48.
Human topoisomerase II is generally not inhibited by these agents at the
doses normally employed since it is often at least 100-1000times less
sensitive to them51. Despite significant homologies with the bacterial
enzyme, creative analoguing is able to distinguish clearly between them,
and safe agents are readily produced.
Absorption of quinolones following oral administration is usually good,
mostly 50% or better, and, in some cases, in excess of 95%52.They are well
distributed in the body; however, efflux pumps protect the central nervous
system to some extent53. Comparatively little metabolism takes place with
them, and excretion is mostly in active form in the urine.
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Overall, the quinolones possess antimicrobial spectra and potency attractive
for clinical use. In particular, they are bactericidal in achievable oral doses
and possess significant postantibiotic effects. These features are especially
useful for treating infections of immune-suppressed patients. Microorganisms
regarded as highly susceptible to quinolones have minimum inhibitory
concentration values ranging from 0.01 to 0.2 ì g/ml. Examples include E. coli,
Klebsiella pneumoniae, Enterobacter, Salmonella, Shigella, Vibrio,
Hemophilus influenzae, Neisseria, and Legionella. Less susceptible but still
sensitive microorganisms lie in the range of 0.25-2 ì g/ml. These organisms
include those that become resistant more easily. Especially notable are
Pseudomonas aeruginosa and S. aureus (with particular emphasis on MRSA).
Organisms that are regarded as insensitive have MIC values of 2 ì g/ml or
higher. Examples include Nocardia, Treponemia, and anaerobes.
A comparison of the susceptibilities of a wide number of pathogenic bacteria
with representatives of each generation of quinolones is presented in Table-1
Table 1. Antimicrobial Sensitivities of Selected Quinolonesa
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Resume of Structure-Activity Relationships of Quinolones
Figure-1 contains a pictorial summary of findings with reference to the parts
of the molecule that are presumed to be in contact with the enzyme, with DNA,
and with other quinolone moieties (thus forming the ternary complex). At the
left is a cartoon viewed from the top. In this view, north and south represent
DNA-binding sites wherein the keto and carboxyl groups hydrogen bond to
single-stranded segments made available to them by enzymic action. West
and east represent binding sites to DNA gyrase. In the interior of the complex,
the quinolone molecules are associated with each other through hydrophobic
contacts. Virtually every portion of the quinolone molecule is employed in one
or more of these interactions. The requirement for the enzyme to open a
saturable drug-binding pocket is implicit. The important role of having a basic
moiety attached to C-7 is also apparent. The need for the groupsattached to
N-1 and C-8 to be small and hydrophobic is also rationalized. The two
molecules are aligned “head to tail” with respect to each other by electrostatic
interactions involving the carboxyl and the amino substituents. A second pair
of interacting quinolone molecules can also be aligned in a vertical stack by
the ð- ð  interactions and the same electrostatic interactions.
            Figure-1. Proposed ternary
 complex drug-binding pocket.
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An end view with the N-1, C-8 edge closest to the viewer is shown on the
right side of the figure-1. The significance of the chiral preference conveyed
by the methyl group of flumequine and levofloxacin and their analogues is
rationalized by invoking the presence of a lipophilic drug-binding site above
and below the pocket. The methyl portion of the N-ethyl moieties is illustrated
as fitting into this pocket and providing a favorable interaction.
Pharmacology
?Voltage-Gated Potassium Channel Blockers (Kv1.3)
The Shaker-related K+ channel Kv1.3 is involved in the control of membrane
potential, production of lymphokines, and proliferation of human T-
lymphocytes54,55.  Inhibition of Kv1.3 channels causes depolarization which
reduces the electrochemical driving force for the increase in intracellular
Ca2+ concentration required for lymphocyte activation: stimulation of gene
transcription, production of lymphokines(e.g. interkeukin 2, IL-2), DNA
synthesis, and finally cell division54-56. The Kv1.3 channel has a limited
distribution in the periphery, being found mainly in B-cells, macrophages,
platelets, osteoclasts, and fibroblasts, besides T-lymphocytes. In addition,
the K+ channel in human T-cells is a homomultimer of Kv1.3 subunits in
contrast to the heterotetrameric form of channels in brain, where Kv1.3 is
combined with at least Kv1.1 and Kv1.2. Thus, a selective Kv1.3 blocker
may have ion channel selectivity against other tissues56.
41. J.Blondeau, Expert Opin. Invest. Drugs,9, 1877(2000).
42. C.Nightingale, Pharmacotherapy, 20, 245(2000).
43. T.Ling, E.Liu, A.Cheng, Chemotherapy,45, 22(1999).
44. N.Bron, M.Dorr, T.Mant, C.Webb, A.Vassos, J. Antimicrob. Chemother .,38 ,
1023(1996).
45. M.Gellert, K.Mizuuchi, M.O’Dea, H.Nash, Proc. Natl.Acad. Sci. U.S.A.,  73 ,
3872(1976).
46. N.Cozzarelli, Science,207, 953(1980).
47. J.Kato, Y.Nishimura, R.Imamura, H.Niki, S.Hiraga, H.Suzuki, Cell,63, 393(1990).
48.M.Takei, H.Fukuda, R.Kishii, M.Hosaka, Antimicrob. Agents Chemother.,45, 3544(2001).
49. X.Pan, L.Fisher, Antimicrob. Agents Chemother.,42, 2810(1998).
50. M.Tanaka, Y.Onodera, Y.Uchida, K.Sato, I.Hayakawa, Antimicrob. Agents Chemother.,
41, 2362(1997).
51. K.Hoshino, K.Sato, T.Une, Y.Osada, Antimicrob. Agents Chemother.,33, 1816(1989).
52.M.Bazin, F.Bosca, M.Marin, M.Miranda, L.Patterson, R.Santus, Photochem.
Photobiol.,72, 451(2000).
53. T.Ooie, T.Terasaki, H.Suzuki, Y.Sugiyama, Drug Metab.Dispos., 25, 784(1997).
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Using peptidyl inhibitors, such as margatoxin (MgTX), several groups have
demonstrated that blockade of Kv1.3 channels suppresses activation and
proliferation of human T-cells57. MgTX has been shown to suppressdelayed-
type hypersensitivity and allogenic-antibody responses in miniswine58,
providing in vivo evidence that Kv1.3 is a novel pharmacological target for
immunosuppressive therapy56,59. Potent, specific Kv1.3 inhibitors have the
potent ia l  to  be novel  immunosuppressive agents wi th ut i l i ty  in
transplantation, autoimmune disease, and inflammation therapy56. Efforts
to identify a small, nonpeptidyl inhibitor of Kv1.3 channels have resulted in
the discovery of submicromolar Kv1.3 blockers such as the dihydroquinoline
CP-33981860, the piperidine UK-7828261 and correolide, a triterpene
isolated from the root and bark of a Costa Rican tree, Spachea correae 62-
64. However, both CP-339,- 818 (half-blocking concentration, IC50, for Kv1.3
channels, 0.23 ì M)60 and UK-78282 (IC50(Kv1.3) ) 0.28 ì M)
61 block Kv1.3
and Kv1.4, a Shaker-related K+ channel expressed in the heart and brain,
with similar potency,60,61 thus lacking selectivity. The most promising
compound seems to be correolide, which has a 4-14-fold selectivity for
Kv1.3 over other Shaker-related Kv channels64.
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Inga Butenschon, et. al65 have revealed that the voltage-gated potassium chan-
nel Kv1.3 constitutes an attractive target for immunosuppression because of
its role in T-lymphocyte activation and its functionally restricted expression to
lymphocytes. Blockade of Kv1.3 channels by margatoxin has previously been
shown to prevent T-cell activation and attenuate immune responses in vivo.
Several furo and pyranoquinoline derivatives were synthesized and screened
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for their blocking activities of Kv1.3 channels, stably expressed in mice-fibro-
blasts L929. In addition the activities of the compounds on Kv currents of the
neuroblastoma cell line N1E-115 were determined.
The screening results suggested that  Angular dihydropyranoquinolinones were
in general more potent than their linear isomers (Table 2): angular
dihydropyranoquinolinones bearing hydroxy groups (39a,b) displayed weak
blocking activities, whereas angular dihydropyranoquinolinones lacking the
hydroxy group (39c-e) were found to block both Kv channels of N1E-115 and
Kv1.3 currents and N-alkylation increased the blocking activity of the angular
dihydropyranoquinolinones on Kv currents of both cell lines (Table 2).The sub-
stituent in position 9 of the angular dihydropyranoquinolinones was important
for their selectivity: Compounds (39c,d) without substitution in position 9 were
found to be more potent blockers of Kv channels of N1E-115, whereas a
methoxy group (39e) increased the blocking activity of Kv1.3 currents.
The second remarkable result is the higher potency of furoquinoline
derivatives with an aromatic furan ring compared to dihydrofuroquinolinones.
The linear furoquinolines kokusaginine (43a, R1=R2=OCH3, R3 =H),
skimmianine(43b, R1=H, R2=R3=OCH3,), and dictamnine (43c, R1=R2=R3 =H
) as well as the linear dehydrated furoquinolinones (42a, R1=H) and (42b,
R1=OCH3) were in general more potent than dihydrofuroquinoline
derivatives. Of these linear furoquinolines kokusaginine (43a, R1=R2=OCH3,
R3 =H) seems to be the most promising compound, blocking Kv1.3 currents
in the low-micromolar range and with higher potency than the N1E-115 K+
current. Again the angular isomers (40b,c) displayed higher affinities with
the exception of (40a), the sodium salt of a sulfonic acid, being ineffective,
thus corroborating that hydrophilic substituents diminish potency (Table 2).
Finally, the pyranoquinolinone (41a) showed a slightly higher blocking
activity than the corresponding hydrogenated derivative (39e). The
dehydrated pyranoquinolinone veprisine (41b) bearing two methoxy groups
in positions 7 and 8 was less effective than (41a). Moreover, in contrast to
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veprisine (41b), compound (41a) as well as (40b,c) displayed higher
blocking activities of Kv1.3 currents compared to Kv channels of N1E-115
(Table 2). Na+ currents were largely uneffected by all compounds tested.
Thus, the effective quinolines are selective blockers of Kv channels. The
compounds (39e), ( 41a), and especially (40c) were found to be the most
potent and moreover selective blockers of Kv1.3 channels, showing a much
higher potency than the furoquinoline kokusaginine. For these effective
compounds we determined the half-blocking concentrations for N1E-115
and Kv1.3. The IC50 values are listed in Table 3.
By concluding these results, the following pharmacophoric model for the
Kv channel blocking activity of the quinolines can be deduced. First, an
angular structured furo- or pyranoquinolinone seemed to be required
for optimal interaction with a hydrophobic pocket of limited size at
the receptor site of Kv1.3 channels as well as Kv channels of N1E-115
cells. Moreover, it is striking that the most potent compounds (40c and
41a) on Kv currents have a double bond in the furan or pyran ring in
common, thus pointing toward ð - ð  interaction with the receptor site.
Hydrophilic substituents such as hydroxy or sulfonic groups in this region
diminish potency almost completely. For a favored binding to the receptor
site of Kv1.3 the methoxy group in position 8 of the angular furoquinolinones
40c or in position 9 of the angular pyranoquinolinones 39e and 41a is of
crucial importance. Compound 40c reveals 8-fold selectivity (Table-3) for
Kv1.3 over Kv channels of N1E-115 cells, where as (40b) lacking a
substituent in the quinoline ring is much less selective. Compound (39e)
reveals 2-fold selectivity (Table-3) for Kv1.3, and 6d lacking the methoxy
group is even more potent for Kv currents of N1E-115 cells just like the 7,8-
dimethoxy-substituted angular pyranoquinolinone veprisine (41b). Thus, the
substitution pattern in the quinoline ring is critical for Kv1.3 selectivity.
54. T.deCoursey, K.Chandy, S.Gupta, M.Cahalan, Nature,307, 465(1984).
55. S.Lewis, Annu. Rev. Immunol., 13, 623(1995).
56. R.Slaughter, M.Garcia, G.Kaczorowski, Curr. Pharm. Des.,2, 610(1996).
57. M.Price, S.Lee, C.Deutsch, Proc. Natl. Acad. Sci. U.S.A.,86,10171(1989).
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?Anticancer activity
Ih-Sheng Chen, et. al27b have isolated pyranoquinolone alkaloids
zanthosimuline (44) and huajiaosimuline (45) from the root bark of
Zanboxylum simulans, exhibited cytotoxic activity. In addition, compound
(45) showed significant antiplatelet aggregation activity and induced ter-
minal differentiation with cultured HL-60 cells.
The cytotoxic activity of the new pyranoquinoline alkaloids, zanthosimuline
(44)27a and huajiaosimuline (45)27a is summarized in Table-4. Compound
(44) demonstrated a general cytotoxic response when evaluated with a
variety of cultured human cancer cell lines and cultured P-388 cells using
published methods of bioassay 66. Multidrug-resistant KB-VI cells
demonstrated a sensitivity that was approximately equivalent to that
observed with cultured KB cells. In the presence of vinblastine, activity was
enhanced about 3-fold with KB-VI cells, suggesting reversal of the drug
resistance of the phenotype 67. Conversely, oxidation of the side-chain
produced a more selective profile of cytotoxic activity, as exhibited by
compound (45). Of particular note, of the human tumor cell lines tested,
greatest activity was observed with the estrogen receptor-positive breast
cancer cells, ZR-75-1, and even more pronounced reversal of resistance
to vinblastine was demonstrated with KB-VI cells.In addition, prompted by
the structural similarity of the compound (44) and (45) side-chains and
vitamin D metabolites, studies were performed with cultured HL-60 cells.
As summarized in Table-5, both compounds were able to induce the
expression ofcellular markers associated with cell differentiation, and
compound (45) was more active than compound (44) in this capacity.
However, relative to the positive control compound, 1á,25-dihydroxyvitamin
D3 both compounds are regarded as weakly active.
Finally, zanthosimuline(44) , huajiaosimuline (45) , simulanoquinoline, and
toddaquinoline were evaluated for antiplatelet aggregation activity 68. The
aggregation of rabbit platelets induced by arachidonic acid (100ì M),
collagen (10 ì g/ml), or PAF (2 ng/ml) was inhibited by 100%, 83.9%, and
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100%, respectively, in the presence of huajiaosimuline (45) at 100 ì g/ml. Compound
(44), simulanoquinoline, and toddaquinoline were not active at this concentration.
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Olivia Jansen, et.al69 during their  systematic chemotaxonomic study of
Uzbek Haplophyllum A. Juss. plants selected on ethnopharmacological
data, have screened 14 alkaloids for their cyctotoxic properties. As a first
selection for interesting compounds, each alkaloid was tested against two
human cancer cell lines (HeLa and HCT-116), using WST-1 reagent.
Of the 14 alkaloids, 5 were cytotoxic when tested against the HeLa line
wi th an IC 50<100ì M. These f ive compounds consisted of  three
furoquinol ines:  sk immianine;  haplopine and γ- fagar ine and two
pyranoquinolones:  flindersine and haplamine. Only haplamine was active
against the HCT-116 line.
The cytotoxic properties of these five alkaloids were further investigated
against five additional human cancer cell lines. Of these five pre-selected
alkaloids, only haplamine showed significant cytotoxic activity against all
the tested cell lines. This was the first report of the cytotoxic activity of
haplamine. Finally, this pyranoquinolone  alkaloid was tested here against
14 different cancer cell lines and against normal skin fibroblasts.
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?Anti-HIV activity
Antiviral nucleoside agents such as AZT, ddC, ddl, d4 T and 3TC being
Reverse Transcriptase (R.T.) inhibitors are approved for cl inical
use.Although these nucleoside based drugs can extend the life of the
patient, they are associated with several side effects and are not capable
of curing the disease. The urge for the promising RT inhibitors to cure AIDS,
resulted in the identification of a group of coumarin derivatives isolated
(Ref: M R Boyd et al, J. Med. Chem., 1992, 35, 2735-2743) from genus
Calophyllum as HIV-1 specific non-nucleoside inhibitors, among which
Calanolide A  represented by (46, X=O) is the most potent and is currently
undergoing clinical trials (phase III).
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R = H, alkylC(1-10), alkenylC(1-10), alkynylC(1-10), aryl, 
heteroaryl, carbocyclic aryl, alkyl aryl, alicyclic aryl, 
3oalkylamine, thioalkyl, hydroxy alkyl groups
R1=H, lower dialkylamino alkyl or amino acid, hydroxyalkyl, 
acid amides such as aliphatic, aromatic sulphonic, trihalo acids
X-X = C-C or C=C
R2 and R3, R4 and R5 are each independently H, CH3 there by 
resulting into diastereoisomers and enantiomers
R6 and R7 = are each independently H, OR8, where R8 = alkyl, 
alyl, aryl, amino alkyl, hydroxy alkylC(1-10), monosaccharides 
both furanose and pyranose, aminosugars, disaccharides, 
aminoacids, small peptides through lower alkyl spacer groups 
there by resulting into diastereoisomers and enantiomers 
46
Calanolides, a ‘dipyrano-coumarin‘ class of compounds are active not only
against the AZT-resistant strain of HIV-1, but also against virus strains
resistant to some other non-nucleoside inhibitors such as TIBO pyridinone,
and nevirapine. Calanolides are in the advanced stage of biological
evaluation as anti-HIV agents in clinical trials (phase III).The main drawbacks
of this class of compounds are (a) poor solubility of this class of compounds
in the physiological medium and (b) lesser stability of the coumarin ring
system in biological environment. It, thus, would be desirable to prepare
the New Chemical Entities (NCEs) having calanolide skeleton but with better
therapeutic index. In addition, the NCEs are desirable to overcome the
problems associated with calanolides such as stability and solubility in the
physiological medium.
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Quinolinones are shown to be part structures of several bio-active
compounds with profound bio-efficacy. Unlike the lactone bond in coumarins,
the lactam bond in quinolinones is highly stable.
M.K.Gurjar, et al70 have patented a novel ‘dipyrano-quinolinone‘ class of
compounds related to calanolide structural frame work as NCEs and
envisaged to circumvent the problems associated with calanolides and have
improved therapeutic indices.
The invention deals with the synthesis of novel and new ‘dipyrano-quinolinone‘
class of compounds, where the major differences in the structural
arrangement is the replacement of coumarin ring oxygen (at position 1) of
calanolide structure with nitrogen (at position 1) in the new ‘quinolinone‘ ring
system represented by (47). These quinolinone analogues of calanolides
are NCEs and are envisaged as potential candidate molecules as anti-HIV
agents. The rationale for the synthesis of these ‘dipyrano-quinolinones‘
reported in this specification are as follows: (1) Replacement of oxygen (at
position 1) of natural products, calanolides, with nitrogen leads to dipyrano-
quinolinones as anti-HIV agents with better therapeutic index. (2) The inherent
problems associated with naturally occurring calanolides such as metabolic
stability and solubility in physiological medium can be circumvented with the
new dipyrano-quinolinone derivatives that are reported in this patent. (3) The
derivatisation of water-soluble derivatives of these new chemical entities
represented in this patent are easily possible. (4) The metabolic stability is
expected to enhance due to the presence of nitrogen atom in the skeleton of
dipyrano-quinolinones derivative presented in this patent. (5) The structure
activity relationship coupled with positive activity against calanolide resistant
strain of HIV virus can be explored due to the presence of nitrogen atom in
the dipyrano-quinolinone system.
The dipyrano-quinolone of the present invention screened for anti-HIV activity
( reverse transcriptase inhibition), have shown potential therapeutic values
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as “Candidate Molecules”. The above compound (46, X=NH) reported in
this invention was shown equal potency of activity against  HIV infected
cell lines that observed for calanolide in the in vitro preliminary screening
studies. The IC50, EC50 and TI values of both calanolides and the ‘new
dipyrano-quinolinone chemical entities‘ (46, X =NH) described in the
present invention have equal and more protecting capacity against the HIV
infection. The NCE prepared in this this invention has shown a mean
therapeutic index value of 12 and indicative of superior activity for the new
compound compared to the natural one.
?As Calcium Channel Blockers
Karnail Atwal71 have patented novel pyranyl quinolines (48) having calcium
channel blocking activity.
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R1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, 
haloalkyl, cycloalkyl, (cycloalkyl)alkyl;           
R2 is hydrogen, hydroxy,-OCOR1, where R1 is not hydrogen; 
R3 and R4 are independently selected from hydrogen, alkyl, 
arylalkyl or taken together with the carbon atom to which 
they are attached form a 5-, 6- or 7-membered ring;         
R5 is R1 ;                
R6 is R1, heteroaryl, amino, substituted amino or --OR1, 
where R1 ?hydrogen, or R5 and R6 taken together with the 
nitrogen atom to which they are attached for a 5-, 6- or 
7-membered saturated or unsaturated ring which may 
contain an additional nitrogen atom or an oxygen or sulfur 
atom.
48
It was suggested that compounds (48) and their pharmaceutically accept-
able salts are cardiovascular agents. They act as calcium entry blocking
vasodilators and are useful as antihypertensive agents. Thus, by the ad-
ministration of a composition containing one (or a combination) of the com-
pounds of this invention, the blood pressure of a hypertensive mammalian
(e.g., human) host is reduced. A single dose, or two to four divided daily
doses, provided on a basis of about 0.1 to 100 milligrams per kilogram of
body weight per day, preferably from about 1 to about 50 milligrams per
kilogram per day, is appropriate to reduce blood pressure.
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As a result of the calcium entry blocking activity of the compounds (48),
and the pharmaceutically acceptable salts thereof, these compounds, in
addition to being antihypertensive agents, are especially useful as anti-
ischemic agents, and are also useful as anti-arrhythmic agents, anti-anginal
agents, anti-fibrillatory agents, anti-asthmatic agents, as an agent to
increase the ratio of HDL-cholesterol to total serum cholesterol in the blood
and in limiting myocardial infarction.
Additionally, the compounds of this invention are useful as therapy for
congestive heart failure, therapy for peripheral vascular disease (e.g.,
Raynaud’s disease), as anti-thrombotic agents, as anti-atherosclerotic
agents, for treatment of cardiac hypertrophy (e.g.,  hypertrophic
cardiomyopathy), for treatment of pulmonary hypertension, as an additive
to cardioplegic solutions for cardiopulmonary bypasses and as an adjunct
to thrombolytic therapy.
Compounds of this invention are also expected to be useful in the treatment
of central nervous system vascular disorders, for example, as anti-stroke
agents, anti-migraine agents, therapy for cerebral ischemia and therapy
for subarachnoid hemorrhage, as well as in the treatment of central nervous
system behavioral disorders, for example, in the treatment of psychiatric
conditions including depression, mania, anxiety and schizophrenia, or for
epilepsy or cognition benefit.
Further, compounds of this invention are expected to be used as anti-
diarrheal agents, as therapy for dysmenorrhea, as therapy for tinnitus and
other auditory and vestibulatory disorders, for the alleviation of the various
forms of oedema, for reversal of adriamycin resistance, regulation of cell
growth, for treatment of glaucoma, renal failure, hepatoxicity (e.g., liver
cirrhosis), various endocrine hypersecretory states (e.g., diabetes,
pheochromocytoma), drug-induced tardive dyskenesia, allergies, muscular
dystrophy and cancer.
185
?Antiallergic activity
Repirinast (MY-5116; isoarnyl 5,6-dihydro-7,8-diniethyl-4,5-dioxo-4H-
pyrano[3,2-c ]quino-l ine-2-carboxylate) is an anti-allergic drug of
demonstrated effectiveness for treating bronchial asthma in humans.
N.Yamada, et al72 have  demonstrated that MY-1250(5,6-dihydro-7,8-
dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinoline-2-carboxylic acid), a major
metabolite of repirinast, inhibits antigen induced histamine release from
rat peritoneal mast cells. MY-1250 causes a rapid increase in cyclic
adenosine monophosphate(cAMP) levels in rat peritoneal mast cells MY-
1250 inhibited cyclic AMP phosphodiesterase activities from rat peritoneal
cells and guinea pig lung tissue in a concentration dependent manner with
IC50 value of 2 ì g/ml and 1.67 ì g/ml respectively. However MY-1250 showed
no effect on adenylate cyclase activity from rat peritoneal cells. These
results suggested that the inhibitory effect of MY-1250 on histamine release
may be partly due to the inhibition of cyclic AMP phosphodiesterase activity.
Repirinast(MY-5116)
N
H
O
O
O
O O CH3
CH3
CH3
CH3 N
H
O
O
O
O OH
CH3
CH3
MY-1250
?Antimicrobial activity
Trkovnik et al73 have reported ethyl-2,6-dioxo-6,9-dihydro-substituted-2H-
pyrano[3,2-g]quinoline-7-carboxylates and their antimicrobial activity
against S.aureus, P.aenrgiizosa, Streptococcus pyogens, Streptococcus
faecalis, Staphiloc epiderms etc. El-Taweel et al74 have evaluated
polysubstituted pyrano[3,2-c]quinolones(49) for their bactericidal activity
against various gram negative and gram negative bacterial species.
O N
H
O
O
O
O CH3
R
ethyl-2,6-dioxo-6,9-dihydro-substituted-
2H-pyrano[3,2-g]quinoline-7-carboxylate
N
O
O
N S
N
O
R
R1
49 R = alkyl, R1= H, alkyl
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Synthetic  Approaches
K.C.Majumdar et al75 have synthesized pyrano[3,2-f ]quinolin-2(7H)-ones (52a,b)
by a thermal [3,3]-sigmatropic rearrangement with 60±65% yield by heating the
propargyl ethers (51a,b) in refluxing N,N-dimethylaniline.(Scheme-1)
N
CH3
O
OH
6-hydroxy-1-methyl
-2(1H)-quinolinone
R X
50a, R = CH C CH2
50a,b
50b, R = CH C CH2
CH3
anh. K2CO3 
acetone
N
CH3
O
RO
51a,b          
propargyl ethers 
3,3-sigmatropic 
rearrangement
N
CH3
O
O
H
R
               52a R = H,                    
52b R = CH3 
X.Wang et al76 have described one-step synthesis of 2-amino-4-aryl-1,4,5,6-
tetrahydropyrano[3,2-c]quinolin-5-one derivatives from arylaldehyde,
malononitrile and 4-hydroxyquinolin-2-one by treatment with KF-Al2O3 as cata-
lyst in refluxing ethyl alcohol. Prior to this investigation, the synthesis of
pyrano[3,2-h]quinoline derivatives was reported77 from arylmethylidene
malononitriles and 8-hydroxyquinoline using KF-Al2O3 catalyst which was a ver-
satile solid support reagent for many reactions such as Knoevenaegel
condensation78.(Scheme-2)
Ar CHO
CN
CN
N
H
O
OH
arylaldehyde
malononitrile 4-hydroxy-2(1H)-quinolinone
KF-Al2O3 
ethanol
N
H
O
O
Ar
CN
NH2
2-amino-4-aryl-1,4,5,6-tetra
hydropyrano[3,2-c]quinolin
-5-one derivatives
Scheme-2
The synthesis of the pyranoquinoline system is based on either oxidative
cyclization of 4-hydroxy-3-(3’-methybut-1’-enyl)-2-quinolinones with 2,3-
dichloro-5,6-dicyanoquinone(DDQ)79 or the Prevost reaction of 3-prenyl-2-
quinolones80. Though these methods have proven to be fairly satisfactory,
the overall yield of the alkaloids was only 15-35% because the routes to
obtain the precursor prenylquinolines gave low yields (21-35%)81,82 and of-
ten were attended by undesired side reactions (such as the formation of
unwanted 3-(3’-methylbut-1’-enyl)-2-quinolinones as the major product82).
This note reports a  facile novel one-pot synthesis of 3,4-dihydro-2,2-dim-
ethyl-2H-pyrano[2,3-b]quinolines (56). khaplofoline (57) utilizing
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3-(1’-carboxy-3’-methylbut-1’-enyl)-2-quinolinones81 (53). M.Sekar and
K.Rajendraprasad have suggested85 that treatment of the carboxy derivative of
the 2-quinolinone81 (53a) with polyphosphoric acid (PPA) at 140 °C for 4 h fur-
nished in 60% yield the desired 6-methyl-3,4-dihydro-2,2-dimethylpyrano[2,3-
b]quinoline (56a), identical with an authentic sample81 Extension of this method
to compounds 53b-f gave the respective pyranoquinolines (56b-f).  Analytical
and spectroscopic data were consistent with the proposed structures (56)
(Scheme-3). The formation of (56) from (53) can be assumed to proceed via the
decarboxylated product (54) formed in situ under acidic condition at high tem-
perature84,85. Compound (54) is isomerized to a more stable isoprenyl cation(55),
which then cyclizes to product (56). A similar polyphosphoric acid reaction of 4-
methoxy-2-ono-3-vinylquinolinecarboxylic acid (53g) yielded the quinoline de-
rivative (56g). Compound (56g) was refluxed with 10% ethanolic hydrochloric
acid for 30 h to give khaplofoline(57)
53 a-g
PPA, 
140oC, 4h
Isomerization
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R4 H
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R3
COOH
CH3
CH3
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R4 H
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R2
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CH3CH3 N
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R4
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R3
O
CH3
CH3
54 55
56 a-g
1, 4 a  R1 = R2 = R3 = R4 = CH3, b R1 = R2 = R3 = R4 = H, c R1 = CH3, R2 = R3 = R4 = H, d R1 = R3 = H, R2 = R4 = CH3,         
e R1 = C6H5, R2 = R4 = H, R3 = Cl, f R1 = R2 = R4 = H, R3 = OCH3, g R2 = R3 = R4 = H, R1 = OCH3
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H
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Scheme-3
79. F.Piozzi, P.Venturella, A.Bellino, Gazz. Chim. Ital.,99,711(1969).
80. M.Subramaniam, P.Mohan, P.Shanmugam, K.Rajendra Prasad, K., Naturforsch.  47b, 1016(1992).
81.P.Oels, R.Storer, D.Young, J. Chem. Soc., Perkin Trans.1, 2546(1977).
82. M. Sekar, K. Rajendra Prasad, J. Nat. Prod.,61, 294( 1998)
83. R.Taylor, In Comprehensive Chemical Kinetics; Bamford, T., Ed.;Elsevier Publishing
Co.: New York, 13, 1(1972).
84. B.Brown, Quart. Rev. Chem. Soc., 5, 131(1951).
85.H. Pechmann, C. Duisberg, Ber., 16, 2119(1983)
86.S.Sethna, R.Phadke, Org.React., 7, 1(1953); Organic Name Reactions in the Merck
index, S.Budavi, ed. Merck & Co., Whitehouse Station, N.J.,USA,12th Ed., ORN 67(1996)
87.C.Mayer, Ph.D. Thesis, K.-F. University of Graz, Austria(1971)
88.T. Kappe, C.Mayer, Synthesis, 524(1981)
The condensation of  â-ketoesters with phenolic compounds in the pres-
ence of sulfuric acid yields coumarin derivatives85. This synthesis is known
as Pechmann condensation86 and has extensive application to prepare many
naturally occuring coumarins. Acidic catalyst such as aluminium
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trichloride, zinc chloride, phosphoryl oxychloride, phosphoric acid,
polyphosphoric acid, trifluoro acetic acid and hydrochloric acid have been
used. C.Mayer87 and T.Kappe88 have found that ammonium acetate can be
used as a source of ammonia and that readily react with phenolic hetero-
cyclic compounds to yield corresponding á-pyrone derivatives.
á-acetyl-y-butyrolactone(59), an interesting cyclic â-ketoesters can be used
for the synthesis of heterocyles containing a hydroxyethyl side chain89. R.
Toche, et al90 have reported the pechmann reaction of 4-hydroxy-2(1H)-
quinolones(58)  with (59). Further more this reaction was extended to á-
formyl-y-butyrolactone(used as its sodium salt (62)). (Scheme-4)
Thus the condensation of 4-hydroxy-2-quinolones(58a-d) with á-acetyl-y-
butyrolactone (59)in the presence of ammonium acetate at 120oC gave
pyrano[3,2-c]quinoline-2,5-diones(60a-d) in 70-75% yield, while sodium salt
of á-formyl-y-butyrolactone(62)91(obtained by formylation of y-butyrolactone)
reacted smoothly with 4-hydroxy-2-quinolones(61) in the presence of  am-
monium acetate to yield 3-hydroxyethyl-2-pyranone derivatives (63a-d)
58 a-d
NH4OCOCH3
N
OH
R1 R
O
R2
N
O
R1 R
R2
O
O
CH3
OR3
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60 a-d
58, a  R1 = R2 = R = H,     
b R1 = R2 = H = R = CH3, 
c R = R2 = H = R1 = CH3, 
d R = R1 = H, R2 = Cl
O O
CH3
O
120oC 
60, a  R1 = R2 = R = R3 = H                  
b R1 = R2 = H = R = CH3, R3 = COCH3  
c R = R2 = H = R1 = CH3, R3 = H        
d R = R1 = H, R2 = Cl, R3 = H
N
OH
R1 R
O
R2
61, a  R1 = R2 = R = H,     
b R1 = R2 = H = R = CH3,  
c R = R1 = H, R2 = Cl,    
d R = R1 = H = R2 = CH3,
N
O
R1 R
R2
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O
H
OH62
O O
NaO
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63, a  R1 = R2 = R = H         
b R = R2 = H = R1 = CH3,    
c R = R1 = H, R2 = Cl          
d R = R1 = H = R2 = CH3
61 a-d
NH4OCOCH3
Scheme-4
89(a). E.Badawey, T.Kappe, J. Heterocycl. Chem., 32, 1003(1995)
(b).E.Badawey, J. Heterocycl. Chem., 33, 229(1996)
(c).E.Badawey, T.Kappe, Eur. J. Med. Chem., 32, 815(1997)
(d).E.Badawey, T.Kappe, Arch. Pharma./Pharm. Med. Chem., 330, 59(1997)
90.R.Toche, M.Jachak, R.Sabnis, T.Kappe, J. Heterocycl. Chem., 36, 467(1999)
91. A. Murray, N. Murray, Synth. COmmun., 16, 853(1986)
92.(a) W. Kayser, A. Reissert, Ber., 25, 1193(1892),
(b). H. Harnisch, A. Brach, Ann. Chem., 740, 164(1970)
93.E. Zeigler, K. Gelfert, Monatsh. Chem., 90, 822(1959)
94.T.Kappe, M.Chirazi, H. Stelzl, E.Zeigler, Monatsh. Che., 103, 586(1972)
95. A. Knierzinger, O. Wolfbeis, J. Heterocycl. Chem., 17, 225(1980)
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2-quinolones (65g-i) were synthesized by several methods like (i) thermal
cyclization of aniline with diethyl malonate at 180-200oC92, (ii) condensation
of aniline with diethylmalonate in the presence of phosphorous oxychloride93,
or (iii) condensation of anilines with bis-2,4-dichlorophenyl or bis-2,4,6-
trichlorophenyl malonate94. A. Knierzinger and  O. Wolfbeis95  suggested that
conversion of 2-quinolones(65g-i) into their 3-anilino methylene derivatives
(66) was effected by heating (65) with an equimolar amount of and a 1.5
molar excess of triethoxy methane in glacial acetic acid or DMF.
2-aminomethylene-1,3-diketones are synthetic equivalents to the less
readily available and less stable 2-formaldehyde of 1,3-diketones. Thus
when the enamine (66) was reacted with equimolar amounts of a nitrile(67)
in the presence of strong base in DMF, aniline was replaced by nitrile an-
ion and subsequent acidification affords the corresponding pyrones (68).
The base chosen for must be strong enough to generate the anion of ni-
trile(67) but not so strong as to lead to reaction with enamine(66). Dry po-
tassium hydroxide (potassium t-butoxide for less active nitriles 67a,b) was
found to be a suitable reagent. Since the methylene hydrogens in (67a,b)
are weekly acidic, their anions are increasingly reactive, causing side reac-
tions which  lower the yield of corresponding pyrones (68). On contrary, the
pyrones formed by cyclizations with the strongly acidic (67f-h) were obtained
in high yields. Compounds (67c-d) were of medium reactivity. (Scheme-5)
65 
X
OH
OR1
68
64, 65, 66f  R1 = H  X = N-CH3,                 
g R1 = OCH3 X = N-CH3,    h 
R1 = N(CH3)2 X = N-H         i R1 
= OCH3 X = N-H
67, a  R2 = Phenyl, b R2 = 3-pyridyl,    
c R2 = benzothiazol-2yl,                     
d R2 = Benzoimidazol-2-yl,               
e  R2 = PO(OEt)2, f R2 = SO2C6H5,     
g R2 = COOEt, h R2 = CN
XHR1
 Ar-NH2, CH(OCH3)3
X
O
O
O
R2
R1
X
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O
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H Ar
R1
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67
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Scheme- 5
96.S. Yamaguchi, K. Tsuzuki, M. Kinoshita, Y. Oh-hira, Y. Kawase, J. Heterocyclic.
Chem., 26, 281(1989)
97.Y.Morinaka, K. Takahashi,US Patent, 4298610
98.J.Asherson, D.Young, J. Chem. Soc., Perkin Trans. 1, 512(1980).
 99.K.Majumdar, P. Choudhury, Synth. Commun., 23,1087(1993).
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S.Yamaguchi et al96 have synthesized eight number of 2- and 3-halo-11,12-
dihydro-5H-[1]-benzopyrano[4,3-c]quinolin-5,11-dione(72) by demethyl cy-
c l izat ion of  corresponding halo-3-(2-methoxyphenyl) -2-oxo-1,2-
dihydroquinoline-4-carboxylic acids(71), which were synthesized by
Pf i tz inger  condensat ion o f  5-  or  6-ha lo  isa t ins(69)  w i th  (2-
methoxyphenyl)acetic acid (70)(Scheme-6).
70
72
x = 2-F, 2-Cl, 2-Br, 2-I, 
3-F, 3-Cl, 3-Br, 3-I
N
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O
Anh. NaOAc, AcOH, 
Pfitzinger rxn.
N
H
O
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N
H
COOH
O
O
CH3
71
X
69
OCH3COOH
X X
Scheme-6
Morinaka and Takahashi have patented97 ester derivatives of pyrano[3,2-
c]quinolin-2-carboxylic acid, synthesized by following route.(Scheme-7)
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A couple of 2,3,4,6-tetrahydro-2-hydroxy-2-methylpyrano[3,2-c]quinolin-5-
ones have been prepared by the reaction of 4-hydroxyquinolin-2(1H)-ones
with 1-(dimethylamino)butan-3-one in the presence of potassium hydroxide
and methyl iodide98. Some 6-alkyl-3,4-dihydropyrano[3,2-c]quinolin-5-ones
were prepared by the reaction of 4-hydroxyquinolin-2(1H)-ones 4 with
acetylenic halides and the subsequent intramolecular cyclization of the
acetylenic ethers99.(Scheme-8)
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Scheme-8
Jai-Hai Ye et al100 have reported convinient one pot synthesis of 2,3,4,6-
Tetrahydro-2-hydroxypyrano[3,2-c]quinolin-5-one derivatives (80)  from 4-
hydroxyquinolin-2(1H)-ones(73) by tandem Knoevenagel condensation of (73)
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with aliphatic aldehyde–Michael-type 1,4-addition of the enamine (derived from
the aldehyde and diethylamine in situ) with the quinone methide (quinomethane)
(77). This reaction sequence was achieved in one pot by  direct thermal reac-
tion of (73) with an aldehyde in the presence of diethylamine as a base in reflux-
ing benzene, which afforded the corresponding 2,3,4,6-tetrahydropyrano-[3,2-
c]quinolin-5-one (80) as the main product together with the 3,3’-alkane-1,1-
diylbis(4-hydroxyquinolin-2(1H)-one) (78) as the minor product.(Scheme-9)
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Two possible mechanisms could account for the formation of product (80)
in these reactions. By analogy with reactions of 4-hydroxy-2-pyrone101 with
aliphatic aldehydes, which yield the corresponding quinone methide, base-
catalyzed condensation of a quinolinone (73) with an aldehyde (75) yields
the corresponding 4-hydroxy-3-(1-hydroxyethyl)quinolin-2-one (76), which
is dehydrated on heating in the basic reaction medium to furnish the highly
electrophilic quinone methide intermediate (77). The quinone methide (77)
then undergoes competitive Michael addition at the exocyclic methylene
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carbon by the preformed enamine (from DEA and the aldehyde) and the
carbanion 7 derived from the deprotonation of (73). The Michael-type
addition of the enamine proceeds in a 1,4-fashion and results in an
intramolecular cyclization to give the 2-(diethylamino)pyrano-[3,2-c]quinolin-
5-one (79), which on hydrolysis during the reaction at reflux temperature
under the action of a trace amount of water in the reaction mixture, affords
the final product (80). At the same time, addition of the carbanion 7 afforded
the alkane-1,1-diylbisquinolone(78).
Alternatively, in the case of (80a–c) and (80g) from (73) and acetaldehyde,
these syntheses were carried out by way of a photochemical variant by
photolysis of a benzene solution of (73) as an electron acceptor and tri-
ethylamine as an electron donor, where acetaldehyde and diethylamine are
generated in situ from triethylamine in redox processes initiated by single-
electron transfer (SET) between photoexcited (73) and triethylamine100.
Inga Butenschon, et al65 have synthesized Voltage-Gated potassium channel
blocker pyranoquinolinones from central intermediates substituted 4-hy-
droxy-3-(3-methylbut-2-enyl)quinolin-2-ones102-105, the strategy suggested  that
Oxidative cyclization of (81a) with iodine and silver acetate gave the linear
dihydropyrano[2,3-b]quinolinone(82a)106.  Use of bromine instead of iodine
led to the format ion of  the main product   the l inear 3,7-
dibromodihydropyranoquinolinone (82b). Mechanistically, the halogen is first
added to the double bond of the prenylquinolinone, which then spontane-
ously undergoes intramolecular cyclization by an SN1 reaction involving a
tertiary carbonium ion. Thus, the cyclization proceeds via the electronically
favored 6-endo process. Dihydropyranoquinolinones without substitution in
pos i t ion 3  are  obta ined v ia  ac id-cata lyzed r ing c losure o f  3-
prenylquinolinones. Refluxing (81a-c) in concentrated hydrochloric acid re-
su l ted in  mix tures o f  l inear  (82g- i )  and angular  (83c-e)
dihydropyranoquinolinones, the later being the main products109, 110. N-
Methylhaplamine (84a) was prepared via dehydrocyclization of (81c) with
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The reaction pathway with iodine and silver acetate failed in the case of
the N-methyl-substituted adducts (81b,c). Thus, the isomeric linear
dihydropyranoquinolinones (82c,d) to isoplatydesmine (85a) and O-
methylriba-line (85b) were synthesized by rearrangement reaction of the
dihydrofuroquinol inones in pyridine and acetic anhydride107.  The
corresponding angular dihydropyranoquinolinones were obtained from
dihydrofuroquinolines(85a,b) via rearrangement reaction,  when heated for
18 h under reflux with sodium hydroxide in methanol108 . (Scheme-11)
DDQ(2,3-dichloro-5,6-dicyanobenzoquinone) according to the analogous
synthesis of haplamine111(Scheme 10).
100.J. Ye, K. Ling, Y. Zhang, N. Li , J. Xu,J. Chem. Soc., Perkin Trans. 1, 2017(1999)
101.(a) P.March, M. Moreno-Manas, R. Pi, A.Trius, J. Heterocycl. Chem.,19,335(1982)
(b).P. March, M. Moreno-Manas, J. Casado, R. Pleixats, J. Roca, A. Trius, J.
Heterocycl. Chem., 21, 85(1984)
(c).M. Moreno-Manas, E. Papell, R. Pleixats, J. Ribas , A. Virgili, J. Heterocycl.Chem.,23,413(1986)
102. D.Boulanger, B.Bailey, W.Steck, Phytochemistry,12, 2399(1973).
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M. Gurjar et al70 have synthesized dipyranoquinolinone class of compounds
as a analogues of calanolide A (coumarin based natural product) and pat-
ented them as anti HIV agents by following synthetic routes(Scheme-12).
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H. Abd el-Nabi112 suggested that 4-Hydroxy-2-quinolone (92) reacts with
cinnamonitrile derivatives(93) in presence of catalytic amounts of triethy-
lamine to afford pyrano[3,2-c]quinolines (94). The reaction of (94) with re-
agents such as acetic anhydride/pyridine, formamide and formic acid/
formamide gave the fused heterotetracyclic system of the type of
pyrimido[4’,5’:6,5]pyrano[3,2-c]quinoline (95).(Scheme-13)
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N. Venkatesh Kumar and S. Rajendran113 have described that 4-hydroxy-2-
quinolone being endowed with both nucleophilic and electrophilic proper-
ties furnishes the dimeric quinoline in a base catalyzed self-condensation
process. A one step synthesis, starting from 4-hydroxy-2-quinolone with ethyl
acetoacetate and pyridine proceeded through the Michael addition, which
was followed by cyclization, gave an angular isomer 4-methylpyrano[3,2-
c]quinolin-2,5[6H]-dione(Scheme-14). V. Mulwad and M. Lohar115 have syn-
thesized novel spiro [3H-indole-3,7’ -(9’ -amino-8’ -cyano-[7’H]-pyrano- [3,2-
c]-quinolin)]-2,6’ -[1H]-diones (96) by the reaction of N-methyl-4-hydroxy-
2-quinolone with isation and malononitrile.(Scheme-14)
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Work Done at Our Laboratory
The reaction of phenols with malonic acid in the presence of an admixture
of condensing agents zinc chloride and phosphorous oxychloride giving
yields of  4-hydroxy coumarins115 more over the specific condensing action
of this admixture have also been observed116.
From the begin ing of  our  ongoing research on studies of  2 ,4-
dihydroxyquinoline derivatives and their analogues, Dodia117 has extend-
ing this reaction with primary aromatic amines and found that with malonic
acid and admixture of the condensing agents zinc chloride and phospho-
rous oxychloride at temperature suitably between 60oC to 100oC to give
fairly good yields of 2,4-dihydroxyquinolines.
By using 2,4-dihydroxyquinolines as a central intermediate a good number
of substituted fused and dimeric analogues have been prepared, which in-
cludes 3-substituted-2,4-dihydroxyquinolines, pyrano[3,2-c]quinolines,
pyrimido[5’,4’:5,6]pyrano[3,2-c]quinolines and dimeric 2,4-dihydroxy quino-
line derivatives and screened them for various biological activity. A num-
ber of 2,4-dihydroxyquinoline analogues have shown potent activity as anti-
HIV, antitubercular, antimicrobial and antimalarial activity.
Acharya118, Mishra119 and Manvar120 have extended the analogue making
with the condensation of N-methylaniline, N-ethylaniline and N-benzyl
anilines with diethylmalonates in 1:2 mole proportion to afford pyrano[3,2-
c]quinolones which further reacted with cinnamonitrile derivatives to yield
pyrano[2’,3’:4,5]pyrano[3,2-c]quinolone derivatives.
The current work encompasses with N-methyl and N-benzyl substitution of
quinoline ring so as to study the changes in the biological activity. The cur-
rent work presents a direct, efficient and operationally convenient approach
to the synthesis of some novel Pyranoquinolone derivatives.
In the present Chapter Micheal addition and cyclocondensation reaction
between N-methyl-2,4-dihydroxyquinoline and cinnamonitrile derivatives of
aromatic and heteroaromatic aldehydes were studied.
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In another approach, the study  of the reaction between secondary aro-
matic amine and malonic acid derivatives was elaborated with thermal con-
densation of one mole of N-benzylaniline with two moles of diethyl mal-
onate   at 220oC and was found to afford4-hydroxy-6-benzyl-5,6-dihydro-
2,5-dioxo-2H-pyrano[3,2-c]quinoline121,122.
When later was allowed to undergo Micheal addition followed by
cyclocondensation with cinnamonitrile derivatives of aromatic and
heteroaromatic aldehydes having various functional groups of different elec-
tronegativity and steric geometry ,  afforded the product was characterized
to be 2-amino-6-benzyl-5-oxo-4-phenyl-5,6-dihydro-4H-pyrano[3,2-
c]quinoline-3-carbonitrile derivatives on the basis of  IR, NMR and Mass
spectral  and elemental analysis.
The final compounds 2-amino-6-methyl-5-oxo-4-substituted phenyl-5,6-
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitriles(KUQ series) and 2-
amino-6-benzyl-5-oxo-4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-
c]quinoline-3-carbonitriles(KUQP series) synthezised in three and four
steps respectively, as described in experimental part. For synthesis of  2-
amino-6-benzyl-5-oxo-4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-
c]quinoline-3-carbonitrile(KUQP series), it is important to mention that when
6-benzyl-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione treated with 2-
substituted benzylidenemalononitriles under alkaline condition, instead of
resulting into 3-amino-6-benzyl-5,12-dioxo-1-substituted phenyl-6,12-
dihydro-1H,5H-pyrano[2',3':4,5]pyrano[3,2-c]quinoline-2-carbonitrile, pyran
lacton undergoes hydrolytic ring opening along with subsequent decarboxy-
lation to yield 2-amino-6-benzyl-5-oxo-4-substitutedphenyl-5,6-dihydro-4H-
pyrano[3,2-c]quinoline-3-carbonitrile,  which were finally characterized by
FT-IR, NMR and Mass Spectral and elemental analysis.
All the synthesized compounds were screened for different biological
activities.
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 Experimental Protocols
All the starting materials, N-methylaniline, diethyl malonate, malononitrile
and substituted benzaldehydes were obtained from the commercial sources
commercial sources namely Spectrochem Ltd., s.d.fine chem. ltd., Sisco
Research Lab., Ranbaxy Lab., Allied Chem. Ltd., etc. Melting points of the
synthesized compounds were recorded by open capillary method  on con-
trolled temperature (using standard Zeal’s thermometer) and are uncor-
rected.  The commencement of the reaction and purity of the  synthesized
compounds  were ensured using thin layer chromatography (TLC) silica
gel-G, used as stationary phase, the TLC plates were purchased from
Merck India Ltd. The ethyl acetate:hexane solvent system was used as the
mobile phase. However other solvent systems like acetone:benzene and
chloroform:methanol were also employed, but the best results observed
with ethyl acetate:hexane system.
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Experimental (Scheme - 1)
Synthesis of 4-hydroxy-1-methyl-2(1H)-quinolinone :
In 250ml RBF N-methyl aniline(0.1 mole), anhydrous malonic acid(0.11 mole),
anhydrous  zinc chloride(30gms) and  phosphorous oxy chloride (40ml) were
thoroughly mixed together. The content was heated on a water bath till the
reaction mass become viscous. The reaction mass  was poured into crushed
ice. The crude product was filtered and  thoroughly  washed with water till
become acid free. The crude product was treated with 30%NaOH solution
and  filter ed. The filterate was acidified with 30%HCl solution to give 4-
hydroxy-1-methyl-2(1H)-quinolinone, which was filtered and dried and recrys-
tallized from methanol. Yield 75%, m.p. 258-262oC (Reported m.p. 256oC95).
Purity was checked by TLC using ethyl acetate:hexane( 4:6) as mobile phase.
Synthesis of 2-amino-6-methyl-5-oxo-4-substituted phenyl-5,6-dihydro-4H-
pyrano[3,2-c]quinoline-3-carbonitrile (General Method) :
A substituted aromatic or heteroaromatic aldehyde(0.01 mole)  was dis-
solved in minimum quantity of methanol and  malanonitrile(0.03 mole) was
added and mixed thoroughly. Catalytic amount  of piperidine or triethyl
amine was added and the reaction mixture was stirred at  room tem-
perature to afford crude 2-benzelidinemalononitriles. The crude product
was crystallized from methanol. Yield  87-93%. Purity of each was checked
by TLC using ethyl acetate:hexane (3:6) as mobile phase.
4-hydroxy-1-methyl-2(1H)-quinolinone(0.01mole) and 2-benzylidene
malononitrile(0.01 mole) were dissolved  in  N,N-dimethyl formamide(17ml)
along with catalytic amount of piperidine or triethyl amine. The reaction
mixture was refluxed in a water bath for 1hour. The reaction mixture was
cooled gradually to room temperature, to afford 2-amino-6-methyl-5-oxo-
4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitriles.
The crystallized product was filtered and throughly washed with chilled
N,N-dimethylformamide and recrystallized from hot N,N-dimethylformamide.
The purity of each compound  was check by TLC using ethyl acetate:hexane
(5:5) as mobile phase.
The physical constants of the synthesized compounds are shown in Table 6.1.
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Experimental (Scheme - 2)
Synthesis of N-Benzylidene aniline:
In  a 100ml round bottomed flask fitted with a reflux condenser, a mixture of
benzaldehyde(0.05 mole), aniline(0.05 mole) and rectified spirit(20ml) was
refluxed in a water bath for 20minutes. A portion of water was added  until a
slight cloudiness persists and the solution was allowed to set on one side to
cool. The oil which seperated may be induced to crystallise by rubbing with
a glass  rod. The solid deposited was collect  by filteration and washed well
with cold aqueous ethanol. Crude Schiff base obtained was  recrystallized
from small portion of aqueous methanol  to give light  yellow crystalls. Yield
88%, m.p.  52-54oC (Reported m.p. 52oC123). Purity was checked by TLC
using ethyl acetate:hexane (5:5) as mobile phase.
Synthesis of N-Benzyl aniline:
A solution of N-Benzylidene aniline(0.044mole) in methanol(100ml) was
warmed  to about 40oC and over a period of 30 minutes sodium
borohydride(0.044mole)  was added portionwise  with stirring ; which
led to a steady evolution of hydrogen gas. The solution was heated un-
der reflux for 15 minutes, and the reaction mixture was poured into crushed
ice. The solid amine deposited was collected by filteration and recrystal-
lized from aqueous methanol. Yield 90%,m.p.36-38oC, b.p.306-307o
C(Reported m.p. 35-38 oC124, b.p.307o C124). Purity was checked by TLC
using ethyl acetate:hexane (5:5) as mobile phase.
Synthesis of 6-Benzyl-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione
A mixture of N-Benzyl aniline(1.0 mole) and diethyl malonate(2.0 mole) was
heated in an oil bath equipped with a distilation apparatus. At about 160oC
liberation of ethanol took place and the temperature was increased  slowly
to 220o C, where it was kept  until no more ethanol was formed. Then the
reaction mixture was allowed to cool  to room temperature by remaining in
the oil bath over night. The precipitate was filtered and  washed  with  xy-
lene or dioxane. Crystallized  from toluene.Yield 57%, m.p. 238-240oC. (Re-
ported m.p. was 239o C126). Purity was checked by TLC using ethyl
acetate:hexane(7:3) as mobile phase.
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Synthesis of 2-Amino-6-benzyl-5-oxo-4-sub.phenyl-5,6-dihydro-4H-
pyrano[3,2-c]quinoline-3-carbonitrile (General Method) :
A mixture of 6-benzyl-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione
(0.01mole) and  2-benzylidenemalononitrile(0.01 mole) in N,N-dimethyl
formamide(17ml) along with catalytic amount of piperidine or triethyl amine
was refluxed in a water bath for 1hr. After completion of reaction the reac-
tion mixture was gradually cooled to room temperature, to afford 2-amino-
6-benzyl-5-oxo-4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-c]quinoline-
3-carbonitriles. The crystall ized product was filtered and throughly
washed with chilled N,N-dimethylformamide and recrystallized from hot
N,N-dimethylformamide. The purity of each compound  was checked by
TLC using ethyl acetate:hexane  (5:5) as mobile phase.
The elemental analysis of compounds performed by PERKIN ELMER 470R
are in total agreement with the theoritical values.
The physical constants and elemental analysis of all compounds were
shown in Table no. 6.2
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SPECTRAL CHARACTERIZATION
The constitution of newly synthesized compounds were supported by FT -
IR, 1H NMR and  FAB-Mass spectral study.
IR Spectral Study
Instrument: SHIMADZU FT-IR 8400 Spectrophotometer
Sample technique: KBr pellet    Frequency range: 400-4000 cm-1
The 2-Amino-6-methyl-5-oxo-4-substi tutedphenyl-5,6-dihydro-4H-
pyrano[3,2-c]quinoline-3-carbonitriles(KUQ Series) and 2-Amino-6-benzyl-
5-oxo-4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-
carbonitriles(KUQP Series) indicates the presence of very specific func-
tional groups like cyano, amino, cyclic amide,  aromatic ring skeleton
etc. as well as N-methyl  and N-benzyl substituents respectively,  which
absorb IR radiations of specific frequency and show sharp, medium or
weak intense signals and hence supports in identifiction and confirma-
tion of the molecule.
The IR spectrums of 2-Amino-6-methyl-5-oxo-4-substituted phenyl-5,6-
dihydro-4H-pyrano[3,2-c ]quinol ine-3-carbonitr i les  show common
frequences as 3440-3300cm-1 for amino, 3114-3190cm-1 for aromatic C-H
str.,2980-2830cm-1 for alkyl str., 2205-2180 cm-1 for cyano str., 1690-
1665cm-1 for carbonyl str. of cyclic amide, aromatic ring skeleton observed
between 1650-1480cm-1, 1460-1400cm-1 for alkyl in plane deformation,
1380-1360cm-1 for tertiary N-C str.  mono,di & tri phenyl substitutions
observed between 890-740cm-1. In case of 2-Amino-6-benzyl-5-oxo-4-substi-
tuted phenyl-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitriles that observed
as  3440-3330cm-1 for amino, 3185-3050cm-1 for aromatic C-H str., 2950-
2860cm-1 for methylene str., 2351-2175 cm-1 for cyano, 1680-1630cm-1 for car-
bonyl of cyclic amide, aromatic ring skeleton observed between 1600-1480cm-
1, 1460-1430cm-1for methylene in plane deformation, 1400-1300cm-1 for
3o N-C str.  mono,di & tri phenyl substitutions  observed between 870-
730cm-1. The IR spectral data of all compounds of KUQ and KUQP series
are show in Table 6.3 and Table 6.4 respectively.
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  IR Spectrum of 2-Amino-6-methyl-5-oxo-4-(2-nitro)phenyl-5,6 dihydro-4H-pyrano[3,2-c]
  quinoline-3-carbonitrile (KUQ- 5)
N
O
O
CH3
NH2
N
NO2
   IR Spectrum of 2-Amino-6-methyl-5-oxo-4-(4-fluoro)phenyl-5,6 dihydro-4H-pyrano[3,2-
   c]quinoline-3-carbonitrile (KUQ- 8)
N
O
O
CH3
NH2
N
F
  KUQ - 5 KUQ - 8
lanoitcnuF
puorG edoMnoitarbiV
ycneuqerF
mc( 1- )
HN- 2 .rtsH-N 3343
HC-
citamorA .rtsH-C- 0913
HC- 3
lyklA
.rtsH-C-
.tamrofedp/iH-C- n
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NC-
)onayc( C= .rtsN 0022
O=C- .rtsO=C- 5861
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noitutitsbusid4:1 848
3o C-N .rtsC-N- 0831
oroulF .rtsF-C- 6211
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  IR Spectrum of 2-Amino-6-methyl-5-oxo-4-(3-chloro)phenyl-5,6 dihydro-4H-pyrano[3,2-c]
  quinoline-3-carbonitrile (KUQ- 5)
   IR Spectrum of 2-Amino-4-(1H-indol-3-yl)-6-methyl-5-oxo-5,6-dihydro-4H-pyrano[3,2-c]
   quinoline-3-carbonitrile (KUQ- 25)
  KUQ - 3 KUQ - 25
N
O
O
CH3
NH2
N
Cl
N
O
O
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N
N
H
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  IR Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-fluoro)phenyl-5,6 dihydro-4H-pyrano[3,2-c]
  quinoline-3-carbonitrile (KUQP-2)
   IR Spectrum of 2-Amino-6-methyl-5-oxo-4-(4-methoxy)phenyl-5,6 dihydro-4H-pyrano[3,2-
   c]quinoline-3-carbonitrile (KUQP-1)
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1H NMR Spectral Study
1H NMR Spectrum of the 2-amino-6-methyl-5-oxo-4-(3-chloro)phenyl-5,6
dihydro-4H-pyrano [3,2-c]quinoline-3-carbonitrile(KUQ) and 2-amino-6-
benzy l -5 -oxo-4 - (3 -ch lo ro )pheny l -5 ,6 -d ihydro -4H -py rano [3 ,2 -c ]
quinoline-3-carbonitrile(KUQP) show signals relevant to the number of
protons and their  electronic environment known as chemical shift.
Chemical shift have been observed either to upfield (Shielding) or down
field(deshielding),  according to the  electronic environment of the
corresponding proton.  In addition  to  this each 1H NMR signal  further
splitted  into  number of subpeaks  according  to  the  number of neighbouring
protons present in the skeleton of molecule. The splitting of the NMR signal
further provides signification about the degree of  interaction  between
neighbouring  protons by means of spin-spin coupling constant  J.
Instrument : BRUKER AC 300MHz FT-NMR
Internal Reference : TMS Solvent : CDCl3  or DMSO d6
2-Amino-6-methyl-5-oxo-4-(3-methoxy)phenyl-5,6 dihydro-4H-
pyrano [3,2-c]quinoline-3-carbonitrile (KUQ-26)
1H NMR Spectrum of KUQ-26 shows a singlet of N-CH3 protons appears at
δ2.886 ppm,  where as a singlet of methyne proton of the pyran ring ap-
pears at δ 2.726, a singlet of methoxy protons of phenyl residue  appears
at δ3.703. Two protons of an amine group resonate at   δ4.497. Protons
H(e) & H(g) appear as multiplet due to close electronic environment at δ6.754,
while proton H(c) appears at δ 7.298  as singlet and H(f) appears at δ7.194
splitted into triplet  with J value of  8.1 & 7.8Hz, which reveals that methoxy
substitution situated at meta position at phenyl residue. Protons H(5) , H(6), H(7)
& H(8) of the benzenoid part shows a doublet at δ8.02 for  with J value 7.8Hz,
a triplet at  δ 7.394 with J value of 7.5 & 8.1Hz, a triplet at δ7.715 with J
value of 7.8 & 7.2Hz and a doublet δ7.583 with J value 8.4Hz respectively,
which reveal that H(5) & H(6) , H(6) & H(7) and H(7) & H(8)  are in ortho position to
each other, while H(5) & H(7) and H(6) & H(8) are relatively in meta position.
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2-Amino-6-methyl-5-oxo-4-(3-phenoxy) phenyl-5,6 dihydro-4H-
pyrano [3,2-c]quinoline-3-carbonitrile (KUQ-10)
 1H NMR Spectrum of KUQ-10 shows a singlet due to three protons of N-
CH3 group at chemical shift value of δ3.561ppm, a singlet of methyne pro-
ton appears at  3.389δ, while two amino protons resonate at  δ 4.531as
singlet. In aromatic chemical shift region two multipletes  corresponding to
m-phenoxy phenyl residue appears at chemical shift range between 6.895-
7.006δ ppm and 7.248-7.422δ ppm.  Protons H(5) , H(6), H(7) & H(8) of the
benzenoid part shows a doublet at δ8.012  with J value 7.8Hz,  a triplet at δ
7.120 with J value of 7.5 & 7.2Hz, a triplet at δ 7.364 with J value of 8.1&
7.5Hz and a doublet at δ 7.583 with J value 8.7Hz respectively, which re-
veals that H(5) & H(6) , H(6) & H(7) and H(7) & H(8)  are in ortho position to each
other, while H(5) & H(7) and H(6) & H(8) are relatively in meta position.
2-Amino-6-methyl-5-oxo-4-(3,4,5-trimethoxy)phenyl-5,6 dihydro-4H-
pyrano [3,2-c]quinoline-3-carbonitrile (KUQ-18)
In case of  1H NMR Spectrum of KUQ-18  a singlet is observed due to N-CH3
protons at chemical shift δ 2.724, a singlet of methyne proton of the pyran
ring appears at  δ2.884, two singlets due to  three methoxy groups ap-
peared at δ 3.563 & 3.685. While two amino protons resonate at δ4.539.
Phenyl residue having two chemically equivalent protons H(c)  show a sin-
glet at δ6.6478. Protons H(5) , H(6), H(7) & H(8) of the benzenoid part shows a
doublet at δ 8.02 with J value 7.8Hz, a triplet at δ7.394 with J value of 7.5 &
8.1Hz, a triplet at δ 7.715 with J value of 7.8 & 7.2Hz and a doublet at
δ7.583 with J value 8.4Hz respectively, which reveals that H(5) & H(6) , H(6) &
H(7) and H(7) & H(8)  are in ortho position to each other, while H(5) & H(7) and
H(6) & H(8) are relatively in meta position.
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2-Amino-6-benzyl-5-oxo-4-(4-methoxy)phenyl-5,6 dihydro-4H-pyrano
[3,2-c]quinoline-3-carbonitrile (KUQP-1)
1H NMR Spectrum of KUQP-1 shows a singlet due to methyne proton at
δ2.502, while a singlet of methoxy protons of phenyl substitution  appears
at δ3.7103. Two amine protons resonate at δ 4.565. Protons H(a) & H(b) of
methylene group of benzyl residue show  two doublet at δ 5.3406 with J
value of 16.19Hz and δ5.537 with J value of 16.22Hz respectively which
reveals that these two protons undergo methylene gem coupling with each
other, evidenced by it’s higher coupling constant value. Among the five pro-
tons of phenyl ring of the benzyl residue, the signals due to protons of type
H(2) & H(3) are merged because of close electronic environment, hence ap-
pear as multiplet at chemical shift range between δ7.102-7.172 ppm, while
H(1) shows a doublet at δ 6.857 with J value of 8.55Hz. Where as phenyl
residue substituted at pyran ring possess two pair of chemically equivalent
but magnetically non-euivalent protons viz. H(d) & H(e) appear as two doublet
at δ7.270 with J value of 8.14Hz and δ7.223 with J value of 4.5Hz respec-
tively. Protons H(5) , H(6), H(7) & H(8) of the benzenoid part show a doublet at
δ8.04 with J value 7.6Hz, a triplet at 7.35 with J value of 7.6 & 7.8Hz, a
triplet at δ7.58 with J value of 7.4 & 7.5Hz and a doublet at δ 7.423 with J
value 8.5Hz respectively, which reveals that H(5) & H(6) , H(6) & H(7) and H(7) &
H(8)  are in ortho position to each other, while H(5) & H(7) and H(6) & H(8) are
relatively in meta position.
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2-Amino-6-benzyl-5-oxo-4-(4-fluoro)phenyl-5,6 dihydro-4H-pyrano
[3,2-c]quinoline-3-carbonitrile (KUQP-2)
1H NMR Spectrum of KUQP-2 shows a singlet due to methyne proton of
the pyran ring at δ 2.502. Two amino protons are resonate at δ 4.565.
Protons H(a) & H(b) of  methylene group of benzyl residue show  two dou-
blets at δ5.352 with J value of 16.22Hz and δ5.527 with J value of 16.27Hz
respectively which reveals that these two protons undergo methylene gem
coupling with each other, evidenced by it’s higher coupling constant
value. Among the five protons of phenyl ring of the benzyl residue, the sig-
nals due to protons of type H(1), H(2) & H(3) are merge because of close elec-
tronic environment, hence appear as multiplet at chemical shift range be-
tween δ7.275-7.172 ppm. Where as phenyl residue substituted at pyran
ring possess two pair of chemically equivalent but magnetically non-
euivalent protons viz. H(d) & H(e) appear as two doublet at δ7.102 with J
value of 6.8Hz and δ7.135 with J value of 9.01Hz  respectively. Protons H(5)
, H(6), H(7) & H(8) of the benzenoid part shows a doublet at δ8.05  with J value
7.2Hz, a triplet at δ7.364 with J value of 7.85 & 4.97Hz, a triplet at δ 7.583
with J value of 7.4 & 7.5Hz and a doublet at δ7.437 with J value 8.5Hz
respectively, which reveals that H(5) & H(6) , H(6) & H(7) and H(7) & H(8)  are in
ortho position to each other, while H(5) & H(7) and H(6) & H(8) are relatively in
meta position.
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NMR Spectrum of 2-Amino-6-methyl-5-oxo-4-(3-methoxy)phenyl-5,6
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQ-26)
N
O
O
CH3(a)
NH2(h)
N
OCH3(d)
H(5)
H(b)
(6)H
(7)H
H(8)
H(c)
H(e)
H(f)
H(g)
                  KUQ - 26
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HC-N )a(3 688.2 3 s -
HC- )b( 627.2 1 s -
HCO- )d(3 307.3 3 s -
HN )h(2 794.4 2 s -
H-rA )g,e( 457.6 2 m -
H-rA )c( 892.7 1 s -
H-rA )f( 491.7 1 t 8.7&1.8
H-rA )6( 204.7 1 t 8.7&2.7
H-rA )8( 85.7 1 d 7.8
H-rA )7( 27.7 1 t 2.7&5.7
H-rA )5( 20.8 1 d 2.7
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NMR Spectrum of 2-Amino-6-methyl-5-oxo-4-(3-phenoxy)phenyl-5,6
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQ-10)
N
O
O
CH3(a)
NH2(k)
N
O
H(5)
H(b)
(6)H
(7)H
H(8)
H(c)
H(d)
H(e)
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HC-N )a(3 165.3 3 s -
HC- )b( 983.3 1 s -
HN )k(2 135.4 2 s -
H-rA )d( 377.6 1 dd 8.1&3.6,8.1
H-rA )f,e,c( 600.7-598.6 3 m -
H-rA )k-g( 224.7-842.7 1 m
H-rA )6( 21.7 1 t 2.7&5.7
H-rA )8( 385.7 1 d 7.8
H-rA )7( 463.7 1 t 5.7&1.8
H-rA )5( 210.8 1 d 8.7
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NMR Spectrum of 2-Amino-6-methyl-5-oxo-4-(3,4,5-trimethoxy)phenyl-
5,6 dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQ-18)
N
O
O
CH3(a)
NH2(f)
N
OCH3(d)
H(5)
H(b)
(6)H
(7)H
H(8)
H(c)
OCH3(e)
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                   KUQ-18
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HC-N )a(3 427.2 3 s -
HC- )b( 488.2 1 s -
HCO-2 )d(3 586.3 6 s -
HCO- )e(3 365.3 3 s -
HN )f(2 935.4 2 s -
H-rA )c( 874.6 2 s -
H-rA )6( 493.7 1 t 1.8&5.7
H-rA )8( 385.7 1 d 4.8
H-rA )7( 517.7 1 t 2.7&8.7
H-rA )5( 20.8 1 d 8.7
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NMR Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-methoxy)phenyl-5,6
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-1)
N
O
O
C
NH2(f)
N
H(e)
H(5)
H(c)
(6)H
(7)H
H(8)
H(d)
OCH3
H(e)
H(d)
H(a)
H(b)
H(1) H(2)
H(3)
H(1)(2)H
                   KUQP-1
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HCO- 3 3017.3 3 s -
HC- )c( 9105.2 1 s -
HC- )a( 6043.5 1 d 91.61
HC- )b( 1735.5 1 d 22.61
HN- 2 565.4 2 s -
H-rA )d( 2072.7 2 d 41.8
H-rA )e( 422.7 2 d 5.4
H-rA )1( 758.6 2 d 5.8
H-rA )3,2( 531.7 3 m -
H-rA )6( 2053.7 1 t 6.7&6.7
H-rA )8( 324.7 1 d 5.8
H-rA )7( 4085.7 1 t 5.7&4.7
H-rA )5( 740.8 1 d 6.7
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NMR Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-fluoro)phenyl-5,6
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-2)
              KUQP-2
N
O
O
C
NH2(f)
N
H(e)
H(5)
H(c)
(6)H
(7)H
H(8)
H(d)
F
H(e)
H(d)
H(a)
H(b)
H(1) H(2)
H(3)
H(1)(2)H
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM eulaVJ
HC- )c( 205.2 1 s -
HC- )a( 353.5 1 d 22.61
HC- )b( 825.5 1 d 72.61
HN- 2 936.4 2 s -
H-rA )d( 4201.7 2 d 8.6
H-rA )e( 631.7 2 d 10.9
H-rA )3,2,1( 672.7 5 m -
H-rA )6( 463.7 1 t 79.4&58.7
H-rA )8( 734.7 1 d 5.8
H-rA )7( 485.7 1 t 5.7&4.7
H-rA )5( 50.8 1 d 2.7
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Mass Spectral Study
The MASS spectral data have reveald sigificant clues in the strucure charac-
terization of all the newly synthesized  2-Amino-6-methyl-5-oxo-4-substituted
phenyl-5,6 dihydro-4H-pyrano[3,2-c] quinoline-3-carbonitriles(KUQ series) and
2-Amino-6-benzyl-5-oxo-4-substituted phenyl-5,6 dihydro-4H-pyrano[3,2-c]
quinoline-3-carbonitriles(KUQP series). By both the Fast Atomic Bombartment
an Electron Impact Mass spectral analysis of  the products obtained by the
Micheal addition and cyclocondensation reaction between 6-Benzyl-4-hydroxy-
2H-pyrano[3,2-c]quinoline-2,5(6H)-dione and 2-benzelidinemalononitrile de-
rivatives, the molecular ion peak generated of m/z value correspond to the
molecular  weight  of 2-Amino-6-benzyl-5-oxo-4-substituted phenyl-5,6 dihydro-
4H-pyrano[3,2-c] quinoline-3-carbonitriles,   which indicated  that rupture of
the α-pyranone ring takes place during the reaction. However, 1H NMR spec-
tral analysis was failed to interpret this data as the α-pyranone ring of the pre-
dicted tetracylic derivative was in lack of proton.
The molecular ion peak(M+) of the compounds are in total agreement with
it’s molecular weight.
FAB - MASS  Spectral analysis
Instrument: JEOL SX 102/DA-6000 Spectrograph for FAB
2-Amino-6-methyl-5-oxo-4-(3-methoxy) phenyl-5,6 dihydro-4H-
pyrano[3,2-c] quinoline-3-carbonitrile (KUQ-26)
In the case of FAB Mass spectrum of KUQ-26 the Molecular ion peak ap-
pears at m/z 360, base peak of the fragmentation is M+1peak appears at
m/z 360, other ions generated are m/z307, m/z 289, m/z 252, m/z 242, m/z
227, m/z 156, m/z 136 etc.
2-Amino-6-methyl-5-oxo-4-(3-phenoxy) phenyl-5,6 dihydro-4H-
pyrano[3,2-c] quinoline-3-carbonitrile (KUQ-10)
In the case of FAB Mass spectrum of KUQ-10 the Molecular ion peak ap-
pears at m/z 421, M+1peak appears at m/z 422, base peak of the frag-
mentation appears at m/z 307, other ions generated are m/z391, m/z 350,
m/z 289, m/z 252, m/z 194, m/z 167 etc.
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2-Amino-6-methyl-5-oxo-4-(3,4,5-trimethoxy) phenyl-5,6 dihydro-4H-
pyrano[3,2-c] quinoline-3-carbonitrile (KUQ-18)
In the case of FAB Mass spectrum of KUQ-18 the Molecular ion peak ap-
pears at m/z 419, M-1peak appears at m/z 418, base peak of the fragmen-
tation appears at m/z 252, other ions generated are m/z391, m/z 388, m/z
350, m/z 307, m/z 289, m/z 194 etc.
Comparative Study of FAB Mass and EI Mass Spectral analysis
2-Amino-6-benzyl-5-oxo-4-(4-methoxy) phenyl-5,6 dihydro-4H-
pyrano[3,2-c] quinoline-3-carbonitrile (KUQP-1)
In the case of FAB Mass spectrum of KUQP-1 the Molecular ion peak ap-
pears at m/z 435, M+1peak appears at m/z 436, base peak of the frag-
mentation appears at m/z 307, other ions generated are m/z391, m/z 344,
m/z 328, m/z 289, m/z 251, m/z 120 etc.
On the other hand EI Mass spectrum of KUQP-1 shows the Molecular ion
peak appears at m/z 435, M+1peak appears at m/z 436, base peak of the
fragmentation appears at m/z 93, other ions generated are m/z368, m/z
344, m/z 328, m/z 301, m/z 278, m/z 221 etc.
2-Amino-6-benzy l -5-oxo-4- (4 - f luoro)phenyl -5 ,6-d ihydro-4H -
pyrano[3,2-c] quinoline-3-carbonitrile (KUQP-2)
In the case of FAB Mass spectrum of KUQP-1 the Molecular ion peak ap-
pears at m/z 423, base peak of the fragmentation is M+1peak appears at m/
z 424, other ions generated are m/z409, m/z 397, m/z 358, m/z 344, m/z
328, m/z307, m/z289, m/z289, m/z273, m/z251, m/z238 etc.
Where as EI Mass spectrum of KUQP-1 shows the Molecular ion peak ap-
pears at m/z 435, M+1peak appears at m/z 436, base peak of the fragmen-
tation appears at m/z 93, other ions generated are m/z357, m/z 332, m/z
328, m/z 266, m/z 237, m/z 209, m/z180, m/z163, m/z163, m/z144, m/z132,
m/z120 etc.
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FAB MASS Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-methoxy)phenyl-
5,6 dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-1)
EI MASS Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-methoxy)phenyl-
5,6 dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-1)
N
O
O
NH2
N
H
OCH3
Mol. Weight = 435.47gm/mole
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FAB MASS Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-fluoro)phenyl-
5,6 dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-2)
EI MASS Spectrum of 2-Amino-6-benzyl-5-oxo-4-(4-fluoro)phenyl-5,6
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile (KUQP-2)
N
O
O
NH2
N
H
F
Mol. Weight = 423.43gm/mole
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CHAPTER-4
     Synthesis and Characterization of Some
  1-[2,4-Dimethyl-5-(5-(un)substituted phenyl-
1,3,4-oxadiazol-2-yl)-1H-pyrrol-3-yl]ethanones
239
Part-A. 1,3,4-Oxadiazole
1,3,4-oxadiazole(1) is a thermally stable aromatic heterocycle and exist in two
partially reduced forms; 2,3-dihydro-1,3,4-oxadiazole(Ä2 - 1,3,4-oxadiazoline)(2)
and 2,5-dihydro-1,3,4-oxadiazole(Ä3 - 1,3,4-oxadiazoline)(3) depending on the
position of the double bond. The completely reduced form of the 1,3,4-oxadiazole
is known as 2,3,4,5-tetrahydro-1,3,4-oxadiazole (1,3,4-oxadiazolidine)(4)1
O
N N
O
N N
H
O
N N
O
N
H
N
H
1 2 3 4
Bactericidal and/or fungicidal activity was reported for oxadiazole(5a), amino-
oxadiazole(5b)2 and oxadiazolinethiones(6a)3. The tin derivatives (6b) is an
effective fungicide and antimicrobial activity is shown by thiones(6c)4. Anti-
inflammatory, sedative and analgesic properties were reported for
aryloxadiazoles(5c)5. Amino-oxadiazoles(5d) show analgesic activity and
amono-oxadiazoles(5e) exhibit both antiinflammatory and antiproteolytic prop-
erties6. Anticonvulsant and nervous system depressant activity was reported
for amino-oxadiazoles(5f), where R is quinazolin-3-yl group7. Amino-
oxadiazole(5g) show local anaesthetic activity8. The oxadiazolinone(6d) is an
orally active antiallergic agent, for example in the treatment of asthma and
allergy disease and is claimed to be more potent than sodium cromoglycate9.
Examples of the many oxadiazolones for the many herbicidal activity(week
killers) are(6e,6f) and “oxadiazon”(6g), which is the subject of many regular
reports in the literature. Insecticidal activity is shown by oxadiazolones(6h,6i
the later is an aphicide), and oxadiazole(5h)
1.J.Hill, Comp.Heterocycl.Chem., 1st edition, 6427(1984)
2.K.Roda, R.Vansdadia, H.Parekh, J.Ind.Chem.Soc.,65,807(1988)
3.V.Adhikari, V.Badiger, Ind.J.Chem. Sect-B,27, 542(1988)
4.S.Hiremath, N.Gaudar, M.Purohit, Ind.J.Chem. Sect-B,21,321(1982)
5.G.Mazzone, F.Bonina, G.Puglisi, A.Panico, R.Arrigo, Farmaco Ed Sci., 39, 414(1984),
Chem.Abstr., 101, 16831(1984)
6.K.Raman, S.Parmar, S.Salzman,J.Pharm.Sci., 78, 999(1989)
7.N.Ergenc, S.Buyuktimkin, G.Capan, G.baktir, S.Rollas, Pharmazie, 46,290(1991)
8.V.Saxena, A.Singh, R.Agarwal, S.Mehra,J.Ind.Chem.Soc., 60, 575(1983)
9.J.Musser et al., J.Med.Chem.,27, 121(1984)
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O
N N
R2R1
O
N N
XR1
R2
5 (a-h) 6 (a-i)
  R1     R2
5a Ar     CH2CONHCONHR                  
5b AROCH2    NHCOR                
5c trimethoxy   or 3,4-dimethoxyphenyl                    
5d 2-pyridyl    NR2HCl                
5e 4-biphenylylmethyl  NHAr          
5f Ar     NHCH2CONHR         
5g Ar    NHCO(CH2)nNRR'HCl(n=2or3)
  R1     R2               X
6a heteroarylOCH2   H                                   S  
6b 1-methylcyclopropyl  Sn(Ph)3                O   
6c 5-Cl-2-phenylindol-3-ylNH H     S  
6d 3-Cl-benzo[b]thiophen-2-yl H                         O  
6e 4-cyclohexylphenoxy  H                  O  
6f 2,4-diCl-phenoxymethyl Bn        O  
6g t-Bu    2,4-diCl--5-isopropoxyphenyl      O 
6h OCH3    o-methoxyphenyl         O 
6i CH3NH   2,3-diH-2,2,4-triMebenzofuran-7-yl  O
Pharmacology
?As Phenylene-Glycine dipeptidomimetics
Although several different strategies have been used in the development of
peptidomimetic compounds, it is still not fully understood how to rationally
convert a peptide into a nonpeptide while maintaining the desired biological
activity. The structural and biological effects caused by replacement of
important dipeptide fragments in biologically interesting peptides with
nonpeptidic moieties were reported10,11. Frequently, only a small part of the
peptide(4-8 amino acids), the binding epitope, is responsible for the
recognition and binding to the receptor. These key amino acids can be used
as the starting point for the design of nonpeptidic receptor ligands.
Susana Borg e t  a l 12 have synthes ized enant iopure,  Phe-Gly
dipeptidomimetics containing 1,3,4-oxadiazole, 1,2,4-oxadiazole, and
1,2,4-triazole ring systems as building blocks in the synthesis of
pseudopeptides. Three derivatives (7-9) have the carboxylic acid function
directly bound to the heterocyclic ring, and three derivatives (10-12) have
an extra methylene group between the heterocyclic ring and the acid function
to allow for an increased conformational flexibility. The three heterocycles
are known as efficient ester and/or amide isosteres,13 but only the 1,2,4-
triazole has previously been used in peptide mimicry.14,15 Although similar
in size and shape, the ring systems show variations in aromatic,
electrostatic, and hydrogenbonding properties: (i) all three heterocycles
can participate in hydrogen bonding, the oxadiazoles as acceptors and
the triazole as both acceptor and donor; (ii) the triazole and the 1,3,4-
oxadiazole rings are aromatic, whereas the 1,2,4-oxadiazole
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is better described as a conjugated diene;16 and (iii) only the 1,2,4-triazole
displays any acidic or basic properties with pKa values of 2.19 (as base)
and 10.26 (as acid).17 These variations provide an opportunity to evaluate
properties of importance for amide bond mimicry and to determine the
characteristics of the peptide backbone that are crucial for bioactivity.
The mimetics were used as Phe-Gly replacements in the biologically active peptides
dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) and substance P (Arg-Pro-Lys-
Pro-Gln-Gln-Phe-Phe-Gly-Leu-MetNH2, SP). The biological evaluation was
performed by testing the µ- and ä-opioid receptor affinities of the dermorphin
pseudopeptides and the NK1 receptor affinities of the SP pseudopeptides.
Structures of the Phe-Gly Mimetics
In order to carry out appropriate conformational searches, molecular
mechanics calculations were performed on the N-acetylated and C-terminally
methyl-amidated (Ac- Phe-Gly-NHMe) derivatives, to better simulate the Phe-
Gly moiety  within a peptide chain. Two tautomers of the 1,2,4-triazole
derivatives were used for further calculations and comparisons [9a(1H),
9a(2H) and 12a(1H), 12a(2H)].13d Low-energy conformations  of all
derivatives were identified and imported for further analysis.
NH
NH
O
O
Phy-Gly
NH
O
R2
R1
NN
7a-e
NH
N
R2
R1
NO
8a-e
NH
N
R2
R1
NNH
9a-e
NH
OR1
NN R2
10a-e
NH
NR1
NO R2
11a-e
NH
NR1
NNH R2
12a-e
a, R1 = Ac; R2 = CONHMe                b, R1 = Boc; R2 = COOMe or COOEt       
c, R1 = Boc; R2 = COOH/COO
-K+,   d, R1 = H-Tyr-D-Ala; R2 = Tyr-Pro-SerNH2 
e, R1 = H-Arg-Pro-Lys-Pro-Gln-Gln-Phe, R2 = Leu-MetNH2
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Only 12 unique conformers were found by the conformational search of Ac-
Phe-Gly-NHMe. Among these  three stretched conformations (maximum
distance between terminal ends), two ‚â-turn conformations, four
conformations with a ã-turn in the Gly part, and one conformation with a ã-
turn were  identified in the Phe part. The later conformation was highest in
energy. The stretched conformations were among the low-energy
conformations, whereas the ‚â-turn conformations were higher in energy.
To study the geometrical similarities, all individual low-energy conformations
of each mimetic were superimposed on the 12 low-energy conformations
of Ac-Phe-Gly-NHMe. In total six atoms were fitted, the amide oxygen and
nitrogen atoms of the dipeptide and the corresponding atoms in the
mimetics. Thus, the 12 conformations of  Ac-Phe-Gly-NHMe were
superimposed on 48 conformations each of 7a and 8a, 36 conformations
of 9a(1H), 38 conformations of 9a(2H), 116 conformations of 10a, 74
conformations of 11a, 72 conformations of 12a(1H), and 108 conformations
of 12a(2H). Comparisons of fits to one stretched and one ‚-turn low-energy
conformation of Ac-Phe-Gly-NHMe, to which the peptidomimetics have
energetically ‘allowed’ conformations with close resemblance (good fits),
are shown in Figure(A-D). The geometric comparisons of 7a-9a with Ac-
Phe-Gly-NHMe in the stretched conformation show good fits (Figure A),
but the same comparisons with the turn conformation are less attractive
(Figure C). The geometric comparison using the mimetics containing a
methylene spacer (10a-12a) produce considerably better fits with the turn
conformation of Ac-Phe-Gly-NHMe (Figure D) compared to the stretched
conformation (Figure B), demonstrating that the additional conformational
flexibility inherent in these mimetics can improve the similarity of certain
geometric properties.
NH
N
CONHMe
Ac
NNH9a(1H)
NH
N
CONHMe
Ac
N
H
N9a(2H)
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Figure A-D. Geometric comparisons of Ac-Phe-Gly-NHMe and the Phe-Gly
mimetics 7a-9a in a stretched conformation (A) and in a ‚â-turn conformation
(C) and the corresponding comparisons of Ac-Phe-Gly-NHMe and 10a-12a (B
and D, respectively). Six atoms were fitted in the comparisons: the amide
oxygen and nitrogen atoms of the dipeptide and the corresponding atoms of the
mimetics. Ac-Phe-Gly-NHMe is shown in white,7a and 10a in yellow, 8a and
11a in green, 9a(1H) and 12a(1H) in blue, and 9a(2H) and 12a(2H) in red.
In order to consider  electrical properties along with geometrical and
confirmational similarities, the confirmations used in the fits were subjected
to electrostatic potential calculations from AM1 atomic charges18.  In Fig-
ures E and F the electron density surfaces of the compounds are displayed
and color-coded according to magnitude. The results obtained for Ac-Phe-
Gly-NHMe and 10a (Figure F) were compared with ab initio calculations19.
The energy density surfaces obtained by both levels of calculations were in
good agreement thereby providing support for the use of the less
timeconsuming semiempirical calculations. None of the mimetics perfectly
matched the electrostatic propertiesof the parent dipeptide. However, the
oxadiazole derivatives seem to be better mimetics of Ac-Phe-Gly-NHMe than
the triazole derivatives in terms of electrostatics, the 1,3,4-oxadiazoles be-
ing the best in both series of  mimetics.
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Figure E. Comparisons of electron density surfaces of  Ac-Phe-Gly-NHMe
and 7a-9a in stretched conformations (see Figure A), displayed and color-
coded according to magnitude. Four different orientations are shown, to
allow for accurate comparisons (rotation in 90° increments around the x-
axis). Red areas represent potentials ranging from -40 to -20 kcal/mol, purple
areas represent potentials ranging from -20 to +20 kcal/mol, and blue areas
represent potentials ranging from +20 to +40 kcal/mol.
10.A.Jenmalm, K.Luthman, G.Lindeberg, F.Nyberg, L.Terenius, U.Hacksell, Bioorg. Med.
Chem. Lett.,2, 1693(1992).
11.Y.Li, K.Luthman, U.Hacksell, Tetrahedron Lett. , 33, 4487(1992).
12.S.Borg, C.R.Vollinga, M.Labarre, K.Payza, L.Terenius, K.Luthman,J. Med. Chem.,42,
4331(1999)
13.(a)A.Giannis, T.Kolter, Angew.Chem., Int. Ed. Engl.,32, 1244(1993).
(b).G.Olson, D.Bolin, M.Bonner, M.Bos, C.Cook, D.Fry, B.Graves, M.Hatada, D.Hill,
M.Kahn, V.Madison, V.Rusiecki, R.Sarabu, J.Sepinwall, G.Vincent, M.Voss, J. Med.
Chem.,36,3039(1993).
(c).R.Freidinger, Prog. Drug. Res. 1993, 40, 33-98.
(d).S.Borg, G.Estenne-Bouhtou, K.Luthman, I.Cso¨regh, W.Hesselink,U.Hacksell, J. Org.Chem.,60,
3112(1995).
14.G.Burrell, J.Evans, M.Hadley, F.Hicks, G.Stemp, Bioorg. Med.Chem. Lett.,4, 1285(1994).
15.S.Thompson, A.Eppley, J.Frazee, M.Darcy, R.Lum, T.Tomaszek, L.Ivanoff, J.Morris,
E.Sternberg, D.Lambert, A.Fernandez, S.Petteway, T.Meek, B.Metcalf, J.Gleason,  Bioorg.Med.
Chem. Lett.,4, 2441(1994).
16.L.Clapp, In Comprehensive Heterocyclic Chemistry; K.Potts, Ed., Pergamon Press:Oxford,365(1984).
17.J.Polya, In Comprehensive Heterocyclic Chemistry;K.Potts, Ed., Pergamon Press:
Oxford,733(1984).
18.W.Dewar, E.Zoebisch, E.Healy, J.Stewart, J. Am. Chem. Soc. , 107, 3902(1985).
19.P.Hariharan, J.Pople, Chem. Phys. Lett.,16,217(1972).
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Figure F. Comparisons of electron density surfaces of Ac-Phe-Gly-NHMe and 10a-
12a in ‚â-turn conformations as shown in (Figure D), displayed and color-coded
according to magnitude (see legend to Figure E for color coding).
The results showed that all mimetics except 3 were excellent replacements of Phe-
Gly in dermorphin since they displayed affinities for the ì-receptor (IC50 12-31 nM)
in the same range as dermorphin itself (IC50  6.2 nM).The agonist  activity of  three
pseudopeptides at human ì-receptors was also evaluated. It was shown that the
tested compounds retained their agonist activity. The SP pseudopeptides showed
considerably lower affinities (IC50 > 1 ìM) for the NK1 receptor than SP itself (IC50
1.5 nM) indicating that the Phe-Gly replacements prevent the pseudopeptides from
adopting bioactive conformations. Insertion of the novel dipeptide mimetics
into SP led a dramatic loss in affinity for the rat NK1 receptor, the most
potent pseudopeptide being 150-fold less potent than SP in terms of NK1
receptor affinity. Hence, the heterocyclic mimetics
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used herein are not useful as mimics of Phe-Gly in SP. The reduction in affinity
of the pseudopeptides might be due to undesirable steric, electrostatic, or
other properties such as an inability to adopt energetically favorable bioactive
conformations. However, during the design process,  force-field calculations
were used to establish that the conformational preferences of the synthesized
Phe-Gly mimetics were quite similar to those of Phe-Gly. Therefore, it was
more likely that other properties of the Phe-Gly mimetics were detrimental to
the activity of the SP pseudopeptides. In contrast to the above, insertion of the
dipeptide mimetics into dermorphin led to potent and selective pseudopeptides
as they had high affinities for ì-receptors and low affinities for ä-receptors.
?As Tyrosinase Inhibitors
Tyrosinase, also known as polyphenol oxidase (PPO), is a multifunctional
copper-containing enzyme, widely distributed in plants and animals. It
catalyses the o-hydroxylation of monophenols and also the oxidation of o-
diphenols to o-quinones. Tyrosinase is known to be a key enzyme for melanin
biosynthesis in plants and animals. Therefore, tyrosinase inhibitors should
be clinically useful for the treatment of some dermatological disorders
associated with melanin hyperpigmentation and also important in cosmetics
for whitening and depigmentation after sunburn.
In addition, tyrosinase is known to be involved in the molting process of insect
and adhesion of marine organisms.20 In insects, several functions of this
enzyme have been reported in the generation of o-diphenols and quinones for
pigmentation, wound healing, parasite encapsulation, and sclerotization and
the enzyme is an alternative target site for the control of insect pests. In food
industry, tyrosinase is responsible for the enzymatic browning reactions in
damaged fruits during post-harvest handling and processing. Control of
enzymatic browning during processing is important in fruit pulp manufacturing.
In addition, tyrosinase inhibitors are becoming important constituents of
cosmetic products that relate to hyperpigmentation.
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Therefore, there is a concerted effort to search for naturally occurring
tyrosinase inhibitors from plant, because plants constitute a rich source of
bioactive chemicals and many of them are largely free from harmful adverse
effects.21
Ahmad et al. in 2004 reported that, a new coumarinolignoid 80-epi-
cleomiscosin A together with the new glycoside 8-O-â-D- lucopyranosyl-6-
hydroxy-2-methyl-4H-1-benzopyrane-4-one, exhibited strong inhibition
against the enzyme tyrosinase, when compared to the standard tyrosinase
inhibitors kojic acid and L-mimosine. The new coumarinolignoid exhibited
two times more potency than that of the standard potent inhibitor L-
mimosine.22 Karbassi et al. reported the inhibition kinetics of two new
synthetic bi-pyridine molecules, [1,4’]bipiperidinyl-10-yl-naphthan- 2-yl-
methanone and [1,4’]bipiperidinyl-10-yl-4- methylphenyl-methane  of the
catecholase activity of mushroom tyrosinase. The kinetics studies indicated
that these are uncompetitive inhibitors and the values of the Ki are 5.87
and 1.31 µM,  respectively, which showed high potency. Fluorescent studies
confirmed the uncompetitive type of inhibition for these two inhibitors. They
also suggested that, the inhibition mechanism presumably coming from the
presence of a particular hydrophobic site which can accommodate these
inhibitors. This site could be formed due to a probable conformational
change that was induced by binding of substrate with the enzyme.23
Very recently, Mahmud Tareq hassan Khan, Atta-ur-Rahmann and co-
researchers24 have demonstrated tyrosinase inhibition studies of library of
2,5-disubstituted-1,3,4-oxadiazoles along with their structure activity
relationship. There were 26 derivatives of two types of basic oxadiazole
skeleton have been studied to explain their inhibition patterns and structure
activity relationship against tyrosinase enzyme. In one type of compounds,
substitutions were changing at different positions of the phenyl ring at C-5
while keeping the pyridine ring constant at C-2 (13a-m),
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while another type of compounds, substitutions were changing at different
positions of the phenyl ring while keeping the o-methoxy phenyl ring constant
at C-2 position (14a-m).
O
N N
N
R'
O
N N
R'
OCH3
13 a-m 14 a-m
13a, R' = C6H5, 13b, R' = o-NO2C6H4, 
13c, R' = o-BrC6H4, 13d, R' = m-BrC6H4 , 
13e, R' = p-BrC6H4, 13f, R' = 3-pyridyl, 
13g, R' = CH2Cl, 13h, R' = CHCl2, 13i, R' 
= CCl3, 13j, R' = p-CH3C6H4, 13k, R' = 
3,4,5-triOCH3C6H2,  13l, R' = 2-naphthyl, 
13m, R' = 1-naphthyl
14a, R' = C6H5, 14b, R' = o-NO2C6H4, 
14c, R' = o-BrC6H4, 14d, R' = 
m-BrC6H4 , 14e, R' = p-BrC6H4, 14f, R' 
= 3-pyridyl, 14g, R' = CH2Cl, 14h, R' 
= CHCl2, 14i, R' = CCl3, 14j, R' = 
p-CH3C6H4, 14k, R' = 
3,4,5-trimethoxyphenyl, 14l, R' = 
2-naphthyl, 14m, R' = 1-naphthyl
The biological screening results suggested that compound 13a exhibited
potent tyrosinase inhibition and the IC50 value was 5.15ìM, where the IC50
value of reference tyrosinase inhibitor kojic acids (KA) was 16.67 ìM. This
compound was totally unsubstituted. Substitution with nitro group the re-
sulting 3b was showing highly potent (IC50 =3.18 ìM) inhibition against ty-
rosinase, when compared with highly potent reference tyrosinase inhibitor
L-mimosine (LM) (IC50 = 3.68 ìM). Due to the substitution of this nitro group
the resulting compound exhibited potent inhibition. But when the same phe-
nyl ring was found to have bromine atom at ortho position (13c,IC50 = 5.23
ìM) and meta position (13d, IC50 = 6.04 ìM) , the activities were decreased
although the potency was much better than the KA. Again when the bromi-
nation was done at para position, the resulting compound 13e exhibited
highest potency against the enzyme tyrosinase and IC50 value is 2.18 ìM,
which is 1.96 times more potent than the LM. When pyridine was attached
at C-5 position, the resulting
compound 13f was showing highly potent (IC50 = 3.29 ìM) inhibition against
tyrosinase, even better than the LM.When chloromethyl group was present
at the C-5 position, the resulting compound 13g was showing highly potent
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(IC50 = 4.18 ìM) inhibition against tyrosinase, if compared with the KA,
which is 3.99 times more potent. At the same position one more chlorine
was attached, the resulting compound 13h exhibited little more potency
(IC50 = 4.01 ìM) than the previous one. Finally when all chlorine atoms are
attached, the resulting 13i exhibited more potency (IC50 = 3.98 ìM) than
the previous two compounds. These compounds confirmed that, for the
better inhibition of tyrosinase, electronegativity is necessary and the
tyrosinase inhibition is directly proportional to the electronegativity of
substituent(s). When the compound was substituted with 2-naphthyl group
at C-5 position, the resulting compound 13l was showing potent (IC50 =
3.23 ìM) inhibition, if compared with LM.
In the second series of the library of compounds, substitutions introduced
at C-5 position of the oxadiazole ring, while keeping the methoxy group at
C-2. When bromine was present at meta position, the resulting compound
14d was showing potent inhibition (IC50 = 7.18 ìM) when compared with
KA. When bromine was present at para position as in the case of compound
14e, then the potency of the compound decreased (IC50 = 7.82 ìM). Again it
has been noted that when bromine is present at ortho rather than at meta, as
in the case of compound 14c, the potency has been found to increase (IC50 =
5.16 ìM) and exhibit better inhibition than the 14d and 14e. When the
bromine was totally replaced by phenyl ring, as in the case of compound
14a, then the potency of the compound decreased (IC50 = 8.71 ìM). It means
that, the presence and the position of the –Br is essential for tyrosinase
inhibition, which is also supporting the .ndings of Wang et al.25 When the
tricholoromethyl group is present at C-5 position 14i of oxadiazole ring the
compound showed better inhibition (IC50 = 6.21 ìM), when compared with
the compound 14h (IC50 = 7.28 ìM), where one –Cl was replaced with proton.
The compound 14j, containing methyl group at aromatic ring, exhibited
excellent potency (IC50 = 6.45 ìM).
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The comparative tyrosinase inhibition study of each candidate summerized
graphically in Figure-G. It can be concluded from this study that for the better
inhibition of enzyme tyrosinase, electronegative changeover is crucial and
the location of the group is also imperative in support of the inhibition. If
the electronegativity is increased the inhibition also increases. The
compound 13e (3-[5-(4-bromophenyl)-1,3,4-oxadiazol- 2-yl]pyridine)
exhibited most potent inhibition against the enzyme tyrosinase, while
compared with both of the reference inhibitors.
Graphical presentation of the
comparative IC50 values of the series 3
(a–m) against the enzyme tyrosinase.
Graphical presentation of the
comparative IC50 values of the series 4
(a–m) against the enzyme tyrosinase.
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?As TNF-á Inhibitors & Cyclic Nucleotide Phospodiesterase Inhibitors
Tumor necrosis factor-á is a cytokine which is released preliminary by cells
of immune systems in response to certain immunostimulators. When
administered to animals or humans, it causes inflammations, fever,
cardiovascular effects, haemorrhage, coagulation, cachexia and acute phase
responses similar to those seen during acute infections, inflammatory
diseases and shock states. Excessive or unregulated TNF-á production has
been implicated in a number of disease conditions. These include
endotoxamia and/or toxic shock syndrome35.1,35.2, rheumatoid arthritis,
inflammatory bowel disease, cachexia35.3 and lupus. TNF-á concentration in
excess of 12,000pg/ml have been detected in pulmonary aspirates from Adult
Respiratory Distress Syndrom(ARDS) patients35.4. Systemic infusion of
recombinant TNF-á resulted in changes typically seen in ARDS35.5.
TNF-á appears to be involved in a number of bone resorption diseases,
including arthritis. When activated, leukocytes will produce bone resorption.
TNF-á apparently contributes to this mechanism35.6,35.7. TNF-á also has been
shown to stimulate bone resorption and inhibit bone formation in vitro and
in vivo through stimulation of osteoclast formation and activation combined
with inhibition of osteoblast functions. Another compelling link with disease
is the association between production of TNF-á by tumor or host tissues
and malignancy associated hypercalcemia35.8. In Grant versus Host
Reactions, increased serum TNF-á levels have been associated with major
complications following acute allogenic bone marrow transplants35.9. High
levels of TNF-á are associated with Crohn’s disease35.10.
Cerebral malaria is a lethal hyperacute neurological syndrome associated
with high blood levels of TNF-á and the most severe complications occuring
in malaria patients. Elevated levels of serum TNF-á correlated directly with
the severity of disease and the prognosis in patients with acute malaria
attacks 35.11
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TNF-á plays a role in the area of chronic pulmonary inflammatory diseases.
The deposition of silica particles leads to silicosis, a disease of progressive
respiratory failure caused by a fabrotic reaction. Antibodies to TNF-á
completely blocked the silica induced lung fibrosis in mice35.12. High levels
of TNF-á production(in the serum and isolated macrophages have been
demonstrated in animal models of silica and asbestos induced fibrosis35.13.
Alveolar macrophages from pulmonary sarcoidosis patients have also been
found to spontaneously release massive quantities of TNF-á as compared
with macrophages from normal donars35.14.
Elevated levels of TNF-á are implicated in reperfusion injury, the inflammatory
response which follows reperfusion and is a major cause of tissue damage
after blood loss35.15. TNF-á also alters the properties of endothelial cells and
has various pro-coagulant activity, supressing the anticoagulant protein-c path
way and down regulating the expression of thrombomodulin13.16. TNF-á has
proinflammatory activities which together with its early production(during the
initial stage of an inflammatory event) make it a likely mediator of tissue injury
in several important disorders including but not limited to, myocardial infarction,
strock and circulatory shock.
It has been reported that TNF-á is apotent activator of retrovirus replication
including activation of HIV-135.17 - 35.21. Cytokines, specifically TNF-á, are
implicated in activated T-cell mediated HIV protein expression and/or virus
replication by playing a role in maintaining T-Lymphocyte activation.
Therefore, interference with cytokine activity such as prevention or inhibition
of cytokine production, notably TNF-á, in an HIV infected individual assist
in limiting the maintanance of T-lymphocyte caused by HIV infection.
Additional studies have identified TNF-á as a common factor in the activation
of HIV in vitro and have provided a clear mechanism of action via nuclear
regulatory protein found in the cytoplasm of cells35.22.  AIDS viral replication
of latent HIV in T-cell and macrophage lines can be induced by TNF-á35.23. A
molecular mechanism for the virus inducing
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activity is suggested by TNF-á‘s ability to activate gene regulatory protein.
(transcription factor, NFkB) found in the cytoplasm of the cells, which
promotes HIV replication through binding to a viral regualtory gene
sequence(LTR)35.22. TNF-á in AIDS associated cachexia is suggested by
eleveted serum TNF-á and high levels of spontaneous TNF-á production in
peripheral blood monocytes from patients35.24. TNF-á has been implicated
in various roles with other viral infections, such as the cytomegalia
virus(CMV), influenza virus, adeno virus and the herpes family of viruses
for similar reasons as those noted.
Many cellular functions are mediated by levels of adenosine-3’,5’-cyclic
monophosphate(cAMP). Such cellular functions can contribute to
inflammatory conditions and diseases including asthma, inflammation and
other conditions35.25. It has been shown that the elevation of cAMP in
inflammatory leukocytes inhibits their activation and the subsequent release
of inflammatory mediators, including TNF-á and NFkB. Increased level of
cAMP also leads to the relaxation of airway smooth muscle.
The primary cellular mechanism for the inactivation of cAMP is the
breakdown of cAMP by a family of isoenzymes refered to as cyclic
nucleotide phosphodiesterase (PDE)35.26. There are ten known members
of the family of PDEs. It is well documented that the inhibition of PDE type
IV (PDE4) enzyme is particularly effective in both the inhibition of
inflammatorymediator release and the relaxation of airway smooth
muscle35.27
Decreasing in TNF-á levels constitutes a valuable therapeutic strategy for
the treatment of many inflammatory, infectious, immunological and malignant
diseases. These include but are not restricted to: septic shock, endotoxic
shock, hemodynamic shock and sepsis syndrome, post  ischemic reperfusion
injury, malaria, mycobacterial infections, meningitis, psoriasis and other
dermal diseases, congestive heart failure, fibrotic disease, opportunistic
infections in  AIDS, rheumatoid arthritis, rheumatoid
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spondylitis, osteoarthritis, other arthritic conditions, inflammatory bowel disease,
Crohn’s disease, ulcerative colitis, multiple sclerosis, systemic lupus,
erythrematosis ENL in leprosy, radiation damage and hyperoxic injury.
Prior efforts directed to the supression of the effects of TNF-á have ranged from
the utilization of steroids such as dexamethasone and prednisolone to the use
of both poly clonal and monoclonal antibodies35.28. Validation of TNF-á inhibition
as a clinical therapy has been demonstrated by use of TNF-á antibodies and
soluble TNF-á receptors.TNF-á blockage with monoclonal antiTNF-á antibodies
has been shown to be beneficial in rheumatoid arthritis35.29.
Hon-Wah Man and George W.Muller35.30 have patented substituted 1,3,4-
oxadiazole of formula-5 based on the discovery that certain classes of non-
polypeptide compounds descreasesthe level of TNF-á and/or inhibit PDEs
particularly PDE4 and/or inhibit angeiogenesis and/or useful in the
treatment of cancer, inflammatory and autoimmune diseases.
Compounds that selectively inhibit PDE4 specifically would atleast partially
inhibit inflammation and relaxation of airway smooth muscle with minimum of
unwanted side effects, such as cardiovascular or anti-platelet effects. The
compound of the invention are useful in the inhibition of phosphodiesterases,
particularly PDE4 and in the treatment of disease states mediated thereby.
More over the compound described in the invention can inhibit the action of
NFkB in the nucleus and thus are useful in the treatment of a variety of diseases
including but not limited to rheumatoid arthritis, rheumatoid spondylitis,
osteoarthritis, other arthritic conditions, septic shock, sepsis, endotoxic shock,
graft versus host disease, wasting, inflammatory bowel disease, Crohn’s
disease, ulserative colitis, multiple sclerosis, systemic lupus, erythrematosis,
ENL in leprosy, HIV-AIDS and opportunistic infections in AIDS.
The compounds of invention can also be used topically in the treatment of
prophylaxisof topical disease states including, but not limited to atopic
dermatitis, psoriasis, viral infections such as those caused by the herpes
viruses or viral conjuctivitis.
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  Y= C=O, CH2, SO2 or CH2C=O, X = H, H-(CH2)n-H where n=1 to 4,
  R1, R2, R3, R4 = H, halogen, CF3, acetyl, alkyl of 1 to 6 carbons, NO2, CN,
  OH, -CH2NR’R, -NR’R, fused benzo, fuzed naphtho, fused quinoxaline,
  fused benoimidazole etc
  R5, R6= H, alkyl of 1 to 4 carbons, alkoxy of 1 to 6 carbons, CN,
  benzocycloalkoxy, cycloalkoxy and bicycloalkoxy and tricycloalkoxy
  of upto 18 carbons, cycloalkylalkoxy of upto 18 carbons.
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?As Monoamine OxidaseType-B Inhibitors
Monoamine oxidase (MAO; EC 1.4.3.4) is a FAD-containing enzyme35.31
located in the outer membrane of mitochondria35.32. On the basis of specificity
for substrates and sensitivity to inhibitors, two MA0 forms, called MAO A
and MAO B, have been distinguished35.33,35.34. The two forms catalyze the
oxidative deamination of a wide variety of biogenic monoamines35.35, as well
as xenobiotics.35.36. It has been shown that the two isoenzymes are distinct
with about 70% homology in their primary sequence35.37 and are coded by
two different genes located on the X chromosome35.38.
Both enzymes present a considerable pharmacological interest because of
their key role in the metabolism of monoamine neurotransmitters like serotonin,
catecholamines, and dopamine and their possible involvement in many
neuropsychiatric disorders35.39. For example, motor disability in Parkinsonism
is linked to a deficit of dopamine striatum, resulting from degeneration of the
dopamine nigrostriatal neurones which project to striatum.
According to a concept which is gaining acceptance, MAO’s of glial cells
neighbouring nerve terminals play an important role in the metabolism of
certain amine neurotransmitters as well as other amines such as false
transmitters or intruding monoamines35.40.
The origin of Parkinsonism is not yet known. It has been suggested that hydroxyl
radicals •OH are implicated in the genesis of the disease.35.41 Due to a deficit of
glutathione in substantia nigra in Parkinsonian brains, accumulation of H2O2 from
dopamine deamination with concommitant increase of Fe2+ would lead, via
Fenton reaction, to an overproduction of •OH and nigral degeneration.
Alternatively, proliferation of glial cells in replacement of dead neurons35.42 may
contribute to the breakdown of the neurotransmitter.
In modern Parkinson therapy, one major approach to overcome the lack of
dopamine is substitution by L-dopa with adjunction of a MAO B inhibitor35.43,
either alone or with an antioxidant35.44.  From controlled clinical
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trials with L-deprenyl, a preferential MAO B inhibitor,35.34 it has been
confirmed that selective inhibitors of MAO B either alone35.45 or as adjuncts
to L-dopa35.46 are beneficial in Parkinson management, especially in the
early stages of the disease.
During decade of ninties, more attention has been focused on the
development of reversible inhibitors, believed to be advantageous in
therapeutic uses.35.47. The previously developed Ro 16632735.48 and its less
potent analogue Ro 16649135.49  were the only two reversible MAO B inhibitors
available. Interestingly, Ro 166327 has even proved to surpass the “suicide”
inhibitors both in activity and selectivity.35.40, 35.50.  Another new promising class
of reversible MAO B inhibitors are the 1,3,4-oxadiazol-2(3H)-one
derivative35.51, with 16 as the representative compound.
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RO-166491
On the basis of this findings, F.Mazouz, et al35.52 have synthesized thirty-
three new 5- [4-(benzyloxy)phenyl] - 1,3,4-oxadiazol-2( 3H)-one derivatives
including related analogues, designed as inhibitors of monoamine oxidase
type B (MAO B) and investigated both in vitro and ex vivo for their abilities
to inhibit selectively rat brain MAO B over MAO A. Three inhibitors were
found to act as reversible, highly potent, and selective MAO B inhibitors,
namely the nitrile derivative 5- [4-(benzyloxy)phenyll-3-(2-cyanoethyl)-l,3,4-
oxadiazol-2(3H)-one (17a) and two closely related homologues, the corre-
sponding oxadiazolethione 17b and the alcohol 18. Their IC50(MAO B) val-
ues are in the low nanomolar range of 1.4-4.6 nM and their selectivities,
estimated by the ratio of IC50 values (A/B), are from 3200 to >71400. Com-
pound 17a exhibited the highest activity against MAO B. Its IC50 was evalu-
ated to be 1.4 nM with a quasitotal selectivity (>71400) toward this en-
zyme. In ex vivo studies, 17a showed a reversible and short duration of
action. MAO B was markedly inhibited with the
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oral dose of 1 mg/kg without any alteration of MAO A, and the inhibition al-
most did not exceed 24 h. Its ED50 (1 h after oral administration) was evalu-
ated to be 0.56 mg (1.7 µmol)/kg. Remarkably, MAO A was not affected at
doses as high as 1500 mg/kg. In addition, no apparent toxicity or behavioral
anomaly was observed during the treatment even at the maximum adminis-
trated dose. SAR studies emphasize the existence of three binding sites to
the enzyme with a special importance of the terminal phenyl. Analysis of the
inhibition kinetics indicated that 17a acts in a two-step mechanism as a com-
petitive, slow, and tight-binding inhibitor of MAO B with a Ki value of 0.22 µM
and an overall Ki* value at equilibrium of 0.7 nM.
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?As Antidepressants
Various substituted 2-pyrrolidine-2-yl-[1,3,4]-oxadiazole derivatives are
known from literature. Common to all of them is the fact that they are used for
the treatment of neuronal diseases. Hagen-Heinrich Hennies and
coresearchers35.53 have patented 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole of gen-
eral formula 19 have a pronounced anto-depressive and analgesic effect
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(2-chloro-pyridin-3-yl)-[2-(5-pyrid
in-4-yl-[1,3,4]-oxadiazol-2-yl)-pyrr
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(2,5-bistrifluoromethylphenyl)-{2
-[5-(4-chlorophenyl)-[1,3,4]-oxadi
azol-2-yl)-pyrrolidin-1-yl)methan
one
O
N N
N
R2
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Formula-19
The biological screening result suggested that the three compounds were
found to be most potent serotonin uptake inhibitors namely (2,5-
bistrifluoromethylphenyl)-{2-[5-(4-chlorophenyl)-[1,3,4]-oxadiazole-2-yl]-
pyrrolidin-1yl}-methanone, (2,4-dimethoxyphenyl)-[2-(5-pyridin-4-yl-[1,3,4]-
oxadiazol-2-yl)-pyrrolidin-1yl]-methanone and (2-chloro-pyridin-3-yl)-[2-(5-
pyridin-4-yl-[1,3,4]-oxadiazol-2-yl)-pyrrol idin-1yl]-methanone with
Serotonine reuptake inhibition of 80%, 81% and 84% respectively.
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?Fungicidal activity
The idea of bioisosterism is one of the most successful techniques of
bioactive compound design26. The substitution of sulfur for oxygen in the
heterocyclic ring represents an example of an approach that is commonly
known as bioisosterism. The 1,3,4-oxadiazole ring is a bioisosteric analogue
of the 1,3,4-thiadiazole ring.
Zu-Xing Zhang et al27,28 reported that pyridazinone-substituted 1,3,4-
thiadiazole exhibited highly fungicidal activity against wheat leaf rust,
Puccinia recondita. On the other hand, 1,3,4-oxadiazoles exhibit a broad
spectrum of biological activity 29-31. In view of these facts and on the basis
of chemistry of pyridazinones 32-34, Xia-Juan Zou et al35 have synthesized
bioisosterism based series of novel 5-[1-aryl-1,4-dihydro-6-methylpyridazin-
4-one-3-yl] -2-arylamino-1,3,4-oxadiazoles,  and tested in vivo against
wheat leaf rust, Puccinia recondita.
These compounds were shown to be fungicidally active, and their activity was
influenced by the nature of the substituents. By using the three-dimensional
quantitative structureactivity relationships (3D-QSAR) method of comparative
molecular field anaysis (CoMFA), the structure and activity relationship of the
compounds containing both pyridazinonesubstituted 1,3,4-thiadiazoles(20a-
q) and pyridazinone-substituted 1,3,4-oxadiazoles(21a-k) was established.
The fungicidal screening results of the compounds studied are summarized
in Table-1. The results indicate that pyridazinone-substituted 1,3,4-
oxadiazoles exhibited the same fungicidal activity as that of pyridazinone
substituted 1,3,4-thiadiazoles. The fungicidal activity varies with the
substituents of the phenyl moiety
N
N
S
N
N NH
O
CH3
R1
R2
N
N
O
N
N NH
O
CH3
R1
R2
20a-q
21 a-k
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Table-1. Experimental & Calculated Activities and Residual Values of the Title Compounds
In CoMFA study, compound 20m was selected as the template molecule
because of its scaffold being involved in all compounds and its high activ-
ity. Nine features were selected for the alignment of all compounds. These
atoms are numbered 1-9 in Figure H. The alignments of the bioactive con-
formation are showed in Figure I.
Figure H. Superposition modes.  .  Figure I. Alignment of     27 compounds
The predictive activity versus the experimental activity is graphically
represented in Figure J. The analyses results are presented in Tablel-1.
The 3D-QSAR modes gave good correlation between the variations on
percent inhibition and the steric-electrostatic properties. The CoMFA
contour maps of this series of compounds are presented in Figures K and
L, respectively. The green-yellow steric contour in Figure K describes
Compd.  R1  R2  X  EA
a  CoMFA  PAb  Residuec    
20a      o-Cl     m-CF3   S  0.7     185         0.838     −0.138 
20b         o-Cl      o-F      S        0.1        172         0.099       0.001
20c         o-Cl        H    S        0.1 165   0.032       0.068
20d       H      o-F    S  0.5  164   0.609      -0.109
20e       H   m-CF3   S  0.6 180   0.544      0.056
20f   2,6-Cl2  m-CF3   S 0.5 184   0.489      0.011
20g   2,6-Cl2     o-F    S  0.3  174    0.364      -0.064
20h     p-Cl   m-CF3   S 0.6 192   0.574       0.026
20i     p-Cl      o-F   S 0.5 169   0.532     -0.032
20k  2,4,5-Cl3  o-F    S  0.6  180    0.619      -0.019
20l  2,4,5-Cl3 m-CF3 S  0.7  179    0.681       0.019
20m  2,4-2CH3 m-CF3 S  0.9  199   0.909     -0.009
20n  2,4-2CH3  o-F   S  0.9  181    0.800       0.100
20o  2,4-Cl2      o-F   S  0.8 172   0.680       0.120
20p 2,4-Cl2    m-CF3  S  0.9  185    0.851       0.049
20q  2,4-Cl2         H    S  0.2   171    0.280      -0.080
aExperimental activities (percent inhibition × 10-2). bPredictive activities(percent inhibition × 10-2).  cResidue = EA − PA.
Compd.  R1  R2  X  EA
a  CoMFA  PAb  Residuec   
21a   o-Cl   m-CF3  O  0.9   181    0.770       0.130
21b   o-Cl       o-F    O 0.8   165    0.768       0.032
21c   o-Cl         H    O  0.1   161     0.128     -0.028
21d      H        o-F   O  0.9   161     0.949     -0.049
21e  2,6-Cl2        o-F   O  0.8   172     0.828     -0.028
21f        p-Cl     m-CF3  O  0.9   172     0.967     -0.067
21g  p-Cl        o-F    O  0.7   160     0.681      0.019
21h  2,4,5-Cl3     o-F    O  0.9   181     0.881      0.019
21i  2,4-2CH3  m-CF3  O  0.7   196     0.727      -0.027
21j  2,4-2CH3      o-F   O  0.8   185     0.792      0.008
21k   p-Cl     p-OCH3 O  0.8   187     0.810      -0.010
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that region in space where increasing (green) or decreasing (yellow) steric
bulk is consistent with enhanced percent inhibition. The red-blue
electrostatic contour in Figure L illustrates that the large blue areas are the
regions where positive charge is favorable for the percent inhibition; red
areas are unfavorable. One red polyhedra near the paraphenyl ring B moiety
indicates that electron rich groups are beneficial to the activity. Six blue
contours in the molecules suggest that positive-charged substituents are
favorable to increase the activity.
Figure J. Predictive and experimental activities for the CoMFA model.
   Figure K. Steric field contour map of CoMFA.  Figure L. Electrostatic field contour map of CoMFA
These results are consistent with a common mode of action for the
pyridazinone- substituted 1,3,4-thiadiazoles and the pyridazinone-
subsituted 1,3,4-oxadiazoles, which further confirms that the 1,3,4-
oxadiazole ring is a bioisosteric analogue of the 1,3,4-thiadiazole ring.
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In 1994 Ashour et al31 have sugeested that 1,3,4-oxadiazole and 1,3,4-
thiadiazole derivatives being fungicidal. If they are linked to pyrazole ring,
the resulting biheterocyclic compounds could have better fungicidal activ-
ity. In continuation with this, Lee H.S. et al21 have synthesized some series
of 2-alkyl (alkythio)-5-((4-chloro)-3-ethyl-1-methyl-1H-pyrazole-5-yl)-1,3,4-
oxadiazoles (thiadiazoles) as potential fungicides. Their fungicidal activity
was evaluated against rice sheath blight, which is a major disease of rice
in China.
The Structure-Activity Relationship derived from fungicidal screening re-
sults, revealed that 5-(4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-yl)-1,3,4-
thiadiazole-2-thione has the higher fungicidal activity. The screening re-
sults indicated that compounds 23 had significant potency against Rhizoc-
tonia solani, and compounds 22 had hardly any inhibition against R.solani,
that is to say, the activity of compounds that were substituted by alkylthio at
the 2-position of the 1,3,4-oxadiazole ring was higher than the activity of
those compounds that were substituted by mercapto. The activity was found
to fall off with increasing size of the alkyl group (R). The preferred
substituent for R was found to be methyl. Loss of biological activity was
observed if the chloride atom at the 4-position of the pyrazole ring was
substituted by hydrogen. Oxidation of the sulfide group of compound 3 to
2-one analogue almost eliminated the activity. Removal of the sulfur atom,
by replacement of the alkylthio group with an alkyl group, resulted in some
decrease in activity. A sulfur atom at the 2-position of 1,3,4-oxadiazole is
necessary for fungicidal activity to occur.
23 
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O
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CH3
CH3 X
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N
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CH3
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5-(4-chloro-3-ethyl-1-methyl-1H-pyraz
ol-5-yl)-1,3,4-thiadiazole-2(3H)-thione
X = H, Cl                   
R = CH3, n-C3H7, n-C5H11, n--C7H15, 
n-C9H17, CH(CH3)COOEt, C2H5
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Drug
Name/Code Chemical Structure Activity Phase Originator
Chinoin-170 Antitussive, Bronchodilator Phase-I Sanofi-Synthlabo
Pleconaril Antirhinoviral,Antiviral Phase-III Viro pharma
Proxodolol
Antihypertensive, Antianginal,
Antiglaucoma agent,
Beta-adrenoceptor antagonist
Phase-II Center for Chemistryof Drugs
SB-224289 Antidepressants,Anxiolytic, 5-HT1D Antagonist
Biological testing Smithkline Beecham
SB-236057 Antidepressants, Anxiolytic, 5-HT1D Inverse agonist
Preclinical Smithkline Beecham
SX-3933
Cognition enhancing drug,
GABA(A) receptor modulator,
GABA(A) B2 site inverse
agonist
Preclinical Dainoppon pharma
N
N N
N
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CH3
CH3
N
N
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O
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N
O
CH3
Some Oxadiazole drugs & derivatives under Preclinical/Phase clinical trials.
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Drug
Name/Code Chemical Structure Activity Phase Originator
- Analgesic Preclinical Universidade federalpernambuco
-
Antiobesity drug,
Antidiabetic drug,
Beta3 adrenoceptor agonist
Preclinical Merck
-
Antiobesity drug,
Antidiabetic drug,
Beta3 adrenoceptor agonist
Preclinical Merck
- Bronchodilator,Phosphodiesterase Inhibitor Preclinical Smithkline Beecham
- Antitrypanosomal Preclinical Universidad de larepublica
-
Antiepileptic drug,
Neuronal Injury Inhibitor,
AMPA antagonist,
Sodium channel blocker
Preclinical Boehringer Ingelaeim
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Some Oxadiazole drugs & derivatives under preclinical/Phase clinical trials.
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Synthetic Approaches
There were several routes for the synthesis of 1,3,4-oxadiazoles reported in the literature
among which the most important aspects of  synthesis were discussed as under.
?Cyclization with formation of one Bond
2,5-d isubst i tu ted 1 ,3 ,4-oxadiazo le  can be accompleshed by
cyclodehydration of 1,2-diacylhydrazine either by using chlorosulphonic
acid36 or phenyl dichorophosphite37in dimethylformamide. A nonaqueous,
nonacedic, route involves treatment of hydrazine with hexamethyl
disilazane(HMDS) and tetrabutylammoniumfluoride, the last step presum-
ably being fluoride catalysed cyclization of intermediate bis silyl ether37
(Scheme-1)
R1
O
NH NH
R2
O
Diacyl hydrazine 
R1, R2 = alkyl, aryl 
ClSO3H/Cl2POPh
O
N N
R2R1
2,5-disubstituted-1,3,4-oxadiazole 
R1, R2 = alkyl, aryl 
HMDS
(H3C)3SiO
R1
N N
OSi(CH3)3
R2
(C4H9)4N-F
Scheme-1
In a related reaction, 1,1,2-triacetylhydrazine with trimethylsilylchloride/tri-
ethylamine gave oxadiazolinyl silylether39. Cyclodehydration(PCl5/POCl3) of
hydrazinyl diester gave the diphenyloxyoxadiazole40. (Scheme-2)
R2
O
NNH
R1
O
COCH3
(CH3)3SiCl/(Et)3N
O
N N
R2
R1
O
CH3
OSi(CH3)3
1,1,2-triacylhydrazine 
R1, R2 = alkyl 
OPh
O
NHNH
PhO
O
Hydrazine diester
O
N N
PhO OPh
POCl3/PCl5
2,5-diphenoxy-1,3,4-oxadiazolScheme-2
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The malonate derivative(24) reacted with acylhydrazine(25) to give a mix-
ture of diacylhydrazine monoamine(26) and oxadiazole(27). The later was
also formed from (26) on heating41. (Scheme-3)
NH2
OEt
COOEt
24
+
NH2 NH
O
N
25
(Et)3N, ∆
NH2
NHNHCOCH2CN
COOEt
+
O
N N
NCH2C CH2COOEt
26 27∆Scheme-3
Oxidation of acylhydrazones derived(27) from aldehydes has been developed into
a useful route to disubstituted oxadiazoles(28). The use of potassium permangante
with acetone as solvent was claimed to give yields than the use of other oxidizing
agents (e.g.halogens)42. An improved synthesis of bis-oxadiazolylbenzenes (30)
involved oxidation of bishydrazones (29) with lead tetraacetate43. Acylhydrazones(31)
were oxidized by iodosobenzene diacetate to oxadiazolinones (32), with acetates
(33) also being formed in some cases. A similar oxidation of ethyl esters(9, X=OEt)
gave oxadiazolyl ethers(11,X=OEt)44. Oxidative cyclization(FeCl3/AcOH) of
semicarbazone(34) yielded amino-oxadiazoles(35)45.( Scheme-4)
NNHCOX
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27 O
N N
R1 X
R1, X = alkyl, aryl
28
KMnO4 CH=NNHCOAr
CH=NNHCOAr
(m - or p -)
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N
N
Ar
O N
N
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(m - or p -)
29
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Pb(OAc)4
NNHCOX
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O
N N
H
R1 O
R1 = alkyl, aryl, 
X=OBut
32
Iodosobenzene diacetate +
O
N N
R1 OAc
33
Scheme-4
NNHCOX
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34
R1 = Ph, X=NHR
FeCl3/AcOH
O
N N
R1 X
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36. C.Chiriac, Rev.Chim.,(Bucharest),34,1131(1983), Chem.Abstr.,100,174735(1984)
37.C.Chiriac, Rev.Chim.,(Bucharest),27,935(1982), Chem.Abstr.,98,107216(1983)
38.B.Rigo, P.Cauliez, D.Fasseur, D.Couturier, Synth.Commun.,16,1665(1986)
39.A.Kalinin, B.Khasapov, E.Aposav, I.Kalikhman, S.Ioffe, Izv.Akad Nauk SSSR
Ser.Khim.,694(1984),Chem.Abstr.,101,91045(1984)
40.A.Theocharis, N.Alexandrou,J.Heterocycl.Chem., 27,1685(1990)
41.M.Elnagdi, N.Ibrahim, F.Abdelrazek, A.Erian, Liebigs Ann.Chem.,909,1988
42.P.Reddy, P.Reddy, Ind.J.Chem.Sect-B, 26,890(1987)
43.S.A.Rekkas, N.A.Rodias, N.E.Alexandrou,Synthesis, 411(1986)
44.H.Baumgarten, D.Hwang, T.Rao, J.Heterocycl.Chem.,23, 945(1986)
45.S.Hiremath, N.Goudar, M.Purohit, Ind.J.Chem.Sect-B, 21,321(1982)
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?Cyclization with formation of Two Bonds
Important routes to monosubstituted oxadiazoles (36), aminooxadiazoles
(37), oxadiazolinones(37a) and oxadiazolinethiones(38) involve reaction
of hydrazides(R1CONHNH2) with triethyl orthoformate, cyanogen bromide,
phosgene, or carbon disulphide(or CSCl2) respectively. (Scheme-5)
An alternative to cyanogenbromide is phenyl cyanate(PhOCN), which re-
acted with hydrazines(R1CONHNH2) to give aminooxadiazoles(42, R1 = 4,6-
dimethyl-2-pyrimidyl)47. From oxadiazol-2-carbohydrazides(43) bi-
oxadiazolyls(44) and(45) were prepared using cyanogen bromide48 or
thiophosgene49 respectively. (Scheme-7)
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Reaction of hydrazide(39) with triethylorthoformate, or with CS2/KOH, al-
lowed the synthesis of oxadiazolyl methyl ketones(40) and (41) respectively
after hydrolysis of the acetal group46. (Scheme-6)
R1 C
O
NH NH2
OCN
O
N N
R1 NH2
42
R1=4,6-dimethyl-2-pyridylR1=4,6-dimethyl-2-pyridyl
43
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N N
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CNBr
O
N N
R1 O
N N
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A variation of the oxidative cyclization of acyl-thiosemicarbazides to amino-
oxadiazoles52. A variation of the reaction of acylhydrazines and carbon dis-
ulfide forming oxadiazolinethiones, is the reaction of thiosemicarbazide
(RNHCSNHNH2) with carbon oxysulfide and benzyl chloride, which yields
amino-oxadiazolyl thioethers(48)53. (Scheme-9)
It has been shown that o-aminobenzoylhydrazine reacted with (i) 1,1’-car-
bonyl-bis- imidazole(a var iat ion of the use of phosgene) to give
oxadiazolinone(46)50 and (i i) 1,3-dicyclohexylcarbodiimide and an
isothiocyanate RNCS to give aminooxadiazole(47)51. (Scheme-8)
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NH2
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N N
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NH2 46
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N N
H
NHR
NH2 47
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NH NH2R
CH2Cl
O=C=S
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SRHN
48Scheme-9
?Ring Synthesis by Transformation of another Ring
Two variations of the useful routes to 2,5-disubstituted-1,3,4-oxadiazoles via
loss of nitrogen from 5-substituted tetrazoles were reported as (i) the reaction
of tetrazole (49) with diketene to give the oxadiazolylmethyl ketone(50)54 and (ii)
the reaction of oxaloyl chloride with the sodium salt of tetrazole(51, prepared
from F2NCF2CN and NaN3) to give the bi-oxadiazolyl(52)55. Ultraviolet irradia-
tion of 1,2,4-oxadiazole(53) gave 1,3,4-oxadiazoles(54)56. On heating 3,3-dialkyl
-N,N’-dibenzoyldiazeridines(55) rearrange to oxadiazolines(56)57.(Scheme-10)
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?Miscellaneous apects
Susanna Borg et. al12 have suggested that dehydration of the appropriate
diacylhydrazines(57)( which were derived from Boc-L-phenylalanine hydrazide
and methyl malonyl chloride)  with thionyl chloride and pyridine  afforded a 1,2,3,4-
oxathiadiazole S-oxide intermediate, by heating the crude intermediate result-
ing into 1,3,4-oxadiazole of type 58 with loss of sulfur dioxide.( Scheme-11)
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57Scheme-11
Tohru Miyazaki, et al58 have synthesized 1,3,4-oxadiazole derivatives by
cyanurization of  benzyloxy carbonyl protected amino alcohol(59) with either
sulfur trioxide-pyridine complex and triethyl amine or acetone cyanohydrine,
the resulting cyano derivative (60) was hydrolysed by either acetic anhydride
in pyridine or by hydrochloric acid to yield corresponding  acid derivative(61)
along with benzyloxy carbonyl deprotection of amino group. Which was again
protected with Benzyloxycarbonyloxysuccinimide in the presence of base to
give á-hydroxy carboxylic acid derivative(62) which was o-acetylated with acetic
anhydride to protect hydroxy group, the resulting compound (63) was fused
with appropriate hydrazide to produce diacetyl hydrazine derivative(64) and
later upon cyclized with p-toluenesulfonyl chloride gave 1,3,4-oxadiazole de-
rivative (65) was deprotected with base (K2CO3) and acid(CF3COOH) to give
corresponding hydroxy-1,3,4-oxadiazole(66) and amino-1,3,4-oxadiazole(67)
derivatives.(Scheme-12)
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Atta-ur-Rahmann et al24 have synthesized a library of 2,5-disubstituted-1,3,4-
oxadiazoles by the reaction of commercially available hydrazine with different aro-
matic carboxylic acids in the presence of phosphorous oxychloride.(Scheme-13)
POCl3R NH
NH2
O R O
N N
Ar
ArOH
O
Substituted Hydrazide Aromatic acids Substituted 1,3,4-oxadiazole
R = 3-pyridyl, 2-methoxyphenyl
Scheme-13
Hennies, et al35.53 have suggested that to produce 2-pyrrolidine-2-yl-[1,3,4]-
oxadiazole derivatives, tertiary butoxy carbonyl protected proline was re-
acted with ethyl chloroformate and hydrazine in a suitable solvent like tet-
rahydrofuran. The resulting hydrazide was reacted with an acid chloride to
afford diacyl hydrazide. For ring closure, acid and and a dehydrating re-
agent like phosphorous pentoxide, methanesulfonic acid, pyridine and/or
thionyl chloride were added to di acyl hydrazide. The cyclized derivative
allowed for deprotection and resulting product was substitued with appro-
priate acid chloride or isocyanate.(Scheme-14)
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Hansong Chen et al30 have descibed that  5-pyrazole formic acid hydrazide
(68) when  reacted  with carbon disulfide and potassium hydroxide in ethanol,
afforded 5-pyrazolyl-1,3,4-oxadiazole-2-thiones(69). The chemical literature
records several synthetic routes leading to the formation of 2,5-disubstituted-
1,3,4-oxadiazoles(Yang J., Hua, W., Review: Synthesis of 2,5-substituted-1,3,4-
oxadiazole derivatives, Chemistry, 9, 18(1996)). 2-alkyl-5-pyrazolyl-1,3,4-
oxadiazoles were synthesized from (68) and aliphatic acid in the presence of
phosphorous oxychloride via one pot synthesis.(Scheme-15)
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Xia-Juan Zou et al28 revealed that treatment of 2-[(6-methyl-4-oxo-1-substi-
tu ted pheny l -1 ,4-d ihydro-3-pyr idaz iny l )carbony l ] -N -subst i tu ted
phenylhydrazinecarbothioamide with mercuric acetate yields 3-(5-
substitutedanilino-1,3,4-oxadiazol-2-yl)-6-methyl-1-substitutedphenyl-
4(1H)-pyridazinone.( Scheme-16)
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Part-B. Pyrrole
Pyrrole is an important ð-excessive aromatic heterocycle because this ring
system is incorporated in as a basic structural unit in porphyrins;porphin
(heam) and chlorin(chlorophyll) and corrins (vitamin B12). More over the
presence of pyrrole ring in system in porphobilinogen (intermediate in bio-
synthesis of porphyrins and vitamin B12), biliverdin and bilirubin(pyrrole-
based bile pigments) and pyrrolnitrin(with antibiotic activity) has provided
an impetus to the pyrrole chemistry.
Pyrrole has a planar pentagonal structure with four carbon atoms and nitrogen
sp2-hybridized. Each ring atom forms two sp2-sp2 ó -bonds to its neighbouring
ring atoms and one sp2-só -bond to a hydrogen atom. The remaining
unhybridized p-orbitals, one on each ring atom(with one electron on each car-
bon and two electron on nitrogen), are perpendicular to the plane of ó -bondsand
overlap to form a ð-molecular system with three bonding orbitals. The six ð-
electrons form an aromatic sextet which is responsible for aromaticity and
renders stability to the pyrrole ring. The Cá-N and Câ-Câ bonds are shroter than
normal single bonds, where as Cá-Câ bonds are normal than normal double
bonds. The molecular dimentions of the pyrrole reflect cyclic delocalization
with the environment of lone pair of electrons on the nitrogen atom.
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Pyrrole is extremely weak base because the lone pair of electrons on the
nitrogen atom involved in the cyclic delocalization and is, therefore, less
available for protonation. Moreover, pyrrole is a weaker base than pyridine
and even than aniline in which lone pair on the nitrogen atom is involved in
the resonance and not essentially contributes to the aromatic sexlet. The
protonation of pyrrole at nitrogen or C2 or C3 atom of the ring reduces its
basicity and destroys its aromaticity. However, C- and N- alkyl substituents
enhance the basicity of pyrrole but the electron withdrawing substituents
on the ring make pyrrole a weaker base59-69.
Pharmacology
?As slective Mono Amine Oxidase type A Inhibitors
Monoamine oxidase (MAO, EC 1.4.3.4) is a flavoprotein located at the outer
membranes of mitochondria in neuronal, glial, and other cells. It catalyses
the oxidative deamination of monoamine neurotransmitters such as
serotonin (5-hydroxytryptamine, 5-HT), norepinephrine, and dopamine, and
appears to play important roles in several psychiatric and neurological
disorders 70.71. In addition, it is also responsible for the biotransformation
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into 1-methyl-4-
phenylpyridinium (MPP), a Parkinson producing neurotoxin 72-74. Recently,
it has been shown that MAO contributes to the apoptotic process because
inhibition of MAO activity suppresses cell death 75.
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MAO exists in two forms, namely, MAO-A and MAO-B, distinguishable by
their molecular cloning,substrate and inhibitor selectivity, and tissue
distribution 76-79. MAO-A preferentially oxidizes serotonin and is irreversibly
inhibited by low concentrations of clorgyline77. MAO-B preferentially
oxidizes b-phenylethylamine (PEA) and benzylamine, and it is irreversibly
inactivated by low concentrations of L-deprenyl 80. Dopamine, tyramine, and
tryptamine are commonsubstrates for both MAOs.
Due to the key role played by monoamine oxidases (MAOs) in the metabolism
of neurotransmitters, MAO inhibitors (MAOIs) represent an useful tool for the
treatment of several neurological diseases. Among selective MAOIs, MAO-
A inhibitors (e.g.clorgyline) are used as antidepressant and antianxiety drugs
and are claimed to protect neuronal cells against apoptosis, and selective
MAO-B inhibitors (e.g. L-deprenyl) can be used in the treatment of Parkinson’s
disease either alone or in combination with L-DOPA. However, they engender
covalent bonds with the active site of the enzyme and induce irreversible
inhibition; moreover, they tend to lose their initial selectivity at high dosages
or with repeated administrations. Phenyloxazolidinones belong to
thirdgeneration-MAOIs, characterized by a selective and reversible inhibition
of the enzyme. Among these molecules, the most representative are
toloxatone and befloxatone, two selective and reversible MAO-A inhibitors
used in therapy as antidepressant drugs.
Going on searches on CNS potentially active compounds containing pyrrole
moiety  A. Mai, et.al81 have synthesized 3-(1H-pyrrol-1-yl)-2-oxazolidinones (70)
and isomeric 3-(1H-pyrrol-2-and -3-yl)-2-oxazolidinones (71 and 72)(Table-2)
as anti-MAO agents.The majority of compounds showed inhibitory activity
against the A isoform of MAO enzyme higher than that exerted against the
MAO-B.
Among compounds 70, derivatives 70a-e, g, j, k, p, s, t were the most active
with concentration values of MAO-A inhibitory activity in the nanomolar
range. In particular, (R/S)-toloxatone and the related pyrrole analog (racemic
mixture of 70a and 70n) were equipotent as MAO-A inhibitors,
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the later being 6-fold less MAO-A selective than the former. Furthermore,
the assays performed on the R (70a) and S (70n) enantiomers showed
70a to possess the best activity and selectivity. O-alkylation of this
compound afforded, i.e. (R)-5-methoxymethyl-3-(1H-pyrrol-1-yl)-2-
oxazolidinone (70b), a MAO-A inhibitor endowed with very high potency
and A-selectivity. In fact, compound 70b (KiMAO-A/4.9nM), was equipotent to
befloxatone (R,R form) (KiMAO-A/2.5 nM), a new toloxatone analog, and it
was characterized by very high selectivity towards the MAO-A isoenzyme
(A-selectivity/10,200, about 116-fold greater than that of befloxatone).
The potency abatement is strictly dependent on the steric hindrance exerted
by N1-alkyl substituents: N1-methyl-pyrrole derivatives represented the
products belonging to the most active series, followed by the N1-ethyl and
N1-allyl analogues. N1-Benzyl derivatives are practically inactive as anti-
MAO agents, with the exception of the R-5-methylamino-3-(1-benzyl-1H-
pyrrol-2-yl)-2-oxazolidinone (71p), which was endowed with both anti-MAO-
A and anti-MAO-B activities (KiMAO-A/0.14 ìM; KiMAO-B/0.5 ìM).Among
derivatives 71 and 72, the most active compound resulted the R-5-
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azidomethyl-3-(1-methyl-1H-pyrrol-2-yl)-2-oxazolidinone 71c (Ki against
MAO-A/0.004 mM;Ki against MAO-B/4 ìM; A-selectivity/1000), being as
potent as befloxatone and 10 times more A-selective.
X-ray diffraction-crystallographic studies coupled with conformational and
electronic characterization (by the ab initio molecular orbital method)
performed on toloxatone 82,83 showed that the drug is a planar molecule within
the presence of an electron delocalization of both the oxazolidinone and
phenyl rings. Such structural and electronic properties account for the
existence of a charge-transfer complex between toloxatone and riboflavine
and establish the mechanism of MAO-A reversible inhibition exerted by
toloxatone. Starting from these data, was performed conformational analysis
on pyrrole analogue of toloxatone ,70a, to verify if such co-planarity between
pyrrole and oxazolidinone rings could exist also in this molecule. Surprisingly,
it was found that global minima conformations for toloxatone and 70a (from
MOPAC93 calculations) resulted quite different, being optimal torsion angles
= -1.28o (toloxatone) and +70.1o (70a) (Figs. M and N).
  Fig.M. AM1 calculations of optimal torsion angles of toloxatone (left) and 70a (right).
     Fig. N. Global minima conformations for toloxatone (left) and 70a (right).
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?Antitubercular activities
The frequent appearance of multidrug-resistant strains of Mycobacterium
tuberculosis and the growing importance of nontuberculosis mycobacterial
(NTM) strains in infections of immunosuppressed patients have accentuated
the need to search for new antimycobacterial drugs 84-90. Previously, among
the various active compounds already discovered, some azole derivatives
have been shown to possess strong inhibitory activities in vitro and in vivo
against M. tuberculosis strains91. In addition, metronidazole was found to
be able to kill dormant cells of M. tuberculosis92.
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Delia Deidda, et al93 have described that the pyrrole derivative BM212 [1,5-
diaryl-2-methyl-3-(4-methylpiperazin-1-yl)methyl-pyrrole]  was shown to pos-
sess strong inhibitory activity against both Mycobacterium tuberculosis
and some nontuberculosis mycobacteria.  It was suggested that  BM212
appeared to be endowed with part icular ly potent  and select ive
antimycobacterial properties, and consequently, some experiments were
devised in order to characterize its activity against both drug resistant and
intramacrophagic mycobacteria. Isoniazid (INH) and streptomycin (SM) were
used as controls. The results suggested that BM212 showed potent
antimycobacterial activities against several strains of M. tuberculosis. The
MICs were between 0.7 and 1.5 ìg/ml for both collection and clinical strains;
for only one strain was the MIC as high as 6.2 ìg/ml. These values were a
little higher than those of INH (0.05 to 0.2) for most strains but were gener-
ally comparable with those of SM (from 0.4 to 6.2 ìg/ml). Also, some NTM
strains appeared to be quite susceptible to the action of BM212. In fact,
the MIC ranges were 3.1 to 12.5 ìg/ml for M. fortuitum, 3.1 to 25 ìg/ml for
M. smegmatis, and 3.1 to 6.2 for M. kansasii, while for M. avium, it was
between 0.4 and 3.1 ìg/ml. M. marinum (a single strain) and M. gordonae
appeared less susceptible to the inhibiting activity of BM212.
The activity of BM212 against various drug-resistant mycobacteria was tested.
Two strains were only resistant to ethambutol (EMB), three were resistant to
amikacin (AMK), two were resistant to SM, two were resistant to INH, and two
were resistant to both rifampin (RIF) and rifabutin (RIB). Two strains were
resistant to both INH and RIF, and strain MSS3 was highly resistant to four
drugs (INH, EMB, RIF, and RIB). BM212 had inhibitory activity against all strains
tested, with MICs between 0.7 and 1.5 ìg/ml. The BM212 MIC for one strain of
AMK-resistant mycobacterium was as high as 6.2 ìg/ml.
BM212 was inhibitory to drug-resistant mycobacteria and also exerted bac-
tericidal activity against intracellular bacilli residing in the U937 human his-
tiocytic lymphoma cell line. The activity study suggested that after 7days of
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contact, BM212 completely inhibited the intracellular mycobacteria. The
effect was dose dependent, and the MIC was found to be 0.5 ìg/ml. From a
concentration of 1 mg/ml onwards the inhibition was 100%. Similar results
were obtained with Rifampin at 3 ìg/ml. No relevant macrophage loss was
detected after 10 days of incubation, both in the control and in the
compound-treated cultures. Furthermore, BM212 exerted no inhibition on
U937 cell culture replication up to a concentration of 12.5 ìg/ml.
The pyrrole derivative BM212 shows some interesting antimicrobial
properties: (i) it is strongly inhibitory against both M. tuberculosis and M.
avium, which are the two most common mycobacteria causing infection in
immunosuppressed patients; and (ii) it also has marked activity against
several species of yeasts, including Candida albicans and Cryptococcus
neoformans. Considering the increased incidence of opportunistic infections
caused by candidae and mycobacteria in immunocompromised patients, the
development and use of new compounds, which would be active against both
these types of microorganisms, is very attractive. Furthermore, BM212 is
also highly efficacious against mycobacteria which show resistance to the
most common traditional drugs, displaying no cross resistance with them,
and it exerts bactericidal activity on intracellular mycobacteria. This fact is
very important because mycobacteria can reside for years inside lymphoid
cells and macrophages, where they are difficult to get rid of.
 Chemical structure of BM212 -1,5-diaryl-2-methyl-3-(4-methylpiperazin-1-yl)-methyl-pyrrole.
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?As HIV-1 intigrase Inhibitors
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of
acquired immunedeficiency syndrome (AIDS). The unique nature of the
rep l icat ive cyc le  o f  HIV-1 prov ides many potent ia l  targets  for
chemotherapeutic intervention. One of these, the viral integrase, catalyzes
the insertion of the proviral DNA into the genome of the host cell. Integration
is a multistep process which includes three different biochemical processes:
assembly of proviral DNA on integrase, endonucleolytic processing of the
proviral DNA, and strand transfer of the proviral DNA to host cell DNA94-96.
Recently, diketo acid derivative 73 was reported to be a selective inhibitor
of the strand-transfer process. This compound effectively prevents proviral
DNA integration and inhibits HIV-1 replication in cell culture95.
73
         Strand Transfer IC50 0.17ìM(n=37)94-96
        Antiviral Activity CIC95 9.6ìM(n=166)97
?As Tyrosine Kinase Inhibitors
Vascular endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) receptors have been well validated as targets for the treatment
of cancers because of their critical roles in tumor growth and suvival via
autocrine and paracrine loops98-101. In this regard, both receptor tyrosine
kinases (RTKs) have been found to be expressed on the tumor cells and to
directly affect tumor cell proliferation (e.g.,VEGF receptor in melanoma and
PDGF receptor ingliomas)98. In addition, both RTKs have been found to
play prominent roles in tumor angiogenesis by participating in the
transmission of proliferation, migration, differentiation and survival signals
between tumor cells and endothelial cells99-101. Thus, simultaneous inhibition
of both endothelial growth factor receptor-2 (VEGF-R2) and platelet-derived
growth factor receptor-â‚ (PDGFR‚) might be expected to show better
antitumor activity than by inhibiting only one of these RTKs.
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To improve the antitumor properties and optimize the pharmaceutical
properties including solubility and protein binding of indolin-2-ones, a number
of different basic and weakly basic analogues were designed and synthesized
by Li Sun, et al102. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (75b or
SU11248) has been found to show the best overall profile in terms of potency
for the VEGF-R2 and PDGF-Râ‚ tyrosine kinase at biochemical and cellular
levels, solubility, protein binding, and bioavailability. 75b was in phase-I
clinical trials for the treatment of cancers.
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The screening results(Table-3) suggested that converting the carboxylate group
of 74b into an amino group (74c) enhances the inhibitory activity for VEGF-R2
(8-fold) while retaining the potency against PDGF-R‚ kinase. The difference in
potency observed between inhibition of PDGF-induced BrdU incorporation and
inhibition of cellular kinase activity for 74b might be related to its poor solubility.
75a-d exhibited potent inhibitory activity against VEGF-R2 and PDGF-Râ‚ in
biochemical and cellular assays. Specifically, compared to 74b, 75b was about
30-fold more potent against VEGF-R2 and PDGF-R‚ in biochemical assays,over
10-fold more potent in cellular kinase assays, and significantly more soluble
under neutral (20-fold) and acidic (>500-fold) conditions.
a IC50 and LD50 values were determined by at least two separate tests and reported as mean values. b Solubility of the
compounds was determined in 20 mM buffered solutions (pH 2, KCl/HCl; pH 6, phosphate) after shaking for 24 h at
22 °C. Data presented are from a single determination or an average of two determinations. c LD- limit for detection.
d Not tested.
Table-3
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Compared to 74b, the cellular potency of 75b against PDGF-induced
proliferation was less likely to be affected by the presence of serum protein.
In this regard, 75b was still a very potent inhibitor of PDGF-R‚ while 74b
became inactive in the presence of a high level of serum.
?Antiproliferative activity
Antiproliferative and cytotoxic drugs play a major role in cancer therapy,
whether used alone or in concert with other treatment modalities such as
surgery, radiation and biological therapy. Recently, aryl pyrroles have been
reported as potent inhibitors of Ras farnesyltransferase with regression of
tumors grown in nude mouse xenograft models103.
For developing new antitumoral agents, Jose Pardon, et.al104 have
synthesized a number of 1,2,3,4-tetrasubstituted pyrrole derivatives (76a-t)
(Table-4) and evaluated for their in vitro antiproliferative activities using
the human promyelocytic leucamia cell line HL60. The activity of the
compound was measured in terms of Growth inhibition of 50% (GI50), which
is the drug concentration resulting in a 50% reduction of cellular net growth
when compared with values of untreated control cells, the drug concentration
resulting in total growth inhibition (TGI), and the net loss in 50% of cells
following treatment (LC50) denoting cell kill.
The group of active compounds exhibited GI50 values in the range of 4-
45ìM. From this series compounds 76h and 76n were the most active
against HL60 cells, with GI50 values of 4.8 and 5.1ìM, respectively. The
remaining active derivatives showed modest activity with GI50 values in the
range 15–45ìM. Only five products proved to be inactive at the maximum
test concentration, that is, 100ìM. Interestingly, compounds 76a, 76c, 76j–l,
and 76n were the only products from the active group series that reached a
TGI value. The TGI values for those products were in the range 80–95ìM.
None of the evaluated pyrroles was able to show a LC50 value.
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When considering GI50 data the following structure– activity relationship was
obtained: (a) the aliphatic substituent on the nitrogen atom of compound
76t decreases activity when compared to compounds 76f and 76s, which
posses aromatic side chains; (b) the absence of a substituent in position 3
of the pyrrole ring led to inactive compound 76d; (c) ethyl ester derivatives
76g, 76j, and 76n are more active than their corresponding methyl esters
76f, 76i, and 76m respectively; (d) hydrolysis of the aliphatic ester of 76m
led to a less potent derivative 76l; (e) conversion of the aliphatic methyl
ester in 76f to benzyl amide 76h led to the most potent compound of the
series; (f) substituents other than methyl, ethyl, i-propyl, cyclopropyl, and n-
hexyl at R3 produces decrease in activity as shown with products 76o, 76p,
and 76r; and (g) the absence of an alkoxy carbonyl moiety at R2 position in
76b makes the compound more active than 76f, but such a difference was
not observed for compounds 76a and 76c, when compared to 76e and 76m.
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X.Wang, H.Chen, A.Sistla, T.Luu, F.Tang, J.Wei, C.Tang, J. Med. Chem.,46,1116(2003)
103.H.Lee, J.Lee, S.Lee, Y.Shin, W.Jung, J.Kim, K.Park, K.Kim, H.Cho, S.Ro, S.Lee, S.Jeong,
T.Choi, H.Chung, J.Koh, Bioorg. Med. Chem.Lett.,11, 3069(2001).
104.J.Padro, D.Tejedor, A.Santos-Exposito, F.Garcya-Tellado, V.Martin, J.Villar,
Bioorganic & Medicinal Chemistry Letters,15, 2487(2005)
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?As Glycogen Synthase Kinase-3(GSK-3) Inhibitors
Glycogen synthase kinase-3(GSK3) is a serine-threonine kinase encoded
by two independent genes, GSK3-á and â105. Purified GSK3-á and â show
similar biochemical and substrate properties and display high sequence
homology, 85% overall and 95% in the catalytic domain106. GSK3 was first
identified as one of several kinases that phosphorylates glycogen synthase
(GS), the enzyme that catalyzes the last step in glycogen synthesis. This
phosphorylation step, in contrast to most signaling pathways, inhibits the
action of GS107.  It was later shown that signaling from the insulin receptor
inactivates GSK3 via AKT-catalyzed phosphorylation of serine #9 on the
amino terminus of GSK3108. Thus, inhibitors of GSK3 would be expected to
have some of the same effects as insulin, such as its ability to activate
glycogen synthase and stimulate the conversion of glucose to glycogen,
thereby lowering plasma glucose. Abnormal regulation of GSK3 has also
been demonstrated in insulin resistant rodent and human muscle tissue109
Because of these facts, GSK3 has become an attractive target for the po-
tential treatment of  noninsulin-dependent diabetes mellitus(NIDDM)110.
Recently, several groups have reported a variety of bis-aryl maleimide
(BAM) inhibitors of GSK3 (As shown in figure below ). BAMs GF 109203x
and Ro 31-8220 were shown to inhibit GSK3 with IC50 values of 170-360
nM and 3-7nM, respectively, depending on the source of GSK3111.
SmithKline Beecham reported SB-216763 and SB-415286 to inhibit GSK3-
á with an IC50 of 34 and 77 nM, respectively,112 while J&J PRD reports a
GSK3-â‚ IC50 of 34 nM IC50 for their macrocyclic BAM.113
105.A.Ali, K.Hoeflich, J.Woodgett, Chem. Rev.,101, 2527(2001).
106.J.Woodgett, EMBO J.,9, 2431(1990).
107.P.Cohen, The Enzymes; Academic Press: New York, 17, 461(1986).
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T. Engler, et.al114 reported the results of a new class of orally available, highly
selective and potent GSK-3 inhibitors, the 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-
tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones (77-82).
N O
R2
N
O
R1
N
H
O
N
N
R3
O
Inhibition of GSK3-â by compounds 77-72 was determined in both biochemical
and cellular assays. As shown in Biochemical and Cellular Assay Data, all
compounds are very potent inhibitors of GSK3-â in the biochemical assay IC50s
ranging from 1 to 5 nM. In the P-Tau assay a larger differentiation in activities
ranging from 0.7 to 41 nM. Compound 79, bearing a 6-methyl group on the
imidazopyridine, was the least potent inhibitor in both assays and was 25-fold
less active in the P-Tau assay than the parent 78. The piperidine (78, 82) and
morpholine (80) ureas were found to be favored substituents on the aliphatic
ring nitrogen over other groups such as N,N-dimethylurea (81) and the isopropyl
carbamate (77). Further, fluorine substitution on the 5-position of the indole in
82 resulted in a modest activity enhancement over the parent compound 78.
77  R1 = OCH(CH3)2, R2, R3 = H            
78  R1 = piperidinyl,  R2, R3 = H           
79  R1 = piperidinyl, R2=H, R3 = CH3    
80 R1 = morpholinyl, R2, R3 = H  
81 R1 = dimethylaminyl, R2, R3 = H     
82 R1 = piperidinyl, R2=F, R3 = H
     Biochemical and Cellular Assay Data
108.D.Cross, R. Alessi, P.Cohen, M.Jelkovich, B.Hemmings, Nature ,378, 785(1995).
109.S.Nikoulina, T.Ciaraldi, S.Mudaliar, P.Mohideen, L.Cartet, R.Henry, Diabetes,49, 263(2000).
110.(a)A.Wagman, K.Johnson, D.Bussiere, Curr. Pharm. Design ,  10 ,  1(2004)
(b)P.Polychronopoulos, P.Magiatis, A.Skaltsounis, V.Myrianthopoulos, E.Mikros,
A.Tarricone, A.Musacchio, S.Roe, L.Pearl, M.Leost, P.Greengard, L.Meijer, J. Med.
Chem.,47,935(2004).
(c) C.Kunick, K.Lauenroth, M.Leost, L.Meijer, T.Lemcke,  Bioorg. Med. Chem. Lett.,14, 413(2004).
111.I.Hers,J.Tavare, R.Denton, FEBS Lett.,460, 433(1999).
112.M.Coghlan, A.Culbert, D.Cross, S.Corcoran, J.Yates, N.Pearce, O.Rausch, G.Murphy,
P.Carter, L.Cox, D.Mills, M.Brown, D.Haigh, R.Ward, D.Smith, K.Murray, A.Reith, J.Holder,
Chem.Biol. ,7, 793(2000).
113.G.Kuo, C.Prouty, A.DeAngelis, L.Shen, D.O’Neill, C.Shah, P.Connolly, W.Murray,
B.Conway, P.Cheung, L.Westover, J.Xu, R.Look, K.Demarest, S.Emanuel, S.Middleton,
L.Jolliffe, M.Beavers, X.Chen, J. Med. Chem.,46, 4021(2003).
114.T. Engler, J.Henry,S.Malhotra, B.Cunningham, K.Furness, J.Brozinick,T.Burkholder, M.Clay,
J.Clayton, C.Diefenbacher, E.Hawkins, P.Iversen, Y. Li, T. Lindstrom, A. Marquart, J.McLean,
D. Mendel, E.Misener, D. Briere, J. O’Toole, W. Porter, S. Queener, J. Reel, R. Owens, R.
Brier, T. Eessalu, J. Wagner, R. Campbell,  R. Vaughn, J. Med. Chem. , 47, 3934(2004)
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?Analgesic and Antiinflammatory activity
Oxime derivatives containing pyrrole and pyridine fragments were studied
as inhibitors of Raf kinase115. All these compounds can be used as analge-
sics and agents againts migraine and the oxime (83) was one of the most
active.The O-lauroyl and O-nicotinoyloximes of 1-methyl-2-acetylpyrrole
possessed antiinflammatory activity116.
N
H
N
HON
O
N
CH3
CH383
? Bactericidal activities
Derivatives of 2-pyrrolecarbaldehyde oximes have exhibited high bacteri-
cidal activity117-119. The pyrrole oxime fragment also enters into the structure
of certain penicillin antibiotics120. It was shown that ethers of pyrrole oximes
(8) have high bactericidal activity against resistant strains of bacteria121.
O
N
H O
O
OH
CH3
CH3
H3CO O
O
NOR'
CH3
O
CH3CH3
84 R, R' = Alk
? As Fungicides and Plant Growth Regulators
The ethers of pyrrole oximes exhibited high fungicidal, insecticidal and
acaricidal activity122. Among these compounds, in particular, the ether(85)
should  be ment ioned 123.  The e thers  o f  pyr ro le  amidox imes
[(pyrrolyl)C(NH2HCl)=NOCHR’CO2R”, where R’, R” = alkyl] exhibited good
bactericidal activity124.
NOCH3
N
CH3
CHOCH3H3COOC
85
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115.D.Dean, A.Naylor, A.Takle, D.Wilson, PCT Int. Appl. WO Pat. 0322833; Chem.
Abstr.,138, 255102 (2003).
116.T. Katagi, H. Kataoka, K. Takahashi, T. Fujioka, M. Kunimoto, Y. Yamaguchi, M.
Fujiwara, T. Inoi, Chem. Pharm. Bull., 40, 2419 (1992).
117.K. Hattori, M. Hashimoto, Jpn. Patent 4662 (1967); Chem. Abstr., 67, 90663 (1967).
118. D. Bailey, US Patent 3883516; Chem. Abstr., 83, 79072 (1975).
119. M.Hania, Asian J. Chem., 14, 1074 (2002); Chem. Abstr., 137, 247572 (2002).
120. Glaxo Laboratories Ltd., French Patent 2204404; Chem. Abstr., 81, 169535 (1974).
121. P. Laurin, D. Ferroud, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A.
Bonnefoy, B. Musicki, Bioorg. Med. Chem. Lett., 9, 2079 (1999).
122. P. Gerdes, H. Gayer, S. Hillebrand, U. Heinemann, B.-W. Krueger, A. Mauler-Machnik,
U. Wachendorff-Neumann, G. Haenssler, K. Stenzel, P. Loesel, Ger. Patent 19929086;
Chem. Abstr., 134, 56561 (2001).
123. M. Clough, C.Godfrey, P.De Fraine,B.Snell, Eur. Patent 718299; Chem. Abstr.,
109, 190240 (1988).
124. D. Farge,  J. Leboul, Y. Le Goff, G. Poiget, Ger. Patent 2640484; Chem. Abstr., 87, 39141 (1977).
125.A. Mizuno, N. Inomata, M. Miya, T. Kamei, M. Shibata, T. Tatsuoka, M. Yoshida, C.
Takiguchi, T. Miyazaki, Chem. Pharm. Bull., 47, 246 (1999).
126.A. Mizuno, A. Ogata, T. Kamei, M. Shibata, T. Shimamoto, Y. Hayashi, K. Nakanishi,
C. Takiguchi, N. Oka, N. Inomata, Chem. Pharm. Bull., 48, 623 (2000).
127.A. Mizuno, H. Cho, M. Hamaguchi, T. Tatsuoka, Eur. Patent 441349; Chem. Abstr.,
115, 232223 (1991).
128.A. Mizuno, M. Miya, N. Inomata, T. Tatsuoka, T. Ishihara, PCT Int. Appl. WO Pat.
9303032;Chem. Abstr., 119, 180819 (1993)
129.R. Granados, D. Mauleon, M. Perez, Ann. Quim. Ser. C, 79, 275 (1983); Chem.
Abstr., 102, 62011(1985).
129a.A.Baxter, J.Dixon, F.Ince, C.Manners, S.Teague, J.Med.Chem., 36(19), 2739(1993)
129b.T.Ginap, D.Dooley, T.Feuerstein, Neuroscience Lett.,156(1-2), 35(1993)
129c.T.Hoogland, P.Saggau, J.Neuroscience, 24( 39),  8416( 2004)
?Action on the Cardiovascular System
A.Mizuno, et al125, 126 have described that pyrrole oximes(86), which exhib-
ited anti-serotonin 5-HT2-receptor activity were proposed as antihyperten-
sive and anticoagulation drugs.The oxime derivatives of pyrroloazepines
also exhibited vasodilation activity.  Among these compounds the oxime
(87) was mentioned as one of the most active127,128. The blocking action of
pyrrole O-(2-alkylamino-2-hydroxypropyl)oximes (88) on â-adrenoceptors
has also been investigated129.
N
N
HON
(CH2)n N
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R
86 R = H, Alk; n = 3-5
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CH3
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CH3
CH3
R'
R OH
88 R = H, Alk, Ar; R' = H, CH3
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A.Baxter et.al129a have suggested that Methyl 2,5-dimethyl-4-[2-
(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate, FPL 64176  is the first
example of a new class of calcium channel activator (CCA) that does not
act on any of the well-defined calcium channel modulator receptor sites, as
typified by verapamil, diltiazem, and the dihydropyridines. The potent ac-
tivity of FPL 64176, having the 2- (phenylmethyl)benzoyl substituent, was
predicted using QSAR on an initial set of less potent benzoylpyrroles. When
compared to the CCA Bay K 8644, FPL 64176 has similar potency on cal-
cium uptake into GH3 cells (both have EC50 ~ 0.015 ìM) but is appreciably
more potent functionally at increasing contractility in a guinea pig atria
preparation (FPL 64176 has EC50 = 0.049 ìM vs Bay K 8644 EC50 = 1.95
ìM). FPL 64176 is an achiral, pharmacologically clean agonist with no de-
monstrable partial agonist properties and possesses appreciably higher
efficacy than Bay K 8644. It should therefore become a useful biochemical
and pharmacological tool for the study of calcium channels in many cell
types.
N
H
CH3 CH3
O O
O
CH3
FPL - 64176
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CH3CH3
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CH3N+
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?As Neuronal L-type Calcium channel activator
T.Ginap, and co-workers129b  tested FPL 64176 (methyl-2,5-dimethyl-4-(2-
(phenylmethyl)benzoyl-[1 H]pyrrole-3-carboxylate)  for an interaction with
neuronal L-type voltage-sensitive calcium channels (L-VSCCs) by using a
[3H]isradipine ([3H]ISR) binding assay, and for its ability to enhance K+-
evoked [3H]norepinephrine ([3H]NE) release from rat neocortical slices. The
classical L-VSCC activator, the dihydropyridine (DHP) BAY K 8644, was
also used for comparative purposes. FPL 64176 and BAY K 8644 both
produced a similar concentration-dependent enhancement of 15 mM K+-
290
evoked[3H]NE release which could be completely blocked by the L-VSCC
blocker ISR (0.1ìM). FPL 64176, in contrast to BAY K 8644, was a very
weak inhibitor of [3H]ISR binding to L-VSCCs. These findings indicate that
FPL 64176 is a novel non-dihydropyridine L-VSCC activator, most probably
by acting on a site different from the DHP binding site.
More over, T.M.Hoogland, et. al129c studied the contribution of L-type Ca2+
channels to action potential-evoked Ca2+ influx in dendritic spines of CA1
pyramidal neurons and the modulation of these channels by the ²2 adrenergic
receptor. L-type Ca 2+ channel activators FPL64176 and Bay K8644 (both
10 ìM) significantly enhanced the spine Ca2+ transients by 40-50%, which
revealed that L-type Ca2+ channels are functionally present in dendritic
spines of CA1 pyramidal neurons, contribute to spine Ca2+ influx, and can
be modulated by the â- adrenergic receptor through protein kinase-A(PKA)
in a highly compartmentalized manner.
130.(a) J.Handrickson, R.Rees, J.Templeton, J.Am.Chem.Soc., 86, 107(1964)
130(b) S.Khetan, J.Hiriyakkanavar, M.George, Tetrahedron, 24, 1567(1968)
130(c) S.Khetan, M.George, Tetrahedron, 25, 527(1969)
131.H.Meyer, Leibigs Ann.Chem., 1534(1981)
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D rug
N ame/C ode C hemical Structure Activity Phase Originator
FR-168888 Antianginal, Antiarrhythmic,Na+/H+ exchange inhibitor Preclinical Fugisawa
NSC -651016 Anti-HIV, C hemokine C CR5,C CR1 &  C CR2 antagonist
Preclinical Uni. of vermont
RS-57067000 C ycloxygenase-2 inhibitor,NSAID Preclinical Roche
ER-34617 Oncolytic,  Retinoid RARalpha agonist B iological testing E isai
Eniporide Acute myocardial infarction,Na+/H+ exchange inhibitor Phase-II Merck
ER-65250
D ermitologic,
 Immunomodulator, Oncolytic,
Retinoid RA Ralpha agonist
B iological testing E isai
FR-193517
Bronchodilator,
 Bradykinin antagonist,
Bradykinin B 2 antagonist
Preclinical Fugisawa
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Some Pyrrole drugs & derivatives under Preclinical/Phase clinical trials.
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Drug
Name/Code Chemical Structure Activity Phase
Originator
Anirolac NSAID Phase-II Roche Bioscience
Ramipril Antihypertensive,ACE Inhibitor Launched-1989
Aventis
Ketorolac Non-opioid analgesic, NSAID Launched-1990 Roche Bioscience
Pyrextramine Alpha adrenoceptor antagonist Biological testing
Universita degli study
di
Pamicogrel Antiplatelet therapy,Cyclooxygenase inhibitor Preregistered
Kanebo
Medosan-27
Antiplatelet therapy,
Bronchodilator,
Thromboxane A2 antagonist,
NSAID,
  Thromboxane synthetase Inhib.
Phase-I Medosan
A-2545
Antiarrhythmic,
Sodium channel blocker,
Calcium channel antagonist
Preclinical Alkaloida
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Drug
Name/Code Chemical Structure Activity Phase
Originator
- DNA damaging drug,   Oncolyticdrug Biological testing
Pharmacia
Mopidralazine Antihypertensive, Vasodilator Biological testing Lepetit
Pirprofen,
Rengasil NSAID Launched-1982
Novartis
Glimepiride Antidiabatic Launched-1995 Aventis
Prinomide Non-opioid analgesic,  NSAID Phase-III Novartis
Zalderide Antidiarrheal agent,Calmodulin antagonist Phase-III
Novartis
Amtolmetin
guacil Antiarthritic, NSAID Launched-1997 Sigma-Ta
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Drug
Name/Code Chemical Structure Activity Phase Originator
PI-091 Antiplatelet Therapy Preclinical Taisho
IPM-125I Oncolytic,Monoclonal antibodies Preclinical University of Alabama
Atorvastatin Lipoprotein disorder,HMG-CoA reductase inhibitor Launched-1997 Pfizer
FR-143187 Antihypertensive, Angiotensine AT1 Antagonist
Preclinical Fugisawa
Epiroprim
Antibacterial,
 Protozoal disease,
Dihydrofolate reductase Inhib ,
Trimethoprim analogue
Phase-I Roche
SX-3202((+)-(-
s)-isomer)
Symptomatic antidiabatic,
Aldose reductase inhibitor Phase-II Dainippon
ML-3000
Antiarthritic,
Cyclooxygenase inhibitor,
Lipoxygenase inhibitor, NSAID
Phase-II Merck
Iy-81149
Gastroesophageal reflux
disease, Agents for,
  Anti-Helicobacter pylori agent ,
Gastric antisecretory drug,
 H+/K+ ATPase inhibitor
Phase-II II-Yang
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Drug
Name/Code Chemical Structure Activity Phase Originator
L-167307
Antiarthritic,
  P38 protein kinase inhibitor,
TNF-alpha release inhibitor
Preclinical Merck
AG-3433
Oncolytic,
 Angiogenesis Inhibitor,
 Matrix metalloproteinase inh
Preclinical Agouron
SU-5402
Oncolytic, Inhibitor of signal
trnansduction pathways,
Tyrosine kinase inhibitor,
 Matrix metalloproteinase inhib.
Preclinical Sugen
L-168049 Antidiabatic, Glucagon antagonist Preclinical Merck
PNU-107922 Antibacterial Preclinical Pharmacia
-
Treatment of Osteoporosis,
Antiarthritic,
  Matrix metalloproteinase inh,
TNF-alpha release inhibitor
Biological
testing Abbott
BM-212 Antimycobacterial agent Biologicaltesting
Universita degli study
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Drug
Name/Code Chemical Structure Activity Phase Originator
-
Dermatologic drug,
Immunomodulator, Oncolytic,
Retinoid RARalpha agonist
Biological testing Eisai
- Antidiabatic,Glucagon antagonist Biological testing Merck
- Antidiabatic,Glucagon antagonist Biological testing Merck
LB-42908
Oncolytic, Inhibitor of signal
transduction pathways,
 Farnesyl transferase inhibitor
Preclinical LG Chem.
L-731988 Anti-HIV,HIV-integrase inhibitor Biological testing Merck
ER-35368
Oncolytic, Dermatologic drug,
Immunomodulator,
Retinoid RARalpha agonist
Biological testing Eisai
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Synthetic Approaches
? Cyclization Reactions
Pyrroles are generally synthesized by the cyclization reactions involving
nucleophilic-electrophilic interactions.
A. (3+2)Cyclization Reactions
A-1. Reaction of á-aminoketones or á-amino-â-keto esters with â-
diketones or â-ketoesters (Knorr Pyrrole Synthesis)
This is the most widely used method and involves the cyclizative condensation
of á-aminoketones or á-amino-â-keto esters(three atom fragment with nucleo-
philic nitrogen and electrophilic carbonyl carbon) with â-diketones or â-
ketoesters(two atom fragment with electrophilic carbonyl carbon and a nucleo-
philic carbon) with the formation of N-C2 and C3-C4 bonds. (Scheme-17).
CH3
O
R
NH2R = H, CH3, COOC2H5
+
CH3
O
R1
R1 = COCH3, COOC2H5
H+
CH3COOH N
H
CH3
CH3 R1
R
Scheme-17
A-2. Reaction of á-aminoketones with alkynes
The reaction of á-aminoketones with alkynes proceeds with the nucleophilic
addition of amino group to the electrophilic carbon of alkyne with the forma-
tion of enamine intermediate (89) which on intramolecular cyclization provides
pyrroles (90) involving nucleophilc(â-carbon of the enamine intermediate)-elec-
trophilic (carbonyl carbon) interaction with the formation of C3-C4 bond130.
CH3
O
R
NH2
R = H, CH3, C2H5
+
H3COOC
COOCH3
N
H
CH3
CH3 R1
R
Alkyne
CH3 O
R N
H
COOCH3
COOCH3
89
N COOCH3
COOCH3
R
H
OH
CH3
H
90Scheme-18
A-3. Reaction of â-amino-á,â-unsaturated esters with nitroalkenes
The reaction of â-amino-á,â-unsaturated esters 91(three atom fragment)
with nitroalkenes(two atom fragment) provides substituted pyrrole 92 in-
volving (3+2) cyclization with N-C2 and C3-C4 bonds131.(Scheme-19).
132.M.Friedman, J.Org.Chem., 30, 859(1965)
133.(a)H.Posvic, R.Dombro, H.Ito, T.Telinski, J.Org.Chem., 39, 2575(1974)
(b)H.Fritz, P.Uhrhan, Leibigs Ann.Chem., 744, 81(1971)
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A-4. Reaction of á-diketones with amines
Base catalysed (3+2) cyclizative condensation of á-diketones(93) with
amines(94) substituted with electron withdrawing substituents at á , á’-po-
sitions results in the corresponding pyrroles (95) with the formation of C2-
C3 and C4-C5 bonds132. (Scheme-20).
H5C6
O
O
C6H5
93
+ NH
E
E
94
E = CN, COOC2H5
(CH3)3O
--K+
N
H
E
H5C6 C6H5
E
95
Scheme-20
B. (2+2+1) Cyclization Reactions
B-1. Reaction of â-ketoesters with á-haloketones (Hantzsch Synthesis)
The reaction of â-ketoesters(96) with á-haloketones or aldehydes(98) in the
presence of ammonia or primary amine affords pyrroles(99) involving (2+2+1)
cyclization with the formation of N-C2, C3-C4 and N-C5 bonds. The reaction
proceeds via stabilized enamine intermediate (97) which on C-alkylation and
N-alkylation by á-haloketone leads to the formation of corresponding pyrrole.
H5C2OOC
R1 O
96
R NH2+
99
N
H5C2OOC
R1
R
R2
NH
R
O
O
C2H5
OH
R1 NH
H5C2OOC
R1
R97
+
O
Cl
R2
98 R = H, alkyl, arylScheme-21
B-2. Reaction of aldehydes or ketones with hydrazine (Piloty-Robinson
Synthesis)
The condensation of aliphatic aldehydes or ketones with hydrazine under
strongly acidic conditions affords pyrroles involving (3+3) sigmatropic re-
arrangement and cyclization. This reaction can also be applied for the
preparation of N-substituted pyrroles by condensing ketones with methyl
hydrazine or N,N’-dimethyl hydrazine133.(Scheme-22)
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B-3. Reaction of Benzoin with Benzyl aryl ketones
The reaction of benzoin(100) with benzyl aryl ketones in the presence of
ammonium acetate results in the formation of polyaryl substituted pyrroles
(101) involving (2+2+1) cyclization134.( Scheme-23)
Ar
Ar O
OH
100
+
Ar
ArO
CH3COO
--NH4
+
N
H
Ar
Ar Ar
Ar
101
Scheme-23
B-4. Reaction of aldehydes with alkyl isocyanoacetates
The condensation of alkyl isocyanoacetates with aldehydes in 2:1 ratio pro-
ceeds to involve an initial conjugated addition followed by an anionic cy-
clization with the formation of C2-C3, C3-C4 and C4-C5 bonds135.(Scheme-24)
H
R O
+
N
H
COOC2H5
H5C2OOC R
NC
COOC2H5 Scheme-24
C. (4+1) Cyclization Reaction
C-1. Reaction of 1,4-diketones with ammonia or ammonium deriva-
tives (Paal-KnorrSynthesis)
It is the most general method and involves (4+1)cyclizative condensation
of 1,4-dikitones(enolizable) with ammonia or its derivatives with the for-
mation of N-C2 and N-C5 bonds59-64,136-137. The reaction is considered to pro-
ceed with the successive attacks of nucleophilic nitrogen on the carbonyl
carbon and finally followed by dehydration(aromatization) for which driving
force is provided by the stability of the resulting pyrrole.(Scheme-25)
+
N
H
RRO
R R
O
R1 NH2
R1
 = H, alkyl, OH, NH2
Benzene, 
acid
Scheme-25
134. B.Tanaseichuk, S.Vlasova, E.Morozov, Zh.Org.Khim., 7, 1264(1971)
135.M.Suzuki, M.Miyoshi, K.Matsumoto, J.Org.Chem., 39, 1980(1974)
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C-2. Reaction of 1,4-dienes or diynes with amines
Metal ion assisted amination of 1,4-dienes or diynes with primary amines
followed by cyclization provides N-substituted pyrroles138-140, Scheme-26.
CH2 CH2
PdCl2, 
Cu(OCOCH3)2 
CH3COOH
H2C OAc
Pd
(i) AgBF4 (ii) PPh3 
RNH2
OAc
RHN
CH2RHN
Pd
N
R
aromatization, 
Pd/c
N
R
Scheme-26
R R
+ R1 NH2
CuCl2 
N
R1
RR
? Ring Expansion Reaction
2-Acylaziridines undergo ring expansion reactions to provide pyrroles(99)
involving ring-opened dipolar intermediates141.(Scheme-27)
N
R
CH3
O
R1 ∆
N
R
CH2
OH
R1
N
R
R1
Cyclization
Scheme-27
Vinylazirines 102 also undergo ring expansion reactions, but two isomeric
pyrroles 105 and 106 are obtained depending on the reaction conditions.
Thermal reactions involves a nitrene intermediate 103, while photochemi-
cal reaction proceeds via a nitrile ylide intermediate142 (Scheme-28)
N
H5C6 R
N
+
H5C6 CH
- R
hv
102
104
∆
H5C6
CH3N
2-
103N
H
C6H5
R
106
N
H
C6H5R
103
Scheme-28
?Extrusion Reaction
The complex ring systems, formed by (3+2) cycloaddition of activated
alkynes substituted with electron-withdrawing substituents, with mesoionic
heterocycles 107-109, undergo extrusion reactions with the cleavage of
larger ring leaving the pyrrole ring system intact143-144.(Scheme-29)
136.(a) A.Kartritzky, J.Suwinski, Tetrahedron,31, 1549(1975)
(b) P.Chiu, K.Lui, P.Maini, M.Sammes, J.Chem.Soc. Chem.Commun., 109(1987)
(c)V.Amarnath, D.Anthony, K. Amarnath, W.Valentine, L.Wetterau, D.Graham, J.Org.Chem.,
56, 6924(1991)
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E E +
O
N+
R
O
-
E = COOCH3
O
N
R
OE
E
N
R
EE
107
∆
-CO2
E E +
N
N+
R
R2
R
R1
O-E = COOCH3 108
N
R
EE
R1R2
111
E E +
S
N+
R
R1
O-E = COOCH3 109
N
R
EE
R1
112
110
Scheme-29
137.(a) N.Kozlov, L.Moiseenok, S.Kozintsev, Khim. Geterosikl. Soedin., 1483(1979)
(b) R.Ramanasseul, A.Rassat, Bull.Soc.Chim.France, 4330(1970)
138. J.Backvall, J.Nystrom, J.Chem.Soc.Chem.Commun., 59(1981)
139.A.Makhsumov, A.Safaev, N.Madikhanov,Khim. Geterosikl. Soedin.,125(1970)
140.A.Chalk, Tetrahedron.Lett.,3487(1972)
141.A.Padwa, D.Dean, T.Oine, J.Am.Chem.Soc., 97, 2822(1975)
142.A.Padwa, J.Smolanoff, A.Tremper, J.Am.Chem.Soc., 97, 4682(1975)
143.(a) R.Huisgen, H.Gotthardt, H.Bayer, F.Schaefer, Chem.Ber., 103,2611(1970)
(b) I.Benages, S.Albonico, J.Org.Chem., 43, 4273(1978)
144. K.Potts, S.Chen, J.Org.Chem., 42,1639(1977)
145.(a) S.Niitsuma,K.Kato, T.Takita, H.Umezawa, Tetrahedron Lett.,26, 5785(1985).
(b) A.Geies, A.El-Dean, O.Moustafa, Monatsh. Chem.,127,1263(1996).
(c) A.Monge, J.Palop, P.Parrado, C.Perez, E.Fernandez, J. Heterocycl. Chem.,24, 437(1987).
(d) A.Monge, J.Palop, T.Goni, F.Martinez-Crespo, I.Recalde, E.Fernandez-Alvarez,  J.
Heterocycl. Chem.,23, 647(1986).
?Miscellaneous Approaches
Ethyl-3-amino-5-phenyl-1H-pyrrol-2-carboxylate  found to be a useful inter-
mediate in the sysnthesis of other nitrogen heterocycles145. How ever Elliott
and co-workers146,147 have described that condensation of aldehyde(113)
with aminomalonate(114) gave 3-substituted enamine(115), which was cy-
clized in the presence of sodium methoxide to give 3-amino-4-benzyl-1H-
pyrrol-2-carboxylate (116)(Scheme-30)
Ph
NC
CHO
113
EtOOC
NH2
COOEt
114
NC
N
EtOOC
EtOOC
Ph
Ph
H
115
N
H
Ph
NH2
EtOOC
116
Scheme-30
Using a similar approach toward the synthesis of pyrrole (119), Ning Chen,
et. al148  were failed to synthesize 2-substituted enamine intermediate(118)
from benzoyl acetonitrile(117) and diethyl aminomalonate(114) using stan-
dard conditions such as azeotropic removal of water149, dehydration with
molecular sieves or Lawis acid catalysis(TiCl4150, BF3.OEt2)(Scheme-31)
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CN
Ph
O
117
EtOOC
NH2
COOEt
114
NC
N
EtOOC
EtOOC
Ph
H
118
N
H
NH2
EtOOC Ph
119Scheme-31
Considering the lower electrophilicity of the aryl ketone (117) compared to
the aldehyde (113), an alternative strategy for preparing enamine (118) was
examined. Since amines are known to undergo substitution reactions with
chloro- and alkylthio-substituted olefins to yield enamines151, a similar
approach was considered and the reaction of p-toluenesulfonyl enol ester
of á-cyano ketone (120) with diethyl aminomalonate (114)  was investigated.
Tosylate (120) was prepared by reacting benzoyl acetonitrile with p-
toluenesulfonic anhydride (1.2 equiv) in dichloromethane and triethylamine
(1.5 equiv) in 99% yield. When a mixture of tosylate (120) and diethyl
aminomalonate hydrochloride (1.2 equiv) were treated with an ethanolic
solution of sodium ethoxide (0.2 M, 3.5 equiv)152, the pyrrole (119) was
directly obtained without isolation of enamine (118). Addition of the amine,
cyclization and decarboxylation occurred in one pot at room temperature
to give a 46% overall yield of (119) from benzoyl acetonitrile.(Scheme-32)
CN
Ph
O
117
(p-CH3-C6H4-SO2)2O
CH2Cl2 99%
CN
O(p-SO2C6H4-CH3)Ph
120
EtOOC
NH2HCl
COOEt
114
NaOC2H5 47% NH
NH2
EtOOC Ph
119Scheme-32
(e)A.Monge, I.Aldana, M.Font, J.Arraras, E.Santiago, M.Lopez-Unzu, J.Martinez-de-Irujo,
E.Alberdi, E.Fernandez-Alvarez, Arch. Pharm. (Weinheim, Ger.),325, 439(1992).
146.A.Elliott, P.Morris, S.Petty, C.Williams, J.Org. Chem.,62, 8071(1997).
147.(a) M.Lim, R.Klein, J,Fox, J. Org. Chem.,44, 3826(1979).
(b) M.Lim, W.Ren, B.Otter, R.Klein, J. Org. Chem.,48, 780(1983).
148.N.Chen,Y. Lu, K.Gadamasetti, C.Hurt, M.Norman,C.Fotsch,J. Org. Chem.,65, 2603(2000)
149.(a) M.Furukawa, T.Okawara, Y.Noguchi, Y.Terawaki, Chem. Pharm. Bull. , 27, 2223(1979).
(b) G.Birnberg, W.Fanshawe, G.Francisco, J.Epstein,J.Heterocycl.Chem.,32, 1293(1995).
150.(a)R.Carlson, A.Nilsson, M.Stroemqvist, Acta Chem.Scand.,B37, 7(1983).
(b) M.Selva, P.Tundo, C.Marques, Synth. Commun., 25, 369(1995).
151(a).B.Erdmann, A.Knoll, J.Liebscher, J. J. Prakt. Chem.,330, 1015(1988).
(b)K.Gewald, H.Schaefer, P.Bellmann, U.Hain, J. Prakt. Chem.,334, 491(1992).
152.A.Elliott, J.Montgomery, A.Walsh, Tetrahedron Lett.,37, 4339(1996).
153.K.Raval, Ph.D. Thesis, Saurashtra University (2004)
154.
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Work Done at Our Laboratory
The literature servey described in the present chapter reveals that 1,3,4-
oxadiazole shows potent biological activities as antimicrobial, analgesic,
antiinflammatory, antiproteolytic, anticonvulsant, local anaesthetic,
antiasthmatic, phenyl-glycine dipeptidomimetics, tyrosine kinase inhibitors,
TNF-α-inhibitors and cyclic nucleotide inhibitors, monoamine oxidase type-
A inhibitors  and antidepressent, while pyrrole derivatives are showing
promissing pharmacological activities like monoamine oxidase type-B in-
hibitors, antitubercular, tyrosine kinase inhibitors, antitubercular, HIV-1
integrase inhibitors, antiproliferative, glycogen synthase kinase-3 inhibitors,
analgesic and anti-inflammatory, bactericidal, fungicidal and plant growth
regulators, cardiovascular and neuronal L-type calcium channel activators.
With an innovative approach to study the biological activity of the
1,3,4-oxadiazoles and 1H-pyrrole derivatives clubed with each other, from
this laboratory, K. Raval153 has initiated to sythesize 3,5-bis-1,3,4-
oxadiazolyl-2,4-dimethyl-1H-pyrrole derivatives, which includes synthetic
stretagy starting from acid catalysed cyclocondensation of ethyl ester de-
rivative of 3-amino-2-butenoic acid (generated insitu from ethylacetoacetate
upon oximenation followed by reduction)with ethylacetoacetate to afford
diethyl-2,4-dimethyl-1H-pyrrole-3,5-dicarboxylate, which was derivatized
into corresponding dihydrazide derivative on treatment with hydrazine hy-
drate. The dihydrazide derivative on reaction with different aromatic and
heteroaromatic acid, in the presence of phosphorous oxychloride affords
3,5-bis-1,3,4-oxadiazolyl-2,4-dimethyl-1H-pyrrole derivatives.
Current Work Plan
In continuation with our study on 1H-pyrrole derrivatives clubed with substi-
tuted-1,3,4-Oxadiazoles, in the present chapter 1-[2,4-dimethyl-5-(5-phe-
nyl-1,3,4-oxadiazol-2-yl)-1H-pyrrol-3-yl]ethanone derivatives were synthe-
sized. The synthetic stretagy follows starting with acid catalysed
cyclocondensation of ethyl ester derivative of 3-amino-2-butenoic acid (gen
304
erated insitu from ethylacetoacetate upon oximenation followed by
reduction)with acetylacetone to afford ethyl-3-acetyl-2,4-dimethyl-1H-pyr-
role-5-carboxylate, which was derivatized into corresponding hydrazide de-
rivative on treatment with hydrazine hydrate. The hydrazide derivative on
reaction with different aromatic and heteroaromatic acid, in the presence
of phosphorous oxychloride affords 1-[2,4-dimethyl-5-(5-phenyl-1,3,4-
oxadiazol-2-yl)-1H-pyrrol-3-yl]ethanone derivatives.
The structures of all the synthesized compounds were confirmed by IR,
1HNMR and Mass spectral data and elemental analysis.
The compounds of the present invention were screened for antitubercular
and antibacterial activity.
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Experimental Protocols
All the starting materials, ethyl acetoacetate, sodium nitrite, gla. AcOH, Zinc
dust, acetyl acetone, hydrazine hydrate, substituted aromatic acids and
phosphorous oxychloride were obtained from the commercial sources i.e.
Spectrochem Ltd., s.d.fine chem. ltd., Sisco Research Lab., Ranbaxy Lab.,
Allied Chem. Ltd. Melting points of the synthesized compounds were re-
corded by open capillary method  on controlled temperature using stan-
dard Zeal’s thermometer and are uncorrected.  The commencement of the
reaction and purity of the synthesized compounds  were ensured using thin
layer chromatography (TLC) silica gel-G, used as stationary phase, the TLC
plates were purchased from Merck India Ltd. ethyl acetate: hexane  was
used as the mobile phase. However other solvent systems like acetone
:benzene and methanol:chloroform was also employed but the best results
observed with ethyl acetate:hexane system.
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Experimental
Synthesis of Ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate:
In a 3-l. three-necked flask provided with a stirrer and surrounded by an ice
bath are placed 402 g.(3.09 moles) of ethyl acetoacetate and 1.2 l. of glacial
acetic acid. To this solution is then added dropwise with stirring a solution
of 246 g. (3.55 moles) of sodium nitrite in 400 ml. of water. The rate of
addition is controlled so that the temperature does not rise above 12°. After
the sodium nitrite solution has been added, the mixture is stirred an
additional 2–3 hours. It is then allowed to warm up to room temperature
and stand about 12 hours, after which 348 g. (3.48 moles) of acetylacetone
is added at one time. To the reaction mixture 450 g. of zinc dust is added
in portions of about 10 g. with vigorous stirring. The rate of addition is
regulated so that the emperature never rises above 60°. After the addition
is complete, the mixture is refluxed for 2–3 hours on a hot plate until the
unreacted zinc dust collects in balls. The hot solution is then poured through
a fine copper sieve, with stirring, into 30 l. of ice water. The crude product
which separates is contaminated with zinc. On recrystallization from 1.5 l.
of 95% ethanol, pure 2,4-dimethyl-3-acetyl-5-carbethoxypyrrole is obtained.
Yield 55–60%, m.p. 140-142oC(Reported m.p.143oC154).Purity was checked
by TLC using ethyl acetate: hexane(3:7) as mobile phase.
Synthesis of 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carbohydrazide :
A mixture of 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate(0.01 mole) and
99% hydrazine hydrate(0.32 mole) in 20ml methanol was refluxed in a
waterbath for 12-14hrs. The reaction mixture was poured into crushed ice
to afford crude 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carbohydrazide. The
solid product was filtered out and recrystallized from rectified spirit. Yield
71%, m.p.172oC. Purity was checked  by TLC using ethyl acetate: hex-
ane(3:7) as mobile phase.
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Synthesis of 1-{2,4-dimethyl-5-[(5-sub.phenyl-1,3,4-oxadiazol-2-
yl)carbonyl]-1H-pyrrol-3-yl}ethanone (General method):
A mixture of 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carbohydrazide(0.01mole),
substituted aromatic acid(0.01mole) and 15ml POCl3 was refluxed on wa-
ter bath for 5 hrs. The reaction mixture was poured into crushed ice. The
crude product was filtered and washed thoroughly with cold water till it be-
come acid free.  The product so obtained was recrystallized from
methanol.The purity of each compound was checked by TLC using ethyl
acetate:hexane (4:6) as mobile phase.
The elemental analysis of all the compounds performed by PERKIN ELMER
470R are in total agreement with the theoritical values.
The physical constants and elemental analysis of all compounds were
shown in Table 4.1.
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SPECTRAL CHARACTERIZATION
The constitution of newly synthesized compounds were supported by FT - IR, 1H
NMR and  EI-Mass spectral study.
IR Spectral Study
Instrument: SHIMADZU FT-IR 8400 Spectrophotometer
Sample technique: KBr pellet
Frequency range: 400-4000 cm-1
The 1-{2,4-dimethyl-5-[(5-sub.phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-1H-
pyrrol-3-yl}ethanones (KUPO Series) indicates the presence of very spe-
cific functional groups like secondary amine group of pyrrole skeleton,
methyl group, carbonyl group, C=N and C-O-C vibration of 1,3,4-
oxadiazole ring, aromatic ring skeleton,  etc.,  which absorb IR radiations
of specific frequency and show sharp, medium or weak intense signals
and hence supports in identifiction and confirmation of the molecule.
The IR spectrums of The 1-{2,4-dimethyl-5-[(5-sub.phenyl-1,3,4-oxadiazol-
2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones show common frequences as 3400-
3450cm-1 for 2oamino group, 3140-3110cm-1 for aromatic C-H str., 1660-
1650cm-1 for C=Ostr.of carbonyl group,1620-1600cm-1 for C=Nstr., merge with
aromatic ring skeleton, where as aromatic region was observed  extended
upto 1480cm-1. Methyl groups situated at 2 and 4 position give band
according to stretching vibrations between 2925-2920cm-1 and 2855-
2850cm-1 respectively as well as a merge band of in plane deformation
range between 1405-1400cm-1, secondary N-Cstr. was observed range
between 1360-1256cm-1, while sharp intense band observed in range bet
ween 1159-1060cm-1 for O-C str., Phenyl substitutions  observed between
970-730cm-1.  While characteristic vibration corresponds to substitution at
phenyl residue was clearly observed in each case.
A comparative chart of  IR spectral data of all compounds of KUPO series
are shown in Table 4.2
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  IR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-methoxy)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-1H -
  pyrrol-3-yl}ethanone (KUPO-7)
      KUPO-7 KUPO-4
N
O
N
N
H
CH3
CH3
O
CH3
H3CO
N
O
N
N
H
CH3
CH3
O
CH3
N+
O-
O
   IR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-nitro)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-1H-
   pyrrol-3-yl}ethanone (KUPO-4)
Functional
Group Vibration Mode
Frequency
(cm-1)
-NH N-H str. 3435
-CH
Aromatic -C-H str. 3132
-CH3 -C-H str. 2925,2843
Carbonyl -C=O str. 1657
-C=N C=N str. 1617
Aromatic
Skeleton
 -C=C- str. 1532,1497,1483
1:4 di substitution 840
2oN-C -N-C str. 1280
C-O-C -O-C str. 1074
-OCH3 -C-O str. 1257
Functional
Group Vibration Mode
Frequency
(cm-1)
-NH N-H str. 3419
-CH
Aromatic -C-H str. 3113
-CH3 -C-H str. 2925,2851
Carbonyl -C=O str. 1655
-C=N C=N str. 1608
Aromatic
Skeleton
 -C=C- str. 1556,1521,1482
1:4 di substitution 854
2oN-C -N-C str. 1293
C-O-C -O-C str. 1066
NO2 -N-O str. 1343
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  IR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-bromo)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-1H-
  pyrrol-3-yl}ethanone (KUPO-15)
      KUPO-15 KUPO-4
N
O
N
N
H
CH3
CH3
O
CH3
Br
   IR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-chloro)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-1H-
   pyrrol-3-yl}ethanone (KUPO-3)
N
O
N
N
H
CH3
CH3
O
CH3
Cl
Functional
Group Vibration Mode
Frequency
(cm-1)
-NH N-H str. 3404
-CH
Aromatic -C-H str. 3136
-CH3 -C-H str. 2923,2852
Carbonyl -C=O str. 1650
-C=N C=N str. 1600
Aromatic
Skeleton
 -C=C- str. 1542,1476,1459
1:4 di substitution 837
2oN-C -N-C str. 1268
C-O-C -O-C str. 1073
Halogen -C-Br str. 737
Functional
Group Vibration Mode
Frequency
(cm-1)
-NH N-H str. 3419
-CH
Aromatic -C-H str. 3126
-CH3 -C-H str. 2923,2853
Carbonyl -C=O str. 1650
-C=N C=N str. 1620
Aromatic
Skeleton
 -C=C- str. 1604,1581,1530
1:4 di substitution 839
2oN-C -N-C str. 1320
C-O-C -O-C str. 1091
Halogen -C-Cl str. 737
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1H NMR Spectral Study
1H NMR Spectrum of the 1-{2,4-dimethyl-5-[(5-sub.phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones show  signals relevant to
the number of protons and their  electronic environment known as chemical
shift.  Chemical shift  may move to either upfield (Shielding) or down
field(deshielding),  according to the  electronic environment of the
corresponding proton.  In addition  to  this, each 1H NMR signal  further
splitted  into  number of subpeaks  according  to  the  number of neighbouring
protons present in the skeleton of molecule. The splitting of the NMR signal
further provides signification about the degree of  interaction  between  neighbouring
protons by means of spin-spin coupling constant  J.
Instrument : BRUKER AC 300MHz FT-NMR
Internal Reference : TMS Solvent : CDCl3  or DMSO d6
1-{2,4-Dimethyl-5-[(5-(4-methyl)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-
1H-pyrrol-3-yl}ethanones (KUPO-3)
1H NMR Spectrum of KUPO-1 shows two singlets due to methyl protons
occupied at 4-position of phenyl residue and C-4 and C-2 substitutions of
pyrrole ring, relevant to six and three protons appears at δ 2.38 ppm
and δ2.57 respectively. Which reveals that the methyl protons of the C-4
substitution of the phenyl residue and that of C-3 of the pyrrole ring experi-
ence almost same electronic environment while methyl protons of the C-2
substitution of the pyrrole ring were slightly more deshielded.  A singlet
relevant to C-3 substituted acetyl protons of the pyrrole ring appears at δ
2.51. While an amine proton of the pyrrole ring resonates at  12.17δ ppm.
Phenyl residue substituted at 1,3,4-oxadiazole ring possess two pair of
chemically equivalent but magnetically non-equivalent protons viz. H(e) &
H(d) appear as two doublet at δ 7.405 with J value of 3Hz and δ7.93 with J
value of 6Hz respectively.
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1-{2,4-Dimethyl-5-[(5-(4-nitro)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-
1H-pyrrol-3-yl}ethanones (KUPO-4)
1H NMR Spectrum of KUPO-4 shows two singlets appears due to C-4
and C-2 methyl protons of pyrrole ring at chemical shift value of δ2.39
and δ2.60 ppm respectively. A singlet due to C-3 substituted acetyl pro-
tons of pyrrole ring appears at δ 2.53. While amine proton of the pyrrole
ring resonates at δ12.28 ppm. Phenyl residue substituted at 1,3,4-
oxadiazole ring possess two pair of chemically equivalent but magneti-
cally non-euivalent protons viz. H(d) & H(e) appear as two doublet at δ 8.275
with J value of 9Hz and δ 8.435 with J value of 9Hz respectively.
1-{2 ,4 -Dimethyl -5 - [ (5 - (4 -methoxy)phenyl -1 ,3 ,4 -oxadiazol -2 -
yl)carbonyl]-1H-pyrrol-3-yl}ethanones (KUPO-7)
In the 1H NMR Spectrum of KUPO-7 shows two singlets due to C-4 and C-
2 substituted methyl protons of pyrrole ring appears at  δ 2.38 and δ2.57
respectively. A singlet due to acetyl protons substituted at C-3 position of
pyrrole ring appears at chemical shift value of δ 2.51 ppm. An amine pro-
ton of the pyrrole ring resonates at δ12.14. Phenyl residue substituted at
1,3,4-oxadiazole ring possess two pair of chemically equivalent but mag-
netically non-euivalent protons viz. H(e) & H(d) appear as two doublet at δ7.14
with J value of 6Hz and δ 7.975 with J value of 9Hz respectively.
1-{2,4-Dimethyl-5-[(5-(4-chloro)phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-
1H-pyrrol-3-yl}ethanones (KUPO-3)
In the 1H NMR Spectrum of KUPO-3 the C-2 and C-4 methyl protons of the
pyrrole ring shows two singlets at δ2.73 and δ 2.54 respectively. The dif-
ference between chemical shift indicates the difference in their relevant
electronic envirment. A singlet  due to acetyl proton occupied at C-3 posi-
tion of pyrrole ring, appears at δ 2.67.  An amine proton of the pyrrole ring
resonates at δ12.35 ppm. Phenyl residue substituted at 1,3,4-oxadiazole
ring possess two pair of chemically equivalent but magnetically non-
equivalent protons viz. H(e) & H(d) appear as two doublet at δ 7.83 with J
value of 6Hz and δ 8.195 with J value of 9Hz respectively.
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1H NMR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-chloro)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones (KUPO-3)
                      KUPO-3
N
O
N
N
H
CH3(c)
CH3(a)
O
CH3(b)
Cl
H(d)H(e)
H(e) H(d)
Type of Proton
(Group)
Chemical Shift
delta ppm No. of Protons
Multiplicit-
y J Value
- CH3(c) 2.54 3 s -
-COCH3(b) 2.67 3 s -
-CH3(a) 2.73 3 s -
Ar-H(e) 7.83 2 d 6
Ar-H(d) 8.195 2 d 9
-NH 12.35 1 s -
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1H NMR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-nitro)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones (KUPO-4)
                      KUPO-4
N
O
N
N
H
CH3(c)
CH3(a)
O
CH 3(b)
N+
O-
O
H(d)H(e)
H(e) H(d)
Type of Proton
(Group)
Chemical Shift
delta ppm No. of Protons
Multiplicit-
y J Value
- CH3(c) 2.39 3 s -
-COCH3(b) 2.53 3 s -
-CH3(a) 2.60 3 s -
Ar-H(d) 8.275 2 d 9
Ar-H(e) 8.435 2 d 9
-NH 12.28 1 s -
321
1H NMR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-methoxy)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones (KUPO-7)
N
O
N
N
H
CH3(c)
CH3(a)
O
CH3(b)
H3CO
H(d)H(e)
H(e) H(d)
                      KUPO-7
Type of Proton
(Group)
Chemical
Shift delta
ppm
No. of Protons Multiplicit-y J Value
- CH3(c) 2.38 3 s -
-COCH3(b) 2.51 3 s -
-CH3(a) 2.57 3 s -
-OCH3 3.84 3 s -
Ar-H(e) 7.14 2 d 6
Ar-H(d) 7.975 2 d 9
-NH 12.14 1 s -
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1H NMR Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-methyl)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones (KUPO-11)
N
O
N
N
H
CH3(c)
CH3(a)
O
CH3(b)
(f)CH3 
H(d)H(e)
H(e) H(d)
                      KUPO-11
Type of Proton
(Group)
Chemical
Shift delta
ppm
No. of Protons Multiplicit-y J Value
-CH3(c,f) 2.38 6 s -
-COCH3(b) 2.51 3 s -
-CH3(a) 2.57 3 s -
Ar-H(e) 7.405 2 d 3
Ar-H(d) 7.93 2 d 6
-NH 12.17 1 s -
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Mass Spectral Study
The FAB mass analysis of  the 1-{2,4-Dimethyl-5-[(5-substituted phenyl-
1,3,4-oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanones molecular ion
peak(M+) of the compounds are in total agreement with it’s molecular weight.
Instrument: JEOL SX 102/ DA-6000 Spectrograph for FAB
FAB MASS Spectrum of 1-{2,4-Dimethyl-5-[(5-phenyl-1,3,4-oxadiazol-
2-yl)carbonyl]-1H-pyrrol-3-yl}ethanon (KUPO-1)
The FAB Mass spectrum of the KUPO-1 shows the  Molecular Ion peak at m/
z value of 281,  the base peak of the fragmentation is M+1 peak at m/z282,
while other ions generates are m/z  266, m/z 240, m/z 223, m/z 210, m/z
154, m/z 136 etc.
FAB MASS Spectrum of 1-{2,4-Dimethyl-5-[(5-(2-chloro)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanon (KUPO-2)
The FAB Mass spectrum of the KUPO-2 shows the  Molecular Ion peak at m/
z value of 315,  the base peak of the fragmentation is M+1 peak at m/z316,
while other ions generates are m/z  300, m/z 274, m/z 164,  m/z 154, m/z
135,m/z 120 etc. In addition to this a characterestic ionization patern of (m+1),
(m+2), (m-1) peaks of chloro substitution is also observed.
FAB MASS Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-nitro)phenyl-1,3,4-
oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanon (KUPO-4)
The FAB Mass spectrum of the KUPO-4 shows the  Molecular Ion peak at m/z
value of 326,  the M+1 peak obsrved at m/z327, while other ions generates
are m/z  307, m/z 240, m/z 289, m/z 273, m/z258, m/z 242, m/z 136 etc.
FAB MASS Spectrum of 1-{2,4-Dimethyl-5-[(5-(4-methoxy)phenyl-
1,3,4-oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanon (KUPO-7)
The FAB Mass spectrum of the KUPO-4 shows the  Molecular Ion peak at m/z
value of 312,  M+1 peak obsrved at m/z 313, while other ions generates are
m/z  289, m/z 282, m/z 266, m/z 211, m/z164, m/z 149, m/z 135etc.
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CHAPTER-5
     Synthesis and Characterization of Some
   6-Chloro-2oxo-4-[(E)-2-phenylethyl]-2H-
  chromene-3-carbonitriles
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Introduction
Coumarins comprise a group of natural compounds found in a variety of plant
sources. The very long association of plant coumarins with various animal species
and other organisms throughout evolution may account for the extraordinary range
of biochemical and pharmacological activities of these chemicals in mammalian
and other biological systems. The coumarins that were studied have diversed
biological properties and various effects on the different cellular systems. A lot of
biological parameters should be evaluated to increase our understanding of
mechanisms by which these coumarins act. Coumarins have important effects in
plant biochemistry and physiology, acting as antioxidants, enzyme inhibitors and
precursors of toxic substances. In addition, these compounds are involved in the
actions of plant growth hormones and growth regulators, the control of
respiration, photosynthesis, as well as defense against infection. The
coumarins have long been recognized to possess anti-inflammatory,
antioxidant, antiallergic, hepatoprotective, antithrombotic, antiviral, and
anticarcinogenic activities. The hydroxycoumarins are typical phenolic
compounds and, therefore, act as potent metal chelators and free radical
scavengers. They are powerful chain-breaking antioxidants. The coumarins
display a remarkable array of biochemical and pharmacological actions,
some of which suggest that certain members of this group of compounds
may significantly affect the function of various mammalian cellular systems.
The coumarins are extremely variable in structure, due to the various types
of substitutions in their basic structure, which can influence their biological
activity. Vast majority of coumarins, completely innocuous, may be beneficial
in a variety of human disorders, in spite of some ongoing controversy.
There has been, in recent years, a major rekindling of interest in
pharmacognosy. Coumarins turn out to be present in many natural
therapeutically utilized products. They hold a place apart in view of their
cytotoxic activity. It was suggested that alterations in the chemical structure
of coumarins could change their cytotoxic properties1.
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Coumarin and its hydroxy derivatives have been prominently accepted as natu-
ral pharmaceuticals2  world wide, has revealed new biological activities with
interesting therapeutic applications, besides their traditional employment as
anticoagulants(anti-vitamin K activity)3, antibiotics(novobiocin and analogues4)
and anti AID5.  Apart from this, they also possess anti-cancerous1, antibacte-
rial6, neurotropic7, immunosupressive8, anti inflammatory9, antiulcerous10, anti
PAF(anti platelet activating factor)11 and antimutagenic12 effects.
1. I.Kostava, Curr. Med. Chem.- Anti Cancer Agents, 5, 29(2005)
2(a). B. Nielsen, Coumarin patterns in the Umbelliferae, in: V.H. Heywood(Ed.), The
biology and chemistry of the Umbelliferae, Acedemic Press, London, 325(1971)
(b). A.Estevez-Braun, A. Gonzalez, Nat. Prod. Reps., 14, 465(1997)
3(a). M. Stahmann, T. Wolff, K. Link, J. Am.Chem.Soc., 65, 2285(1943)
(b). E. Renk, W. Stoll, Prog. Drug. Res., 14, 226(1968)
(c). W.Levin, In The Pharmacology Basis of Therapeutics; 4th ed., L.Goodman, A.Gilman,
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?Anti Cancer activity Profile of Benzopyran Derivatives
Analysis of scientif ic l iterature revealed numerous reports on the
antiproliferative and antitumor activit ies of a variety of coumarin
compounds, e.g., both coumarin itself and 7-hydroxycoumarin have been
reported to inhibit the proliferation of a number of human malignant cell
lines in vitro 13-16 and have demonstrated activity against several types of
animal tumors 17-21. These compounds have also been reported in clinical
trials to demonstrate activity against prostate cancer, malignant melanoma,
and metastatic renal cell carcinoma 22-24.
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For coumarins, generally the in vitro structure-activity relationship studies
have shown that cytotoxicity is found with derivatives containing ortho-
dihydroxy substituents25. Also, the chemical-structure/ biological activity
study of the coumarins showed that the addition of a cathecolic group to
the basic structure induces increased cytotoxic activity in tumor cell lines
25. The different cytotoxic values found for the coumarins could be related
to presence and the positions of the hydroxyls in their structures.
The cytotoxicity of 22 natural and semi-synthetic simple coumarins was
evaluated in GLC4, a human small cell lung carcinoma cell line, and in
COLO 320, a human colorectal cancer cell line25. From the structure-
cytotoxicity relationship, it is conspicuous that all the potentially active
natural compounds possess at least two phenolic groups in either the 6, 7-
or 6, 8-positions. In addition, the 5-formyl-6-hydroxy substituted semi-
synthetic analogue was found to be potent, reflecting the importance of at
least  two polar functions for high cytotoxicity.
Several hydroxylated and/or methoxylated coumarin derivatives were
tested for their relative cytotoxicity on four human tumor cell lines (oral
squamous cel l  carcinoma HSC-2, HSC-3, melanoma A-375 and
promyelocytic HL-60) and three normal human cells (gingival fibroblast
HGF, periodontal ligament fibroblast HPLF and pulp cell HPC) 26. Tumor
cell-specific cytotoxicity was detected in all 6, 7-dihydroxy-substituted
coumarins only. The observations indicated that the tumor-specific
cytotoxici ty of the natural ly occurr ing coumarin esculet in (6, 7-
dihydroxycoumarin) could be further enhanced by proper substitutions at
3- and/or 4-position(s) of the molecule. Agarose gel electrophoresis
revealed that esculetin and its derivatives with tumor-specific cytotoxicity
induce internucleosomal DNA fragmentation in HL-60 cells.
A selected  group of natural and synthetic coumarin compounds, including
the hydroxylated and nitrated derivatives, were assessed for their cytotoxic
potential for cellular viability27. This study utilized both human skin malignant
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melanocytes (SK-MEL-31) and normal human skin fibroblastic cells
(HS613.SK), allowing identification of those coumarin derivatives that are
select ively toxic.  Novel  synthet ic ni t rated coumarins,  6-ni t ro-7-
hydroxycoumarin and 3, 6, 8-nitro-7-hydroxycoumarin, were shown to be
significantly more toxic to SK-MEL-31 than HS613.SK cells. In the malignant
melanocyte skin cell line (SK-MEL-31), the cytotoxic effects of these nitro-
derivatives were shown to be dose and time dependent. Therefore, the
cytotoxic potential of coumarins appears to be highly dependent on the
nature and position of the functional group. In addition, nitration of 7-
hydroxycoumarin produced compounds that were cytotoxic to malignant
melanocytes, suggesting that these nitro-derivatives may have a
chemotherapeutic role in future.
Protective effects of coumarins against cytotoxicity induced by linoleic acid
hydroperoxide were examined in cultured human umbilical vein endothelial
cells28. When the cells were incubated in medium supplemented with linoleic
acid hydroperoxide and coumarins, esculetin (6, 7-dihydroxycoumarin) and
4-methylesculetin protected cells from injury by linoleic acid hydroperoxide.
O OOH
OH
Esculetin
O OOH
OH
CH3
4-Methyl Esculetin
O OOH
H3CO
Fraxetin
Esculetin and 4-methylesculetin provided synergistic protection against
cytotoxicity induced by linoleic acid hydroperoxide with alpha-tocopherol.
Furthermore, the radical-scavenging ability of coumarins was examined in
electron spin resonance spectrometry. Esucletin, 4-methylesculetin, fraxetin,
and caffeic acid showed the quenching effect on the 1, 1-diphenyl-2-
picrylhydrazyl radical. These results indicate that the presence of an ortho
catechol moiety in the coumarin molecules plays an important role in the
protect ive act iv i t ies against l inoleic acid hydroperoixde-induced
cytotoxicity28.
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An antioxidant auraptene (7-geranyloxycoumarin) isolated from the peel of
citrus fruit (Citrus natsudaidai Hayata) has been reported to have
chemopreventive effects on chemically induced carcinogenesis. Dietary
administration of auraptene significantly increased the activities of
detoxification (phase II) enzymes, such as quinone reductase and
glutathione S-transferase, in the liver and colon of rats. In addition,
expression of cell proliferation biomarkers, such as ornithine decarboxylase
activity and polyamine biosynthesis, in the colonic mucosal epithelium was
significantly inhibited by dietary feeding of auraptene. These biological
functions of auraptene may contribute to its anti-tumorigenic effect29.
In addition to this, auraptene have been demonstrated its anti-tumor
promoting effect in mouse skin and anti-carcinogenesis activities in rat
tongue, esophagus and colon30. Murakami A. et al.30 reported that Auraptene
suppresses superoxide anion (O2
– )generation from inflammatory leukocytes
in in vitro experiments. In the study, they investigated the anti-inflammatory
activities of Auraptene and compared them with those of Umbelliferone (7-
hydroxycoumarin), a structural analog of Auraptene that is virtually inactive
toward O2– generation inhibition. Double pre-treatments of mouse skin with
Auraptene, but not Umbelliferone, markedly suppressed edema formation,
hydrogen peroxide production, leukocyte infiltration, and the rate of
proliferating cell nuclear antigen-stained cells. These inhibitory effects by
Auraptene are attributable to its selective blockade of the activation stage.
Umbelliferone did not show any inhibitory effect. This contrasting activity
profile between Auraptene and Umbelliferone was rationalized to be a result
of their distinct differences in cellular uptake efficiencies, i.e. the geranyloxyl
group in Auraptene was found to play an essential role in incorporation.
Auraptene
O OOH
Umbelliferon
O OO
CH3CH3
CH3
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The rat  hepat ic  tox ic i ty  of  coumar in and methyl  analogues (3-
methylcoumarin, 4-methylcoumarin  and 3, 4-dimethylcoumarin) has been
determined in vivo and in vitro31. Coumarin at a dose of approximately 1
mmol/kg produced clear histological evidence of centrilobular necrosis,
while the methyl analogues at an equivalent dose were much less toxic. By
use of a systematic random sampling protocol and quantitative morphometry
it was determined that there was a lobar variation in the extent of hepatic
damage but that this exhibited random inter-animal variation. The order of
cytotoxicity in vitro was identical to that observed in vivo.
O O
CH3
CH3
O O
CH3
O O
CH3
3-Methyl coumarin 4-Methyl coumarin 3,4-Dimethyl coumarin
Geiparvarin, containing coumarin moiety, is an antiproliferative compound
isolated from the leaves of Geijera parviflora, and may represent a new
drug which targets tubulin. To better explore the potential use of this agent,
A. Miglieta, et al32 investigated the antimicrotubular and cytotoxic effects
of new synthetic aromatic derivatives of geiparvarin. These drugs inhibited
polymerization of microtubular protein, particularly when the assembly was
induced by paclitaxel.
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Paclitaxel
Bocca C. et al. 33 investigated biological activity of ferulenol, a prenylated
4-hydroxycoumarin from Ferula communis. Ferulenol stimulates tubulin
polymerization in vitro, and inhibits the binding of radiolabeled colchicine
to tubulin. It rearranges cellular microtubule network into short fibres, and
alters nuclear morphology. Remarkably, ferulenol exerts a dose dependent
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cytotoxic activity against various human tumor cell lines.
Three new coumarin derivatives along with furanocoumarins and a novel
dioxocane derivative were isolated from the fern Cyclosorus interruptus
(Willd.)H.Ito34. Based on spectrometric and spectroscopic analysis (FAB or El
mass spectrometry as well as 1D and 2D NMR experiments) their structures
were characterised as 5,7- dihydroxy - 6 - methyl - 4 - phenyl - 8 - ( 3 -
phenylpropionyl ) -benzopyran-2-one (1), 5, 7-dihydroxy-6-methyl-4-phenyl-8-
(3-phenyl-trans-acryloyl)-1-benzopyran-2-one (2), 5,7-dihydroxy - 8 - (2 -
hydroxy - 3 - phenylpropionyl) - 6 - methyl - 4phenyl-1-benzopyran-2-one (3).
Among which compounds 5,7- dihydroxy - 6 - methyl - 4 - phenyl - 8 - (3 -
phenylpropionyl) - 1benzopyran-2-one and 5, 7-dihydroxy-6-methyl-4-phenyl-
8-(3-phenyl-trans-acryloyl)-1-benzopyran-2-one, were cytotoxic to a KB cell
line.
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3
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 A new coumarin, 5-(4-hydroxyphenethenyl)-4, 7-dimethoxycoumarin (4) was
isolated from the combined ethylacetate extracts of the root bark, root wood
and stem bark of Monotes engleri, and found to be cytotoxic against two
cell lines in a human tumor panel 35. Its structure was determined on the
basis of spectroscopic methods.
In a Chinese herb cytotoxicity screening test, the ethanol extract of Cnidii
monnieri Fructus exhibited strong effects on human leukemia (HL-60),
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cervical carcinoma (HeLa) and colorectal carcinoma (CoLo 205) cells. Then,
the Cnidii monnieri Fructus extract was subjected to silica gel column
chromatography and recrystallization to give five coumarins:osthol (5),
imperatorin (6), bergapten (7), isopimpinellin (8), and xanthotoxin (9). Among
these compounds, osthol showed the strongest cytotoxic activity on tumor cell
lines. The structure-activity relationship established from the results indicated
that the prenyl group has an important role in the cytotoxic effects. However,
imperatorin showed the highest sensitivity to HL-60 cells and the least
cytotoxicity to normal PBMCs. Osthol and imperatorin both caused apoptotic
bodies, DNA fragmentation, and enhanced PARP degradation in HL-60 cells
by biochemical analysis. These results indicate that osthol and imperatorin
can induce apoptosis in HL-60 cells. Therefore, osthol and imperatorin are
cytotoxic marker substances in the fruits of Cnidium monnieri36.
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Five coumarins (seselin, 5-methoxyseselin, suberosin, xanthyletin and
xanthoxyletin) were isolated from the roots of Plumbago zeylanica37.  All
coumarins were not previously found in this plant. Cytotoxicity of these
compounds to various tumor cells lines was evaluated, and they were
significantly suppressed growth of Raji, Calu-1, HeLa, and Wish tumor cell
lines.
O OO
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Fractionation of the methanol extract of Angelica dahurica Benth et Hook
resulted in the isolation of six furocoumarins, imperatorin, isoimperatorin,
(+/-)-byakangelicol, (+)-oxypeucedanin, (+)-byakangelicin and (+)-aviprin
38. Among these, compounds imperatorin and (+)-byakangelicin exhibited
strong hepatoprotective activities, displaying EC50 values of 36.6 +/- 0.98
and 47.9 +/- 4.6 mM, respectively.
OxypeucedaninIsoimperatorin
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O
O
CH3
CH3
O
O OO
O
O
CH3
CH3
A coumestan derivative, psoralidin  was found to be a cytotoxic principle of
the seeds of Psoralea corylifolia L.(Leguminosae) with the IC50 values of
0.3 and 0.4 mg/mL against the HT-29 (colon) and MCF-7 (breast) human
cancer cell lines, respectively39.
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 A series of styrylcoumarin derivatives had been designed by Xu Song et
al40  in order to find compounds of antitumor activities by screening in vitro.
The title compounds were synthesized by phase-transfer Wittig reaction
and screened by several antitumor models in vitro.Thirty new compounds
of 6- or 7-styrylcoumarin were synthesized and their configurations were
determined. Seven compounds(10-16) showed different inhibitory effects
on L-1210, HL-60, HCT-8, KB and Bel-7402 cell lines in vitro. The activity
data representes as shown in Table-1. Some 6- or 7-styrylcoumarin
derivatives showed antitumor activities and is worth further study.
O O
R
Compd R  Geoisomer                          
10      3-COOEt         Trans   
11          H          Trans           
12      3-COOEt         Trans          
13      3-COOEt           Cis          
14      3,4-OCH2O-     Trans          
15          2-Cl              Trans           
16         3-NO2            Trans
10-11, 14-16
O O
CH3
R
12- 13
         Table-1: In vitro antitumor activities of the analogues (IC50) (ì g/ml)
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In continuation with this, a series of 4-styryl coumarin had been synthe-
sized for in vitro antitumor activity study41. The titled compounds were syn-
thesized by Phase transfer Wittig reaction or Wittig-Horner reaction and
screened by several antitumor modeles in vitro. Among a series of 20 com-
pounds, only one had effects on KB cell lines in vitro and possess certain
antitumor activities and it was selected for further studies.
O O
R
4-Styrylcoumarin derivatives
?Antiviral activity
The ether soluble fraction of the roots of Ononis vaginalis Vahl. Symb.
afforded three new compounds: 3-hydroxy-4, 9-dimethoxycoumestan,
maginaldehyde [2-(4-hydroxy-2-methoxyphenyl)-5, 6-dimethoxy-3-
benzofurancarboxaldehyde] and 5, 7, 4'-trihydroxy-4-styrylcoumarin42. The
styrylcoumarin derivative showed significant antiviral activity against
Herpes simplex type 1 and weak cytotoxicity.
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5,7,4'-trihydroxy-4-Styrylcoumarin 
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?Benzopyran analogues as Xanthine Oxidase(XO) Inhibitors
XO is a highly versatile enzyme, which is widely distributed among species
and within the various tissues of mammals43.  XO exhibits a broad activity
toward reducing substrates. It can hydroxylate a wide variety of purines (notably
xanthine and hypoxanthine), pteridines, related aromatic heterocycles, and also
a range of aliphatic and aromatic aldehydes, taking these to the corresponding
carboxylic acids, with concomitant reduction of molecular oxygen44 – 46. In XO-
catalysed reactions, oxygen is reduced by one or two electrons giving rise to
superoxide radical (O2
-) or hydrogen peroxide(H2O2)
47,48. Consequently, xanthine
oxidase is considered to be an important biological source of reactive oxygen
species (ROS), which induce oxidative stress and are involved in many
pathological processes such as inflammation, atherosclerosis, cancer and
aging49.  It has also been shown that xanthine oxidase decomposes low
molecular weight S-nitrosothiols (e.g. S-nitrosoglutathione and
Snitrosocysteine) by superoxide-dependent and -independent mechanisms,
and, according to the availability of oxygen in the system, secondarily leads to
peroxynitrite formation50. This may alter the transport and storage of nitric oxide
(NO) by Snitrosothiols and the activity of proteins that are regulated by S-
nitrosylation. Thus, the superoxide radical destroys the endothelium-derived
vascular relaxing factor (nitric oxide) causing vascular constriction51. It is of
note that XO tissue levels are increased after ischaemia reperfusion52 with
serum levels increased in hepatitis53 and brain tumours54.  It is also known that
an extensive metabolism of xanthine by XO will increase body uric acid levels.
Due to the low solubility of uric acid, there is a tendency for urate crystals to be
deposited in the urinary tract and in the synovial fluid of joints, a process
associated with painful inflammation, designated gout55. Therefore, XO
inhibitors are expected to be therapeutically useful for the treatment of the
aforementioned pathological states.
2-Styrylchromones are a small group of natural heterocyclic compounds.
Only two natural 2-styrylchromones are known and they were extracted from
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the blue-green algae Chrysophaem taylori in the 1980s56,57. Natural
derivatives have demonstrated cytotoxic activity against leukaemia cells,
while those obtained by synthesis have exhibited anti-allergic, antitumour
and anticancer properties56,57,58,59.
2-Styrylchromones have a common structural feature with flavones in containing
the benzopyrone moiety. Taking into account that flavones are known to be xanthine
oxidase (XO) inhibitors,60-63 the evaluation of this activity for 2- styrylchromones
was thought to be of prime importanceby E. Fernandes and co-workers64 and
have studied the activity profile of some synthetic 2-styrylchromone derivatives of
type shown in figure below as Xanthine Oxidase inhibitors.
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   Structure of the tested 2-Styrylchromones (17-19)
All the tested 2-styrylchromone derivatives 17–19 were found to be inhibitors
of the XO-mediated oxidation of xanthine to uric acid in a concentration-
dependent manner. Allopurinol, a known xanthine oxidase inhibitor clinically
used in the treatment of gout65 was also very effective in the present assay,
giving an IC50 of 5.43 ± 0.8 µM. Four of the tested 2-styrylchromones were
found to be more potent than this drug and the rank order of xanthine oxidase
inhibition was 19c>19b>17d>19a>allopurinol>18c>17c>18b>17b>18a>17a.
Kinetic studies were performed in order to determine the type of inhibition
of these compounds indicated that the inhibition by the most potent
compound 19c, as well as two other representative compounds 17d and 18c,
was of a non-competitive inhibition type.
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The structure activity relationship derived from the screening resultssuggested
that the catechol group linked to the styryl moiety of the molecule (compounds
19a–c) strongly contributes to the inhibition of xanthine oxidase. In fact, the
absence of hydroxyl groups in the aromatic ring linked to the styryl moiety
(compounds 17a–d), or the presence of only one phenolic group (compounds
18a–c) substantially decreased the inhibition.
The low IC50 found for 3c was probably the result of a potentiation of effects
by the catechol group linked to the styryl moiety of the 5,7-dihydroxylated
benzopyrone. The hydroxylation pattern in the benzopyrone moeity was
important for the potency of  XO inhibition. This finding is in agreement with
previous studies with flavones62 and coumarins.61 The presence of hydroxyl
groups at the C-5 and C-7 positions of the benzopyrone lead to an
observed increase in activity, when compared with the presence of only one
substitution.It was found that the 7-hydroxylated derivatives were more potent
than the respective 5-hydroxylated derivatives. Again, the importance of the
C-7 hydroxylation has also been observed for the XO inhibitory activity of
flavone derivatives62 and coumarin derivatives.67 Some other interesting
structural features of flavones including the presence of the double bond
between C-2 and C-3 (essential for planarity of the molecule) as well as the
absence of a hydroxyl at C-3 enhances XO inhibitory activity.66 Furthermore,
the presence of an additional hydroxyl at C-6 has been shown to considerably
increase the activity of some flavones and decrease it in others.66
The mode of inhibition of the studied compounds was of a mixed non-
competitive inhibition type. This means that the binding site of these
compounds to XO is not the molybdenum site but more probably the iron–
sulfur group of the enzyme.
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Antimicrobial activity
As an attempt to to preliminary exploration B.Varu,  A.Shah, M. Kawase
and et al68 have synthesized a series of  polyfunctionalized 3-cyano-4-
styrylcoumarin(20-31) of the following general formula as novel antimicro-
bial agents to determine basic structural features required for the required
biological activity.
O OR1
R
Compd.   R    R1     
20  2,4-diCl Phenyl   H   
21          3-Phenoxyphenyl  H   
22  2-Cl Phaenyl   H  
23  4-Methylthiophenyl  H   
24  1- Naphthyl   H   
25  4-Hydroxyphenyl  H   
26  2-Hydroxy Phenyl  H   
27  3-Bromophenyl   H   
28  3-OCH3-4-OH Phenyl  H   
29  2-NitroPhenyl   H   
30  2-Methoxy Phenyl  H  
31  1-Naphthyl   CH3
3-Cyano-4-Styryl Coumarin Derivatives (20-31)
The screening results suggested that compounds 20, 21, 29, 30 and 31 shows
moderate activity as 20,29-31against S.aureus NCTC 8530, S.aureus NCTC
8531, S.aureus ML 36, 20 and 21 against Sh. dysenteriae 1, E.coli Raw, 21
and 29 against V. cholerae 945, V. cholerae 946, 29, 30 and 31 against  E.coli
Raw, 30 against Shigella Sonnei in terms of MIC value of 25 µg/ml.
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Synthetic approaches
In 1953, Schroeder and Link69 prepared 3-cyano coumarin(34) by reaction
of 2-hydroxyacetophenone with ethylcyanoacetate in the presence of so-
dium ethoxide as catalyst. The reaction was conviniently carried out in one
operation. It is suggested that it proceeds with the formation of an aldol
condensate (32), which on dehydration forms intermediate(33). The in-
tramolecular Claisen condensation let to yield 3-cyano-4-methyl cou-
marin(34) (Scheme-1). The catalyst such as pyridine and piperidine70 were
also employed in the preparation but comparatively lower yields were ob-
tained. Other catalysts used were triethylamine71 and ammonium acetate70,72.
O
CH3
OH H5C2O
CN
O
2-hydroxyac
etophenone ethyl cyanoacetate
C2H5ONa
OH
OH CH3
CN
O
C2H5
O
-H2O
OH
CH3
CN
O
C2H5
O
O
CH3
O
CN
32 33 34Scheme-1
Junek73 modified the route where 2-hydroxyacetophenone reacted with
malanonitrile72 or cyanoacetamide72 or ethylcyanoacetate in the presence
of ammonium acetate and acetic acid, using benzene as solvent medium.
Further it appears that  if  any electron withdrawing groups like cyano70,72-77,
carboxylic acid74, amide74, trifluoroacetyl76, acetyl78 etc. if present at C3 po-
sition of substituted 4-methylcoumarin, the methyl group becomes highly
reactive towards electrophilic reagents.
Dimitrova et al78 studied the reaction of 3-acetyl-4-methylcoumarin with different
aromatic aldehydes in presence of piperidine afforded 4-(2-arylvinyl)-acetyl
coumarins(35). The condensation process in the case of different aldehydes
occurs at only one of the methyl group, which was confirmed by IR and NMR
data. But in case of benzaldehyde and p-tolualdehyde over and above the prod-
uct, another distyryl(36) derivative was also obtained in small yield.(Scheme-2)
O
CH3
O
O
CH3
3-acetyl-4-methyl 
coumarin
O H
R
O O
CO
O O
CO
CH3
R
35
R = H, p-CH3, p-N(CH3)2, p-Br, o-Cl
36
R = H, p-CH3
R
R
Scheme-2
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In a similar vein, 3-cyano-4-methylcoumarin was condensed with different
aldehydes in the presence of sodium acetate74 or piperidine75,77 to yield
various 3-cyano-4-(2-arylvinyl)coumarins70,72(37). Anghelova and co-work-
ers79 have used sodalime in hexamethylenetetramine (HMT) but were un-
able to obtained the product(37).(Scheme-3)
O
CH3
O
CN
3-cyano-4-methyl 
coumarin
O H
R
O O
CN
37
R = Different functional group
R
NaOAc, piperidine
Sodalime, HMT
Scheme-3
In 1924, Wittig80 prepared alkenes by Wittig reaction of aldehydes or ketones
with alkylidine triphenylphosphoranes. Thus 4-(2-aryl vinyl)coumarin was pre-
pared(38)81 by action of Witt ig reagent (carbethoxy methylene)
triphenylphosphorane [Ph3P=CHCOOC2H5] on 2-hydroxy chalcone.(Scheme-4)
O
OH
R Ph3P CHCOOC2H5
O O
CN
R = Different functional group
R
38Scheme-4
Ghiya and Lokhande82 have carried out systematic work on different path-
ways for preparation of styryl coumarins. Substituted 3-phenyl-4-(2-aryl
vinyl)coumarins of the type (39) were prepared by the condensation of ap-
propriate chalcone of 2-hydroxyacetophenone with phenylacetic acid in  pres-
ence of phosphorous oxychloride to form corresponding ester, which was
further cyclized with pulverized potassium hydroxide in pyridine.(Scheme-5)
O
OH
R1
R2
O
OCOCH2C6H5
R1
R2
O
OH POCl3/ 
Pyridine
KOH/ 
Pyridine
O O
R1
R2
39
R1 = H, CH3, Cl  R2 = H, OCH3
Scheme-5
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Barot83 has prepared 7-ethoxy-3-phenyl-4-(2-aryl vinyl) coumarins(40) by a
similar method. Mahal and Venkataraman84 have prepared 3-phenyl-4-(2-
arylvinyl) coumarin by condensation of 2-hydroxy acetophenone, sodium
salt of phenyl acetic acid and acetic anhydride.
O O
R
H5C2O
40
R = different aryl or heteroaryl
Dey and Row85 and subsequently Soliman and co-workers86 have studied
the reactivity of -CH2COOH group, where removal of carbondioxide under
specific conditions paved the way for styryl derivative formation. Thus, 7-
methyl coumarin acetic acid was reacted with aromatic aldehydes in the pres-
ence of piperidine to form 7-methyl-4-(2-arylvinyl) coumarin(41).(Scheme-6)
O
CH2COOH
OCH3
7-methylcoumarin
-4-acetic acid
O H
R
O O
CN
CH3
41
R = Different functional group
R
-CO2, -H2O
Scheme-6
Contrary to this, Ghiya87 reported that the presence of methyl group at 6 or
7position of coumarin-4-acetic acid, didn’t allow reaction with aromatic al-
dehydes. The hydroxy group is necessary at 7 position for condensation with
aldehydes to form substituted 4-(2-aryl vinyl)coumarin(42)88.(Scheme-7)
O
CH2COOH
O
O H
R
O O
CN
42
R = Different functional group
R
-CO2, -H2O
R1 = 6- or 7- CH3
R1 R1
R1 =  7-OH
Scheme-7
Shr idhar  and co-workers 89 prepared subst i tu ted 4- [ (2-
heteroaryl)vinyl]coumarins (43) as reaction product from substituted cou-
marin-4-acetic acid and formyl heterocycles.
82.P.Lokhande, B.Ghiya, J.Ind.Chem.Soc., 66314(1989)
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O OOH
R'
R
43
R = O,S                                       
R' = different functional groups
Dutta and Prabir Kumar90 prepared β-coumarinyl acrylates(44) by reaction
of  4- formyl  coumar in  wi th  Wi t t ig  reagent  Ph 3P=CRCOOC 2H5 or
(H5C2O)2P(O)CHRCOOC2H5 .(Scheme-8)
O OR1
H5C2O O
R
44
R = H, CH3,    R1 = H, OCH3
O O
O
R1
4-formyl coumarin 
derivatives
P
OC2H5
OC2H5
O
R
COOC2H5
Scheme-8
Aly and co-workers74 reported the reaction of 4-methyl-3-cyano coumarin
with phthalic anhydride and confirmed that with different substitution in ph-
thalic anhydride, the condensation product were found to be different.
Unsubstituted and dichloro phthalic anhydride gave the same product (i.e.
phthalidylidine methyl)coumarins(45), while tetrahalogeno(dichloro,
dibromo) phthalic anhydride gave exclusively dioxoindanyl coumarins(46).
This reaction was carried out successfully both in 4-methylcoumarin-3-car-
boxylic acid and 3-aminocarbonyl-4-methyl coumarin.(Scheme-10)
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Walter et al91 reported the reaction of 3-cyano-4-methyl coumarin with N,N-
dimethylamino dimethyl orthoformate leading to the styryl coumarin of
type(47).(Scheme-10)
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OCH3
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Scheme-10
Youssef et al92  have described that 6-chloro-3-cyano-4-methyl coumarin
reacted with 3-phenyl-1-aryl-2-propyn-1-ones to give the corresponding 3-
amino-4-aroyl or carbomethoxy-8-chloro-5-arylbenzo[c]coumarins(48) as
wel l  as propenylcoumar ins and benzo[c ]coumar ins by Michael
addition.(Scheme-11)
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O O
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Ph O
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48
Ar
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6-Chloro-3-cyano-
4-methyl coumarin
Scheme-11
An intramolecular aldol condensation  enables the phosphate to be pre-
pared, from which 3-alkenylcoumarins are readily obtained93.(Scheme-12)
O H
OH
O O
P
O
OC2H5
OC2H5
P
OC2H5
OC2H5
O
COCl
pyridine, -30oC
O
CHO
O
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OC2H5O
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NaH, THF (i)LDA, THF
(ii) R-CHO
O O
R
3-alkenylcoumarinsPhosphate derivativeScheme-12
The intramolecular cyclization of cyclization of o-Iodophenyl-but-3-
enoate(R=H) leads to 4-methyl coumarin only if the palladium catalysed
process is carried out in the presence of carbon monoxide and a promoter
such as phenyl acetylenewhich can coordinate to the catalyst94. However,
in case where R=alkyl or aryl, the phenyl acetylene is incorporated into the
product(49)95.(Scheme-13)
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O 49O O
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The condensation of 2-hydroxyacetophenone with ethylcyanoacetate runs
nearly analogously to the reaction of salicylic aldehyde  and gives rise to
the formation of 3-cyano-4-methyl-coumarin, usually the reaction of 2-
hydroxyacetophenone with malanonitrile gives, independent of the ratio of
the educts used and the conditions applied, differently substituted prod-
ucts. Thus, by starting with equimolar amounts of 2-hydroxyacetophenone
and malanonitrile, the iminocoumarin is formed in moderate yields only.
Using an excess of malononitrile, the products 2-[amino(2-imino-4-methyl-
2H -chromen-3-y l )methy lene]malononi t r i le  and 2- {amino[2-
(dicyanomethylene)-4-methyl-2H-chromen-3-yl]methylene}malononitrile,
together with some other products of unknown structure, are obtained 73.
The reason for the differences in the reactivity between salisaldehyde and
2-hydroxyacetophenone seems to be the lower carbonyl reactivity of 2-hy-
droxy acetophenone caused by the methyl group at C-4 96.(Scheme-14)
A raising of the carbonyl reactivity in 2-hydroxy-acetophenone as well as in its
ring substituted derivatives is expected if these compounds are transformed
into 4-methyl-substituted 2,2-difluoro-benzo[d]-1,3,2-2H-dioxaborines by the
reaction of a substituted- 2-hydroxy- acetophenone  with boron trifluoride in
acetic acid solution97 or by condensation of a suitably substituted phenol  with
acetic acid anhydride in the presence of boron trifluoride 98.
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A characteristic property of the 3-cyano-4-methyl-coumarins is, inter alia, the
acidity of the methyl group at C-4. Thus, these compounds are able to
condense with aromatic aldehydes under the influence of bases. With 4-
dimethylamino-benzaldehyde and catalytic amounts of piperidine, the 4-
dimethyl-amino-sub-stituted styryl derivatives are available. These compounds
are able, to react with amines, such as piperidine, to give pyrido[3,4-
c]benzo[h]pyran-2-one derivatives. Thus, the pyrido[3,4-c]benzo[h]pyran-2-one
derivative(Scheme-15)  has been synthesized either by adding an excess of
piperidine to the reaction mixture of 4-methyl-3-cyanocoumarin derivatives and
4-dimethylamino-benzaldehyde or by addition of piperidine to a solution of
styryl derivatives in acetonitrile, the styryl coumarins are deeply coloured
compounds which exhibit intense absorption bands in the visible region at
about 500 nm. Their absoptions are strongly influenced by the polarity of the
solvent. Therefore, the styryl coumarins  are promising candidates for
manufacturing materials with non-linear optical properties.
Boutome and Hartmann99 have described that the 4-methyl-substituted 2,2-
difluoro-benzo [d]-1,3,2-2H-dioxaborines  condense with ethyl cyanoacetate
or malononitrile  under the influence of weak bases to give the corresponding
3-cyano-4-methyl-coumarins  or their imino derivatives, respectively. The later
compounds can be hydrolyzed to the parent 3-cyano-4-methyl-benzo[b]pyran-
2-ones (3-cyano-4-methyl-coumarins) by reaction with mineral acid in
aqueous solution.(Scheme-15)
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Xu Song et al25 have synthesized a series of styryl coumarin derivatives by
phase transfer Wittig reaction.(Scheme-17)
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Work Done At Our Laboratory
Earlier B.Varu100 has synthesized 3-cyano-4-methylcoumarin derivatives by Kendall
and Axford method71 from 2-Hydroxyacetophenone or 5-methyl-2-
hydroxyacetophenone and ethylcyanoacetate in the presence of triethyl amine,
heated at 180oC for 7hrs. The 3-cyano-4-methylcoumarin derivatives thus obtained
were reacted with different  aromatic aldehydes to give the styrylcoumarins.
In cont inuat ion with this and in order to obtain subst i tuted 2-
hydroxyacetophenones, P.Adlakha101 has studied the Fries rearrngement with
polysubstituted phenols like 4-chloro-m-cresols. The substituted o-hydroxy
acetophenone thus obtained were well characterized as 5-chloro-4-methyl-2-
hydroxyacetophenone  by it’s physical properties and IR, NMR and Mass Spec-
tral data as well as elemental analysis. The 5-chloro-4-methyl-2-
hydroxyacetophenone thus obtained was again cyclized with ethylcyanoacetate
to yield corresponding 4-methyl-3-cyanocoumarin followed by the styryl
derivatization by the condensation with different aromatic aldehydes.
In the present chapter, it has been shown that acetyl ester derivative of 4-
chlorophenol on Fries rearrangement exclusively gave only single isomer
charachterized as 5-chloro-2-hydroxy acetophenone, which was in agreement
with the theoritical basis, that in case of 4-substituted phenols,  Fries rear-
rangement takes place with the migration of acetyl group only at ortho position
as para position was already occupied with the substitution. Further, it was
interesting to study the cyclization of the 2-hydroxyacetophenone along with
the electron withdrawing substitution(5-Cl) with ethylcyanoacetate by using
sodium ethoxide as catalyst. The method, we have earlier practiced suggested
by Kendall and Axford method71 was very drastic and time consuming. The
current work presents a direct, efficient and operationally convenient ap-
proach to the synthesis of some novel styryl derivatives of the substituted
3-cyano-4-methyl coumarins. During the course of sodium methoxide
catalysed cyclization it was observed that the rate of both the Aldol condensa-
tion and intramolecular Claisen condensation  proceeds very smoothly and
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speedily at mild reaction conditions and the reaction  outcome as high purity
of the product. Thus, the 6-chloro-3-cyano-4-methylcoumarin obtained was
again examined for its characteristic property inter alia, the acidity of me-
thyl group at C-4 position. When this compound was condensed with dif-
ferent substituted aromatic and heteroaromatic aldehydes in the presence
of the basic catalyst, afforded the corresponding 6-chloro-3-cyano-4-
styrylcoumarin derivatives.
All the newly synthesized compounds  were well characterized by IR, NMR
and Mass spectral  and elemental analysis.
In continuation with  work on the styryl coumarins in this laboratory, which
were studied  as potent antibacterial agents, the current work encompasses
with chloro  substitutions in the benzenoid part so as to study the changes
in the biological activity.The titled compounds were screened for antiviral,
antimicrobial and antitubercular activity.
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 Experimental Protocols
All the starting materials, p-chlorophenol, acetic anhydride, ethyl cyano
acetate, sodium, methanol and substituted benzaldehydes were obtained
from the commercial sources like Spectrochem Ltd., s.d.fine chem. Ltd.,
Sisco Research Labs., Allied Chem. Ltd., etc. Melting points of the synthe-
sized compounds were recorded by open capillary method  on controlled
temperature using standard Zeal’s thermometer and are uncorrected.  The
commencement of the reaction and purity of the synthesized compounds
were ensured using thin layer chromatography (TLC) silica gel-G, used as
stationary phase, the TLC plates were purchased from Merck India Ltd.  by
using acetone :benzene  as the mobile phase. However other solvent sys-
tems like ethyl acetate:hexane and chloroform:methanol were also em-
ployed, but the best results observed with acetone :benzene (2 : 8) system.
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Experimental
1. Synthesis of  4-chlorophenyl acetate
A mixture of 4-Chlorophenol (0.1 mole ) and  acetic anhydride (0.11 mole )
along with catalytic amount of concentrated sulfuric acid  was refluxed  for 2
hours on boiling water bath. The progress and completion of the reaction
was monitored by TLC.  After completion of reaction, the reaction mass was
poured  into crushed  ice. The reaction mass was extracted with
dichloromethane after thorough wash with water. The organic layer was
treated with anhydrous sodium sulphate in order to  arrest  traces of  water.
Solvent  was removed from organic layer by vacuum distillation  to yield  pure
4-chlorophenyl acetate. Yield 90%, b.p. >300oC (Reported b13 105-8
oC102).
Purity was checked by TLC using acetone:benzene (2 : 8) as mobile phase.
2. Synthesis of  5’-chloro-2’-hydroxy acetophenone
4-chlorophenyl acetate (0.1 mole) and anhydrous aluminium trichloride
(0.11 mole)  were mixed throughly in a round bottom flask. The reaction
mixture was heated gradually at 120oC till HCl gas was completely ex-
hausted. The heating  was extended for 2 hrs at 160oC. The resulting alu-
minium complex was decompossed from crushed ice containing little
amount of hydrochloric acid. The crude product was filtered dried and crys-
tallized from methanol. Yield 60%, m. p. 53-55 oC( Reported m.p. was 53
oC102). Purity was checked by TLC using acetone:benzene(2 : 8).
3. Synthesis of  6-chloro-4-methyl-2-oxo-2H-chromene-3-
carbonitrile
 A mixture of 5’-Chloro-2-’hydroxy acetophenone (0.01 mole), ethyl cyano
acetate (0.01 mole) and sodium methoxide in methanol (synthesized in
situ by 0.2g sodium metal and 10ml ethanol) was heated to reflux for 2
hrs. The reaction mixture was cooled, the product  separated from reac-
tion mass was filtered, crystallized from  ethanol to give pure 6-chloro-4-
methyl-2-oxo-2H-chromene-3-carbonitrile.Yield 87%, m.p.221 o C. Purity
was checked by TLC using acetone:benzene(2 : 8) as mobile phase.
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  4. Synthesis of 6-chloro-2-oxo-4-[substituted phenylvinyl]-2H-
chromene-3-carbonitrile (General method)
A mixture of 6-chloro-4-methyl-2-oxo-2H-chromene-3-carbonitrile  (0.01 mole)
and substituted aromatic or heteroaromatic aldehyde(0.01mole) were dis-
solved in minimum quantity of dichloro methane along with catalytic amount
of piperidine. When no solid left, the reaction mixture was stirred  till solid
product precipitated. It  was filtered and thoroughly washed with chilled metha-
nol and crystallized from chloroform. Purity of each compound was checked
by TLC using ethyl acetate: hexane(4:6) as mobile phase.
This method was employed to synthesize various 6-chloro-2-oxo-4-[sub.
phenylvinyl]-2H-chromene-3-carbonitriles using different substituted aro-
matic    aldehydes like benzaldehyde, o-/m-/p-nitro benzaldehyde, o-/m-/p-
hydroxy benzaldehyde, o-/m-/p-chloro benzaldehyde, m-phenoxy ben-
zaldehyde, m-bromo, 4-N,N-dimethyl benzaldehyde, cinnamaldehyde,
furfural, 4-thiomethyl benzaldehyde and indole-3-carbaldehyde etc.
The elemental analysis of all the compounds performed by PERKIN ELMER
470R are in total agreement with the theoritical values.
The physical constants and elemental analysis of all compounds were
shown in Table 2.1
361
Ta
bl
e 
5.
1 
: P
hy
si
ca
l c
on
st
an
ts
 o
f 6
-c
hl
or
o-
2-
ox
o-
4-
[(E
)-2
-s
ub
st
itu
te
d 
ph
en
yl
et
he
ny
l]-
2H
-c
hr
om
en
e-
3-
ca
rb
on
itr
ile
s
O
O
C
l
N
R
     Note:- The underline values denote the calculated
 percentage of composition
.
o
N.r
S
e
d
o
C
st
ne
utits
b
u
S
ral
ucel
o
M
al
u
mr
o
F
ral
ucel
o
M
t
h
gie
W
g
nitle
M
t
ni
o
P
0 C
sesyla
n
Alat
ne
mel
E
C
H
N
1
1-
S
U
K
lyn
eh
P
C
8
1
H
0
1
O
Nl
C
2
7.
7
0
3
5
9
1-
3
9
1
5
2.
0
7
8
2.
3
5
5.
4
9
2.
0
7
5
2.
3
1
5.
4
2
2-
S
U
K
lyn
eh
P
F-
4
C
8
1
H
9
O
N
Fl
C
2
7.
5
2
3
9
4
2-
6
4
2
7
3.
6
6
9
7.
2
0
3.
4
3
3.
6
6
6
7.
2
4
3.
4
3
3-
S
U
K
lyn
eh
Pl
C-
2
C
8
1
H
9
l
C
2
O
N
2
1.
2
4
3
9
5
2-
7
5
2
8
1.
3
6
5
6.
2
9
0.
4
4
2.
3
6
2
6.
2
5
0.
4
4
4-
S
U
K
lyn
eh
Pl
C-
3
C
8
1
H
9
l
C
2
O
N
2
1.
2
4
3
2
4
2-
9
3
2
8
1.
3
6
5
6.
2
9
0.
4
4
2.
3
6
2
6.
2
5
0.
4
5
5-
S
U
K
lyn
eh
Pl
C-
4
C
8
1
H
9
l
C
2
O
N
2
1.
2
4
3
7
7
2-
5
7
2
8
1.
3
6
5
6.
2
9
0.
4
4
2.
3
6
2
6.
2
5
0.
4
362
Ta
bl
e 
5.
1 
: P
hy
si
ca
l c
on
st
an
ts
 o
f 6
-c
hl
or
o-
2-
ox
o-
4-
[(E
)-2
-s
ub
st
itu
te
d 
ph
en
yl
et
he
ny
l]-
2H
-c
hr
om
en
e-
3-
ca
rb
on
itr
ile
s
     Note:- The underline values denote the calculated percentage of composition
.
o
N.r
S
e
d
o
C
st
ne
utits
b
u
S
ral
ucel
o
M
al
u
mr
o
F
ral
ucel
o
M
t
h
gie
W
g
nitle
M
t
ni
o
P
0 C
sisyla
n
Alat
ne
mel
E
)
%
N,
H,
C(
C
H
N
6
6-
S
U
K
lyn
eh
P
r
B-
3
C
8
1
H
9
O
Nl
Cr
B
2
6.
6
8
3
7
3
2-
5
3
2
2
9.
5
5
5
3.
2
2
6.
3
8
9.
5
5
2
3.
2
5
6.
3
7
7-
S
U
K
lyn
eh
P
2
O
N-
2
C
8
1
H
9
Nl
C
2
O
4
7.
2
5
3
2
4
1-
9
3
1
9
2.
1
6
7
5.
2
4
9.
7
3
2.
1
6
6.
2
8
9.
7
8
8-
S
U
K
lyn
eh
P
2
O
N-
3
C
8
1
H
9
Nl
C
2
O
4
7.
2
5
3
7
3
2-
6
3
2
9
2.
1
6
7
5.
2
4
9.
7
3
2.
1
6
6.
2
8
9.
7
9
9-
S
U
K
lyn
eh
P
H
O-
3
C
8
1
H
0
1
O
Nl
C
3
7.
3
2
3
2
3
2-
9
2
2
8
7.
6
6
11.
3
3
3.
4
3
7.
6
6
4
1.
3
7
3.
4
0
1
0
1-
S
U
K
lyn
eh
P
H
O-
4
C
8
1
H
0
1
O
Nl
C
3
7.
3
2
3
3
6
1-
0
6
1
8
7.
6
6
11.
3
3
3.
4
3
7.
6
6
4
1.
3
7
3.
4
11
11-
S
U
K
3
H
C
O-
2
lyn
eh
P
C
9
1
H
2
1
O
Nl
C
3
7.
7
3
3
9
5
1-
7
5
1
6
5.
7
6
8
5.
3
5
1.
4
2
6.
7
6
4
5.
3
11.
4
2
1
2
1-
S
U
K
3
H
C
O-
4
lyn
eh
P
C
9
1
H
2
1
O
Nl
C
3
7.
7
3
3
0
0
3
>
6
5.
7
6
8
5.
3
5
1.
4
2
6.
7
6
4
5.
3
11.
4
3
1
3
1-
S
U
K
3
H
C
Oi
D-
4,
3
lyn
eh
P
C
0
2
H
4
1
O
Nl
C
4
7.
7
6
3
5
0
2-
3
0
2
1
3.
5
6
4
8.
3
1
8.
3
8
3.
5
6
9
7.
3
5
8.
3
363
Ta
bl
e 
5.
1 
: P
hy
si
ca
l c
on
st
an
ts
 o
f 6
-c
hl
or
o-
2-
ox
o-
4-
[(E
)-2
-s
ub
st
itu
te
d 
ph
en
yl
et
he
ny
l]-
2H
-c
hr
om
en
e-
3-
ca
rb
on
itr
ile
s
     Note:- The underline values denote the calculated percentage of composition
.
o
N.r
S
e
d
o
C
st
n
e
utit
s
b
u
S
r
al
u
c
el
o
M
al
u
mr
o
F
r
al
u
c
el
o
M
t
h
gi
e
W
g
nitl
e
M
t
ni
o
P
0
C
si
s
yl
a
n
Al
at
n
e
m
el
E
)
%
N,
H,
C(
C
H
N
4
1
4
1-
S
U
K
3
H
C
OirT-
5,
4,
3
lyn
eh
P
C
1
2
H
6
1
O
Nl
C
5
8.
7
9
3
4
6
2-
1
6
2
0
4.
3
6
5
0.
4
2
5.
3
2
3.
3
6
4
6
4.
3
5
1
5
1-
S
U
K
5
H
6
C
O-
3
lyn
eh
P
C
4
2
H
4
1
O
Nl
C
3
8.
9
9
3
3
2
2-
1
2
2
0
1.
2
7
3
5.
3
0
5.
3
7
1.
2
7
8
5.
3
4
4.
3
6
1
6
1-
S
U
K
lyn
eh
P
3
H
C
S-
4
C
9
1
H
2
1
O
Nl
C
2
S
8.
3
5
3
7
0
2-
5
0
2
0
5.
4
6
2
4.
3
6
9.
3
2
4.
4
6
7
4.
3
2
9.
3
7
1
7
1-
S
U
K
lyn
eht
e-
2
lyn
eh
P
)ly
m
anni
C(
C
0
2
H
2
1
O
Nl
C
2
7.
3
3
3
0
6
2-
7
5
2
7
9.
1
7
2
6.
3
0
2.
4
1
9.
1
7
7
6.
3
4
1.
4
8
1
8
1-
S
U
K
lyc
arhtn
A-
9
C
6
2
H
4
1
O
Nl
C
2
8.
7
0
4
7
11-
5
11
7
5.
6
7
6
4.
3
3
4.
3
5.
6
7
2
4.
3
7
4.
3
9
1
9
1-
S
U
K
lyruf-
2
C
6
1
H
8
O
Nl
C
3
7.
7
9
2
5
7
1-
3
7
1
5
5.
4
6
1
7.
2
1
7.
4
9
4.
4
6
8
6.
2
6
7.
4
0
2
0
2-
S
U
K
lyl
o
dnI-
3
C
0
2
H
11
Nl
C
2
O
2
7.
6
4
3
1
6
1-
8
5
1
7
2.
9
6
0
2.
3
8
0.
8
2.
9
6
5
1.
3
2
1.
8
1
2
1
2-
S
U
K
lyht
e
mi
D,
N,
N-
4
lyn
eh
P
C
0
2
H
5
1
Nl
C
2
O
2
8.
0
5
3
9
5
1-
6
5
1
8
4.
8
6
1
3.
4
9
9.
7
4
5.
8
6
6
3.
4
2
9.
7
2
2
2
2-
S
U
K
yx
oh
e
M-
3
lyn
eh
P
C
9
1
H
2
1
O
Nl
C
3
7.
7
3
3
5
0
2-
2
0
2
6
5.
7
6
8
5.
3
5
1.
4
2
6.
7
6
4
5.
3
11.
4
364
SPECTRAL CHARACTERIZATION
The constitution of newly synthesized compounds were supported by FT -
IR, 1H NMR and  FAB-Mass spectral study.
IR Spectral Study
The wave like patern of all the frequences that make -up the infrared spec-
trum is known as interferogram.  A  mathematical operation which can
seperate individual absorption frequency from the interferogram is known
as Fourier Transform (FT). The instrument known as  Fourier Transform
Spectrophotometer  acquires the interferogram in less than one sec-
ond. When fourier transform is performed on the sum of accumulated
interferograms, a spectrum with a better signal-to-noice ratio can be
ploted. An FT-IR instrument is therefore capable of greater speed and sen-
sitivity than a dispersion instrument.
Instrument: SHIMADZU FT-IR 8400 Spectrophotometer
Sample technique: KBr pellet    Frequency range: 400-4000 cm-1
The 6-chloro-2-oxo-4-[(E)-2-sub.phenylvinyl]-2H-chromene-3-carbonitrile indi-
cates the presence of very specific functional groups like cyano group,
the vinyl group of styryl residue and carbonyl group of  the lactone resi-
due, aromatic ring skeleton etc.,  which absorb IR radiations of spe-
cific frequency and show sharp, medium or weak intense signals and
hence supports in identif iction and confirmation of the molecule.
The IR spectrums of 6-chloro-2-oxo-4-[(E)-2-substituted phenylvinyl]-2H-
chromene-3-carbonitriles shows common  frequences as 3150-3050cm-1 for
vinyl group, 2300-2200 cm-1 for cyano group, 1750-1710cm-1 for carbonyl
group of lacton residue, aromatic ring skeleton observed between 1630-
1480cm-1, bands between 1280-1230cm-1 and 1010-890 for trans CH=CH
group, C-O-C str. was observed between 1120-1030cm-1,  mono,di & tri
phenyl substitutions  observed between 870-750cm-1, while C-Cl str. was
observed between 750-790cm-1. The IR spectral data of all compounds of
KUS series are shown in Table 2.2
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   IR Spectrum of 6-Chloro-2-oxo-4-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]- 2H-
chromene-3-carbonitrile (KUS-14)
 IR Spectrum of 6-Chloro-2-oxo-4-[(E)-2-(2-chlorophenyl)vinyl]- 2H-chromene-3-
carbonitrile (KUS- 3)
O O
O
CH3O
CH3
O
CH3
Cl
N
H
H
O O
Cl
N
H
H
Cl
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   IR Spectrum of 6-Chloro-2-oxo-4-[(E)-2-(3-phenoxyphenyl)vinyl]- 2H-
chromene-3-carbonitrile (KUS-15)
 IR Spectrum of 6-Chloro-2-oxo-4-[(E)-2-(2-chlorophenyl)vinyl]- 2H-chromene-3-
carbonitrile (KUS- 4)
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1H NMR Spectral Study
1H NMR Spectrum of the 6-chloro-2-oxo-4-[(E)-2-substituted phenylvinyl]-2H-
chromene-3-carbonitrile shows signals relevant to the number of protons and
their  electronic environment known as chemical shift.  Chemical shift may
move to either upfield (shielding) or down field(deshielding), according to
the  electronic environment of the corresponding proton.  In addition  to
this, each 1H NMR signal  further splitted  into  number of subpeaks  ac-
cording  to  the  number of neighbouring  protons present in the skeleton of
molecule. The splitting of the NMR signal further provides signification about
the degree of  interaction  between  neighbouring  protons by means of
spin-spin coupling constant  J.
Instrument : BRUKER AC 300MHz FT-NMR
Internal Reference : TMS
Solvent : CDCl3  or DMSO d6
6-chloro-2-oxo-4-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]-2H-chromene-3-
carbonitrile. (KUS-14)
In case of  1H NMR Spectrum of KUS-14 shows two signals,  relevant to
three and six  protons, of  three methoxy groups appears at chemical shift
value 3.359 & 3.364δ ppm. Two signals relevant to vinylic protons appears
at chemical shift value 7.194 & 7.846δ ppm, both further splitted to give
doublet,  having coupling constant 7.77Hz & 6.3Hz respectively, which
reveals that  both vinylic protons are relatively in trans(E) position to each
other.  Phenyl residue having two chemically equivalent protons H(a)  shows
signal  at 6.614δ ppm  as singlet.  Protons H(5) , H(7) & H(8) of the benzenoid
part shows signals at 8.07δ ppm for one proton as doublet with J value
2.1Hz, 7.514δ ppm for one proton as triplet  with J value of 8.7 & 6.3Hz and
7.583δ ppm for one proton as doublet with J value of 9Hz respectively, which
reveals that H(7) & H(8) are in ortho position to each other where as H(5) & H(7)
are relatively in meta position.
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6-chloro-2-oxo-4-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-2H-chromene-3-
carbonitrile (KUS - 13)
  1H NMR Spectrum of the KUS-13 shows two signals, each relevant to three
protons, of two methoxy groups appears at chemical shift value 3.837 &
3.887δ ppm. Two signals relevant to vinylic protons appears at chemical
shift value 6.412 & 6.661δ ppm, both further splitted to give doublet,  with
coupling constant 12.6Hz & 13.8Hz respectively, which reveals that  both
vinylic protons are relatively in trans(E) position to each other. Protons H(a),
H(b) & H(c) of the phenyl residue shows signals  at 7.128δ ppm for one pro-
ton as singlet, 7.064δ ppm for one proton as doublet with J value of 8.4Hz
and 7.422δ ppm for one proton as double doublet with J value of 1.5, 6.9 &
1.5Hz respectively, which reveals that H(b) & H(c) are in ortho position to
each other where as H(a) & H(c) are relatively in meta position. Protons H(5) ,
H(7) & H(8) of the benzenoid part shows signals at 8.263δ ppm for one pro-
ton as doublet with J value 2.4Hz, 7.794δ ppm for one proton as double
doublet with J value of 2.1, 6.6 & 2.1Hz and 7.854δ ppm for one proton as
doubledoublet with J value of 1.2, 6.9 & 1.2Hz respectively, which reveals
that H(7) & H(8) are in ortho position to each other where as H(5) & H(7)   are
relatively in meta position.
371
O O
O
CH 3 (b)O
 (a)CH 3
Cl N
H(f)
H(g)
H
H
H
H(5)
H(8)
(7)H
(a')
(b')
(c')
                      KUS - 13
1H NMR Spectrum of 6-chloro-2-oxo-4-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-
2H-chromene-3-carbonitrile (KUS - 13)
notorPfoepyT
)puorG(
tfihSlacimehC
mppatled snotorPfo.oN yticilpitluM
eulaVJ
)zH(
HC-O )a(3 738.3 3 s -
HC-O )b(3 788.3 3 s -
H-rA )a( 821.7 1 s -
H-rA )b( 460.7 1 d 4.8
H-rA )c( 224.7 1 dd
&9.6,5.1
5.1
HC=HC )f( 214.6 1 d 6.21
HC=HC )g( 166.6 1 d 8.31
H-rA )7( 497.7 1 dd
&6.6,1.2
1.2
H-rA )8( 458.7 1 dd
&9.6,2.1
2.1
H-rA )5( 362.8 1 d 4.2
372
O O
O
CH 3 (b)O
 (a)CH 3
Cl N
H(f)
H(g)
HH
H(5)
H(8)
(7)H
O
(b)CH 3
(a')(a')
         KUS - 14
1H NMR Spectrum of  6-chloro-2-oxo-4-[(E)-2-(3 ,4 ,5-
trimethoxyphenyl)vinyl]-2H-chromene-3-carbonitrile (KUS - 14)
notorPfoepyT
)puorG(
tfihSlacimehC
)mppatled( snotorPfo.oN yticilpitluM
eulaVJ
)zH(
HC-O )a(3 953.3 3 s -
HC-O )b(3 463.3 6 s -
H-rA2 )'a( 416.6 2 s -
HC=HC )f( 491.7 1 d 777.7
HC=HC )g( 648.7 1 d 3.6
H-rA )7( 415.7 1 t 3.6&7.8
H-rA )8( 385.7 1 d 9
H-rA )5( 70.8 1 d 1.2
373
Mass Spectral Study
The molecular ion peaks (M+) of  the compounds  in mass spectra  were
in total agreement  with it’s molecular weight.
Instrument: JEOL SX 102/DA-6000 Spectrograph for FAB
6-chloro2-oxo-4-[(E)-2-(3,4,5-trimethoxypheny)lvinyl]-2H-chromene-
3-carbonitrile (KUS-14)
The FAB Mass spectrum of KUS-14 shows  molecular ion peak at 398m/z
(M+ peak), while fragmantation pattern shows peaks at 384m/z (M+-CH3),
365m/z (M+-OCH3), 363m/z (M
+-Cl), 331m/z (M+-Cl,-OCH3), 307m/z (M
+-
3OCH3), 289m/z (M+-Cl,-CN,-O i.e. rupture of coumarin ring), 273m/z (M+-
Cl,-3OCH3), 257m/z (M
+-3OCH3 ,-Cl,-O), 232m/z (M
+-3OCH3 ,-Cl,-O,-CN),
154m/z (M+-3OCH3 ,-Cl,-O,-CN,-Phenyl)appears as base peak, 136m/z (C8
H8 O2  or dimethoxy phenyl redical)
6-chloro2-oxo-4-[(E)-2-(3,4-dimethoxypheny)lvinyl]-2H-chromene-3-
carbonitrile (KUS-13)
FAB Mass Spectrum of shows  molecular ion peak at 368m/z (M+ peak) and
368m/z (M++1) peak,  while fragmantation pattern shows peaks at 331m/z
(M+-Cl), 317 (M+-Cl,-O ring rupture of coumarin ring), 307m/z (M+-Cl,-CN or
M+-2OCH3), 289m/z (M
+-Cl,-CN,-O or M+-2OCH3,-O), 279m/z (M
+-CN,-
2OCH3), 259m/z (M
+-Cl,-CN,-O,-OCH3), 232m/z (M
+-Cl,-CN,-O,-CO,-OCH3),
227m/z (M+-Cl,-CN,-O,-2OCH3), 202m/z (M
+-Cl,-CN,-O,-CO,-2OCH3), 189m/
z (M+-CN,-O,-2OCH3,-C6H3 redical), 165m/z (M
+-CN,-O,-2OCH3,-C6H3
redical,-ethylene redical),154m/z (M+-Cl,-CN,-O,-2OCH3,-C6H3 redical or M
+-
Cl,-O,-2OCH3,-C6H3 redical,-ethylene redical) appears as base peak, 136m/
z (M+-CN,-CO,-O,-2OCH3,-C6H3 redical,-ethylene redical)
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 Antitubercular and Antibacterial Study
  of  Newly Synthesized Compounds
CHAPTER-6
377
Introduction
The present chapter deals with the preliminary biological screening
results of 120 compounds synthesized during the course of invention,
which are heterocycles like triazolotriazinoindole, 1,5-benzothiazepine,
pyrano[3,2-c]quinolone, 1,3,4-oxadiazol-2-yl-1H-pyrrole and 2-oxo-4-
styryl-2H-chromene-3-carbonitrile.
In the current chapter, biological aspects of antitubercular and anti-
bacterial screening were described along with the activity protocols
and activity data obtained by preliminary screening In vitro.
Finally on the screening results a brief discussion is also narrated.
 Antitubercular Screening
The antitubercular screening of  all the synthesized compounds of KUITT,
KUT, KUQ & KUQP, KUPO and KUS series was carried out at Tuberculosis
Antimicrobial Acquisition and Coordinating Facility (TAACF), Alabama, USA.
Experimental protocols of In vitro Anti-Mycobacterium tuberculosis
activity1.
Level -1. Primary Screen.
The primary screen is conducted at 6.25 µg/ml(or molar euivalents of high-
est molecular weight compound in a series of congeners) against
Micobacterium tuberculosis H37Rv (ATCC 27294) in BACTET 12B medium
using Microplate Almar Blue Assay (MABA)1. Compounds exhibiting fluo-
rescence are tested in the BACTET 460-radiometric system1. Compounds
effecting >99% inhibition in the primary screen (MIC < 6.25 µg/ml) are
generally evaluated further.
Level-2.
Determination of Minimum Inhibitory Concentration (MIC)
Compounds demonstrating at least 90% inhibition in the primary screen are
retested at lower concentration against M. tuberculosis H37Rv to determinethe
actual minimum inhibitory concentration(MIC) in the MABA. The MIC is de-
fined as the lowest concentration effecting a reduction in fluorescence of 90%
relative to controls like isoniazide(ATCC 35822), rifampin (ATCC 35838).
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Determination of 50% Inhibitory Concentration (IC50)
Concurrent with the determination of MICs, compounds are tested for
cytotoxicity(IC50) in VERO cells at concentrations less than or equal to
62.5µg/ml or ten times the MIC for M. tuberculosis H37Rv. After 72hours
exposure, viability is assessed on the basis of cellular conversion of MTT
into a formazan product using the Promega Cell Titer 96 Non-radioactive
cell proliferation assay.
Level-3
Determination of 90% and 99% Effective Concentration (EC90 & EC99)2
Compounds are tested for killing of M. tuberculosis Erdman(ATCC 35801)
in monolayers of mouse bone marrow macrophages2 (EC90 & EC99; lowest
concentration effecting a 90% and 99% reduction, respectively in colony
forming units at seven days compared to drug free controls) at 4-fold con-
centrations equivalent to 0.25, 1, 4 and 16times the MIC. Compounds with
EC90>16×MIC are considered inactive in the model.
Determination of MIC against three strains of single drug resistant
(SDR) M. tuberculosis
Concurrent with the testing of compounds in macrophages, MICs are de-
termined in  the MABA for  three s t ra ins  o f  drug- res is tance M.
tuberculosis(Each strain resistant to single TB drug). Typically all the com-
pounds progressing to this stage of screening will be tested against M.
tuberculosis strains resistant to isoniazide(ATCC 35822), rifampin (ATCC
35838), and one other drug resistant strain (the letter determined by the
compound type) as well as the drug sensitive strains H37Rv and Erdman.
Generally MICs for SDR strains should not be greater than 10×MIC for non-
resistant strains for compound evaluation to continue. However character-
istics such as SAR, solubility and log P values are reviewed to determine
to continue compound evaluation into in vivo testing.
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Primary Screening Methodology
Antitubercular activity was determined using the BACTEC 460 system as
modified below. Stock solutions as test compounds were prepared in
dimethylsulfoxide(DMSO) at 1 mg/ml and sterillized by passage through 0.22
um PFTE filters(Millex-FG, Millepore, Bedford MA). Fifty micro liters was
added to 4ml radiometric 7H12 broth (BACTEC 12B; Bectron Dickinson
Diagnostic Instrument system, Sparks, MD) to achieve a final concentration
of 6.25µg/ml. Controls received 50 µl DMSO. Rifampin (Sigma Chemicals
Co., St. Louis, MO) was included as a possitive drug control. Rifampin was
solubilized and diluted in DMSO and adeed to BACTEC-12 broth to achieve
a range of concentration for concentration of minimum inhibitory concentra-
tion (MIC, lowest concentration inhibiting 99% inhibition of the inoculums).
M. Tuberculosis H37Rv  (ACTT 27294; American type culture
collection(Rockville, MD) was cultured at 37oC on a rotary shaker in middle
brook 7H9 broth(Difco Laboratories, Detroiet, MI) supplemented with 0.2v/v
glycerol and 0.05% v/v Tween 80 unit the culture turbidity achieved an optical
density of 0.45-0.55 at 550nm. Bacteria were pellected centrifugation, washed
twice and resuspended in one fifth of the origional volume in dulbecoo’s phos-
phate buffered saline [PBS, Irvine Scientific, Santa Ana, (A)]. Large bacterial
clumps were removed by passage through an 8µm filter (malgene, Rochester,
NY) and aliquotes were frozen at -80oC. The cultures were showed and an
appropriate dilution performed such that a BACTEC-12B broth containing the
test compounds. An additional control vial was included which received a fur-
ther 1:100 diluted inoculum (as well as 50ml DMSO) for use in calculating the
MIC of the rifampicin, respectively by establishing procedures.
Cultures were incubated at 37oC and the Growth of Inhibition(GI) determined
daily until control cultures acheived a GI of 999. Assays were usually com-
pleted in 5-8days. Percent inhibition was defined as 1-(GI of test sample/
GI of control)×10. Minimum inhibitory concentration of compound effecting
a reduction in daily change in GI, which was less than that observed with a
1:100 diluted control culture on day the later reached a GI of at least 30.
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 Antibacterial Screening (Experimental protocols)
The antibacterial screening of all the synthesized compunds of present
investigation was performed by two methods, described as under.
(Method - A) Measurment of Zone of Inhibition by Cup-plate method3-5.
The screening assay included the nutrient agar broth prepared by usual
method was inoculated especially 0.5ml for 24hrs. The bacterial cultures
E.coli / S.aureus were taken in the seperate conical flask at 40-50o
and mixed well by gentle shaking. About 25ml of the content of the
flask were poured and evenly spread in petridish(13cm in diameter)
and 10mm bore in agar medium and filled with 0.05ml solution of sample
in 10% dimethylsulfoxide(DMSO) in methanol. The plates were incu-
bated at 37oC for 24hrs and the control was also maintained with 10%
DMSO in methanol in similar manner. The zone of inhibition of the
bacterial growth were measured in mm diameter.
(Method - B) Measurment of Minimum Inhibitory Concentration by
Agar dilution method6.
The biological screening assay protocols discussed here are as per rec-
ommendation of NCCL, USA. Each compound was dissolved in dimethyl
sulfoxide (DMSO, 20mg/ml).The required dilution are made to make the
final concentration as 1000 µg/ml, 500µg/ml, 125µg/ml, 75µg/ml, 36µg/ml
and 18µg/ml. The solvent control plate is inoculated  with various bacterial
cultures. The bacterial cultures are inoculated into Mullar Hilton broth and
allowed to grow for 4hrs at 37oC. For the standardization of terbidity of
bacterial cultures Mac Forland solution is used to finalize the terbidities of
cultures. The media used is Mullar Hilton agar medium. Negative control to
check the successful growth of all cultures is used without adding solvent
or compounds. The observations are made to check the visible growth of
bacteria.
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1-TUK lynehP ramlA 52.6> - * *
2-TUK ON-2 2 lynehP ramlA 52.6> 4 * *
3-TUK ON-3 2 lynehP ramlA 52.6> 2 * *
4-TUK HCO-2 3 lynehP ramlA 52.6> 8 * *
5-TUK HCO-3 3 lynehP ramlA 52.6> 3 * *
6-TUK HCO-4 3 lynehP ramlA 52.6> 2 * *
7-TUK lynehPrB-3 ramlA 52.6> - * *
8-TUK lynehPlC-2 ramlA 52.6> 06 * *
9-TUK lynehPlC-3 ramlA 52.6> 8 * *
01-TUK lynehPlC-4 ramlA 52.6> 31 * *
11-TUK lynehPlynehte-2 ramlA 52.6> - * *
21-TUK lynehPF-4 ramlA 52.6> 27 * *
31-TUK HCiDN,N-4 3 lynehP ramlA 52.6> - * *
41-TUK lynehPHO-4 ramlA 52.6> 23 * *
51-TUK ON-4 2 lynehP ramlA 52.6> 39 * *
61-TUK HCS-4 3 lynehP ramlA 52.6> - * *
71-TUK HCOiD-4,3 3 lynehP ramlA 52.6> - * *
81-TUK HCOirT-5,4,3 3lynehP ramlA 52.6> 9 21 *
02-TUK lynehPHO-3 ramlA 52.6> 3 * *
12-TUK lylodnI-3 ramlA 52.6> 08 * *
22-TUK lycarhtnA-9 ramlA 52.6> - * 42
42-TUK HO-2 ramlA 42.6< 49 * *
Table-2. Antitubercular and Antibacterial activity data of 4-hydroxy-3-(2-substi-
tuted phenyl-2,3-dihydro-1,5-benzothiazipine-4-yl)-2H-chromen-2-one
series(KUT 1-24)
   Note:  - and * signs indicate full growth of microorganisms.
S
N
O
R
OH
O
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Table-3. Antitubercular screening Level-2 data of 4-hydroxy-3-(2-(4-nitrophenyl)-
2,3-dihydro-1,5-benzothiazipine-4-yl)-2H-chromen-2-one (KUT-15) and 4-hydroxy-
3-(2-(2-hydroxy phenyl)-2,3-dihydro-1,5-benzothiazipine-4-yl)-2H-chromen-2-one
(KUT-24)
S
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1-QUK H ramlA 52.6> * * *
QUK 2- lC-2 ramlA 52.6> 2 * *
3-QUK lC-3 ramlA 52.6> 9 * *
4-QUK lC-4 ramlA 52.6> 31 * *
5-QUK ON-2 2 ramlA 52.6> 7 * *
6-QUK ON-3 2 ramlA 52.6> 01 * *
7-QUK ON-4 2 ramlA 52.6> - * *
8-QUK F-4 ramlA 52.6> - * *
9-QUK rB-3 ramlA 52.6> - * *
01-QUK CO-3 6H5 ramlA 52.6> 12 * *
11-QUK HCS-4 3 ramlA 52.6> 8 * *
31-QUK HO-3 ramlA 52.6> - * *
41-QUK HO-4 ramlA 52.6> - * *
51-QUK HCid-N,N-4 3 ramlA 52.6> 81 * *
61-QUK HCO-2 3 ramlA 52.6> 24 * *
71-QUK HCO-4 3 ramlA 52.6> 9 * *
81-QUK HCOirt-5,4,3 3 ramlA 52.6> 31 * *
91-QUK HCOid-4,3 3 ramlA 52.6> - * *
12-QUK lycarhtnA-9 ramlA 52.6> - * *
42-QUK CO-3 2H5 HO-4- ramlA 52.6> - * *
52-QUK lylodnI-3 ramlA 52.6> 12 * *
62-QUK HCO-3 3 ramlA 52.6> 41 * *
Table-4. Antitubercular and Antibacterial activity data of 2-amino-6-methyl-5-oxo-
4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitrile series
(KUQ 1-26)
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1-SUK lynehP ramlA 52.6> 55 * *
2-SUK lynehPF-4 ramlA 52.6> - * *
3-SUK lynehPlC-2 ramlA 52.6> - * *
4-SUK lynehPlC-3 ramlA 52.6> 96 * *
5-SUK lynehPlC-4 ramlA 52.6> - * *
6-SUK lynehPrB-3 ramlA 52.6> 32 * *
7-SUK lynehP2ON-2 ramlA 52.6> 11 * 21
8-SUK lynehP2ON-3 ramlA 52.6> 96 * *
9-SUK lynehPHO-3 ramlA 52.6> - * 21
01-SUK lynehPHO-4 ramlA 52.6> - * 21
11-SUK lynehP3HCO-2 ramlA 52.6> 42 * *
21-SUK lynehP3HCO-4 ramlA 52.6> 33 * *
31-SUK lynehP3HCOiD-4,3 ramlA 52.6> 36 * *
41-SUK 3HCOirT-5,4,3 lynehP ramlA 52.6> 78 * *
51-SUK lynehP5H6CO-3 ramlA 52.6> 27 * *
61-SUK lynehP3HCS-4 ramlA 52.6> - * *
71-SUK lynehPlynehte-2 ramlA 52.6> - * *
81-SUK lycarhtnA-9 ramlA 52.6> 18 * *
91-SUK lyruf-2 ramlA 52.6> 36 * *
02-SUK lylodnI-3 ramlA 52.6> - 21 21
12-SUK lyhtemiD,N,N-4 lynehP ramlA 52.6> 97 * *
22-SUK lynehPyxoheM-3 ramlA 52.6> 13 * 21
Table-7. Antitubercular and  Antibacterial activity data of 6-chloro-2-oxo-4-[(E)-2-
substituted phenyl vinyl]-2H-chromene-3-carbonitrile series (KUS  1-22)
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Results and Discussion
Looking to the biological screening results (as per shown in Table 1-7) of
antitubercular and antibacterial activity of all the synthesized compounds
of the current investigation leads to the following conclusion.
Compounds of 1-substituted phenyl-10H-[1,2,4]tiazolo[3’,4’:3,4][1,2,4]
triazino[5,6-b]indole (KUITT 1-22) series possess moderate to weak anti-
tubercular activity(Table-1).
 The screening results revealed that KUITT-22 (R = 9-anthracyl) was shown
maximum inhibition(62%), while that of KUITT (R = 3-chloro) was 53% at
MIC value >6.25µg/ml.
 The antibacterial activity profile of the series(Table-1) revealed that KUITT-
2(R = 4-methoxy), KUITT-6(R = 2-chloro), KUITT-12(R = 3-phenoxy), KUITT-
16 (R = 3-chloro), KUITT-17(R = 2-hydroxy), KUITT-19(R = 3-hydroxy), KUITT-
21(R = 4-methyl) and KUITT-22(R = 9-anthracyl) have shown to inhibit the
growth of E.coli. at  MIC value of  75µg/ml, while KUITT-2(R = 4-methoxy),
KUITT-6(R = 2-chloro), KUITT-13(R = 2,5-dimethoxy), KUITT-14(R = 3-
methoxy), KUITT-16 (R = 3-chloro), KUITT-17(R = 2-hydroxy), , KUITT-21(R
= 4-methyl) and KUITT-22(R = 9-anthracyl) were active against Enterobacter
sp. upto 75µg/ml. Candidates of the series KUITT-2(R = 4-methoxy), KUITT-
6(R = 2-chloro), KUITT-10(R = H), KUITT-17(R = 2-hydroxy), KUITT-19(R =
3-hydroxy), KUITT-21(R = 4-methyl) and KUITT-22(R = 9-anthracyl) were
inhibited growth of P.aeruginosa at  MIC value of 75µg/ml, on the other
hand KUITT-10(R = H), KUITT-11(R = 2-nitro), KUITT-13(R = 2,5-dimethoxy),
KUITT-14(R = 3-methoxy), KUITT-16 (R = 3-chloro), KUITT-17(R = 2-hy-
droxy), KUITT-19(R = 3-hydroxy), KUITT-21(R = 4-methyl) and KUITT-22(R
= 9-anthracyl) were active against S.auereous at the minimum concentra-
tion level of 75µg/ml.
In addition to this KUITT-21((R = 4-methyl) was found to control growth of
S.aureus upto 12mm diameter at 10µg/ml concentration.
Compounds KUITT-3(4-thiomethyl), KUITT-11(R = 2-nitro), KUITT-13(R =
2,5-dimethoxy), KUITT-14(R = 3-methoxy), KUITT-21(R = 4-methyl) and
393
 KUITT-22(R = 9-anthracyl) were inhibit the growth of K.pneumoniae at 75µg/
ml and KUITT-14(R = 3-methoxy), KUITT-21(R = methyl) and KUITT-22(R =
9-anthracyl) were active against B.subtilis upto 75µg/ml.
Over and above to this KUITT-20(R = 3-methoxy,4-hydroxy) was found
to be most potent antibacterial candidate of the series as it is effective to
inhibit  the growth inhibition of all the gram possitive and gram negative
bacterial species used in screening viz., E.coli, Enterobacter sp., P.
aeruginosa, S. aureus, K. pneumoniae and B.subtilis  at minimum inhibi-
tory concentration level of 75µg/ml, more over it inhibits growth of P.
aeruginosa and K.pneumoniae at lowest minimum inhibitory concentra-
tion level of 18µg/ml.
In  case o f  4-hydroxy-3- (2-subst i tu ted pheny l -2 ,3-d ihydro-1,5-
benzothiazipine-4-yl)-2H-chromen-2-one series(KUT 1-24), two candidates
viz.4-hydroxy-3-(2-(4-nitrophenyl)-2,3-dihydro-1,5-benzothiazipine-4-
yl)-2H-chromen-2-one (KUT-15) and 4-hydroxy-3-(2-(2-hydroxy phe-
nyl)-2,3-dihydro-1,5-benzothiazipine-4-yl)-2H-chromen-2-one (KUT-
24) were found to be most potent antitubercular candidates of the present
invention (Table-2 and 3). In primary screening both KUT-15(R = 4-nitro)
and KUT-24(R = 2-hydroxy) have shown 93% and 94% inhibition of  My-
cobacterium tuberculosis H37Rv(TTCC 27294)at MIC value of  >6.25µg/
ml and <6.24µg/ml respectively in BACTET 12B medium using the
Microplate Almar Blue Assay (MABA)1.
Hence, KUT-15(R = 4-nitro) and KUT-24(R = hydroxy) were further evalu-
ated for determination of its actual minimum inhibitory concentration (MIC)
and determination of 50% inhibitory concentration(IC50)(Table-3). Unfortu-
nately IC50 value of both the compounds in Level-2 screening were deter-
mined to be >10µg/ml and 3.63µg/ml respectively, which are to low values
to evaluate them in further screening for the determination of their effective
concentrations on M. tuberculosis.
The anti bacterial profile of the series (Table-2) reveals that KUT-18(R =
3,4,5-trimethoxy phenyl) was found to control growth of E.coli upto 12mm
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 diameter  while  that  of S.aureous is found to be 24mm by KUT-22 (R =
9-anthracyl) at 10µg/ml concentration.
The entire series of 2-amino-6-methyl-5-oxo-4-substituted phenyl-5,6-
dihydro-4H-pyrano[3,2-c]quinoline-3-carbonitriles was neither active against
M.tuberculosis nor showed antibaterial activity(Table-4). On the other hand
one candidate of 2-amino-6-benzyl-5-oxo-4-substituted phenyl-5,6-dihydro-
4H-pyrano[3,2-c]quinoline-3-carbo nitrile series (KUQP 1-16)(Table-5) viz.
2-amino-6-benzyl-5-oxo-4-(2-methoxy phenyl)-5,6-dihydro-4H-pyrano[3,2-
c]quinoline-3-carbo nitrile(KUQP-12) was found to inhibit the growth of
E.coli and Enterobacter sp. at minimum inhibitory concentration level of
75µg/ml.
There are number of compounds of 1-{2,4-dimethyl-5-[(5-substituted phenyl-
1,3,4-oxadiazol-2-yl)carbonyl]-1H-pyrrol-3-yl}ethanone series (KUPO 1-16)
were exhibited moderate antitubercular activity(Table-6).
The primary screening results obtained from Microplate Almar Blue Assay
(MABA)1, suggested that KUPO-3(R = 4-chloro phenyl) to be most potent
candidate of the series as it shows 88% inhibition of the growth of
M.tuberculosis H37Rv, while KUPO-11(R = 4-methyl phenyl), KUPO-15(R
= 4-bromo phenyl), KUO-13(R = 2-indolyl) shows 84%,83%,81% inhibi-
tion respectively while KUO-7(R = 4-OCH3 phenyl) and KUO-16 (R = 2-N-
phenylamino phenyl) shows 70% inhibition at MIC value > 6.25µg/ml.
The antibacterial activity profile of the series(Table-6) reveals that   KUPO-
3(R = 4-chloro phenyl), KUPO-10(R = 2-methylphenyl), KUPO-12 (R =
2-hydroxy naphthyl), KUPO-13 (R = 2-Indolyl) are the most active anti-
microbial candidates of the series as KUPO-3(R = 4-chloro phenyl) and
KUPO-12 (R = 2-hydroxy naphthyl) inhibits growth of E.coli and
Enterobacter sp. while KUPO-10(R = 2-methyl phenyl) and KUPO-13 (R
= 2-Indolyl) inhibits growth of E.coli, at minimum inhibitory concentration
value of 18µg/ml. Where as KUPO-7(R = 4-methoxy phenyl) inhibits growth
of all bacterial species of the screening and KUO-10(R = 2-methyl phenyl)
inhibits growth of Enterobacter sp. at MIC value of 37.5µg/ml.
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However KUPO-3(R = 4-chloro phenyl), KUPO-11(R = 4-methyl phenyl), KUPO-
14(R = 2-acetoxy phenyl), KUPO-15(R = 4-bromo phenyl) and KUO-16 (R =
2-N-phenylamino phenyl) inhibits growth of P. aeruginosa, KUPO-14(R = 2-
acetoxy phenyl) and KUO-16 (R = 2-N-phenylamino phenyl) inhibit growth of
both E.coli and Enterobacter sp., KUPO-11(R = 4-methyl phenyl), KUPO-14(R
= 2-acetoxy phenyl), KUPO-15(R = 4-bromo phenyl) and KUO-16 (R = 2-N-
phenylamino phenyl) inhibits growth of both S.aureous and K. pneumoniae
and KUPO-14(R = 2-acetoxy phenyl) inhibits growth of B.subtilis at minimum
inhibitory concentration level of 75µg/ml.
On the other hand KUPO-12 (R = 2-hydroxy naphthyl), KUPO-13 (R = 2-
Indolyl),  KUPO-14(R = 2-acetoxy phenyl) and KUO-16 (R = 2-N-
phenylamino phenyl) were found to control growth of  S.aureous upto
18, 12, 18 and 18 mm diameter respectively at 10µg/ml concentration.
The series of 6-chloro-2-oxo-4-[(E)-2-substituted phenyl vinyl]-2H-chromene-
3-carbonitrile series (KUS  1-22) shows moderate activity profile(Table-7)
of antitubercular activity against M.tuberculosis H37Rv. KUS-14(R = 3,4,5-
trimethoxy phenyl) is considered to be most potent candidate as it shows
highest inhibition of 87%, subsequently KUS-18(R = 9-anthracyl), KUS-
21(R = 4-N,N-dimethyl phenyl) and KUS-15(R = 3-phenoxy) shows 81%,
79% and 72% inhibition respectively.
The antibacterial activity screening (Table-7) reveals that KUS-7( R = 2-
nitro phenyl), KUS-9(3-hydroxy phenyl), KUS-10(4-hydroxy phenyl),
KUS(3-methoxy phenyl) control the growth of S.aureous, KUS-20(3-
Indolyl) control growth of both E.coli and S.aureous upto 12 mm diam-
eter  all at 10µg/ml concentration.
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List of Paper Presentation at National & International Conferences:
1. 9th National Conference on “Bioactive Heterocycles & Drug Discovery
Paradigm” including One Day International Symposium on ‘Recent
Trends in Drugs Discovery’
(a) Novel Synthesis & Biological Evaluation of Substituted 4-
Hydroxy-3-(2-Subst i tuted Phenyl-2,3-Dihydro-1H-1,5-
Benzodiazepine-4-yl)-2H-Chromen-2-ones
Kuldip Upadhyay, Kena Raval, Gautam Patel & Denish Karia
(b) Synthesis & x-Ray Crystallographic Studies of Biologically
Active asymmetric 1,4-Dihydro Pyridines
Priti Adlekha, Kuldip Upadhyay, Harsukh Gaveriya & Anamik
Shah
2. XVIII Gujarat Science Congress
Microwave assisted Synthesis & X-Ray Crystallographic Study
of ethyl 2-oxo-2H-chromene-3-carboxylate
3.  10th International Conference of ISCB on ‘Drug Discovery:
Perspectives and Challenges(Including Symposium on infectious
diseases) and International Satellite Symposium on Medicinal Plants
and Functional Foods in the Management of the Diabetes, Obesity
and Cardiovascular Diseases’
Synthesis of Substituted 4H-1,4-Benzothiazines
Kuldip Upadhyay, Ravi Chaniyara, Bharat Savaliya, Hardevsinh Vala,
Bhavin Marvaniya and Anamik Shah
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Conferences / Workshops Attended:
1. National Workshop on Spectroscopy & Theoretical Chemistry
organized by Department of Chemistry, The Maharaja Sayajirao
University of Baraoda, Vadodara during 8-12th February 2005
2. 7th National Conference of Indian Society of Chemists & Biologists
organized by Central Drug Research Institute, Lucknow during 26-
28th February, 2003.
3. 9th National Conference on “Bioactive Heterocycles & Drug Discovery
Paradigm” including One Day International Symposium on ‘Recent
Trends in Drugs Discovery’ jointly Organized by Department of
Chemistry, Saurashtra University, Rajkot & Central Drug Research
Institute, Lucknow during 8-10th January, 2005.
4. XVIII Gujarat Science Congress Organized by Gujarat Science
Academy at 13th March, 2004.
5. National Workshop on “Nanotechnology: Opportunities & Challenges”
jointly organized by Saurashtra University, Rajkot and Gujarat Council
of Science & Technology (GUJCOST), Gandhinagar on 17th Oct’ 2005.
6. International Conference on Building Bridges, Forging Bonds for 21st
Century Organic Chemistry and Chemical Biology (ACS-CSIR OCCB
2006) jointly Organized by American Chemical Society and Council
of Scientific & Industrial Research, New Delhi at National Chemical
Laboratory, Pune on 6 – 9 Jan’ 2006.
7. UGC Sponsored One Day National Level Seminar on “Bioinformatics
– Emerging Trends” organized by Shri M. & N. Virani Science
College, Rajkot on 1st Jan’ 2006.
8. DST Sponsored National Workshop on “Green Chemistry” Organized
by Institute of Pharmacy and Faculty of Science, Nirma University of
Science & Technology, Ahmedabad on 25-26 Nov’ 2005.
9. 10th Internat ional  Conference of ISCB on Drug Discovery:
Perspectives and Challenges(Including Symposium on infectious
diseases) and International Satellite Symposium on Medicinal Plants
and Functional Foods in the Management of the Diabetes, Obesity
and Cardiovascular Diseases, jointly organized by Indian Society of
Chemists(India) & Biologists and University of Toronto(Canada) at
Central Drug Research Institute, Lucknow on 24-26th Feb’-2006.
